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Abstract 
The Effects of Antimicrobial Therapy on Faecal Escherichia coli and Mucosal 
Staphylococci in Dogs 
Vanessa Merta Schmidt 
Canine infections with antimicrobial resistant (AMR), particularly multi-drug resistant 
(MDR) bacteria are increasing, severely limiting therapeutic options, and representing an 
animal health issue. In addition, with potential transfer of AMR bacteria between dogs, their 
environment, humans and other animals, there may also be a public health risk. Commensal 
isolates can be a source of clinical infections and studies reporting the prevalence of AMR 
and risk factors for such isolates are important. Furthermore, one of the most significant 
impacts upon commensal bacterial populations is antimicrobial therapy that may select for 
pre-existing AMR organisms or transmission of resistance determinants. The aim of this work 
was to investigate AMR amongst canine commensal bacterial populations and the effects of 
five different antimicrobials, authorised to treat dogs in the UK, on these populations both 
during and after therapy. Three groups of dogs were enrolled: healthy non-antimicrobial 
treated, non-vet visiting dogs (n = 28), to investigate longitudinal carriage of faecal E. coli; 
healthy non-antimicrobial treated, non-vet visiting, dogs (n = 73) and antimicrobial treated, 
non-hospitalised dogs (n = 127) to investigate longitudinal carriage of mucosal staphylococci 
and faecal E. coli. Staphylococci and E. coli isolated from swabs (nose/perineum) and faecal 
samples respectively, were tested for phenotypic AMR and carriage of resistance genes by 
PCR assay. Staphylococci were assigned to species by PCR assay (nuc gene), MALDI-TOF-
MS and sequencing (tuf gene). Healthy dog E. coli underwent phylo-typing, and a selection of 
longitudinal healthy dog E. coli isolates were genotyped. Questionnaire data were used to 
formulate independent variables. Statistical analysis included Pearson’s Chi-square, survival 
analysis and multivariable logistic regression; multilevel for clustered data. The prevalence of 
meticillin-resistant (MR; 42%) and MDR staphylococci (resistant to ≥ 3 antimicrobial classes; 
34%) was high amongst healthy dogs, however MR-coagulase positive staphylococci were 
not detected. The most common species detected was S. epidermidis (52% of dogs), followed 
by S. pseudintermedius (44%). S. aureus was only detected in a small number of dogs (8%). 
Faecal E. coli with AMR to at least one tested drug (63%), MDR (30%) and AmpC-
production (16%) were prevalent in healthy dogs, however ESBL-producers (1%) were rare. 
Healthy dogs carried a predominance of phylogenetic group B1; group B2 E. coli isolates 
were less likely to have AMR while group D isolates were more likely. Carriage of E. coli 
with AMR to at least one tested drug was common and persistent, whereas MDR, AmpC- and 
ESBL-types were intermittent or transient. Genotyping revealed high intra-dog diversity with 
frequent new genotypes and resistance phenotypes detected over time. AMR staphylococci 
and E. coli were detected in more dogs following antimicrobial treatment than baseline, but 
generally returned to pre-treatment levels within three months. Eating raw meat/animal stools, 
living with other dogs/in-contact humans or pets that had been hospitalised/in-contact humans 
working with farm animals were associated with the detection of AMR canine commensal 
bacteria. In particular, following treatment with beta-lactams or fluoroquinolones there was a 
significant increase in the detection of MDR and AmpC-producing E. coli or MR- and MDR 
staphylococci, respectively. However significant differences were not detected at one month 
after the end of treatment. Antimicrobial therapy is a risk factor for antimicrobial resistant 
commensal bacteria in dogs and recovery may take up to three months after the end of 
treatment. This highlights the importance of prudent antimicrobial use and prescribing 
guidelines. However other factors, such as diet, in-contacts, co-selection and bacterial fitness 
may be involved in the carriage of resistant bacteria and should be considered.  
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1. General Introduction and Literature Review
1.1 Commensal bacteria 
Commensal microorganisms inhabit ecological niches on the body that are exposed to the 
environment (Berg, 1996), and the bacteria occupying mucous membranes and the gastro-
intestinal tract form part of the normal commensal microbiome. Canine commensal bacteria 
are generally obtained gradually from the dam during the first week of life (Allaker et al., 
1992). Commensal organisms benefit by receiving protection and nutrients from the host and 
other members of the microbiome, but are usually not detrimental to the host (Tenaillon et al., 
2010). The population density, phyla and species composition of the commensal microbiome 
is generally stable over time for a particular habitat and host (Berg, 1996). A stable 
microbiome is crucial for the health and immune status of the host and helps to provide a 
colonisation barrier against pathogens (Vollaard and Clasener, 1994). If the host is immune-
compromised or the microbiome and/or barrier function is disrupted, commensal bacteria may 
become opportunistic pathogens (Berg, 1996; von Eiff et al., 2002).  
1.2 Intestinal microbiome 
The large intestinal microbiota of humans consists of approximately 1010 to 1011 bacterial 
cells per gram of large intestinal content with more than 500 species, predominately 
anaerobes (Backhed et al., 2005; Berg, 1996; Vollaard and Clasener, 1994). Similar findings 
have been reported in dogs with 108 to 1011 intestinal bacteria per gram of dry faeces (Davis et 
al., 1977; Mentula et al., 2005; Vanhoutte et al., 2005). Bacterial species compete for 
intestinal niches, but may also be mutually beneficial providing nutrients and optimal growth 
conditions for each other (Jones et al., 2007). A stable intestinal microbiome has metabolic, 
trophic and protective functions for the host (Guarner and Malagelada, 2003). Together with 
anatomical and physiological functions of an intact gut, the microbiome provides colonisation 
resistance (Vollaard and Clasener, 1994). Mechanisms of this resistance are likely to include 
production of bacteriocins, competition for attachment sites/nutrients or stimulation of the 
immune system (Hudault et al., 2001; Tenaillon et al., 2010; Vollaard and Clasener, 1994). 
One of the most common and significant disturbances of the intestinal microbiome is 
antimicrobial therapy (Berg, 1996; Vollaard and Clasener, 1994), however fluctuations may 
also occur with disease e.g. acute enteritis or, to a lesser extent, as a result of dietary 
modifications (Guarner and Malagelada, 2003). 
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1.2.1 Escherichia coli 
The most prevalent Gram-negative aerobic bacteria (GNB) in all hosts are Escherichia coli 
(Backhed et al., 2005; Berg, 1996; Vollaard and Clasener, 1994). The gastro-intestinal tract of 
warm-blooded animals and reptiles is the main habitat of E. coli, but they also frequent 
secondary environmental habitats such as water and sediments (Berg, 1996; Gordon and 
Cowling, 2003; Savageau, 1983). The prevalence and density of E. coli in the intestine 
depends on host body size, diet, concurrent microbiota/gut morphology and retention times; 
human prevalence is > 90% (Penders et al., 2006; Tenaillon et al., 2010). In dogs, E. coli was 
reported to account for 98% of the faecal aerobic coliforms (Mentula et al., 2005). The 
intestine of all new-born hosts is colonised shortly after birth by E. coli, likely from maternal 
microbiota. The bacteria reside in and obtain nutrition from the mucous layer covering the 
intestinal epithelium, thereafter they and are shed into the lumen and are excreted in faeces 
(Poulsen et al., 1994). E. coli may contribute to colonisation resistance and inhibit the 
colonisation of further (exogenous) pathogens (Hudault et al., 2001; Tenaillon et al., 2010; 
Vollaard and Clasener, 1994).  
1.2.1.1 Faecal E. coli: an indicator of intestinal health 
E. coli is a well-characterised, widespread gut commensal and potential pathogen that is 
readily cultured from faeces (Russo and Johnson, 2003; Tenaillon et al., 2010). Faecal culture 
is an easy, cheap and non-invasive method to study the colonic bacterial microbiota to 
determine intra or inter-individual differences and investigate antimicrobial selection 
pressures (Eckburg et al., 2005; Gronvold et al., 2010; Mentula et al., 2005; Wang and 
Schaffner, 2011). Impairment of the colonisation resistance barrier (mainly composed of 
anaerobic bacteria) may result in increased detection of antimicrobial resistant E. coli 
(Vollaard and Clasener, 1994). 
1.2.1.2. Faecal E. coli: commensal and pathogen 
E. coli strains have diversified through frequent horizontal gene transfer and recombination 
events (Rasko et al., 2008; Touchon et al., 2009) and are both gut commensals and adaptable 
pathogens (Tenaillon et al., 2010). Commensal strains make up the majority of the gut E. coli 
population and occasionally cause extra-intestinal opportunistic infections in compromised 
patients. However pathogenic strains, intra-intestinal (enteric) and extra-intestinal pathogenic 
E. coli (ExPEC), are more likely to possess virulence genes that facilitate disease (Russo and 
Johnson, 2000, 2003). Virulence genes encode for factors involved in gut colonisation and 
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survival within the microbiome and possession of certain genes is likely an adaptive strategy 
to the strain’s environment and only secondarily involved in intra- and extra-intestinal 
pathogenesis (Tenaillon et al., 2010). Unlike enteric pathogenic strains, ExPEC strains may 
reside in the microbiome along with commensal E. coli and do not cause gastroenteritis. Gut 
colonisation is a pre-requisite for extra-intestinal infection, which causes a diverse range of 
clinical syndromes in humans with considerable morbidity, mortality and associated 
healthcare costs (Russo and Johnson, 2003). ExPEC are also a common cause of urinary tract 
infections in dogs (Johnson et al., 2009). 
1.2.1.3 Classification of E. coli strains by phylogenetic group 
Despite frequent recombination, the population structure of E. coli is predominantly clonal 
with division into four major phylogenetic groups (A, B1, B2 and D) (Clermont et al., 2000; 
Doumith et al., 2012). The original PCR assay to assign isolates to these groups was based on 
the combination of three marker genes: chuA (encoding the outer-membrane hemin receptor 
gene), yjaA (encoding an uncharacterised protein) and TSPE4.C2 (encoding putative lipase 
esterase) (Clermont et al., 2000). This PCR assay had 80–85% test specificity compared to 
multi-locus-sequence-typing (MLST) (Gordon et al., 2008). Doumith et al., (2012) recently 
updated this method with new primers to amplify conserved regions of the same three 
markers and glutamate decarboxylase-alpha gene (gadA), an internal control, with further 
improved specificity (~ 90%). Clermont et al., (2013) also recently updated their method to 
improve specificity and identify four additional phylo-groups: C, E, F and Escherichia cryptic 
clade I.  
1.2.1.3.1 Phylogenetic groups: characterisation and distribution 
Phylo-grouping can help characterise the genetic background, pathogenicity and antimicrobial 
resistance traits of E. coli strains (Sato et al., 2014; Tenaillon et al., 2010). Phylo-groups B2 
and D are more likely to carry virulence genes and cause extra-intestinal infections compared 
to A or B1 (Clermont et al., 2011; Johnson and Stell, 2000; Picard et al., 1999). Phylo-group 
C is closely related to group B1 (Clermont et al., 2011; Moissenet et al., 2010), while phylo-
group E is related to D (Tenaillon et al., 2010) and phylo-group F is related to B2 (Jaureguy et 
al., 2008). Novel Escherichia lineages (cryptic clades) that are genetically distinct, but 
phenotypically similar to E. coli have also been identified (Walk et al., 2009). 
The distribution of phylo-groups amongst different hosts is not random, however host-
specific strains are uncommon and segregation may depend upon both host and 
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environmental characteristics such as signalment, body mass, gut morphology, diet, level of 
hygiene and degree of domestication (Clermont et al., 2011; Escobar-Paramo et al., 2006; 
Gordon and Cowling, 2003; Gordon et al., 2005; Tenaillon et al., 2010). Generally in humans, 
phylo-group A predominates followed by groups B2, B1 and D; in animals, group B1 
predominates followed by groups A, B2 and D (Tenaillon et al., 2010).  
1.2.1.3.2 Phylogenetic groups: antimicrobial resistance 
Some genetic backgrounds appear more likely to develop antimicrobial resistance (Tenaillon 
et al., 2010). This has been reported for the less virulent non-B2 groups in humans, cattle, 
pigs and dogs (Johnson et al., 2009; Johnson et al., 2003; Moreno et al., 2008). Phylo-group 
D isolates are more likely to be resistant to fluoroquinolones, third generation cephalosporins 
(3GCR) or multiple drug classes (MDR) (Deschamps et al., 2009; Platell et al., 2011; Sato et 
al., 2014; Tamang et al., 2012). Group B2 is more likely to be susceptible (Johnson et al., 
2009; Platell et al., 2010; Platell et al., 2011; Sato et al., 2014) than the other groups, however 
antimicrobial resistance is being reported increasingly amongst B2 (ExPEC) strains (Russo 
and Johnson, 2003). 
1.2.1.4 Gut residents and transient E. coli strains 
Intestinal resident E. coli strains are adapted to the gut environment and can persist for 
months or years (Nowrouzian et al., 2001; Nowrouzian et al., 2006; Sears et al., 1950; Sears 
et al., 1956). Resident strains are defined as being detected from individual hosts on at least 
two separate occasions, at least three weeks apart (Damborg et al., 2009), or persisting for at 
least three weeks (Karami et al., 2008). Gut colonisation and persistence may be associated 
with the carriage of virulence genes encoding adherence factors, for example P fimbriae, and 
resident strains in humans are more likely to belong to phylo-group B2 than transient strains 
(Nowrouzian et al., 2006). Clermont et al., (2011b) also identified adhesion factors associated 
with animal associated non-B2 pathogenic strains. Transient strains may be acquired from the 
environment, food, water or in-contact humans or animals (Berg, 1996; Johnson et al., 2008; 
Vollaard and Clasener, 1994; Wellington et al., 2013). In most cases, they do not persist more 
than a few days or weeks and harmlessly pass through the gut (Sears et al., 1950). However, 
they may represent a reservoir of antimicrobial resistance determinants for resident bacteria 
(Wellington et al., 2013), or under antimicrobial selective pressure, they may persist for 
longer in the host (Dethlefsen et al., 2007; Edlund and Nord, 2000; Vollaard and Clasener, 
1994). 
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1.2.1.3 Diversity of E. coli population structure 
The E. coli population structure is diverse and dynamic within both the host, the host 
population, and between host species, for example animals and humans. The aetiology is 
likely to be multifactorial with host, environmental and bacterial factors all playing a role; 
possible influences include: host signalment, climate, level of hygiene, diet, health and 
immune status, bacterial phylogeny, possession of virulence factors, competing bacteria and 
antimicrobial selection pressure and resistance phenotype (Anderson et al., 2006; Damborg et 
al., 2009; Schlager et al., 2002; Tenaillon et al., 2010).   
1.3 Mucosal microbiome 
As with the gastro-intestinal microbiome, the mucosal microbiome consists of a vast number 
of micro-organisms than inhabit the skin and mucous membranes of humans and other 
animals; it has been estimated that there are ~ 1 billion bacteria per cm2 of human skin (Grice 
et al., 2008). Recent advances in molecular diagnostic methods have used sequencing of 
bacterial 16S rRNA genes to investigate the microbiome of the mucosa and skin of healthy 
dogs. This study reported a majority of Staphlyococcaceae, Oxalobacteriaceae, and 
Enterobacteriaceae families from the perineum, and Oxalobacteriaceae, Moraxellaceae 
followed by Staphlyococcaceae and Corynebacteriaceae from the nasal mucosa (Rodrigues 
Hoffmann et al., 2014). This is in agreement with the majority of previous culture based 
studies that have identified staphylococci as important commensals of the mucous membranes 
and skin of humans and other animals (Kloos, 1980; Saijonmaa-Koulumies and Lloyd, 1996). 
In humans, the diversity of the microbiome is influenced by the characteristics of the 
ecological niche, for example Staphylococcus spp. prefers m oist, humid environments (Grice 
et al., 2009). Similar findings have been reported for dogs (Saijonmaa-Koulumies and Lloyd, 
1996). In humans the most consistent microbiomes are in the ear and nasal cavity (Grice et 
al., 2009). 
The cutaneous barrier is physical, immunological and antimicrobial and together with the 
microbiome works to prevent adherence, colonisation and infection by pathogens (Elias, 
2005; Kong and Segre, 2012; Saijonmaa-Koulumies and Lloyd, 1996). The microbiome may 
be involved in competitive inhibition for adherence sites and nutrients, production of 
antimicrobial peptides and priming the local immunity (Kong and Segre, 2012). In addition, 
competitive interference has been demonstrated between CoNS (e.g. S. epidermidis) and 
CoPS (Park et al., 2011; Saijonmaa-Koulumies and Lloyd, 1995). A compromised cutaneous 
barrier, microbiome and/or immune system facilitates disease and commensal microbes may 
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become opportunistic pathogens (Pfaller et al., 2007; von Eiff et al., 2002). Atopic dermatitis 
in humans and dogs is a common cause of reduced barrier function and sufferers have 
increased carriage of staphylococci and a predilection for pyoderma (Bibel et al., 1977; 
Fazakerley et al., 2010; Mason and Lloyd, 1989; Olivry and Hill, 2001).  
1.3.1 Coagulase Positive Staphylococci (COPS) 
The ability to produce free coagulase and clot rabbit plasma differentiates species of 
staphylococci. S. pseudintermedius is the main commensal coagulase positive staphylococci 
(CoPS) of dogs, and the main cause of pyoderma (Berg et al., 1984; Ihrke, 1987; Medleau et 
al., 1986). S. aureus is the human counterpart (Mainous et al., 2006). Puppies acquire 
S. pseudintermedius from their mothers during the first week of life (Saijonmaa-Koulumies 
and Lloyd, 2002) and the main carriage sites appear to be the mucosa (nose, gingiva, oro-
pharnyx, perineum or rectum), where they are considered to be residents; licking by the dog is 
thought to spread bacteria to the skin and hair (Allaker et al., 1992; Devriese and De 
Pelsmaecker, 1987; Mason et al., 1996). These findings have been corroborated by studies 
reporting homogeneity of strains from mucosa and skin of an individual dog, but 
heterogeneity of strains between dogs (Fazakerley et al., 2010; Pinchbeck et al., 2006). In 
addition, metagenomic analysis identified greater numbers of microbial species and diversity 
from haired canine skin compared to mucosa (Rodrigues Hoffmann et al., 2014).  
The prevalence of mucosal S. pseudintermedius carriage in healthy dogs has been reported to 
be between 37% to 92% (Devriese and De Pelsmaecker, 1987; Fazakerley et al., 2010; 
Griffeth et al., 2008; Hanselman et al., 2009; Paul et al., 2012; Rubin et al., 2011), with 
increased carriage for dogs with certain skin diseases such as atopic dermatitis or pyoderma 
(Fazakerley et al., 2010; Saijonmaa-Koulumies and Lloyd, 1995). Long-term carriage of 
S. pseudintermedius may occur in humans living with dogs (Gomez-Sanz et al., 2013), 
particularly if owning more than two dogs (Walther et al., 2012).  
Fewer healthy dogs carry S. aureus (4% to 12% of dogs) (Boost et al., 2007; Fazakerley et al., 
2010; Griffeth et al., 2008; Kottler et al., 2010; Loeffler et al., 2005; Wedley et al., 2014), and 
detected isolates are likely to be of human origin (Weese and van Duijkeren, 2010). The 
longitudinal carriage of S. aureus strains in persistently colonised humans appears to be 
relatively stable over time compared to dogs with S. pseudintermedius carriage, which is 
more diverse and changing over time (Gomez-Sanz et al., 2013). S. schleiferi subsp 
coagulans has also been detected from the skin, mucosa and ears of healthy dogs (Griffeth et 
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al., 2008; Yamashita et al., 2005). Prior to re-classification of the S. intermedius group (SIG) 
in 2007, S. pseudintermedius were referred to as S. intermedius (Bannoehr et al., 2007). 
1.3.2 Coagulase Negative Staphylococci (CoNS) 
Coagulase negative staphylococci (CoNS) are common cutaneous and mucosal residents of 
humans and dogs (Kloos and Bannerman, 1994; Saijonmaa-Koulumies and Lloyd, 1996). 
They were historically considered to be apathogenic (Huebner and Goldmann, 1999), 
however they are now recognised as a significant cause of nosocomial and community-
acquired infections in humans (Barbier et al., 2010; Wertheim et al., 2005), and may also 
cause infections in dogs and other animals (Beck et al., 2012; Hauschild and Wojcik, 2007; 
Kern and Perreten, 2013). Certain CoNS species (S. epidermidis, S. saprophyticus, and 
S. lugdunensis), like CoPS, may carry virulence factors that increase their pathogenesis and 
involvement in severe human infections (Dupont et al., 2010). 
There are at least 40 described species of Staphylococcus with the majority being CoNS. 
S. epidermidis is the most common CoNS isolated from the mucosa (nares, perineum and 
inguinal skin), axillae and interdigital skin of humans (Kloos and Bannerman, 1994; 
Widerstrom et al., 2012). Numerous CoNS have been detected from dogs including 
S. schleiferi subsp schleiferi, S. epidermidis, S. haemolyticus, S. saprophyticus, S. devriesei, 
S. warneri, S. simulans, S. xylosus, S. capitis, S. caprae and S. sciuri (Bagcigil et al., 2007; 
Cox et al., 1988; Fazakerley et al., 2010; Kania et al., 2004; May et al., 2005; Medleau et al., 
1986; Wedley et al., 2014). The prevalence of nasal CoNS detection in dogs has been 
reported in one large UK cross sectional study as 38% (Wedley et al., 2014).  
1.4 Antimicrobials 
There are a limited number of antimicrobials, mostly broad-spectrum, that are authorised for 
use in companion animals in the UK. Broad-spectrum antimicrobials are active against both 
Gram-positive and Gram-negative bacteria, while narrow-spectrum antimicrobials are more 
specific. Amongst the broad-spectrum antimicrobials, beta-lactam and fluoroquinolone 
antimicrobials are commonly used and are critically important for the treatment of various 
bacterial infections in companion animals (Hughes et al., 2012; Li et al., 2007; Mateus et al., 
2011). Common use of beta-lactams in dogs has been reported in the UK (Hughes et al., 
2012; Mateus et al., 2011) and is mirrored by increased recorded sales (VMD, 2012). 
Chapter 1 General introduction and literature review 
8 
1.4.1 Antimicrobials authorised for dogs in the UK 
The majority of antimicrobials are usually administered in an oral form. Cefovecin however, 
is a long-acting subcutaneous preparation of a semi-synthetic third generation cephalosporin. 
It is authorised in Europe to use every 14 days, for the treatment of skin and urinary tract 
infections associated with a number of Gram-positive and negative bacteria (NOAH, 2014). It 
has reported efficacy in the treatment of canine pyoderma (Summers et al., 2012). The 
majority of cefovecin is excreted unchanged in the urine; however unchanged drug also 
occurs in the bile (Stegemann et al., 2006). Oral beta-lactam antimicrobials include cefalexin, 
a first generation cephalosporin that is authorised to treat susceptible bacteria causing skin 
and urinary tract infections, and clavulanate-amoxicillin, authorised to treat a broad range of 
aerobic and anaerobic bacteria associated with skin, soft tissue, dental, urinary or respiratory 
tract infections or enteritis (NOAH, 2014). Both drugs are commonly used to treat canine 
pyoderma (Damborg et al., 2011; Summers et al., 2012). Veterinary fluoroquinolones, 
including oral enrofloxacin and marbofloxacin, are broad-spectrum antimicrobials authorised 
to treat urinary tract, respiratory and skin infections. Fluoroquinolones have been used 
frequently in dogs to treat pyoderma (Guardabassi et al., 2004; Ihrke et al., 1999). 
Clindamycin, an oral lincosamide antimicrobial, is also commonly used to treat bacterial 
pyoderma and dental disease, and while it is not effective against Gram-negative aerobes it is 
very effective against anaerobes (NOAH, 2014). 
1.4.2 Mechanism of action of antimicrobials 
1.4.2.1 Beta-lactams 
Beta-lactams include penicillins and cephalosporins. Peptidoglycan is responsible for the 
structural integrity of bacterial cell walls. Formation of peptidoglycan (transpeptidation) 
involves enzymatic cross-linking of sugars and amino acids to form a crystal lattice structure. 
Peptidoglycan makes up ~ 90% of Gram-positive bacterial cell walls, and ~ 10% of Gram-
negative bacterial cell walls, which have an additional outer cell membrane. To reach the cell 
wall of Gram-negative bacteria, antimicrobials need to penetrate the outer cell membrane 
through porin channels. Beta-lactam antimicrobials inhibit cell wall synthesis by targeting 
transpeptidation. The structure of beta-lactam antimicrobials consist of a four-member ring 
(three carbon and one nitrogen atoms) that bind the enzymes responsible for catalysing cross-
linking of peptidoglycans. The enzymes are called penicillin-binding proteins (PBP’s) 
(Greene and Watson, 2006; Tipper, 1985). 
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Amoxicillin is a synthetic derivative of penicillin, with slightly less activity against Gram-
positive aerobes and anaerobes, but wider activity against Gram-negative aerobes. The 
addition of clavulanic acid, a potent inhibitor of beta-lactamase enzymes, improves the 
effectiveness of amoxicillin. Cephalosporins are divided into four classes based on chemical 
structure and therapeutic activity with decreasing activity against Gram-positive aerobes and 
anaerobes and increasing activity against Gram-negative aerobes. Cefalexin is a first 
generation cephalosporin predominantly active against Gram-positive aerobes and some 
Gram-negative aerobes including E. coli. It is more effective against anaerobes than 
amoxicillin. Third generation cephalosporins are less effective against Gram-positive aerobes 
and anaerobes but more effective against Gram-negative aerobes than first generation 
cephalosporins (Greene and Watson, 2006). Cefovecin is classed as a third generation 
cephalosporin, but its spectrum of activity is more similar to first- and second-class 
cephalosporins than third-generation (Hughes et al., 2012). 
1.4.2.2 Fluoroquinolones 
Fluoroquinolones inhibit DNA synthesis by inhibition of the enzymes DNA topoisomerase II 
(DNA gyrase) and IV, primarily DNA gyrase in GNB and topoisomerase IV in Gram-positive 
bacteria. DNA topoisomerases are involved in cutting DNA during replication to remove 
super-coils and facilitate separation of daughter DNA. The enzymes comprise two pairs of 
subunits, DNA gyrase consists of GyrA and GyrB and topoisomerase IV consists of ParC and 
ParE (E. coli) or GrlA and GrlB (staphylococci) (Hooper, 2001). Enrofloxacin and 
marbofloxacin are veterinary third generation fluoroquinolones that are mainly active against 
Gram-negative aerobes and facultative anaerobes and less so against Gram-positive aerobes. 
Activity against staphylococci is variable. Metabolism is in the liver and excretion of active 
drug or metabolites is in urine and bile. Fluoroquinolones may cause arthropathy in juvenile 
dogs and are contra-indicated during the rapid-growth phase; up to one year old in large breed 
dogs (Greene and Watson, 2006). 
1.4.2.3 Lincosamides 
Bacterial ribosomes consist of a 30S and a 50S subunit. This is the location of where mRNA 
is translated into proteins by tRNA. Lincosamides inhibit protein synthesis by binding the 50S 
ribosomal subunit and causing dissociation of tRNA from the ribosome (Tenson et al., 2003). 
Eukaryote ribosomes differ in structure from bacterial ribosomes and therefore are not 
targeted (Tenover, 2006). Clindamycin is a chloro-substituted lincomycin and is indicated to 
treat Gram-positive aerobes and obligate anaerobes. Most Gram-negative bacteria are 
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resistant. The majority of the drug is excreted in bile (Greene and Watson, 2006; Leigh, 
1981). 
1.4.3 Impact of antimicrobial therapy on the gut microbiome 
Antimicrobials may impact the gut microbiome and disrupt colonisation resistance if they are 
incompletely absorbed and reach the colon in active form, or if they are excreted in saliva, 
bile or intestinal mucus (Heimdahl et al., 1985). Suppression of the susceptible flora allows 
pre-existing, possibly undetectable, resistant isolates (either from mutation and/or from 
acquired resistant determinants) and/or ingested exogenous antimicrobial resistant bacteria to 
proliferate. In addition, therapy may trigger the bacterial stress response resulting in 
mobilisation and dissemination of resistance determinants (Donskey, 2006; Edlund and Nord, 
2000; Sullivan et al., 2001; Wellington et al., 2013). 
Early studies in healthy humans reported disturbances of the gut microflora following 
administration of amoxicillin, cefotaxime, clindamycin or co-trimoxazole with overgrowth of 
aerobic bacteria and yeasts and increased concentrations of antimicrobial resistant GNB 
(Vollaard and Clasener, 1994). Several antimicrobials are more active against anaerobes 
including clindamycin. Following treatment with this antimicrobial there was reported 
disturbance of the Bacteroides species composition for up to two years (Jernberg et al., 2007; 
Lofmark et al., 2006) and increased AMR Enterobacteriaceae for up to nine months (Nyberg 
et al., 2007). Aminopenicillins, including clavulanate-amoxicillin, were found to suppress 
some anaerobic bacteria and aerobic Gram-positive cocci and increase AMR 
Enterobacteriaceae, but with normalisation within a few weeks to months (Jernberg et al., 
2010). Both oral cephalosporins and fluoroquinolones strongly suppressed 
Enterobacteriaceae and selected for AMR amongst these bacteria, but had little impact on 
anaerobes. In addition, cephalosoporins increased aerobic Gram-positive cocci (Edlund and 
Nord, 2000; Sullivan et al., 2001). Susceptible bacteria may be protected from the 
antimicrobial in the intestinal crypts or mucous and proliferate again once the antimicrobial 
pressure is gone (Jernberg et al., 2010). 
1.4.4 Impact of antimicrobial therapy on the mucosal microbiome 
Similar to the impact on the gut microbiome, the use of antimicrobials may suppress the 
antimicrobial susceptible mucosal flora leaving a vacant niche that may be filled by pre-
existing, possibly undetected, antimicrobial resistant isolates or exogenous strains acquired 
from the environment or in-contacts. Horizontal transmission of resistant determinants during 
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therapy may not be as prominent amongst mucosal staphylococci compared with gut GNB. 
Although staphylococci do commonly possess plasmids, the main mechanism of horizontal 
gene transfer is by transduction and is species-specific. While SCCmec cassettes, associated 
with meticillin resistance, can transfer between species, they are generally less mobile than 
other MGEs (Lindsay and Holden, 2006). Furthermore, multiple chromosomal mutations, 
such as those required for clinical fluoroquinolone resistance, may take time to accumulate 
(Hacker and Carniel, 2001). 
Fluoroquinolone and beta-lactam therapy may select for fluoroquinolone or beta-lactam 
resistance amongst staphylococci directly or by co-selection (Westh et al., 2004). MRSA, 
compared to meticillin susceptible S. aureus (MSSA), are more prone to develop 
fluoroquinolone resistance following ciprofloxacin therapy in humans (Isaacs et al., 1988). 
This may be associated with the up-regulation of adhesion factors, promoting colonisation of 
resistant strains (Weber et al., 2003). In addition, fluoroquinolone resistant MRSA isolates 
may demonstrate augmented oxacillin resistance following fluoroquinolone therapy (Venezia 
et al., 2001). This may be due to a SOS response and increased mutational rates (Mamber et 
al., 1993), or by repression of mecA regulator genes and upregulation of mecA gene 
expression (Venezia et al., 2001). The extent and duration of the effect on the microbiome 
from antimicrobial therapy depends on the dose, duration, pharmacokinetics and the 
pharmacodynamics of the antimicrobial, and the level of antimicrobial resistance present 
before treatment (Edlund and Nord, 2000; Jernberg et al., 2010; Vollaard and Clasener, 
1994). 
1.5 Antimicrobial resistance 
Antimicrobial resistance amongst bacteria is not a new phenonmenom. Even before 
antimicrobials were used therapeutically, microorganisms had mechanisms to combat 
naturally produced antimicrobial substances (Piddock, 2006). However in recent years, under 
intense antimicrobial selection pressure, there has been the development and global 
dissemination of MDR amongst clinical and commensal bacteria of humans and other animals 
(Ewers et al., 2012; Gould, 2009; Hunter et al., 2010). 
1.5.1 Antimicrobial Resistance (AMR) mechanisms 
Intrinsic antimicrobial resistance (AMR) is a functional or structural trait that infers inherent 
tolerance of an entire bacterial species to one or more antimicrobials, for example 
Pseudomonas aeruginosa is intrinsically resistant to tetracycline due to lack of drug uptake 
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into the cell. Whereas acquired AMR, that is responsible for the development and spread of 
resistance amongst bacterial populations, arises from either random gene mutation or 
horizontal transfer of resistance genes. AMR mechanisms include the prevention of cell entry 
by porin channel modification, the expulsion of the antimicrobial agents out of the cell via 
efflux pumps, the inactivation of antimicrobial agents by enzymes and the modification of the 
antimicrobial target within the bacteria. Multiple mechanisms may occur together and result 
in MDR (resistance to three or more antimicrobial classes) (Magiorakos et al., 2012) and/or 
multiple mechanisms may need to occur before there is clinically significant antimicrobial 
resistance. Efflux pumps in particular are associated with MDR. Some pumps are specific for 
certain antimicrobials, for example tetracycline in E. coli, while other pumps can remove a 
variety of structurally diverse antimicrobials including antiseptics, for example 
fluoroquinolone and quaternary ammonium compounds in S. aureus (Alekshun and Levy, 
2007). 
1.5.1.1 Mobile Genetic Elements (MGEs) 
Mobile Genetic Elements (MGEs) are segments of DNA that encode factors allowing them to 
mobilise within or between genomes (Frost et al., 2005). They frequently transfer and often 
carry AMR and/or virulence genes, and are often responsible for AMR dissemination 
between bacteria. MGE’s include plasmids, transposons, staphylococcal cassette chromosome 
mec (SCCmec), integrons and bacteriophages. Plasmids are circular double stranded DNA 
that can multiply independently of chromosomal DNA and may carry one or more AMR 
and/or virulence genes. They are ubiquitous amongst bacterial cells, but usually don’t carry 
genes for essential functions, and furthermore multiple plasmids can exist within a single 
bacterium (Alekshun and Levy, 2007; Frost et al., 2005). Transposons are small fragments of 
DNA that can change their position in the genome. They are usually integrated into other 
DNA (chromosomal, other transposons, plasmids or SCCmec) and hence may facilitate the 
incorporation of one or multiple AMR genes (Tenover, 2006). SCCmec are large pieces of 
DNA that frequently carry the mecA gene encoding meticillin resistance (Hartman and 
Tomasz, 1984). They can also carry other resistance genes on transposons or plasmids. 
SCCmec are relatively stable and move infrequently compared to other MGEs. Integrons 
carry gene cassettes that encode recombination enzymes; they can carry AMR genes and may 
integrate into transposons. Another method of horizontal gene transfer is via bacteriophages, 
which are viruses that infect and replicate in bacteria. Bacteriophages may carry genes 
encoding toxins and virulence factors (Frost et al., 2005).  
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1.5.1.2 Transformation, conjugation or transduction 
Horizontal gene transfer may occur by transformation, conjugation or transduction. 
Transformation involves the uptake of free DNA or plasmids into the chromosome by some 
species of bacteria, conjugation involves the synthesis of pilli to allow passage of plasmids or 
other elements between cells, and transduction involves the packaging of DNA (chromosomal 
or MGE) into the bacteriophage head and injection into a recipient cell after the donor is 
lysed. Conjugation is however, the most common mechanism of acquired AMR in GNB such 
as E. coli and transduction in staphylococci (Lindsay and Holden, 2006; Tenover, 2006).   
1.5.1.3 Beta-lactam resistance 
Resistance to beta-lactam antimicrobials occurs via two resistance mechanisms: inactivation 
of antimicrobial agents by beta-lactamase enzymes and modification of the antimicrobial 
target site, with the former important for extended spectrum beta-lactamase resistance (ESBL) 
in Gram-negative bacteria, and the latter for meticillin resistance in staphylococci (MRS).  
1.5.1.3.1 Beta-lactam resistance: Gram-negative bacteria 
ESBL- and AmpC-producing GNB, including E. coli have emerged (Gould, 2008), and are 
increasingly detected from clinical and commensal animal samples (Ewers et al., 2012; Li et 
al., 2007). These beta-lactamase enzymes cleave the beta-lactam ring of penicillins and 
cephalosporins. ESBL enzymes hydrolyse oxyimino-cephalosporins but can be inhibited by 
clavulanic acid, whereas AmpC enzymes additionally hydrolyse cephamycins and are not 
inhibited by clavulanic acid (Bradford, 2001; Thomson, 2010). Genes encoding ESBL- 
(blaSHV, blaTEM, blaCTX-M and blaOXA) and AmpC-type (blaFOX, blaCIT, blaDHA, blaMOX, blaEBC and 
blaACC) enzymes are carried on mobile genetic elements so can be readily spread between 
bacteria by horizontal transmission (Li et al., 2007). CTX-M-type ESBL enzymes and CMY-
2 (blaCIT) AmpC- beta-lactamases are the most widespread types. They are prevalent amongst 
E. coli isolated from humans and animals, including dogs (Ewers et al., 2012; Jacoby, 2009; 
Wedley et al., 2011). 
AmpC-production may also be chromosomally mediated (Woodford et al., 2007), with the 
potential for high-level constitutive production in E. coli strains. Additionally, mutations 
encoding the loss of outer membrane porin channels and hence decreased drug uptake, may 
enhance the resistance phenotype (Jacoby, 2009). ESBL- and plasmid-mediated-AmpC-
producers are commonly MDR because of linkage to other antimicrobial resistance 
determinants on plasmids (Paterson and Bonomo, 2005), including other ESBL- and/or 
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AmpC-type genes. MDR may result in co-selection of ESBL- or AmpC-producing E. coli by 
non-beta-lactam antimicrobials (Jiang et al., 2008; Livermore and Hawkey, 2005). When 
carried together with ESBLs, AmpC-type enzymes may mask the production of ESBL-type 
enzymes complicating detection (Thomson, 2010). 
1.5.1.3.2 Beta-lactam resistance: Staphylococci 
Staphylococci may also produce beta-lactamase enzyme, encoded by the blaZ gene carried on 
plasmids, resulting in penicillin resistance. However, broad beta-lactam resistance is 
associated with an altered target site. Meticillin resistant staphylococci (MRS) carry the mecA 
gene, which encodes an altered penicillin binding protein (PBP2a) and confers resistance to 
all beta-lactam antimicrobials (Hartman and Tomasz, 1984). The mecA gene is carried on a 
large mobile genetic element (MGE), the staphylococcal cassette chromosome mec (SCCmec) 
that can be transferred horizontally (mechanism unknown) between staphylococci (Black et 
al., 2009). CoNS may be the original source of the mecA gene (Tsubakishita et al., 2010) and 
act as reservoirs for CoPS (Barbier et al., 2010; Descloux et al., 2008; Smyth et al., 2011). 
Integration of SCCmec into the host genome is usually stable and transfer occurs less 
frequently than other MGEs (Lindsay and Holden, 2006). Several SCCmec types have been 
described (Descloux et al., 2008; Perreten et al., 2013). They differ by the combination of 
resistance (mecA) and recombinase (ccr) genes that they possess, but smaller classes, for 
example SCCmec type IV, may be more easily transferred between strains and have less 
fitness cost (Lee et al., 2007). Resistance determinants for other antimicrobials may also be 
carried on SCCmec (Hiramatsu et al., 2001), or other MGEs, and chromosomal mutations 
may occur also giving rise to resistance. Hence these isolates are commonly MDR, and often 
fluoroquinolone resistant (Descloux et al., 2008). Co-selection of fluoroquinolone resistant 
MRS isolates by beta-lactams or fluoroquinolones may lead to the rapid emergence and 
persistence of these strains (Descloux et al., 2008; Weber et al., 2003; Westh et al., 2004). 
1.5.1.4 Fluoroquinolone resistance 
Fluoroquinolone resistance is due to altered bacterial target with or without reduced drug 
uptake. Spontaneous point mutations of DNA gyrase and/or topoisomerase IV genes results in 
altered antimicrobial target enzymes. Spontaneous mutations conferring various levels of 
resistance (increased MIC) are thought to occur at a frequency of 106 to 1010 cell divisions. 
Step-wise mutations confer higher levels of resistance creating a small number of bacteria 
within a large population with reduced quinolone susceptibility (Hooper, 2001). 
Fluoroquinolone selection pressure may lead to proliferation of first-step resistant mutants 
that may develop secondary mutations, further increasing the MIC. Mutations in the genes 
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encoding the DNA gyrase are important for E. coli while mutations in the genes encoding 
topoisomerase IV are important for staphylococci. Reduced drug uptake via porin channel 
modification and up-regulation of efflux pumps are conferred by chromosomal mutations. 
High-level resistance usually involves multiple mutations in DNA topoisomerase/gyrase 
genes as well as other mechanisms, such as multidrug efflux pumps (Alekshun and Levy, 
2007). 
1.5.1.4.1 Fluoroquinolone resistance: Gram-negative bacteria 
Fluoroquinolone resistance results from mutations of DNA gyrase and/or topoisomerase IV 
with or without porin modification and/or upregulation of efflux pumps. Multiple mutations 
of DNA gyrase and/or topoisomerase IV genes, or other concurrent resistance mechanisms 
are required for clinical resistance. Plasmid-mediated qnr genes encode for a protein that 
protects DNA gyrase and topoisomerase IV from fluoroquinolones. In addition, plasmid-
mediated qepA genes encode for a fluoroquinolone-specific efflux pump. Plasmid-mediated 
resistance mechanisms result in low-level fluoroquinolone resistance but are additive with 
other mechanisms for clinical resistance. In addition, strains that solely possess plasmid-
mediated mechanisms may also have a selective advantage under low fluoroquinolone 
concentrations (Alekshun and Levy, 2007; Strahilevitz et al., 2009). 
1.5.1.4.2 Fluoroquinolone resistance: staphylococci  
Fluoroquinolone resistance in staphylococci is associated with mutations of topoisomerase IV 
and/or DNA gyrase, which may be augmented by the over-expression of multidrug efflux 
pumps. Single point mutations in S. aureus strains have been associated with clinical 
resistance to ciprofloxacin. For newer fluoroquinolones, particularly dual targeting drugs, 
additional mutations are generally required (Strahilevitz and Hooper, 2005).  
1.5.1.5 Fitness costs 
In the absence of antimicrobial exposure, susceptible isolates (endogenous or exogenous) may 
out-compete resistant isolates due to the fitness cost of resistance (Andersson and Hughes, 
2010; Lenski, 1998). However, after a period of adaption, compensatory mechanisms may 
occur negating such costs (Cottell et al., 2012; Karami et al., 2008; Lofmark et al., 2008). 
Together with co-selection, this can result in long term carriage of antimicrobial resistant 
isolates and/or genes in the absence of direct antimicrobial pressure (Jernberg et al., 2010). 
1.5.2 AMR in Escherichia coli 
1.5.2.1 Prevalence of AMR E. coli in dogs 
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MDR, ESBL- and AmpC-producing E. coli have been detected in the rectum or faeces of 
healthy and hospitalised dogs (Gibson et al., 2011a, b; Guo et al., 2013; Wedley, 2012; 
Wedley et al., 2011), and have been reported to cause opportunistic infections (O'Keefe et al., 
2010; Sanchez et al., 2002; Sidjabat et al., 2006). A small number of studies have reported 
canine carriage prevalence of AMR E. coli in healthy and sick animals. AMR, MDR 
(resistance to three or more antimicrobial classes), ESBL- or AmpC-producing faecal E. coli 
were detected in 29 - 45%, 15 - 18%, 1 - 4% and 3 – 7% of healthy UK dogs (n = 183 - 581) 
respectively (Wedley, 2012; Wedley et al., 2011). Similarly, a recent Canadian study, 
investigating dogs frequenting dog-walking parks, reported AMR, MDR (resistance to two or 
more antimicrobial classes), ceftiofur resistance and cefoxitin resistance in 18%, 10%, 4% 
and 5% of dogs (n = 251) respectively (Procter et al., 2013). Ampicillin, tetracycline and 
sulfamethoxazole/trimethoprim resistance was most frequent while 4 - 5% of dogs carried 
faecal E. coli resistant to clavulanate–amoxicillin and up to 2% of dogs carried 
fluoroquinolone resistant isolates (Procter et al., 2013; Wedley et al., 2011). 
Other smaller prevalence studies include Moreno et al., (2008), that found all isolates from 
healthy Chilean dogs (n = 15) were resistant to at least one tested antimicrobial, while 3GCR 
or fluoroquinolone resistance were not detected. Damborg et al., (2011) also did not detect 
3GCR isolates in healthy dogs (n = 22) from Denmark. The dogs in both studies had not 
received antimicrobials within three to six months of sampling, but further potential risk 
factor information was not provided. Harada et al., (2011) reported a high level of MDR and 
ESBL-producing faecal E. coli (67% and 7% respectively) in pups (< 2 months old; n = 43) 
from two kennels in Japan. Although the pups had not received antimicrobials, the dams may 
have received lincomycin post-partum and in addition, extensive sharing of bacterial clones 
was demonstrated within kennels. This prevalence agrees with the findings of Costa et al., 
(2004) who reported ESBL-producing E. coli in 10% of healthy dogs (n = 39) from Portugal. 
However, Murphy et al., (2009) reported MDR (resistance to two or more antimicrobial 
classes) and AmpC-producing E. coli in 11% and 1% respectively, of healthy vet-presenting 
dogs in Canada; fluoroquinolone resistant or ESBL-producing E coli were not detected. 
Finally a study in the Netherlands identified a higher prevalence of either faecal ESBL- or 
AmpC-producing Enterobacteriaceae (45%) in healthy dogs (n = 20) (Hordijk et al., 2013). 
The treatment history of the dogs in this study was unknown and further detail about the dogs 
was not given. The reported differences in the prevalence of AMR may be due to different 
study populations, methodologies, geographical location and local antimicrobial selective 
pressures. 
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In sick dogs, including hospitalised dogs and/or dogs under antimicrobial therapy, the 
reported prevalence of AMR E. coli is higher.  Hordijk et al., (2013) detected ESBL- or 
AmpC-producing Enterobacteriaceae in 55% of diarrhoeic dogs (n = 20) in the Netherlands 
and Damborg et al., (2011) detected AmpC-producing E. coli in 62% of dogs (n = 13) 
receiving cephalosporin therapy in Denmark. Guo et al., (2013) detected fluoroquinolone 
resistant faecal E. coli in 19% (n = 123) of hospitalised dogs in an Australian referral hospital 
and Moreno et al., (2008) detected ESBL-producing E. coli in 30% of hospitalised dogs 
(n = 15) treated with enrofloxacin in Chile.  
1.5.2.2 Risk factors for AMR E. coli in dogs 
Risk factors for the detection of AMR E. coli in dogs have been reported in a small number of 
studies. Attending a dog day care, where multiple dogs are looked after together, was 
associated with the carriage of AMR E. coli, in particular ampicillin resistance (Procter et al., 
2013). This may be due to increased sharing of E. coli isolates in multi-dog situations 
(Johnson et al., 2008). In addition, consumption of commercial dry food and cooked 
homemade diets were protective against AMR and MDR faecal E. coli, possibly due to 
cooking/processing removing bacteria. Whilst large dogs of a mixed breed were more likely 
to harbour AMR E. coli than smaller mixed or pure breeds, possibly associated with lifestyle 
differences, and contact with compost was a risk factor for MDR faecal E. coli (Procter et al., 
2013), possibly due to ingestion of AMR E. coli in soil/manure/decomposing foodstuffs.  
Another study examining dogs, dog-owners and a control population of humans found the 
receipt of antimicrobials in the previous month to be associated with the detection of MDR 
(resistance to three or more antimicrobials) faecal E. coli in all participants, and drinking from 
the toilet was a risk factor for ciprofloxacin resistant faecal E. coli in dogs (Stenske et al., 
2009). 
A number of other studies have also found that antimicrobials, in particular beta-lactams or 
fluoroquinolones, may select for AMR intestinal E. coli in dogs (Gibson et al., 2011a, b; 
Gronvold et al., 2010; Lawrence et al., 2013; Moreno et al., 2008; Trott et al., 2004). 
Cefalexin was a risk factor for rectal carriage of MDR, predominantly AmpC- producing 
E. coli in hospitalised dogs (Gibson et al., 2011a), and selected for blaCMY-2  (Damborg et al., 
2011). Therapy with cefovecin selected for beta-lactam resistance and carriage of blaCMY-2 
gene (Lawrence et al., 2013) and fluoroquinolone therapy selected for fluoroquinonlone, 
ESBL-producing and MDR resistant canine faecal/rectal E. coli isolates (Gibson et al., 2011b; 
Moreno et al., 2008; Ogeer-Gyles et al., 2006). Hospitalisation was associated with increased 
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risk of acquiring MDR E. coli (Gibson et al., 2011a, b; Hamilton et al., 2013; Ogeer-Gyles et 
al., 2006). Gibson et al., (2011b) reported that cumulative veterinary admission, greater than 
or equal to four days was associated with the rectal carriage of MDR rectal E. coli in dogs. 
1.5.2.3 Longitudinal carriage of AMR E. coli in animal faeces 
There are very few studies that have examined the longitudinal shedding of AMR faecal E. 
coli in healthy dogs. One study in Denmark, reported the detection of an ESBL-producing E. 
coli on two occasions from one dog; other antimicrobial resistance profiles were not reported. 
Genotyping was also performed in this study and while one or two resident clones were 
present in 69% of dogs (n = 13), the overall E. coli population was highly diverse with 
multiple clones being detected in the majority of dogs (Damborg et al., 2009). Anderson et 
al., (2006) reported similar genotypic diversity in humans, horses and cattle in the USA, and 
in addition, found that a small number of unique AMR phenotypes persisted in some subjects 
for up to six months. Likewise Maddox, (2010) reported shedding of faecal E. coli with 
resistance to at least one antimicrobial, in healthy and hospitalised UK horses, for a median of 
188 days. 
Further studies have examined the longitudinal shedding of AMR faecal E. coli following 
antimicrobial therapy and/or hospitalisation in various animals. Trott et al., (2004), reported 
shedding of MDR faecal E. coli for up to 27 days following 21 days of enrofloxacin in a dog 
model in Australia; Cavaco et al., (2008) reported the selection of CTX-M-ESBL-producing 
faecal E. coli for up to 22 days following a three-day course of amoxicillin or oxyimino-
cephalosporins in pigs in Denmark; Gronvold et al., (2010) reported the selection of AMR 
faecal E. coli for up to two weeks after seven days of amoxicillin in dogs in Norway;  Singer 
et al., (2008) reported the selection of MDR, AmpC-producing faecal E. coli for four days 
following five-days of ceftiofur treatment in dairy cows in the USA; Damborg et al., (2011) 
demonstrated intermittent faecal shedding of CTX-M-ESBL-producing faecal E. coli for up to 
two weeks following 4 - 7 days of cefquinome in hospitalised horses in Denmark;  Boothe 
and Debavalya, (2011) reported shedding of fluoroquinolone, MDR E. coli for at least three 
weeks following one week of enrofloxacin treatment in laboratory dogs in the USA and 
Lawrence et al., (2013) reported the selection of beta-lactam resistant, AmpC-producing 
faecal E. coli at 28 days following a single injection of cefovecin in laboratory Beagles in the 
USA. Two longitudinal studies have been performed in horses under antimicrobial therapy 
with or without hospitalisation, in UK referral hospitals. Johns et al., (2012) detected AMR 
faecal E. coli in non-hospitalised horses for two weeks and in hospitalised horses for two 
months following antimicrobial treatment. Similarly, Maddox, (2010) calculated the survival 
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of MDR and ESBL-producing E. coli as a median of 61 and 22 days respectively, in both 
healthy community and previously hospitalised and antimicrobial-treated horses. 
1.5.3 AMR in staphylococci 
1.5.3.1 Prevalence of AMR staphylococci in dogs 
Meticillin resistant S. pseudintermedius  (MRSP) has been detected in 0 to 4.5% of healthy 
dogs (Griffeth et al., 2008; Hanselman et al., 2008; Hanselman et al., 2009; Kania et al., 2004; 
Murphy et al., 2009; Vengust et al., 2006; Wedley et al., 2014), and from the mucosa and/or 
skin of between 3.5 - 66% of dogs with skin infections and/or veterinary hospital admission 
from Germany, USA, or Japan (Beck et al., 2012; Griffeth et al., 2008; Kania et al., 2004; 
Kawakami et al., 2010; Nienhoff et al., 2011; Onuma et al., 2012; Sasaki et al., 2007). 
Meticillin resistant S. aureus (MRSA) has been reported to colonise up to 4% of healthy 
community-dogs in the UK, USA, Slovenia and China and up to 9% of hospitalised dogs in 
the UK, Canada and Denmark (Weese and van Duijkeren, 2010). 
Several studies have reported high prevalence of meticillin-resistant CoNS (MR-CoNS) in 
humans (Diekema et al., 2001), horses (Bagcigil et al., 2007) and livestock (Huber et al., 
2011), but there are few canine reports.  Bagcigil et al., (2007) and Vengust et al., (2006) 
detected MR-CoNS in 13% of healthy dogs (n = 100 and 200, respectively) and Malik et al., 
(2006) isolated MR–S. haemolyticus from two healthy dogs out of 252 diseased and healthy 
dogs.  
Meticillin-resistant S. schleiferi (MRSS; subsp coagulans or schleiferi) have been detected 
from the skin and ears of a small number of healthy dogs, and dogs with pyoderma or otitis 
(Griffeth et al., 2008; Kawakami et al., 2010; May et al., 2005). However, S. schleiferi has not 
yet been confirmed as a member of canine skin and/or mucosal flora. 
1.5.3.2 Risk factors for AMR staphylococci in dogs 
The main reported risk factors for the mucosal carriage of, or infection with MRS in dogs are 
antimicrobial therapy, frequent veterinary premise contact and hospital admission (Eckholm 
et al., 2013; Faires et al., 2010; Hamilton et al., 2013; Huerta et al., 2011; Lehner et al., 2014; 
Nienhoff et al., 2011; Soares Magalhaes et al., 2010; Weese et al., 2012; Windahl et al., 
2012). Similar risk factors have been reported or proposed for MRSA and MR-CoNS in 
humans (Barbier et al., 2010; Soares Magalhaes et al., 2010). In particular, risk factors for 
MRSA infections in dogs (UK, Canada and USA) included the number of previous 
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antimicrobial courses (greater than three courses in the last six months), treatment with beta-
lactams or fluoroquinolones, prolonged hospitalisation, surgical implants, intravenous 
catheterisation and contact with hospitalised humans (Faires et al., 2010; Soares Magalhaes et 
al., 2010). Hamilton et al., (2013) reported extended hospitalisation as a risk factor for MRSA 
carriage. In addition, recent studies have reported surgery, hospitalisation, frequent veterinary 
premises contact, and antimicrobial therapy and topical ear medication as risk factors for 
carriage of, or infection with MRSP in dogs from Germany, Canada and Sweden (Bergstrom 
et al., 2012; Lehner et al., 2014; Nienhoff et al., 2011; Weese et al., 2012; Windahl et al., 
2012).  Lehner et al., (2014) also reported an association between glucocorticoid therapy and 
MRSP infection, but this was not reported in a previous study (Weese et al., 2012). Eckholm 
et al., (2013) reported antimicrobial therapy and hospitalisation within the last 12 months as 
risk factors for the detection of MRS in dogs with pyoderma from the USA. Similarly, Huerta 
et al., (2011) reported the detection of MRS/beta-lactam/ fluoroquinolone resistant 
staphylococci to be associated with recurrent pyoderma in dogs that had received long-term 
antimicrobial therapy and had frequent veterinary premise contact. Furthermore MRS/MDR 
staphylococci were more likely detected from urban rather than rural dogs and MRS in male 
dogs from Spain.  
The transfer of MRS isolates has been reported to occur between individuals within 
households and veterinary clinics, and contaminated environments and clothing may facilitate 
dissemination (Laarhoven et al., 2011; Paul et al., 2011; Singh et al., 2013; van Duijkeren et 
al., 2011). 
1.5.3.3 Longitudinal carriage of AMR staphylococci in dogs 
Longitudinal studies have reported long-term carriage of MRSP in dogs of up to a year 
following infection (Laarhoven et al., 2011; Windahl et al., 2012) and the duration of 
detection was extended by three or more weeks of antimicrobial therapy to which the isolates 
were resistant (Windahl et al., 2012). However, in the absence of ongoing risk factors, MRSA 
carriage in dogs is likely to be transient (Weese and van Duijkeren, 2010). 
1.5.4 Maintenance & spread of AMR by the microbiome 
Commensal microbiotas are important in the emergence and dissemination of antimicrobial 
resistance (Wang and Schaffner, 2011). The gut microbiome in particular, with its dense 
bacterial populations, large gene pool, potentially high mutation rates (Berg, 1996) and its 
susceptibility to direct and indirect antimicrobial selection pressures, is an ideal location for 
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the development of AMR (Jernberg et al., 2010). Thus the intestinal microbiota of humans 
and other animals is the main reservoir of AMR GNB (Wellington et al., 2013) and 
potentially pathogenic microorganisms including ExPEC strains (Katouli, 2010; Vollaard and 
Clasener, 1994). 
There is evidence that both intestinal E. coli and mucosal staphylococci, including AMR or 
pathogenic isolates, are shared between in-contact humans and pets in both directions.  
Transmission is likely to occur within households, but also within veterinary premises 
(Damborg et al., 2009; Gomez-Sanz et al., 2013; Huebner and Goldmann, 1999; Johnson et 
al., 2008; Laarhoven et al., 2011; van Duijkeren et al., 2011), where extended veterinary 
hospitalisation is a risk factor for acquiring MDR E. coli, MRSA or MRSP (Hamilton et al., 
2013; Nienhoff et al., 2011).  Clinical outbreaks of extra-intestinal infections caused by MDR 
E. coli have been reported in veterinary hospitals associated with the carriage of such isolates 
(Sidjabat et al., 2006). Similarly mucosal microbiomes, particularly after exposure to health-
care environments or antimicrobial therapy, may be potential reservoirs of MRS and MDR 
staphylococci (Eckholm et al., 2013; Guclu et al., 2007; Hamilton et al., 2013; Nienhoff et al., 
2011; Salgado et al., 2003) and facilitate the clonal dissemination of strains between patients, 
staff, the environment and healthy contacts (Eveillard et al., 2004; Huebner and Goldmann, 
1999; Miller and Diep, 2008; van Duijkeren et al., 2011). 
Very few healthy people carry MRSP (0.4%) (Hanselman et al., 2009).  Zoonotic 
transmission and infection has been reported (Kempker et al., 2009), but isolation of MRSP 
from humans tends to be transient (Laarhoven et al., 2011). Carriage may be higher among 
veterinary staff, owners of infected pets and dogs with concurrent skin disease (Griffeth et al., 
2008; Ishihara et al., 2010; Kania et al., 2004; Morris et al., 2010; Paul et al., 2011; van 
Duijkeren et al., 2011); one study reported two veterinarians being MRSP-positive on two 
occasions, one month apart (Paul et al., 2011). Additionally, while the source of MRSA 
carriage in dogs is likely to be an in-contact human (Weese and van Duijkeren, 2010), owners 
and attending veterinarians of MRSA infected pets were more likely to harbour MRSA 
compared to owners and attending veterinarians of MSSA infected pets (Loeffler et al., 2010).  
1.6 Concluding summary and aims 
Canine infections with AMR, particularly MDR bacteria are increasing, severely limiting 
therapeutic options. In addition strain sharing between humans and animals represents a 
potential public health risk. Antimicrobial therapy is a risk factor for the detection of AMR 
amongst faecal E. coli and mucosal staphylococcal in humans and other animals. It has been 
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suggested that reducing antimicrobial prescriptions will reduce the emergence and spread of 
AMR bacteria and antimicrobial prescribing guidelines have proven useful in this respect. 
However, due to reduced fitness cost and co-selection, AMR strains may continue to persist. 
It is therefore important to characterise the impact of antimicrobial therapy on canine 
commensal bacterial populations to be able to make informed decisions on preventative 
strategies. In addition, microbiomes are diverse in healthy individuals and maybe influenced 
by factors such as signalment, diet, hospitalisation and contact with human health-care. This 
diversity and associated factors should be taken into account when investigating the effects of 
antimicrobial selective pressure on microbiomes.  
Firstly this work aimed to investigate the mucosal staphylococci and faecal E. coli 
populations (AMR and community structure), in non-antimicrobial treated and non-vet-
visiting healthy dogs. Previous studies have either reported shorter exclusion periods for 
antimicrobial therapy or not stipulated an exclusion period. Moreover, reports in humans 
suggest prolonged changes within gut microbiomes following antimicrobial therapy. The 
second aim of this work was to investigate the longitudinal carriage of faecal E. coli in non-
antimicrobial, non-vet-visiting healthy dogs. In particular, to investigate the stability, 
diversity and change within gut E. coli populations (AMR phenotype and genotype). One 
small longitudinal study has reported carriage of resident clones and marked diversity of 
canine gut E. coli populations, but AMR phenotypes were not reported. In addition, both 
healthy dog studies planned to investigate potential risk factors for the detection of AMR 
bacteria for consideration in further studies. The final aim of this work was to investigate 
longitudinal carriage of mucosal staphylococcal and faecal E. coli populations in dogs 
receiving different antimicrobials and to perform risk factor analysis. Antimicrobial therapy 
has been reported to select for AMR bacteria, but no other canine study has compared the 
effects of different antimicrobials, or monitored changes in AMR for three months following 
therapy.
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2. General Materials and Methods
2.1 Study populations 
2.1.1 Healthy dog cohort study 
Labrador retriever dogs were recruited on a convenience basis from two dog shows in the 
North West UK between November 2010 and June 2011; the aim was to recruit 30 dogs per 
show. Owners were approached during the shows and one healthy dog of any age was 
enrolled from each household following a clinical examination. Dogs that had received 
topical or systemic antimicrobial therapy, had been admitted to veterinary premises within the 
last 12 months, or were determined not to be healthy were excluded. All dog owners gave 
written informed consent before enrolment in this study and completed a questionnaire 
regarding potential risk factors for the carriage of antimicrobial resistant bacteria. Swabs (one 
nasal and one perineal) were taken at the time of enrolment and the owners were asked to 
collect the very next faecal sample. The University of Liverpool, School of Veterinary 
Science Ethics-Committee approved the study protocol.  
2.1.2 Healthy dog longitudinal study 
A convenience sample of staff-owned healthy dogs was recruited from the University of 
Liverpool, Leahurst Campus, between October 2011 and May 2012. Dog owners were made 
aware of the study by advertisement in a University Bulletin and by staff email. Exclusion 
criteria included antimicrobial therapy or veterinary admission within three months of 
enrolment. Dogs were excluded during the study if they became ill, were prescribed systemic 
antimicrobials or attended veterinary premises. Before enrolment, all owners read the study 
information sheets and gave written informed consent and completed a questionnaire 
regarding potential risk factors for the carriage of antimicrobial resistant bacteria. A second 
questionnaire was completed at the end of the study to detect changes in circumstances during 
the study. Owners were asked to provide a fresh faecal sample from their dog once daily for 
seven days (days 0, 1, 2, 3, 4, 5, & 6), once weekly for four weeks (days 13, 20, 27 & 34) and 
once monthly for two months (days 62 & 90). The University of Liverpool, School of 
Veterinary Science Ethics-Committee approved the study protocol in October 2011.  
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2.1.3 Antimicrobial treatment longitudinal study 
A convenience sample of dogs attending veterinary consultations at three centres including 
first opinion and referral practice, in the North West of England between June 2011 and 
September 2012 were recruited for the study if they met the inclusion and exclusion criteria. 
Inclusion criteria included diagnosis of a bacterial infection requiring systemic antimicrobial 
therapy with one of five different antimicrobials authorised for use in dogs in the UK 
(cefalexin [CFX], clavulanate-amoxicillin [AC], cefovecin [CVN], clindamycin [CD], or a 
fluoroquinolone [enrofloxacin or marbofloxacin; FL]). Exclusion criteria included 
antimicrobial therapy or veterinary admission within three months of enrolment and dogs 
aged less than 12 months old. Dogs were excluded during the study if they were prescribed a 
further course of systemic antimicrobial. The veterinarian in charge of the case determined if 
the dog required systemic antimicrobials and approached the owner of the dog regarding the 
study. Before enrolment, all dog owners read the study outline and gave written informed 
consent and completed a questionnaire regarding potential risk factors for the carriage of 
antimicrobial resistant bacteria. In addition vets completed a questionnaire regarding 
diagnosis and previous therapies and/or supplied the clinical history of each case. Samples 
were collected before starting treatment (D0), at the end of treatment (End) and at one (M1) 
and three months (M3) after the end of treatment. Swabs (one nasal and one perineal) were 
collected at the time of consultations and the owners were asked to collect the very next 
faecal sample. Questionnaires were completed at each sample point. The University of 
Liverpool, School of Veterinary Science Ethics-Committee approved the study protocol in 
June 2011.  
2.2 Specimen collection 
For all staphylococcal studies, the attending veterinarian or veterinary nurse/technician 
collected one nasal swab and one perineal swab from each dog (Copan Eswab LQ Amies 
Minitip Nylon Flocked Applicator, Appleton Woods, Birmingham, UK). The swab was 
inserted 5 mm into one nostril or rubbed on the skin of the perineum for 3 to 5 seconds, 
placed in Amies transport media and stored at 4°C. All samples were processed within 36 
hours or receipt. For all E. coli studies the owner of the dog collected a fresh faecal sample 
from the ground into a sterile universal faecal pot at the appropriate time points. Sterile 
disposable gloves were used to collect all samples. 
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2.3 Processing swab samples  
2.3.1  Staphylococcal isolation 
On receipt, the swabs and 250 µl of transport media were transferred to 3 ml of nutrient broth 
with 6.5% sodium chloride and incubated aerobically overnight at 37°C. The broth was 
vortexed and streaked onto one mannitol salt agar (MSA) plate, one oxacillin resistance 
screening agar (ORSA) plate, supplemented with 2 µg/ml of oxacillin, and one Columbia 5% 
horse blood agar (CAB) plate using disposable 5 µl sterile loops; plates were incubated 
aerobically overnight at 37°C. All media were obtained from LabM Ltd, Bury, UK. 
2.3.2 Staphylococcal isolate selection 
Where present, isolates typical of staphylococci (small to medium, pink or yellow colonies on 
MSA, blue colonies on ORSA and white or yellow colonies on CAB) were selected from all 
plates using a 5 µl sterile loop, sub-cultured onto CAB, and incubated aerobically overnight at 
37°C. All fresh cultures on CAB were subject to biochemical tests to identify staphylococci: 
1. Gram stain (Sigma-Aldrich Company Ltd., Gillingham, UK). A drop of sterile water
was placed onto a clean glass slide. A sterile toothpick was used to touch one colony
and emulsify it in the water drop. The slide was air-dried and fixed by passage
through the flame of a Bunsen burner. Gram stain was performed according to the
standard method. Staphylococci are Gram-positive (dark purple) coccoid bacteria,
usually in groups of 2 – 4 cells (X 1000 oil immersion).
1.1 Slide flooded with crystal violet stain for 30 seconds and then rinsed  
1.2 Slide flooded with Lugol’s iodine solution for one minute and then rinsed 
1.3 Slide washed briefly in acetone and rinsed 
1.4 Safranin counter stain flooded over slide for one minute and rinsed 
2. Catalase (Sigma-Aldrich Company Ltd., Gillingham, UK) test was performed by
placing one to two colonies with a 5 µl loop into a drop of 3% hydrogen peroxide
solution in a sterile petri dish. The production of bubbles is a positive reaction and
indicates that catalase is causing the formation of hydrogen and oxygen.
Staphylococci produce catalase.
3. Free coagulase production (Rabbit plasma, Pro-Lab, Bromborough, UK) was
examined by emulsifying one to two colonies with 500 µl of rabbit plasma in a sterile
2 ml eppendorf tube. The tubes were incubated at 37°C and examined once hourly for
four hours and again at 24 hours for the presence of a clot. S. aureus ATCC®25923
and S. epidermidis ATCC® 12228 were used as positive and negative controls,
respectively.
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2.3.3 Antimicrobial susceptibility testing of staphylococci 
Disc diffusion testing was performed on all staphylococcal isolates in accordance with the 
Clinical and Laboratory Standards Institute (CLSI) (CLSI, 2008). Two Mueller Hinton agar 
plates with 5% defibrinated horse blood were inoculated with each isolate homogenised in 
saline (0.5 McFarland standards) for semi-confluent growth using a cotton swab and rotary 
plating device. Ten antimicrobial discs were then applied to the surface: 1 µg oxacillin (OX), 
1 µg ciprofloxacin (CIP), 10 µg gentamicin (GM), 10 µg fusidic acid (FA), 30 µg cefalexin 
(CFX), 30 µg cefovecin (CVN), 25 µg trimethoprim-sulfamethoxazole (TS), 10 µg 
tetracycline (Tet), 2 µg clindamycin (CD) and 5 µg vancomycin (Va) (Oxoid, Basingstoke, 
UK). The plates were incubated aerobically at 35°C for 16 to 18 hours for all discs other than 
oxacillin and vancomycin, which were incubated for 24 hours. The diameter in millimetres of 
the zone of inhibition for each antimicrobial disc was recorded. Micro-dilution susceptibility 
testing1 (Trek Diagnostic Systems, Cleveland, Ohio, USA) was performed on a subset of the 
CoNS isolates, using the same antimicrobial panel, other than vancomycin (CLSI, 2008). 
Interpretation was based on the CLSI guidelines for animal species-specific zone diameter 
(mm) interpretive standards and minimal inhibitory concentration (MIC; mg/l) breakpoints 
for veterinary pathogens or human-derived interpretive standards when available. The 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) zone diameter 
interpretive standards and MIC breakpoints were used for CIP and FA (EUCAST, 2013). The 
breakpoints used for interpretation of OX resistance were a zone of inhibition of ≤ 17 mm and 
MIC ≥ 0.5 mg/l for S. pseudintermedius and CoNS, and ≤ 10 mm and MIC ≥ 4 mg/l for S. 
aureus (Bemis et al., 2009; CLSI, 2013). The breakpoints used for interpretation of resistance 
to CVN were as a zone of inhibition of ≤ 19 mm and MIC ≥ 8 mg/l in accordance with the 
manufacturer’s recommendations. The reference strain S. aureus ATCC®25923 (LGC 
Standards, Teddington, UK) was used for quality control for MIC and zone diameter 
determinations. 
2.3.4 Isolate storage and DNA extraction 
Isolates were stored at − 80°C in Microbank vials (Pro-Lab, Bromborough, UK) and 
recovered by inoculation of one bead onto CAB with overnight aerobic incubation at 37°C. 
To extract DNA, one fresh staphylococcal colony was homogenised in 90 µl of sterile 
distilled water (SDW) and 10 µl of lysostaphin (1 mg/ml; Sigma-Aldrich Company Ltd., 
Gillingham, UK) and vortexed for 5 seconds. The suspensions were then incubated at 37°C 
1
Micro-dilution susceptibility testing was performed by Cindy Lindeman (Zoetis, Kalamazoo, Michigan, USA)
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for 10 minutes and heated at 100°C for 10 minutes before adding 400 µl of SDW. DNA 
extractions were stored at 4°C before use. 
2.4  Processing faecal samples 
2.4.1   Escherichia coli isolation 
Faecal samples were mixed with an equal volume of brain heart infusion broth containing 5% 
glycerol (BHI-G) on receipt. Each faecal homogenate was streaked, using a 5 µl sterile loop, 
onto one eosin methylene blue agar (EMBA) plate without antimicrobials, one EMBA plate 
impregnated with 1 µg/ml ceftazidime (CZ) and one EMBA plate impregnated with 1 µg/ml 
cefotaxime (CX) (Sigma-Aldrich Company Ltd, Gillingham, UK) (Liebana et al., 2006), to 
obtain single colonies. In addition, to detect antimicrobial resistant isolates, one EMBA plate 
and one MacConkey agar (MAC) plate were inoculated with the faecal homogenate, using a 
cotton swab and a rotary plating device, for confluent bacterial growth (Bartoloni et al., 
2006). Seven antimicrobial discs were applied to the surface: 10 µg ampicillin, 30 µg 
clavulanate-amoxicillin, 1 µg ciprofloxacin, 30 µg chloramphenicol, 30 µg nalidixic acid, 30 
µg tetracycline and 2.5 µg trimethoprim (MAST Group Ltd., Liverpool, UK). A further 500 
µl of faecal homogenate was enriched in 4.5 ml of buffered peptone water.  All plates and 
broths were incubated aerobically for 18 to 20 hours at 37°C. If there had been no growth on 
the EMBA plates impregnated with third generation cephalosporins, the enriched broths were 
streaked onto EMBA plates impregnated with 1 µg/ml ceftazidime (CZ) and one EMBA plate 
impregnated with 1 µg/ml cefotaxime (CX) and incubated aerobically for 18 to 20 hours at 
37°C.  
2.4.2 Escherichia coli isolate selection 
Random colonies (3 or 10 depending on the study) were selected from the plain EMBA plate 
if there morphology resembled E. coli (medium sized metallic green colonies).  If present, 
colonies growing within the zone of inhibition around each antimicrobial disc on the EMBA 
and MAC plates (medium sized pink colonies) and from the CX and CZ plates were selected. 
The selected colonies were streaked, using a 5 µl sterile loop, onto nutrient agar and incubated 
aerobically for 18 to 20 hours at 37°C. Gram stain and biochemical tests to detect E. coli were 
performed. 
1. Gram stain was performed as for staphylococci. E. coli are Gram-negative (pink) rod-
shaped bacteria (X 1000 oil immersion).
2. Catalase production was tested as for staphylococci. E. coli produce catalase.
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3. Oxidase activity was tested by streaking colonies, using a 5 µl sterile loop, onto filter
paper soaked with oxidase reagent (TestOxidase Reagent; PRO-LAB Diagnostics,
Neston, UK). Oxidase production causes a blue colour change within 30 seconds.  E.
coli are negative for oxidase activity. Pseudomonas aeruginosa was used as a
positive control.
4. Lactose fermentation was investigated by streaking colonies onto a MacConkey agar
plate incubated aerobically overnight at 37°C. E. coli ferment lactose in the media
and produce dark pink colonies.
5. Indole production was investigated by streaking colonies onto a Tryptone Soy Agar
(TSA) plate incubated aerobically overnight at 37°C.  A small piece of filter paper
soaked in Kovac’s reagent (bioMerieux, Marcy l’Etoile, France) was added to the
colonies. A pink colour change within 30 seconds indicated indole production. E. coli
produce indole.
6. Citrate use as a carbon source was investigated by streaking colonies onto a
Simmon’s Citrate Agar (SCA) plate incubated aerobically overnight at 37°C. E. coli
do not use citrate as a carbon source. They do not grow well and do not change the
colour of the media from green to blue.
Isolates identified as E. coli by Gram stain and biochemical tests underwent PCR assay for 
the uidA gene for confirmation (McDaniels et al., 1996). 
2.4.3 Antimicrobial susceptibility testing 
Antimicrobial susceptibility disc diffusion testing was performed on all E. coli isolates 
according to the British Society for Antimicrobial Chemotherapy guidelines (BSAC; Version 
11.1 May 2012) (Andrews, 2007). Half a 5 µl sterile loop of fresh isolates, taken from 
nutrient agar plates, were homogenised in 3 ml of sterile distilled water (SDW) (0.5 
McFarland standard) and diluted 1:10 before inoculating one Iso-Sensitest agar plate for 
semi-confluent bacterial growth with a cotton swab and rotary plate device. Seven 
antimicrobial discs were applied: 10 µg ampicillin (Amp), 30 µg clavulanate-amoxicillin 
(AC), 1 µg ciprofloxacin (Cip), 30 µg chloramphenicol (Chl), 30 µg nalidixic acid (Nal), 
30 µg tetracycline (Tet) and 2.5 µg trimethoprim (Tm). After the plates were incubated 
aerobically at 37°C for 18 to 20 hours, the zone diameters around each disc were measured in 
millimeters and recorded. Isolates were categorised as susceptible or resistant based on 
published BSAC guidelines. Isolates with intermediate resistance were classified as 
susceptible. E. coli ATCC® 25922 (LGC Standards, Teddington, UK) cultured overnight on 
nutrient agar at 37°C was used as a control.  
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2.4.4 Phenotypic detection of ESBL- and AmpC-producing E. coli 
Isolates that were resistant to third generation cephalosporins (3GCR) were tested for the 
production of extended spectrum beta-lactamase enzymes (ESBL). One to two fresh colonies 
from nutrient agar were emulsified in 3 ml of SDW (0.5 McFarlands) and an Iso-Sensitest 
agar plate was inoculated for confluent bacterial growth with a cotton swab and rotary plating 
device. Three pairs of third generation cephalosporin discs (with and without clavulanic acid) 
were placed on the surface of the agar plate: 30 µg ceftazidime and 30 µg ceftazidime plus 
10 µg clavulanic acid; 30 µg cefotaxime and 30 µg cefotaxime plus 10 µg clavulanic acid; and 
30 µg cefpodoxime and 30 µg cefpodoxime plus 10 µg clavulanic acid. The plates were 
incubated aerobically at 37°C for 18 to 20 hours and zone diameters around each disc were 
measured and recorded. ESBL production was confirmed when the zone around the 
cephalosporin disc was expanded in the presence of the clavulanic acid by a minimum of 5 
mm for ≥ 1 antimicrobial pairs, according to the manufacturer’s instructions (Extended 
Spectrum Beta-Lactamase Set D52C, MAST Group Ltd., Liverpool, UK) (M'Zali et al., 
2000). E. coli isolates that were resistant to 3GCR or clavulanate-amoxicillin were tested for 
production of AmpC enzyme. An Iso-Sensitest agar plate was inoculated for confluent 
bacterial growth and three discs applied: 10 µg cefpodoxime plus AmpC inducer (A); 10 µg 
cefpodoxime, AmpC inducer plus ESBL inhibitor (B); 10 µg cefpodoxime, AmpC inducer, 
ESBL inhibitor plus AmpC inhibitor (C). The plates were incubated aerobically at 37°C for 
18 to 20 hours and zone diameters around each disc were measured and recorded. AmpC 
production was confirmed when the zone of inhibition around disc C was disc was greater 
than discs A and B by a minimum of 5 mm, according to the manufacturer’s instructions 
(AmpC detection set D69C, MAST Group Ltd., Liverpool, UK) (Halstead et al., 2012). 
E. coli ATCC® 25922 (LGC Standards, Teddington, UK) cultured overnight on CAB at 37°C 
was used as a control. 
2.4.5 Conjugation experiments 
The ability of E. coli isolates to transfer antimicrobial resistance determinants was tested as 
previously described (Karczmarczyk et al., 2011). Rifampin-resistant, lactose-negative strain 
E. coli 26R793 served as a recipient in the assays. Overnight cultures of the donor and 
recipient strains grown in 5 ml of nutrient broth at 37°C were mixed and re-incubated at 37°C 
for 18 hours. The transconjugants were selected by streaking broths onto MacConkey agar 
supplemented with 100  µg/ml rifampin (Sigma-Aldrich) along with either 50 µg/ml 
ampicillin, 50 µg/ml nalidixic acid, 30 µg /ml tetracycline, 50 µg/ml trimethoprim or 1 µg/ml 
of cefotaxime (Sigma- Aldrich, UK). If present, up to three lactose-negative colonies were 
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selected from each plate, using a 5 µl sterile loop, onto nutrient agar. Plates were incubated at 
37°C for 18 hours.  
2.4.6 Isolate storage and DNA extraction 
All confirmed E. coli isolates were stored at – 80°C in Microbank vials (Pro-Lab, 
Bromborough, UK) and recovered as described for staphylococci, but onto nutrient agar. Cell 
lysates were prepared by adding three colonies of each isolate into 500 µl of SDW to yield a 
0.5 McFarland standard and then vortexed. The suspensions were then heated at 100°C for 10 
minutes and the supernatants were stored at 4°C before analysis. 
2.5 Polymerase Chain Reaction (PCR) assays 
PCR assays were used in this work to investigate the carriage of resistant genes, determine 
phylogenetic groups or species of bacterial isolates. The exact PCR assays, primers, 
conditions and references are detailed in individual chapters and appendices.  
2.5.1 PCR substrates 
All the PCR assays, other than for the nuc or tuf genes, were performed with 5 µL of bacterial 
DNA extract, 5 pmol of each primer, 4 µL of 5x FIREPol® Master Mix (12.5 mM MgCl2) 
(Solis-Biodyne, Tartu, Estonia) and RNase-free water made up to a total reaction volume of 
25 µL. For multiplex assays, 0.5 µl of FIREPol® DNA Polymerase 5 U/µl was added per 
reaction (Solis-Biodyne, Tartu, Estonia). PCR assays for the nuc gene were performed in a 
reaction volume of 25 µl, consisting of 5 µl of bacterial DNA extract, 12.5 µl of master mix 
(Qiagen® Multiplex PCR Mix; Qiagen, Crawley, UK), 2.5 µl of 10x primer mix (2 µM of 
each primer) and 5 µl of RNase-free water. Positive control strains were included and 
molecular grade water (Sigma-Aldrich Company Ltd., Gillingham, UK) was used as the 
negative control. All primers were synthesised by Eurofins MGW Operon (Ebersberg, 
Germany). All PCR reactions were performed using ABI 2720 Thermal Cycling Machines 
(Applied Biosystems, UK). 
2.5.2 Visualisation of PCR products 
PCR products were analysed by agarose gel (1.5% or 2%) electrophoresis. Agarose gels (35 
to 400 ml) were made using Hi-pure EEO agarose (Biogene, Cambridge, UK) in 1 x Tris-
acetate EDTA (TAE) buffer (Sigma-Aldrich), with an appropriate volume of peqGREEN (4 –
 6 µl per 100 ml of agarose; Peqlab, Fareham, UK). A 100 base pair ladder (10 µl; Solis-
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Biodyne, Tartu, Estonia) was loaded into the first well. Products (10 µl) were loaded into the 
wells in groups of 24 followed by ladder. Larger gels (400 mls) were run in 1 x TAE buffer at 
a potential difference of 150V and a current of 400mA for 90 minutes; large gels (250 mls) at 
120V, 400mA for 60 to 90 minutes; medium gels (150 mls) at 120V, 400mA for 60 to 75 
minutes and small gels (35 ml) at 100V, 400mA for 45 to 60 minutes. PCR products were 
visualised using UviTec Gel Documentation system (UVItec, Cambridge, UK) under 
ultraviolet (UV) transillumination and images were saved with UVIProMV computer 
program (UVItec). 
2.6 MALDI-TOF-MS identification of staphylococci 
The extraction method was performed as previously described (Alatoom et al., 2011). One to 
three colonies from overnight staphylococcal cultures grown on CAB at 37°C were 
homogenised in 300 µl of molecular grade water (Sigma-Aldrich Company Ltd., Gillingham, 
UK) in sterile 1.5 ml eppendorf tubes (Starlab (UK) Ltd., Milton Keynes, UK). The 
suspensions were mixed with 900 µl of absolute ethanol (Sigma-Aldrich Company Ltd., 
Gillingham, UK) and then centrifuged at 13,000 rpm for 2 minutes. The supernatant was 
discarded and the centrifugation repeated. The remaining supernatant was removed, and the 
pellets dried at room temperature. Depending on the pellet size, 10 to 30 µl of formic acid 
(Sigma-Aldrich Company Ltd., Gillingham, UK) was added to the pellet. After 2 minutes the 
same volume of acetonitrile (Sigma-Aldrich Company Ltd., Gillingham, UK) was added 
gently and the tubes were again centrifuged at 13,000 rpm for 2 minutes. Each target plate 
(MSP 96 well polished steel; Bruker, Bremen, Germany), was spotted in duplicate with 
1 µl of each isolate extract and allowed to air dry before overlaying with 1 µl of HCCA 
matrix portioned (α-cyano-4-hydroxycinnamic acid; Bruker, Bremen, Germany), according to 
the manufacturer’s instructions. After air-drying, the target plate was inserted into the mass 
spectrometer for analysis. The bacterial test standard (E. coli DH5 alpha, Bruker, Bremen, 
Germany) was used for calibration before each experiment and included in duplicate on each 
target plate. Raw spectra were analysed by the MALDI Biotyper 2.0 software programme 
with default settings (Bruker Daltonics, Bremen, Germany) and the mass peak profiles were 
matched to the reference database and a score generated based on similarity. A positive 
identification to species level was made for single result > 2.0 or duplicate results > 1.8 
(Carpaij et al., 2011).  
2.7 Sequencing for the tuf gene 
PCR amplification and sequencing of the tuf gene is recommended for CoNS assignment to 
species (Carpaij et al., 2011; Heikens et al., 2005). Initial PCR assays were performed using 
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HotStarTaq® Master Mix Kit (Qiagen, Crawley, UK) in a 25 µl reaction volume with an 
initial activation step at 95°C for 15 minutes followed by 35 cycles of 95°C for 30 seconds, 
55°C for 30 seconds and 72°C for 30 seconds, with a final extension step of 72°C for 5 
minutes, according to the manufacturer’s protocol. The resulting amplicons were sequenced 
using BigDye Terminator version 1.1 cycle sequencing (Applied Biosystems, Foster City, 
CA, USA), according to the manufacturer’s protocol on the ABI3131 genetic analyser at the 
Department of Microbiology, Royal Liverpool University Hospital2. The sequences were 
aligned using the ABI Sequencing analysis software, with contiguous sequences matched to 
the GenBank database using the Basic Local Alignment Search Tool (BLAST) (Altschul et 
al., 1990) and positively identified if there was ≥ 98% sequence similarity with a reference 
sequence. S. epidermidis ATCC® 12228 was used as the control strain. 
2.8 Macro-restriction pulsed field gel electrophoresis (PFGE) 
Macro-restriction PFGE was performed on a selection of E. coli isolates in accordance with 
standard operating procedure for PULSNET PFGE of Escherichia coli O157:H7, Escherichia 
coli Non-O157 (STEC), Salmonella serotypes, Shigella Sonnei and Shigella Flexneri (Ribot 
et al., 2006), with minor changes.  
2.8.1 Preparation of agarose plugs 
Half a plate of E. coli culture, grown overnight on nutrient agar, was emulsified in 2 ml of 
cell suspension buffer (CSB; 100 mM Tris, 100 mM EDTA [pH 8.0]), and 200 µl of this 
suspension was added to 180 µl of CSB and vortexed. This 1:10 dilution was used to 
determine the optical density (OD) at 610 nm using a spectrophotometer (Anthelie Advanced 
2; Secomam, Ales, France) and 200 µl of the original suspension was diluted with CSB to 
OD610 of 1.35, added to 1.5 ml eppendorf tubes containing 10 µl Proteinase K (20 mg/ml), 
and mixed by pipette. Fresh agarose (1% Bio-Rad PFGE-grade agarose and 1% sodium 
dodecyl sulfate in Tris EDTA buffer [10 mM Tris, 1 mM EDTA; pH 8.0]) was prepared, 
added to the eppendorf tube, and gently mixed by pipette before filling duplicate plug molds. 
The moulds were placed in 4°C for 15 minutes to set and then the plugs were transferred to 
bijouxs containing 3 ml of cell lysis buffer (CLB; 50 mM Tris, 50 mM EDTA [ph 8.0]; 1% 
Sarcosyl) with 15 µl of Proteinase K. The bijouxs were incubated at 54°C for 2 hours with 
shaking (175 rpm). The plugs were then rinsed with sterilised purified water, preheated to 
54°C, and re-incubated at 54°C for 15 minutes with shaking (175 rpm). This process was 
performed three times. After the final incubation, the plugs were rinsed with TE buffer 
2
Sequencing of the tuf gene was performed by Caroline Corless (Royal Liverpool University Hospital, UK)
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(10 mM Tris, 1 mM EDTA [pH 8.0]), preheated to 54°C, and re-incubated at 54°C for 15 
minutes with shaking (175 rpm). This process was repeated four times. 
2.8.2 XbaI restriction digest 
The plugs were transferred to 2 ml eppendorf tubes with 200 µl of 1 x dilution of XbaI 
restriction buffer (Roche, Mannheim, Germany) and incubated at 37°C for 15 minutes. The 
buffer was removed and replaced with 200 µl of restriction buffer with 50U of XbaI before 
further incubation at 37°C for 2 hours. 
2.8.3 Gel electrophoresis 
XbaI digested genomic DNA was analysed in 1% Bio-rad agarose gel in 0.5 x TBE buffer. 
Three quarters of the plug was inserted into each well with Lambda DNA marker (New 
England Biolabs, Ipswich, MA, USA) at the start, middle and end. The plugs were sealed 
with liquefied 1% agarose before the gel was placed into the CHEF-DRIII PFGE system 
(Bio-Rad, Hercules, CA, USA) containing 2 litres of 0.5 x TBE buffer and run at 14°C for 20 
hours (initial switch 2.2seconds, final switch 54.2 seconds, with a gradient of 6 V/cm2 and 
angle of 120°). Gels were stained in 0.5 x TBE containing 200 µl of ethidium bromide for 25 
minutes, visualised under UV transillumination as above, and image files were saved. Isolates 
were considered to be the same genotype if there was less than three bands difference in their 
banding pattern (Tenover et al., 1995). 
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Summary 
Background: Coagulase-positive (CoPS) and coagulase-negative (CoNS) staphylococci are 
normal commensals of the skin and mucosa, but are also opportunist pathogens. Meticillin-
resistant (MR) and multidrug-resistant (MDR) isolates are increasing in human and veterinary 
healthcare. Healthy humans and other animals harbour a variety of staphylococci, including 
MR-CoPS and MR-CoNS.  
Objectives: The main aim of the study was to characterise the population and antimicrobial 
resistance profiles of staphylococci from healthy non-vet visiting and non-antimicrobial 
treated Labrador retrievers in the UK.  
Methods: Nasal and perineal samples were collected from 73 Labrador retrievers. 
Staphylococci were isolated and identified using phenotypic and biochemical methods. They 
were also confirmed by matrix-assisted laser desorption ionisation time-of-flight mass 
spectrometry (MALDI-TOF-MS), PCR of the nuc gene and PCR and sequencing of the tuf 
gene. Disc diffusion and minimum inhibitory concentration (MIC) susceptibility tests were 
determined for a range of antimicrobials.  
Results: In total, 102 CoPS (S. pseudintermedius n = 91; S. aureus n = 11) and 334 CoNS 
isolates were detected from 99% of dogs in this study. In 52% of dogs CoNS only were 
detected, with both CoNS and CoPS detected in 43% dogs and CoPS only detected in 4% of 
dogs. Antimicrobial resistance was not common among CoPS, but at least one MDR-CoNS 
isolate was detected in 34% of dogs. MR-CoNS were detected from 42% of dogs but no MR-
CoPS were isolated.  S. epidermidis (52% of dogs) was the most common CoNS found 
followed by S. warneri (30%) and S. equorum (27%), with another 15 CoNS species isolated 
from ≤ 15% of dogs. S. pseudintermedius and S. aureus were detected in 44% and 8% of dogs 
respectively. 
Conclusions: MR- and MDR-CoPS were rare. However a high prevalence of MR- and MDR-
CoNS was found in these dogs, even though they had no prior antimicrobial treatment or 
admission to veterinary premises. These findings are of concern due to the potential for 
opportunistic infections, zoonotic transmission and transmission of antimicrobial resistant 
determinants from these bacteria to coagulase positive staphylococci. 
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1. Introduction
Staphylococci are normal commensal bacteria of the skin and mucous membranes of humans 
and other animals. They can be differentiated by their ability to produce coagulase, with 
coagulase positive (CoPS) staphylococci regarded as more pathogenic than coagulase 
negative (CoNS) species (Devriese et al., 2005; Kloos, 1980; Kloos and Bannerman, 1994; 
Rich, 2005; von Eiff et al., 2002). 
Healthy humans and other animals may harbour multiple species and strains of staphylococci. 
Staphylococcus aureus is the main human commensal CoPS species and is carried in the nasal 
cavity of approximately 30% of healthy humans (Mainous et al., 2006). S. epidermidis is the 
most common CoNS isolated from the nares, perineum, inguinal skin, axillae and interdigital 
skin of humans (Huebner and Goldmann, 1999; Kloos and Bannerman, 1994). The main 
commensal CoPS of dogs, S. pseudintermedius (Berg et al., 1984), has been isolated from 
37% to 92% of healthy dogs (Devriese and De Pelsmaecker, 1987; Fazakerley et al., 2010; 
Griffeth et al., 2008; Hanselman et al., 2009; Paul et al., 2012; Rubin et al., 2011), while S. 
aureus is carried by 4.3% to 12% of healthy dogs (Boost et al., 2007; Fazakerley et al., 2010; 
Griffeth et al., 2008; Kottler et al., 2010; Loeffler et al., 2005; Pinchbeck et al., 2006; Sasaki 
et al., 2007; Wedley et al., 2014). Other species isolated from the mucosa and skin of healthy 
dogs include the CoPS, S. schleiferi subspecies coagulans (Griffeth et al., 2008; Yamashita et 
al., 2005) and numerous CoNS (S. schleiferi subspecies schleiferi, S. epidermidis, 
S. haemolyticus, S. saprophyticus, S. devriesei, S. warneri, S. simulans, S. xylosus, S. capitis, 
S. caprae, and S. sciuri) (Bagcigil et al., 2007; Cox et al., 1988; Fazakerley et al., 2010; Kania 
et al., 2004; May et al., 2005; Medleau et al., 1986; Wedley et al., 2014). The carriage rate of 
CoNS isolated from the nasal mucosae of healthy dogs was reported to be 38% in one large 
cross-sectional study (Wedley et al., 2014). 
Staphylococci are frequent opportunistic pathogens and commensal isolates are the most 
common source of infection in humans (von Eiff et al., 2002) and dogs (Bannoehr and 
Guardabassi, 2012; Fazakerley et al., 2010; Pinchbeck et al., 2006). Antimicrobial resistance 
can increase the morbidity, mortality and treatment cost of staphylococcal infections. 
Meticillin (oxacillin) resistance associated with carriage of the mecA gene confers resistance 
to all beta-lactam antimicrobials (Hartman and Tomasz, 1984). The mecA gene is located on a 
large mobile genetic element, the staphylococcal cassette chromosome mec (SCCmec), 
enabling horizontal transmission between staphylococcal isolates (Black et al., 2009). 
Meticillin resistant staphylococci (MRS) are important pathogens in human and veterinary 
healthcare and are often multi-drug resistant (MDR; resistant to three or more classes of 
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antimicrobial) (Diekema et al., 2001; Garza-Gonzalez et al., 2011; Hryniewicz, 1999; 
Loeffler et al., 2007; Perreten et al., 2010; Weese and van Duijkeren, 2010), extremely 
limiting therapeutic options. Meticillin resistant S. pseudintermedius (MRSP) clones with a 
broader resistance spectrum than meticillin resistant S. aureus (MRSA) or MR-CoNS are 
increasingly reported in domestic animals throughout Europe, USA and Canada (Loeffler et 
al., 2007; Perreten et al., 2010). MR-CoNS are associated with infections in humans and 
animals (Diekema et al., 2001; Hauschild and Wojcik, 2007; Kern and Perreten, 2013). In 
humans the most prevalent species is MR-S. epidermidis (MRSE), which may be a reservoir 
of mecA for S. aureus (Barbier et al., 2010; Smyth et al., 2011). In addition, the SCCmec 
cassette of the major European MRSP clone (ST71-J-t02-II–III) (Perreten et al., 2010) 
consists of a combination of SCCmec II from MRSE and SCCmec III from MRSA (Descloux 
et al., 2008). 
The prevalence of MRSA and MRSP carriage in healthy humans and dogs in the community 
is low (Abudu et al., 2001; Boost et al., 2007; Hanselman et al., 2009; Loeffler et al., 2010; 
Sa-Leao et al., 2001; Shopsin et al., 2000; van Duijkeren et al., 2011; Zanelli et al., 2002). 
However, human community-based surveys report a wider range of carriage rates for MR-
CoNS (11–50%) (Barbier et al., 2010; Lebeaux et al., 2012; Silva et al., 2001). MR-CoNS 
have also been isolated from the carriage sites of 13% of healthy dogs (Bagcigil et al., 2007; 
Vengust et al., 2006). The reported prevalence of MRS is higher in animals exposed to 
veterinary healthcare environments and antimicrobial therapy (Bergstrom et al., 2012; Huerta 
et al., 2011; Loeffler et al., 2010; Nienhoff et al., 2011) suggesting that these are risk factors 
for colonisation.  
Previous studies looking at the commensal staphylococci in dogs have concentrated on CoPS 
species, particularly MR-CoPS species, the CoNS group or MR-CoNS species (Bagcigil et 
al., 2007; Devriese and De Pelsmaecker, 1987; Griffeth et al., 2008; Hanselman et al., 2009; 
Loeffler et al., 2005; Paul et al., 2012; Rubin et al., 2011; Vengust et al., 2006), but no study 
has characterised the complete canine commensal staphylococcal population. Moreover, 
reporting of the antimicrobial treatment history of dogs in these studies has been inconsistent. 
The aim of this study was to characterise the mucosal staphylococcal population structure and 
antimicrobial resistance profiles in healthy Labrador retrievers in the UK in the absence of 
antimicrobial pressure. This will be important in understanding changes in staphylococcal 
populations and their antimicrobial susceptibility patterns in dogs exposed to antimicrobials 
and other risk factors.  
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2. Materials and Methods 
2.1 Study Population 
 
Labrador retriever dogs were recruited for the study from dog shows in the North West of 
England between November 2010 and June 2011. One healthy dog was enrolled from each 
household if the dog had not received topical or systemic antimicrobial therapy, or had not 
been admitted to a veterinary clinic within the last 12 months. All dog owners gave written 
informed consent before enrolment in this study and completed a questionnaire regarding 
potential risk factors for the carriage of antimicrobial resistant bacteria (Appendix I). The 
University of Liverpool, School of Veterinary Science ethics committee approved the study 
protocol.  
 
2.2 Specimen collection and bacterial isolation 
 
One nasal swab and one perineal swab were collected from each dog (Copan Eswab LQ 
Amies Minitip Nylon Flocked Applicator, Appleton Woods, Birmingham, UK). A sterile 
swab was either inserted 5mm into one nostril or rubbed on the skin of the perineum for 3–5 
seconds before being placed in Amies transport media, stored at 4˚C and processed within 36 
hours. Swabs were incubated aerobically overnight at 37˚C in nutrient broth with 6.5% 
sodium chloride. The broth was streaked onto Mannitol Salt Agar (MSA), Oxacillin 
Resistance Screening Agar (ORSA) supplemented with 2 µg/ml of oxacillin and Columbia 
5% horse Blood Agar (CAB), and incubated aerobically overnight at 37˚C. Where present, 
isolates typical of staphylococci were selected from all plates, sub-cultured onto CAB and 
incubated aerobically overnight at 37˚C. Fresh staphylococcal cultures on CAB were subject 
to Gram stain (Sigma-Aldrich Company Ltd., Gillingham, UK), tested for catalase (Sigma-
Aldrich Company Ltd., Gillingham, UK) and free coagulase production (Rabbit plasma, Pro-
Lab, Bromborough, UK) according the manufacturer’s instructions and stored at -80˚C in 
Microbank vials (Pro-Lab, Bromborough, UK). All media were obtained from LabM Ltd, 
Bury, UK. 
 
2.3 Antimicrobial susceptibility testing 
 
Disc diffusion testing was performed on all staphylococcal isolates in accordance with the 
Clinical and Laboratory Standards Institute (CLSI) and the following panel of ten 
antimicrobial discs were applied: 1 µg oxacillin (OX), 1 µg ciprofloxacin (CIP), 10 µg 
gentamicin (GM), 10 µg fusidic acid (FA), 30 µg cefalexin (CFX), 30 µg cefovecin (CVN), 
Chapter 3 Antimicrobial resistant staphylococci in healthy dogs 
 39 
25 µg trimethoprim-sulfamethoxazole (TS), 10 µg tetracycline (Tet), 2 µg clindamycin (CD) 
and 5 µg vancomycin (Va) (CLSI, 2008). All the discs were purchased from MAST Group 
Ltd., Liverpool, UK, except for CVN, which were obtained from Oxoid, Basingstoke, UK. 
Micro-dilution susceptibility testing (Trek Diagnostic Systems, Cleveland, Ohio, USA) was 
performed on a subset of the CoNS isolates using the same antimicrobial panel, except 
vancomycin (CLSI, 2008). Interpretation was based on the CLSI guidelines for animal 
species-specific zone diameter (mm) interpretive standards and Minimal Inhibitory 
Concentration (MIC; mg/l) breakpoints for veterinary pathogens or human-derived 
interpretive standards when available. The European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) zone diameter interpretive standards and MIC breakpoints 
were used for CIP and FA (EUCAST, 2013). The breakpoints used for interpretation of 
resistance to OX as a zone of inhibition of ≤ 17 mm and MIC ≥ 0.5 mg/l for 
S. pseudintermedius and CoNS, and ≤ 10 mm and MIC ≥ 4 mg/l for S. aureus (Bemis et al., 
2009; CLSI, 2013). The breakpoints used for interpretation of resistance to CVN were a zone 
of inhibition of ≤ 19 mm and MIC ≥ 8 mg/l in accordance with the manufacturer’s 
recommendations. The reference strain S. aureus ATCC®25923 (LGC Standards, 
Teddington, UK) was used for quality control for MIC and zone diameter determinations. 
 
2.4 DNA extraction and characterisation of antimicrobial resistance genes 
 
Three colonies of each staphylococcal isolate were homogenised in 90 µl of sterile distilled 
water (SDW) and 10 µl of lysostaphin (1 mg/ml; Sigma-Aldrich Company Ltd., Gillingham, 
UK) and vortexed for 5 seconds. The suspensions were then incubated at 37˚C for 10 minutes 
and heated at 100˚C for 10 minutes before adding 400 µl of SDW. Samples were stored at 
4˚C. 
 
PCR assays were performed to detect the presence of mecA gene in staphylococcal isolates 
that were phenotypically resistant to oxacillin. All the PCR assays were performed with 5 µL 
of bacterial DNA, 5 pmol of each primer, 4 µL of 5x FIREPol® Master Mix (12.5 mM 
MgCl2) (Solis-Biodyne, Tartu, Estonia) and water to made up to a total reaction volume of 
25 µL (Table 3-1, Appendix 1). Molecular grade water (Sigma-Aldrich Company Ltd., 
Gillingham, UK) was used as the negative control in all PCR assays. PCR products were 
analysed by agarose gel (1.5%) electrophoresis and the DNA fragments were visualised under 
UV light after staining with peqGREEN (Peqlab, Fareham, UK).  
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2.4 Genotypic species identification  
 
PCR assays to detect the presence of the nuc genes of S. pseudintermedius, S. aureus and 
S. schleiferi were performed on all CoPS isolates using Qiagen® Multiplex PCR Mix 
(Qiagen, Crawley, UK), according to the manufacturer’s instructions with minor 
modifications.  In short, the PCR assays were performed in a reaction volume of 25 µl, 
consisting of 5 µl of bacterial DNA extract, 12.5 µl of master mix, 2.5 µl of 10x primer mix 
(2 µM of each primer) and 5 µl of RNase-free water. The cycling conditions consisted of an 
initial activation step at 95°C for 15 minutes, followed by 30 cycles of 95°C for 30 seconds, 
57°C for 90 seconds and 72°C for 60 seconds, and a final extension step at 72°C for 10 
minutes (Table 3-1, Appendix 1). 
 
2.5 MALDI-TOF-MS 
 
All isolates were subjected to matrix-assisted laser desorption ionisation time-of-flight mass 
spectrometry (MALDI-TOF-MS) according to the manufacturer’s protocol. Raw spectra were 
analysed by the MALDI Biotyper 2.0 software programme with default settings (Bruker 
Daltonics, Bremen, Germany). The extraction method was performed as previously described 
(Alatoom et al., 2011) on overnight colonies grown on CAB at 37°C and all isolates were 
tested in duplicate. The bacterial test standard (E. coli DH5 alpha, Bruker, Bremen, Germany) 
was used for calibration before each experiment and included in duplicate on each target 
plate. The mass peak profiles were matched to the reference database and a score generated 
based on similarity (Carpaij et al., 2011). 
 
2.6 Sequencing of the tuf gene 
 
Two subsets of isolates detected from our group of dogs underwent sequencing following 
PCR amplification of the tuf gene (Carpaij et al., 2011; Heikens et al., 2005); a control group 
of CoNS isolates (n = 27) identified by MALDI-TOF-MS and a test group of isolates (n = 52) 
that had not been identified by MALDI-TOF-MS.  Initial PCR assays were performed using 
HotStarTaq® Master Mix Kit (Qiagen, Crawley, UK) in a 25 µl reaction volume with an 
initial activation step at 95°C for 15 minutes followed by 35 cycles of 95°C for 30 seconds, 
55°C for 30 seconds and 72°C for 30 seconds, with a final extension step of 72°C for 5 
minutes, according to the manufacturer’s protocol (Table 3-1, Appendix I). The resulting 
amplicons were sequenced using BigDye Terminator version 1.1 cycle sequencing (Applied 
Biosystems, Foster City, CA, USA), according to the manufacturer’s protocol on the 
ABI3131 genetic analyser at the Department of Microbiology, Royal Liverpool University 
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Hospital. The sequences were aligned using the ABI Sequencing analysis software, with 
contiguous sequences matched to the GenBank database using the Basic Local Alignment 
Search Tool (BLAST) (Altschul et al., 1990) and positively identified if there was ≥ 98% 
sequence similarity with a reference sequence. S. epidermidis ATCC® 12228 was used as the 
control strain. 
 
2.7 Statistical analysis 
 
Data were analysed using SPSS software package (SPSS 20.0 for Mac, SPSS Inc, Chicago, 
Illinois). To examine the association between isolation of S. pseudintermedius with each of 
the 16 different CoNS species Pearson’s chi-square was calculated (P < 0.003; Bonferroni 
correction). To examine the association between MR and MDR with potential risk factors 
(previous antimicrobial therapy or hospitalisation within 12 months of enrolment, owner or 
in-contact pet with health-care association or owner with large animal-association) identified 
from the questionnaires Pearson’s chi-square was calculated (P < 0.0125; Bonferroni 
correction). To examine the agreement between antimicrobial susceptibility tests by disc 
diffusion and MIC a kappa statistic was calculated (Landis and Koch, 1977) and an 
independent t-test was conducted to compare the MIC of oxacillin resistant CoNS isolates 
that were either positive or negative for the mecA gene.  
 
3. Results 
3.1 Specimen collection  
 
Seventy-three Labrador retriever dogs were recruited. Twenty-one dogs were aged between 3 
to 12 months, 25 dogs were aged between 12 months to 2 years, and 27 dogs were >2 years 
old, with 35 female dogs and 38 male dogs in total. The demographics of the dogs included 
three countries of the UK, The Isle of Man, and 23 counties of England (Table 3-2, Appendix 
I). The majority (40%) were from the north west of England (Figure 3-1, Appendix I).   
 
3.2 Bacterial isolation 
 
Staphylococci were isolated in 72 out of 73 dogs (99%; 95% CI: 92.6 - 99.8) and from both 
sample sites in the majority of dogs (78%; 95% CI: 67.3 - 86.0). Isolation of staphylococci 
from the nasal mucosa (16%; 95% CI: 9.7 - 26.6) or perineum (4%; 95% CI: 1.4 - 11.4) only 
occurred in a small number of dogs. If only the nasal mucosa had been sampled, CoPS (all 
S. pseudintermedius) would not have been detected in seven dogs (10%; 95% CI: 4.7 - 18.5) 
and CoNS in six dogs (8%; 95% CI: 3.8 - 16.8). CoNS were detected in the majority of dogs 
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(95%; 95% CI: 86.7 - 97.8) either alone (52%; 95% CI: 40.8 - 63.1) or with CoPS (43%; 95% 
CI: 31.8 - 53.9). Detection of CoPS alone was significantly less common (4%; 95% CI: 1.4 - 
11.4). In total, there were 436 staphylococcal isolates; 102 of which were CoPS and 334 were 
CoNS isolates. 
 
3.3 Antimicrobial susceptibility testing by disc diffusion 
 
The overall prevalence of antimicrobial resistance among the isolates detected in this study 
appeared high, with at least one MDR isolate detected in 34% of dogs. Antimicrobial resistant 
CoNS isolates were detected in more dogs than antimicrobial resistant CoPS isolates for OX, 
GM, FA, CFX, CVN and CD and MDR. At least one OX resistant isolate was detected in 
58% dogs (n = 126 oxacillin resistant isolates), but resistance to the other tested beta-lactam 
antimicrobials, CVN (25%) and CFX (29%), was less common. Few CoPS demonstrated 
antimicrobial resistance; isolates from twelve dogs had Tet resistance, (all 
S. pseudintermedius), seven with FA resistance (S. pseudintermedius = 5, S. aureus = 3); two 
with TS resistance (both S. pseudintermedius); two with CD resistance 
(S. pseudintermedius = 1, S. aureus = 1) and two with CIP resistance (S. pseudintermedius). 
MDR CoPS was detected from only one dog (S. pseudintermedius with FA, Tet and CD 
resistance) (Figure 1).  
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Figure 1. The proportion of dogs (n = 73) carrying at least one staphylococcal isolate with resistance to each 
antimicrobial tested in this study by disc diffusion, mecA gene positive oxacillin resistance or multidrug 
resistance (error bars = 95% CI). 
 
95% CI = 95% confidence interval; Total = CoNS and CoPS; Ox = phenotypic oxacillin resistant; Ox mecA = phenotypic 
oxacillin resistant and mecA gene (meticillin resistant); Cip = ciprofloxacin resistant; GM = gentamicin resistant; FA = fusidic 
acid resistant; CFX = cefalexin resistant; CVN = cefovecin resistant; Tet = tetracycline resistant; TS = Trimethoprim-
sulfamethoxazole resistant; CD = Clindamycin resistant; MDR = multidrug resistant (resistant to three or more antimicrobial 
classes) 
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3.4 MIC compared to disc diffusion testing for antimicrobial resistance 
 
Micro-dilution susceptibility testing (Trek Diagnostic Systems, Cleveland, Ohio, USA) was 
performed on 172 CoNS isolates, of which 52 were OX susceptible and 120 were OX 
resistant by disc diffusion. The OX resistant isolates were further divided into those found to 
be positive (n = 74) or negative (n = 46) for carriage of the mecA gene by PCR. The strength 
of agreement between antimicrobial resistance detected by MIC and disc diffusion was very 
good for OX, GM, CVN, Tet and CD resistance, good for CFX and TS resistance and 
moderate for CIP (Kappa = 0.593) and FC resistance (Kappa = 0.589). MIC testing identified 
more isolates as resistant to OX, GM, CFX, CVN and Tet compared to disc diffusion, and 
disc diffusion identified more isolates as resistant to CIP, FA, TS and CD compared to MIC 
testing (Table 2).  
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Table 2. Cross tabulation of the results of 172 staphylococcal isolates classified as resistant or susceptible to 
the antimicrobials tested in this study by both MIC and disc diffusion testing. 
Antimicrobial resistance   MIC   
   No Yes Total 
Oxacillin  Disc diffusion No 50 10 60 
  Yes 2 110 112 
  Total 52 120 172 
  Kappa = 0.842    
   No Yes Total 
Oxacillin mecA positive  No 115 0 115 
  Yes 1 56 57 
  Total 116 56 172 
  Kappa = 0.987    
   No Yes Total 
Ciprofloxacin   No 146 0 157 
  Yes 14 12 15 
  Total 160 12 172 
  Kappa = 0.593    
   No Yes Total 
Gentamicin   No 156 1 157 
  Yes 0 15 15 
  Total 156 16 172 
  Kappa = 0.965    
   No Yes Total 
Fusidic acid   No 36 5 41 
  Yes 25 106 131 
  Total 61 111 172 
  Kappa = 0.589    
   No Yes Total 
Cefalexin   No 117 15 132 
  Yes 0 40 40 
  Total 117 55 172 
  Kappa = 0.784    
   No Yes Total 
Cefovecin   No 130 11 141 
  Yes 0 31 31 
  Total 130 42 172 
  Kappa = 0.810    
   No Yes Total 
Tetracycline   No 148 1 149 
  Yes 0 23 23 
  Total 148 24 172 
  Kappa = 0.975    
   No Yes Total 
Trimethoprim-sulfamethoxazole   No 156 2 158 
  Yes 3 11 14 
  Total 159 13 172 
  Kappa = 0.799    
   No Yes Total 
Clindamycin   No 148 2 150 
  Yes 4 18 22 
  Total 152 20 172 
  Kappa = 0.837    
MIC = Minimum Inhibitory Concentration; Kappa statistic > 0.8 = very good; 0.61 – 0.8 = good; 0.41 – 0.6 = moderate.  
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3.5 Characterisation of antimicrobial resistance genes 
 
Of the 126 OX resistant CoNS isolates detected by disc diffusion, 75 isolates (60%; 95% CI: 
51 - 68) from 31 dogs (42%; 95% CI: 32 - 54) were positive for the mecA gene (Figure 1). 
Ten additional oxacillin resistant isolates were detected by MIC and two of these were 
positive for the mecA gene, resulting in two additional dogs with MR-CoNS and one 
additional dog with phenotypic oxacillin resistant CoNS. There was a significant difference 
between the MIC of mecA positive (M = 3.84, SD = 0.18) and mecA negative isolates 
(M = 0.97, SD = 0.12, P < 0.001). In addition the epidemiological breakpoint for OX resistant 
CoNS isolates with mecA gene carriage isolated in this study was consistent with the clinical 
CLSI breakpoint (≥ 0.5 mg/l) (Figure 2).   
 
Figure 2. The MIC (µg/ml) data for staphylococcal isolates (n = 172). The isolates consisted of 52 oxacillin 
susceptible, 46 oxacillin resistant mecA negative and 74 oxacillin resistant mecA positive (error bars = 95% 
CI). 
95% CI = 95% confidence interval; MIC = Minimum Inhibitory Concentration; Ox = oxacillin; OxR = oxacillin resistant 
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Eleven different CoNS species (S. epidermidis, S. warneri, S. sciuri, S. equorum, S. fleurettii, 
S. vitulinus, S. saprophyticus, S. haemolyticus, S. lentus, S. succinus and S. pettenkoferi) were 
found to carry the mecA gene. Amongst oxacillin resistant CoNS species, S. epidermidis, S. 
fleuretti and S. sciuri were more likely to carry the mecA gene than S. saprophyticus, 
S. equorum, S. vitulinus and S. succinus (Figure 3).   
 
Figure 3. The percentage of each oxacillin-resistant staphylococcal species by disc diffusion and MIC that 
was either positive (mecA+) or negative (mecA-) for the mecA gene (error bars = 95% CI). 
 
95% CI = 95% confidence interval 
 
MRSE isolates were detected in 18 dogs (25%, 95% CI: 14.8 - 34.5), meticillin-resistant 
S. warneri were detected in 7 dogs (10%, 95% CI: 2.8 - 16.3) and meticillin-resistant S. sciuri 
were detected in 5 dogs (7%, 95% CI: 1.1 - 12.6). The remaining species were only isolated 
from one or two dogs. MDR mecA positive CoNS were detected in 19 dogs (26%, 95% CI: 
17.3 - 37.1). There was no significant association between detection of MR-CoNS or MDR 
isolates and potential risk factors tested in this study (Pearson’s chi-square; P > 0.0125). 
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3.6 Species identification 
 
Phenotypic and biochemical methods identified 436 isolates as Staphylococcus species. Using 
a combination of nuc gene PCR, MALDI-TOF-MS and sequencing of the tuf gene, 399 
isolates (92%, 95% CI: 88.5 - 93.8) were identified to the species level. MALDI-TOF-MS 
identified 345 isolates to the species level including 264 of 334 CoNS isolates (79%, 95% CI: 
74.4 - 83.1). Amplification and sequencing of the tuf gene identified 33 out of 51 CoNS 
isolates (65%, 95% CI: 51 - 76.4) to the species level (n = 11 species; ≥ 98% sequence 
similarity) and an additional control group (n = 27) of CoNS isolates that had also been 
identified by MALDI-TOF-MS. There was 100% agreement between the two methods for the 
identification of the control group. In particular, sequencing of the tuf gene identified all of 
the S. fleurettii, S. arlettae and S. pettenkoferi isolates, 12 isolates closely related to S. felis 
(96% sequence similarity) and an additional 15 isolates to the genus level (Staphylococcus 
spp. ≥ 98% sequence similarity). PCR amplification of the nuc gene detected all of the S. 
aureus n = 11 (100%, 95% CI: 74.1 - 100) and S. pseudintermedius isolates n = 91 (100%, 
95% CI: 96.0 - 100). There was 100% agreement of this assay with MALDI-TOF-MS for the 
identification of S. aureus isolates, however MALDI-TOF-MS only identified 69 out of 91 
S. pseudintermedius isolates.  
 
Overall from the combined results using PCR amplification of the nuc gene, MALDI-TOF-
MS and sequencing of the tuf gene we detected S. epidermidis in 52% (95% CI: 41 - 63) and 
S. pseudintermedius in 44% (95% CI: 33 - 55) of the dogs. S. warneri and S. equorum were 
the next most common species, isolated from 30% and 27% of dogs respectively, and the 
remaining staphylococcal species were carried by no more than 15% of the dogs. S. aureus 
was detected in 6 of the dogs, exclusively from the nasal mucosa, and usually with 
S. pseudintermedius (88%, 95% CI: 52.9 - 97.8). S. pseudintermedius was concurrently 
isolated with 16 different CoNS species, although there was no significant association 
between the presence of S. pseudintermedius and any CoNS species (Pearson’s chi-square; 
P > 0.003) (Figure 4; Table 3).  
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Figure 4. The proportion of dogs (n = 73) carrying each staphylococcal species identified in this study by 
MALDI-TOF-MS, PCR of the nuc gene and sequencing of the tuf gene (error bars = 95% CI). 
 
95% CI = 95% confidence interval; CoNS = grey; CoPS = black 
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Table 3. The number of staphylococcal isolates identified to species level by MALDI-TOF-MS, nuc gene 
PCR (CoPS), and tuf gene sequencing. 
Staphylococcal species 
Number of 
isolates 
Number 
(%) of 
positive 
dogs 
Number (%) 
identified by 
MALDI-TOF-MS 
Number (%) 
of CoPS 
identified by 
nuc PCR 
Number (%) 
identified by tuf gene 
sequencing 
S. pseudintermedius 91 32 (44) 70 (77) 91 (100) 0 
S. aureus 11 6 (8) 11 (100) 11 (100) 0 
S. epidermidis 67 38 (52) 64 (96) N/A 3 (4) 
S. warneri 35 22 (30) 35 (100) N/A 0 
S. equorum 39 20 (27) 36 (92) N/A 3 (8) 
S. saprophyticus 19 11 (15) 15 (79) N/A 4 (21) 
S. sciuri 27 11 (15) 21 (78) N/A 6 (22) 
S. succinus 19 10 (14) 16 (84) N/A 3 (16) 
S. simulans 15 9 (12) 15 (100) N/A 0 
S. capitis 7 8 (11) 7 (100) N/A 0 
S. pasteuri 8 6 (8) 8 (100) N/A 0 
S. xylosus 17 6 (8) 17 (100) N/A 0 
S. lentus 9 5 (7) 4 (44) N/A 5 (56) 
S. hominis 6 4 (5) 6 (100) N/A 0 
S. cohnii 5 3 (4) 3 (60) N/A 2 (40) 
S. vitulinus 14 3 (4) 13 (93) N/A 1 (7) 
S. haemolyticus 4  3 (4) 4 (100) N/A 0 
S. fleurettii 4 2 (3) 0 N/A 4 (100) 
S. arlettae 1 1 (1) 0 N/A 1 (100) 
S. pettenkoferi 1 1 (1) 0 N/A 1 (100) 
Total ID 399d 72e 345f 101f 33f 
Staphylococcus spp. 3 N/A N/A N/A 3 
Species related to S. felis 12 N/A N/A  N/A 12 
No ID 22 N/A N/A 2 3 
Total  436a 73b 436c 102c 51c 
Values in the table are expressed as total numbers and percentage in parenthesis where applicable. aTotal number of isolates in 
study; bTotal number of dogs in study; cTotal number of isolates tested by each method; dTotal number of isolates with positive 
identification (ID); eNumber of dogs with staphylococcal detection; fNumber of isolates with positive ID from each method.  
 
4. Discussion 
 
This is the first study incorporating MALDI-TOF-MS to successfully characterise commensal 
staphylococcal populations in a group of healthy dogs in the absence of antimicrobial 
pressure. We isolated staphylococci from 99% of our dogs, with 95% carrying CoNS and 
47% carrying CoPS. The relative prevalence of the staphylococci concurs with other 
published studies in humans (Kloos and Bannerman, 1994; von Eiff et al., 2002), horses 
(Busscher et al., 2006; De Martino et al., 2010; Karakulska et al., 2012; Moodley and 
Guardabassi, 2009; Yasuda et al., 2000) and dogs (Loeffler et al., 2005; Moon et al., 2012; 
Wedley et al., 2014), although the overall staphylococcal prevalence was double that reported 
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for healthy vet visiting dogs (Wedley et al., 2014). This could be related to the study 
population and techniques, as we sampled both the nose and the perineum to increase 
detection of CoPS (Fazakerley et al., 2010; Moon et al., 2012; Rubin et al., 2011; Windahl et 
al., 2012).  
 
We were able to assign 92% of the staphylococcal isolates to 20 different species, including 
18 CoNS. This is the first study to demonstrate such diversity in dogs, and carriage of this 
number of different species has only been previously reported for humans (Bagcigil et al., 
2007; Cox et al., 1988; Fazakerley et al., 2010; Griffeth et al., 2008; Kania et al., 2004; Kloos 
and Bannerman, 1994; May et al., 2005; Medleau et al., 1986; Wedley et al., 2014; 
Widerstrom et al., 2012; Yamashita et al., 2005). The most common species was 
S. epidermidis, which was detected in 52% of the dogs, mainly from the nasal cavity. This is 
similar to human reports (Rogers et al., 2009), but apart from one canine study (Bagcigil et 
al., 2007), S. epidermidis has not been commonly reported in different animal species 
(Garbacz et al., 2013; Huber et al., 2011; Karakulska et al., 2012). S. pseudintermedius was 
the second most common species and the most common CoPS detected, also in agreement 
with previous reports (Devriese and De Pelsmaecker, 1987; Griffeth et al., 2008; Hanselman 
et al., 2009; Rubin et al., 2011). Unlike S. epidermidis, S. pseudintermedius was carried 
equally in the nose and on the perineum, suggesting that this species may have a wider range 
of mucosal niches. Very few dogs carried S. aureus (8%), which is comparable to other 
studies that reported carriage rates of ~ 7% from healthy vet visiting dogs (Fazakerley et al., 
2010; Wedley et al., 2014). The majority of the CoNS in our study were human-associated 
and included S. epidermidis, S. hominis, S. haemolyticus, S. capitis, S. saprophyticus, 
S. warneri, S. cohnii, S. simulans, S. pettenkoferi and S. pasteuri. Human associated CoNS 
species have previously been isolated from dogs, horses, cows and pigs (Bagcigil et al., 2007; 
Gillespie et al., 2009; Huber et al., 2011; Karakulska et al., 2012; Malik et al., 2006; Tulinski 
et al., 2012). The other CoNS species isolated from our dogs are reported as indigenous to 
animals (S. equorum, S. vitulinus, S. arlettae S. sciuri, S. lentus and S. fleurettii) (Kloos and 
Bannerman, 1994). 
 
We used several methods to identify staphylococcal isolates to species level. Multiplex PCR 
for the nuc gene is an accurate, rapid and cost efficient method to determine the species of 
CoPS (Sasaki et al., 2010), which identified 100% of our S. pseudintermedius (n = 91) and 
100% of our S. aureus isolates (n = 11). Recently MALDI-TOF-MS has been reported as a 
rapid and reliable method to characterise CoNS, S. aureus and S. intermedius group (SIG) 
strains (Carpaij et al., 2011; Decristophoris et al., 2011; Dubois et al., 2010; Huber et al., 
2011; Szabados et al., 2010). MALDI-TOF-MS identified all of our S. aureus isolates, 77% 
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of our S. pseudintermedius isolates and 79% of our CoNS isolates, identified by phenotypic 
and biochemical characteristics, to the species level. Similar results for the identification of 
S. aureus, S. pseudintermedius and CoNS by MALDI-TOF-MS, in comparison to molecular 
methods, have been reported (Bergeron et al., 2011; Decristophoris et al., 2011; Szabados et 
al., 2010). The overall performance of MALDI-TOF-MS to speciate the staphylococcal 
isolates in this study, similar to other reports (Decristophoris et al., 2011), is likely to be 
directly related to the database, which at the time of analysis consisted mainly of common 
human-derived species and only one S. pseudintermedius strain. However species level 
identification will improve as more highly characterised reference isolates are added to the 
database. Amplification and sequencing of the tuf gene is regarded as the gold standard to 
speciate CoNS isolates (Carpaij et al., 2011; Heikens et al., 2005). This method identified 
77% of the tested staphylococcal isolates (n = 79) to the species level. The performance of 
this method in our study may have been affected by the lack of certain-animal derived isolates 
representing different species in the database. Additionally, we may have improved 
identification by sequencing a larger region of the tuf gene. We sequenced a previously 
described 412 base pair region of the tuf gene that was reported to have successfully 
identified 88% of human-derived staphylococcal strains (Heikens et al., 2005). However, a 
more recent publication that sequenced a 660 base pair region of the tuf gene, reported 98.9% 
identification of 186 human and animal-derived staphylococcal strains (Bergeron et al., 
2011).  
 
We did not detect any MR-CoPS isolates. Other studies of healthy dogs have similarly 
reported a low prevalence (Onuma et al., 2012; Vanderhaeghen et al., 2012; Wedley et al., 
2014). In contrast, 58% of the dogs in our study carried at least one CoNS isolate with 
phenotypic oxacillin resistance and 42% carried oxacillin resistant mecA positive isolate. 
Other studies have also reported high levels of meticillin resistance among CoNS isolates 
from humans (Diekema et al., 2001; Garza-Gonzalez et al., 2011; Hanssen and Ericson Sollid, 
2006), horses (Bagcigil et al., 2007; Busscher et al., 2006; De Martino et al., 2010; Moodley 
and Guardabassi, 2009) and livestock (Huber et al., 2011; Zhang et al., 2009). However, the 
prevalence of MR-CoNS carriage in our study is markedly higher than the levels reported in 
other community canine studies (Bagcigil et al., 2007; Malik et al., 2006; Vanderhaeghen et 
al., 2012; Vengust et al., 2006; Wedley et al., 2014). High community carriage rates of MR-
CoNS are of concern for animals and humans, as these organisms may not only be reservoirs 
of resistance genes for CoPS (Barbier et al., 2010; Smyth et al., 2011; Tsubakishita et al., 
2010), but also act as pathogens (Diekema et al., 2001; Duval et al., 2004; Hauschild and 
Wojcik, 2007; Kern and Perreten, 2013; Moran et al., 2007). Cross-transmission is reported to 
be an important mechanism for dissemination of MRS (Cimiotti et al., 2004; Silva et al., 
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2001), and transmission between dogs and in-contact humans may occur in the community 
and in veterinary premises (Laarhoven et al., 2011; van Duijkeren et al., 2011).  
Nine different CoNS species carried the mecA gene in our study with MRSE detected in 25% 
of our dogs. MRSE is the predominant MR-CoNS species in humans both in hospital and 
community settings (Barbier et al., 2010; Lebeaux et al., 2012; Silva et al., 2001), and has 
been reported in one study investigating nasal carriage of MRS in dogs (Bagcigil et al., 2007). 
Other canine studies have isolated meticillin resistant S. sciuri and meticillin resistant 
S. warneri (Bagcigil et al., 2007; Malik et al., 2006). Our research found that the majority of 
the S. sciuri and S. fleurettii isolates were mecA positive, which is consistent with other 
studies in humans, livestock and horses (Busscher et al., 2006; De Martino et al., 2010; 
Garza-Gonzalez et al., 2011; Huber et al., 2011; Karakulska et al., 2012).  
MDR CoNS (n = 38) were isolated from 34% of dogs in this study. MDR was generally 
associated with resistance to beta-lactams, FA and additional antimicrobials. In particular, 
MDR-MRSE were resistant to at least four antimicrobial classes tested in our study. A similar 
finding was reported in a study of hospitalised animals, medical equipment and veterinary 
staff (Moon et al., 2012). MDR among CoNS isolates is widely reported (Garbacz et al., 
2013; Huber et al., 2011; Silva et al., 2001; Wedley et al., 2014; Wisplinghoff et al., 2004) 
and may be associated with the carriage of multiple antimicrobial resistance genes on 
SCCmec cassettes (Smyth et al., 2011). In contrast, the majority of our commensal CoPS 
isolates were susceptible to a broad range of antimicrobials (apart from Tet), in line with 
previous reports for clinical isolates (Hoekstra and Paulton, 2002; Kruse et al., 1996; Lloyd et 
al., 1996) and isolates from healthy vet-visiting dogs (Wedley et al., 2014). There was good to 
very good agreement between disc and MIC antimicrobial susceptibility testing apart for FC 
and CIP. These two antimicrobials were the only ones where human breakpoints were applied 
and emphasises potential species differences in pharmacokinetic and pharmacodynamic data 
for individual antimicrobials. 
The mecA gene was not identified in 40% of the phenotypic oxacillin resistant isolates in this 
study and may include some isolate duplication due to our sampling methods. Other studies 
have reported phenotypic meticillin resistance with absence of the mecA gene in 
staphylococci (Bignardi et al., 1996; Eckholm et al., 2013; Fessler et al., 2010; Suzuki et al., 
1992). Our OX-resistant mecA negative isolates may be truly negative for the mecA gene as 
they were less likely to be resistant to the other antimicrobials tested in this study, including 
CVN and CFX, and had significantly lower MICs compared to the OX resistant mecA 
positive isolates.  It is possible that they had low-level resistance associated with other 
mechanisms such as hyperproduction of beta-lactamases (Rosdahl and Rosendal, 1983), or 
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production of an oxacillin-specific beta-lactamases (Jones et al., 2007). There are bovine 
mastitis CoNS isolates with oxacillin MICs of 0.5 – 1 mg/l that lack the mecA gene (Fessler 
et al., 2010), and the CLSI guidelines state that ‘oxacillin interpretive criteria may overcall 
resistance for these CoNS strains’ (CLSI, 2013). In addition, many of the published PCR 
assays to identify and characterise the mecA gene have been developed for MRSA (Francois 
et al., 2003; Kondo et al., 2007; Mehrotra et al., 2000; Zhang et al., 2005) and may therefore 
lack sensitivity for some CoNS isolates. However, other authors have successfully employed 
the same methods for mecA detection among CoNS isolates as used in our study (Eckholm et 
al., 2013; Moon et al., 2012; Ruppe et al., 2009). Yet it is possible that additional PCR assay 
(Murakami et al., 1991), or latex agglutination for PBP2a (Baddour et al., 2007) may have 
improved the sensitivity of mecA detection or detected phenotypic mecA-associated 
resistance in our oxacillin resistant mecA negative isolates.  
Our study had some limitations, including the small sample size. Nevertheless, these dogs 
yielded 436 staphylococcal isolates and a high prevalence of resistance was identified among 
the CoNS isolates even in the absence of antimicrobial exposure. Another weakness was that 
the study population was limited to one breed (Labrador retrievers) and the dogs were 
recruited at dog shows. Kennelled dogs have been shown to have higher levels of 
antimicrobial resistance in faecal E. coli than individually owned and non-kennelled dogs (De 
Graef et al., 2004). Kennelling was transient in our dogs, but this may have affected the 
results. Many of the dogs came from multi-dog households but only one dog from each 
household was sampled to avoid cluster effects. 
5. Conclusions 
 
This is the first comprehensive study of commensal staphylococcal populations in a group of 
healthy dogs. Staphylococci, particularly CoNS, form a normal part of the canine commensal 
population and were detected from almost all the dogs. The most commonly isolated 
staphylococcal species in this group of dogs was S. epidermidis, although a wide variety of 
other human- and animal-associated CoNS were found. CoPS were less common, and the 
major species was S. pseudintermedius. Antimicrobial resistance amongst the CoPS was 
uncommon, and no MRSP or MRSA were isolated, however the sample size was small. 
Antimicrobial resistance (including MDR and meticillin resistance) however was common 
among the CoNS isolates, even though this was a community population of healthy dogs in 
the absence of direct-antimicrobial pressure or veterinary contact. The clinical significance of 
commensal CoNS and MR-CoNS is unclear, but S. epidermidis carries a number of virulence 
factors and is an increasing cause of nosocomial and community-acquired infections in 
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humans. The possibility of similar infections escalating in companion animals cannot be 
excluded. In addition, there is potential for cross-species transmission of antimicrobial 
resistant bacteria and exchange of resistance determinants between bacterial species. In 
particular, MR- and MDR-CoNS may provide a reservoir of antimicrobial resistance genes 
that could rapidly spread within bacterial populations under the selection pressure exerted by 
antimicrobial therapy. Further longitudinal studies in healthy dogs and in dogs receiving 
antimicrobials are required to assess the population diversity, antimicrobial resistance profiles 
and persistence of antimicrobial resistant staphylococci in dogs.
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Summary 
 
Background: Antimicrobial resistance (AMR), in particular multidrug resistance (MDR; resistance to 
three or more antimicrobial classes) is increasing amongst canine clinical and commensal isolates. 
This represents both an animal welfare and public health concern. Risk factors for the detection of 
AMR faecal E. coli include antimicrobial therapy and veterinary admission but few studies have 
examined commensal isolates in healthy community dogs. 
Objectives: The main aim of the study was to characterise the population and AMR profiles of E. coli 
from healthy non-vet visiting and non-antimicrobial treated Labrador retrievers in the UK and to 
examine potential risk factors for the detection of such bacteria.  
Methods: Faecal samples were collected from 73 Labrador retrievers and owners completed 
questionnaires regarding potential risk factors for AMR E. coli. Isolates were identified using 
phenotypic and biochemical methods and PCR assay for the uidA gene. Disc diffusion susceptibility 
tests were determined for a range of antimicrobials, including combination disc tests for phenotypic 
ESBL- and AmpC-production. PCR assay was used to detect resistance genes (blaCTX-M [groups 1, 2 
and 9], blaSHV, blaTEM, blaOXA, blaCIT) and phylogenetic groups and conjugation tests were used to 
detect in vitro transfer of resistance determinants. Multivariable logistic regression was used to 
examine potential risk factors for the outcomes. 
Results: AMR-, MDR- and AmpC-producing E. coli were detected in 63%, 30% and 16% of dogs, 
respectively. ESBL-producing E. coli (blaCTX-M group 1) were only detected from one dog. In 
conjugation experiments, MDR phenotype and blaCTX-M and blaCIT were transferred from commensal 
E. coli to a recipient E. coli strain. The majority of the isolates were phylo-group B1 and group A. 
Group B2 isolates were more likely to be susceptible (P < 0.001) while group D isolates were more 
likely to be resistant (P = 0.04). Eating raw meat was associated with clavulanate-amoxicillin and 
third generation cephalosporin resistance (3GCR) and phylogenetic groups B1 and D.  Multi-animal 
or multi-dog households were associated with beta-lactam resistance and 3GCR and phylogenetic 
groups A, E, F or Clades.  
Conclusions: AMR, including MDR- and AmpC-producing E. coli were prevalent in this group of 
non-antimicrobial treated and non-vet-visiting dogs; however ESBL-production was rare. The 
majority of the isolates belonged to phylo-genetic groups B1 and A; potentially gut commensals. The 
main risk for the detection of AMR was the consumption of raw meat. These findings are of concern 
due to the potential for opportunistic infections, zoonotic transmission and transmission of 
antimicrobial resistant determinants from commensal isolates to pathogenic bacteria. 
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1. Introduction 
 
Escherichia coli is the main aerobe of the gastro-intestinal flora in humans and other animals 
(Tenaillon et al., 2010), and has been widely studied as an indicator of antimicrobial selection 
pressure (Gronvold et al., 2010). A stable gastrointestinal flora is important for health and acts as a 
colonisation barrier against pathogens (Vollaard and Clasener, 1994); this may be disturbed by a 
number of factors including disease, diet and antimicrobial therapy (Jernberg et al., 2010; Stecher and 
Hardt, 2008; Vincent et al., 2010). 
 
Of particular concern is the emergence and dissemination of extended spectrum beta-lactamase 
(ESBL)- and AmpC-producing E. coli that are resistant to a variety of beta-lactam antimicrobials 
including third generation cephalosporins (3GCR) (Livermore and Hawkey, 2005; Thomson, 2010). 
Genes encoding these enzymes are carried on plasmids, often in conjunction with other antimicrobial 
resistance determinants, enabling horizontal transmission of multidrug resistance (MDR; resistance to 
≥ 3 antimicrobial drug classes) (Dahmen et al., 2012; Karczmarczyk et al., 2011; Li et al., 2007; Zhao 
et al., 2001). AmpC production may also be associated with a chromosomal mutation, but these 
isolates are less likely to be MDR (Jacoby, 2009; Thomson, 2010). ESBL-, AmpC-producing and 
MDR E. coli have been detected in healthy (Carattoli et al., 2005; Costa et al., 2008; De Graef et al., 
2004; Wedley et al., 2011) and sick dogs (Carattoli et al., 2005; Gibson et al., 2011a; Pomba et al., 
2009; Steen and Webb, 2007), and increased detection has been associated with exposure to 
antimicrobials and veterinary healthcare (Damborg et al., 2011; Gibson et al., 2011a, b; Moreno et al., 
2008).   
 
E. coli can to some extent be divided into commensal and pathogenic strains. Although commensal 
strains may cause opportunistic infections in compromised patients, pathogenic strains are more likely 
to cause disease, either intestinal disease associated with enteric strains (intestinal pathogenic E. coli) 
or extra-intestinal disease associated with ExPEC strains (extra-intestinal pathogenic E. coli) (Russo 
and Johnson, 2000, 2003). Compared to commensal strains, pathogenic strains are more likely to 
carry a range of virulence genes that can facilitate disease (Johnson and Russo, 2002; Nowrouzian et 
al., 2006). Pathogenic intestinal strains usually cause disease in a naïve host upon ingestion, whereas 
gut colonisation by ExPEC strains is a prerequisite for extra-intestinal infections. The gut of healthy 
humans and other animals can be a reservoir of ExPEC strains (Johnson et al., 2003; Russo and 
Johnson, 2003), which are potentially zoonotic (Johnson et al., 2009) and may be shared between 
humans and pets within households (Johnson et al., 2008). Food, particularly chicken meat, is also a 
potential source of ExPEC strains for humans and dogs (Johnson et al., 2009; Johnson et al., 2007; 
Vincent et al., 2010). 
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Phylogenetic grouping is a simple and inexpensive method to investigate the genetic background, 
potential pathogenicity, and antimicrobial resistance traits of E. coli isolates (Sato et al., 2014). A 
PCR assay to assign E. coli isolates to four major phylogenetic groups: A, B1, B2 and D (Clermont et 
al., 2000), recently updated by Doumith et al., (2012), has been widely used. Additionally a revision 
of the original method (Clermont et al., 2000) has recently been published (Clermont et al., 2013) and 
assigns isolates to eight different phylogenetic groups: A, B1, B2, C, D, E, F and Escherichia Clade I. 
Phylo-groups D and particularly B2 are more likely to be involved in extra-intestinal infections 
compared to A or B1 (Picard et al., 1999). Amongst the newer groups, C isolates are more likely to be 
commensals (Clermont et al., 2011b; Moissenet et al., 2010), group E and F are more likely to be 
ExPEC (Jaureguy et al., 2008; Tenaillon et al., 2010) and isolates belonging to Escherichia Clades are 
thought to reside outside of the gut (Walk et al., 2009). 
 
The distribution of these phylo-groups amongst different hosts is not random and may depend on 
characteristics such as body mass, gut morphology, diet, environment and degree of domestication 
(Escobar-Paramo et al., 2006; Gordon and Cowling, 2003; Tenaillon et al., 2010). In humans, phylo-
group A generally predominates followed by B2, B1 and D, whereas in animals group B1 
predominates followed by A, B2 and D (Tenaillon et al., 2010). Diversity due to host diet has also 
been reported with phylo-group A predominating in carnivores and omnivores, and group B1 in 
herbivores (Baldy-Chudzik et al., 2008; Carlos et al., 2010; Escobar-Paramo et al., 2006). Moreover 
domestication is associated with reduced B2 and more phylo-group A strains compared to wild 
animals (Escobar-Paramo et al., 2006). 
 
Antimicrobial resistance has been linked to the non-B2 phylo-groups in people, cattle, pigs and dogs 
(Johnson et al., 2009; Johnson et al., 2003; Moreno et al., 2008). In dogs, phylo-group D isolates are 
more likely to be antimicrobial resistant, including fluoroquinolone, 3GCR and MDR (Platell et al., 
2011; Sato et al., 2014; Tamang et al., 2012), and group B2 are more likely to be antimicrobial 
susceptible (Johnson et al., 2009; Platell et al., 2010; Platell et al., 2011; Sato et al., 2014). However 
ESBL-producing fluoroquinolone resistant and MDR ExPEC strains that further challenge therapeutic 
regimes are emerging amongst human clinical isolates, and have been reported in dogs (Johnson et al., 
2009; Platell et al., 2010; Russo and Johnson, 2003). This represents both an animal welfare and 
zoonotic risk. 
 
The majority of human and other animal studies of E. coli have concentrated on clinical isolates. 
However, to further our understanding of the antimicrobial resistance of pathogenic isolates under the 
influence of antimicrobial pressure and other potential risk factors, it is first necessary to elucidate the 
characteristics of gastrointestinal E. coli populations under natural conditions. The aim of this study 
was to determine the prevalence of antimicrobial resistance and phylogenetic groups amongst faecal 
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E. coli from a group of healthy non-vet visiting and non-antimicrobial treated dogs and to investigate 
the relationship of these findings to potential risk factors for antimicrobial resistance.  
 
2. Materials and Methods 
2.1 Study Population 
 
Labrador retriever dogs were recruited on a convenience basis from two dog shows in the North West 
UK between November 2010 and June 2011.  We aimed to recruit 30 dogs per show. One healthy dog 
of any age was enrolled from each household following a clinical examination. Dogs that had 
received topical or systemic antimicrobial therapy, had been admitted to a veterinary clinic within the 
last 12 months, or were determined not to be healthy were excluded. All dog owners gave written 
informed consent before enrolment in this study and completed a questionnaire regarding potential 
risk factors for the carriage of antimicrobial resistant bacteria. The two-page questionnaire was based 
on a previous study (Wedley et al., 2014) and consisted of closed questions with tick box responses 
and space for additional information. A “Don’t Know” response was included for all questions to 
enable the respondent to avoid answering incorrectly if they were uncertain. Data were collected 
regarding patient signalment and diet, the presence, number and type of in-contact pets, previous 
medical history of the household (including antimicrobial therapy or hospitalisation of people or other 
pets), and whether any household member worked with farm animals or in healthcare (Appendix I). 
The University of Liverpool, School, of Veterinary Science Ethics-Committee approved the study 
protocol.  
 
2.2  Specimen collection and bacterial isolation 
 
Owners were asked to collect the next fresh faecal sample in a sterile faecal pot (Appendix I).  Faecal 
samples were returned to the University of Liverpool either at the time of enrolment or by first-class 
post. Faecal samples were mixed with an equal volume of brain heart infusion broth with 5% glycerol 
(BHI-G) on receipt. Each faecal homogenate was streaked onto one eosin methylene blue agar 
(EMBA) plate without antimicrobials, one EMBA plate impregnated with 1 µg/ml ceftazidime (CZ) 
and one EMBA plate impregnated with 1 µg/ml cefotaxime (CX) (Liebana et al., 2006) to obtain 
single colonies. In addition, to detect antimicrobial resistant isolates, one EMBA plate and one 
MacConkey’s agar (MAC) plate were inoculated with the faecal homogenate for confluent bacterial 
growth and seven antimicrobial discs (10 µg ampicillin (Amp), 30 µg clavulanate-amoxicillin (AC), 1 
µg ciprofloxacin (Cip), 30 µg chloramphenicol (Chl), 30 µg nalidixic acid (Nal), 30 µg tetracycline 
(Tet) and 2.5 µg trimethoprim (Tm)) were applied in accordance with the direct plating method 
(Bartoloni et al., 2006).  A further 500 µL of faecal homogenate was enriched in 4.5 ml of buffered 
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peptone water.  All plates and broths were incubated aerobically for 18-20 hours at 37°C. If there had 
been no growth on the EMBA plates impregnated with third generation cephalosporins, the enriched 
broths were plated onto the same selective media and incubated aerobically for 18-20 hours at 37°C. 
Three random colonies, whose morphology resembled E. coli were selected from the plain EMBA 
plate. Where present, one colony growing within the zone of inhibition around each antimicrobial disc 
on both the EMBA and MAC plates and/or from the CX and/or CZ plates were also selected. These 
colonies were sub-cultured onto nutrient agar and incubated aerobically for 18-20 hours at 37°C. 
Gram stains and biochemical tests (catalase production, lack of oxidase, lactose fermentation, indole 
production and inability to use citrate as a carbon source) to confirm E. coli were performed on fresh 
overnight cultures. All antimicrobial discs were obtained from MAST Group Ltd., Liverpool, UK, and 
the media from LabM Ltd, Bury, UK, and the CX and CZ powder from Sigma-Aldrich Company 
Ltd., Gillingham, UK. 
 
2.3 Antimicrobial susceptibility testing 
 
Antimicrobial susceptibility disc diffusion testing was performed on all E. coli isolates according to 
British Society for Antimicrobial Chemotherapy guidelines (BSAC; Version 11.1 May 2012) 
(Andrews, 2007). Iso-Sensitest agar plates were inoculated with each isolate homogenised in sterile 
distilled water (0.5 McFarland standards) for semi-confluent bacterial growth and the same panel of 
seven antimicrobial discs was applied. After the plates were incubated aerobically at 37°C for 18 to 
20 hours, the zone diameters around each disc were measured in millimeters and recorded. E. coli 
ATCC® 25922 (LGC Standards, Teddington, UK) cultured overnight on nutrient agar at 37°C was 
used as a control.  
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2.4 Screening for phenotypic AmpC- and ESBL-producing E. coli 
 
Isolates with 3GCR were tested for the production of ESBL enzymes. An Iso-Sensitest agar plate was 
inoculated for confluent bacterial growth and three pairs of third generation cephalosporin discs (with 
and without clavulanic acid) were placed on the surface of the agar plate: 30 µg ceftazidime and 30 µg 
ceftazidime plus 10 µg clavulanic acid; 30 µg cefotaxime and 30 µg cefotaxime plus 10 µg clavulanic 
acid; and 30 µg cefpodoxime and 30 µg cefpodoxime plus 10 µg clavulanic acid. The plates were 
incubated aerobically at 37°C for 18 to 20 hours and zone diameters around each disc were measured 
and recorded. ESBL production was confirmed when the zone around the cephalosporin disc was 
expanded in the presence of the clavulanic acid by a minimum of 5 mm for ≥ 1 antimicrobial pairs, 
according to the manufacturer’s instructions (Extended Spectrum Beta-Lactamase Set D52C, MAST 
Group Ltd., Liverpool, UK) (M'Zali et al., 2000). E. coli isolates with 3GCR or clavulanate-
amoxicillin resistance were tested for production of AmpC enzyme. An Iso-Sensitest agar plate was 
inoculated for confluent bacterial growth and three discs applied: 10 µg cefpodoxime plus AmpC 
inducer (A); 10 µg cefpodoxime plus AmpC inducer and ESBL inhibitor (B); 10 µg cefpodoxime plus 
AmpC inducer, ESBL inhibitor and AmpC inhibitors (C). The plates were incubated aerobically at 
37°C for 18 to 20 hours and zone diameters around each disc were measured and recorded. AmpC 
production was confirmed when the zone of inhibition around disc C was disc was greater than that 
for discs A and B by a minimum of 5 mm, according to the manufacturer’s instructions (AmpC 
detection set D69C, MAST Group Ltd., Liverpool, UK) (Halstead et al., 2012). E. coli ATCC® 25922 
(LGC Standards, Teddington, UK) cultured overnight on CAB at 37°C was used as a control. 
 
2.5 Genotypic identification of E. coli and characterisation of resistance genes 
 
Cell lysates were prepared from 188 isolates by adding three colonies of each isolate to 500 µl of 
SDW to yield a 0.5 McFarland standard solution. The suspensions were then vortexed, heated at 
100°C for 10 minutes and centrifuged. The supernatants were stored at 4°C. 
PCR assays for the uidA gene (McDaniels et al., 1996) were performed to confirm that the isolates 
were E. coli before further characterisation. E. coli isolates positive for ESBL production by the 
double disc method (MAST Group Ltd., Liverpool, UK) and isolates resistant to either cefotaxime 
and/or ceftazidime and positive for AmpC production (n = 18) were tested for the presence of blaCTX-
M (Batchelor et al., 2005), blaSHV, blaTEM  and blaOXA (Dallenne et al., 2010) genes. If positive for 
blaCTX-M, isolates (n = 2) were tested for the presence of CTX-M group 1, 2 and 9 genes (Batchelor et 
al., 2005; Hopkins et al., 2006). Isolates identified as phenotypic AmpC producers by the AmpC 
detection set (MAST Group Ltd., Liverpool, UK) were tested for the presence of blaAmpC gene 
carriage (Perez-Perez and Hanson, 2002); absence of this gene was supportive of chromosomal 
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AmpC. All isolates (n = 188) were tested for the presence of qnrA, qnrB or qnr S genes (Robicsek et 
al., 2006). All the PCR assays were performed with 5 µL of bacterial DNA, 5 pmol of each primer, 
4 µL of 5x FIREPol® Master Mix (12.5 mM MgCl2), 0.5 µl of FIREPol® DNA Polymerase 5 U/µl 
(Solis-Biodyne, Tartu, Estonia) and water to made up to a total reaction volume of 25 µL. Positive 
control strains were included and molecular grade water (Sigma-Aldrich Company Ltd., Gillingham, 
UK) was used as the negative control (Table 4-1, Appendix II). PCR products were analysed by 
agarose gel (1.5%) electrophoresis and the DNA fragments were visualised under UV light after 
peqGREEN (Peqlab, Fareham, UK) staining. All phenotypically unique antimicrobial resistant and 
susceptible confirmed E. coli, from each dog were stored at – 80°C in Microbank vials (Pro-Lab, 
Bromborough, UK) for further characterisation and analysis.  
 
2.6 Phylogenetic groups 
 
E. coli isolates (n = 188) were segregated into phylogenetic groups by PCR assay. In short, a 
multiplex PCR for the phylo-groups A, B1, B2 and D was performed according to Doumith et al., 
(2012) and analysed according to Clermont et al., (2000). In addition, a multiplex PCR for 
amplification of the phylo-groups A, B1, B2, D, C, E, F and Clade I was performed and analysed 
according to Clermont et al., (2013) (Table 4-1, Appendix II), to compare the results of the two assays 
.   
 
2.7 Conjugation experiments 
 
The ability to transfer antimicrobial resistance determinants was tested as previously described 
(Karczmarczyk et al., 2011). The rifampin-resistant, lactose-negative strain E. coli 26R793 served as a 
recipient in the assays. Multidrug resistant E. coli isolates or those carrying blaAmpC or blaCTX-M were 
tested. Briefly, overnight cultures of the donor and recipient strains grown in 5 ml of nutrient broth 
were mixed and incubated at 37°C for 18 hours. The transconjugants were selected on MacConkey 
agar supplemented with 100 µg/ml rifampin (Sigma-Aldrich) along with 50 µg/ml ampicillin, 
50 µg/ml nalidixic acid, 30 µg/ml tetracycline, 50 µg/ml trimethoprim or 1 µg/ml of cefotaxime 
(Sigma-Aldrich, UK). If present, up to three lactose-negative colonies were selected from each plate 
onto nutrient agar and incubated at 37°C for 18 hours. These isolates were subjected to antimicrobial 
susceptibility tests and PCR assay for blaAmpC or blaCTX-M genes. 
 
2.8 Statistical analysis 
 
All questionnaire derived information and microbiological data were entered into a spreadsheet 
program (Microsoft Excel for Mac 2008, Microsoft Corporation) and these data were reviewed and 
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checked for coding of all variables. Independent (risk factor) variables were created from information 
obtained from the owner questionnaires. Except for the age of the dog, all variables were dichotomous 
or categorical in nature (Table 4).   
 
Data analysis included descriptive statistics and binary logistic regression. Resistance to each tested 
antimicrobial, any antimicrobial (AMR) or multidrug resistance (MDR; resistance to greater than or 
equal to three antimicrobial classes) or the presence of ESBL- or AmpC-producing E. coli were 
expressed as percentages +/- 95% confidence intervals (CI). Each antimicrobial resistance outcome 
for each phylogenetic group and each phylogenetic group at the isolate level was similarly expressed. 
The antimicrobial resistance outcomes were AMR, clavulanate-amoxicillin (ACR), ciprofloxacin 
(CipR), third generation cephalosporin (3GCR; synonymous for phenotypic AmpC- and ESBL-
producing isolates) or beta-lactam resistance (BLR; Amp, ACR, 3GCR) or MDR. The phylogenetic 
group outcomes were group A, group B1, group B2 and group D (Doumith et al., 2012), and groups 
C, E, F and clades (Clermont et al., 2013). For any pair of variables with a correlation coefficient of ≥ 
0.7 only the variable with the smallest P-value was considered for further analysis. 
 
Logistic regression was used to examine the association between the test variables and all resistance 
outcomes, phylogenetic group and antimicrobial resistance outcomes and phylogenetic group and 
conjugation. Initially all variables were analysed in a univariable multilevel model. All variables that 
showed some association with the presence of resistant E. coli or phylogenetic group on univariable 
analysis (P-value < 0.25) were considered for incorporation into a final multivariable model. The final 
models were constructed by a manual backwards stepwise procedure where variables with a 
likelihood ratio P value < 0.05 were retained in the model. Tests for correlation (Spearman’s rho) and 
binary logistic regression were performed using SPSS software package (SPSS 20.0 for Mac, SPSS 
Inc, Chicago, Illinois). 
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3. Results 
3.1 Study population 
In total, 73 Labrador retriever dogs were recruited, with 21 dogs aged between 3 to 12 months, 25 
dogs aged 12 months to two years old, and 27 dogs greater than two years old. There were 35 female 
and 38 male dogs. The demographics of the dogs included three countries of the UK, The Isle of Man, 
and 23 counties of England (Table 3-2, Appendix I). The majority (40%) were from the north west of 
the UK (Figure 3-1, Appendix I).  
 
3.2 Antimicrobial resistance 
Faecal E. coli (n = 188) were isolated from 72 dogs (99%; 95% CI: 92.6-99.8). At least one AMR 
isolate was detected in 46 dogs (63%; 95% CI: 51.5-73.2) and at least one MDR isolate in 22 dogs 
(30%; 95% CI: 20.8-41.4) (Figure 1). A high prevalence of resistance to ampicillin and/or tetracycline 
and/or trimethoprim was observed and this combination was the most common MDR phenotype, 
detected in 9 dogs (12%; 95% CI: 6.6-21.8) (Table 1). Chloramphenicol was the next most common 
resistance phenotype, detected in 19 dogs (26%; 95% CI: 17.3-37.1). Fewer dogs had faecal E. coli 
with resistance to ciprofloxacin (10 dogs; 14%) or clavulanate-amoxicillin (12 dogs; 16%). Combined 
ciprofloxacin and clavulanate-amoxicillin resistance was rare (3 dogs) although the majority of the 
ciprofloxacin isolates were also detected in association with MDR isolates (8 dogs).  
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Figure 1. The percentage of dogs (n = 73) with antimicrobial resistant faecal E. coli (error bars = 95% CI). 
 
AmpR = ampicillin resistance; ACR = clavulanate-amoxicillin resistance; CipR = ciprofloxacin resistance; NalR = nalidixic acid resistance; 
ChlR = chloramphenicol resistance; TetR = tetracycline resistance; TmR = trimethoprim resistance; BLR = beta-lactam resistance; AMR = 
resistance to at least one tested antimicrobial; MDR = multidrug resistance (resistance to ≥ 3 antimicrobial classes) 
 
 
Table 1. The different antimicrobial resistance profiles observed amongst the E. coli isolates from 73 dogs.  
 
Resistance Profile Number of dogs carrying profile Percentage of dogs carrying profile 
AMP 36  53 
TET 30  44 
TM 3  4 
NAL 2  3 
AMP, TET 16  24 
AMP, TM 2  3 
TET, TM 7  10 
AMP, TET, TM 9  13 
CHL, TET 2  3 
CHL, TET, TM 1  1 
AMP, CHL, TET 7  10 
AMP, CHL, TET, TM 5  7 
AMP, AC 4  6 
AMP, AC, TM 1  1 
AMP, AC, TET 2  3 
AMP, AC, TET, TM 2  3 
AMP, NAL, TET, TM 1  1 
AMP, CHL, NAL, TET, TM 1  1 
CIP, NAL 1  1 
CIP, NAL, TET 1  1 
AMP, AC, CHL, TM 1  1 
AMP, AC, CHL, TET, TM 1  1 
AMP, CIP, CHL, NAL, TET, TM 4  6 
AMP, CIP, NAL, TM 1  1 
AMP, CIP, NAL, TET, TM 2  3 
AMP, AC, CIP, CHL, NAL, TET, TM 2  3 
AMP = ampicillin; TET = tetracycline; TM = trimethoprim; NAL = nalidixic acid; CHL = chloramphenicol; AC = clavulanate-amoxicillin; 
CIP = ciprofloxacin 
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3.3 ESBL- and AmpC-producing E. coli 
Only one dog carried ESBL-producing faecal E. coli (CTX-M group 1). The isolate was also MDR 
(AmpR, 3GCR, TetR, TMR) and carried a blaTEM gene. Cefpodoxime and clavulanate-amoxicillin 
resistant, phenotypic AmpC-producing E. coli (n = 16 isolates) were detected in 12 dogs (16%; 95% 
CI: 9.7-26.6), with five of these isolates from four dogs (6%; 95% CI: 2.2-13.3) MDR. However, only 
three isolates from three dogs (4%; 95% CI: 1.4-11.4) carried blaAmpC genes (all CIT) and one isolate 
also carried blaTEM. No isolates carried blaSHV, blaOXA or qnr genes. One isolate carrying blaAmpC was 
also MDR, including ciprofloxacin resistance (Table 2).  
 
Table 2. The resistance profiles of the ESBL- and AmpC-producing E. coli isolates (n = 18).  
Isolate Amp AC Cip Chl Nal Tet TM MDR AmpC ESBL blaAmpC blaCTXM blaTEM 
1 R R S S S R S S Y N N N N 
2 R R S S S R S S Y N blaCITM N Y 
3 R R S R S R R R Y N N N N 
4 R R R R R R R R Y N blaCITM N N 
5 R R S S S R S S Y N N N N 
6 R R S S S R S S Y N N N N 
7 R R S S S R S S Y N N N N 
8 R R S S S R S S Y N N N N 
9 R R S S S R S S Y N N N N 
10 R R S S S S S S Y N N N N 
11 R R S S S S S S Y N N N N 
12 R R S S S R R R Y N N N N 
13 R R R R R R R R Y N N N N 
14 R R S S S S S S Y N N N N 
15 R R S S S S S S Y N blaCITM N N 
16 R R S S S R R R Y N N N N 
17 R S S S S R R R N Y N Gp1 Y 
18 R S S S S R R R N Y N Gp1 Y 
Amp = ampicillin resistance; AC = clavulanate-amoxicillin resistance; Cip = ciprofloxacin resistance; Chl = chloramphenicol resistance; Nal 
= nalidixic acid resistance; Tet = tetracycline resistance; TM = trimethoprim resistance; MDR = multidrug resistance (resistance to ≥ 3 
antimicrobial class); ESBL = phenotypic ESBL-producing E. coli = ESBL, AmpC = phenotypic AmpC-producing E. coli; blaAmpC = carriage 
of AmpC genes; blaCTXM = carriage of CTX-M genes; blaCITM = carriage of CIT genes; Gp1 = ESBL with CTX-M gene group 1; R = 
resistant; S = susceptible 
 
 
3.4 Phylogenetic groups 
The first method by Doumith et al., (2012) assigned 58 E. coli isolates to phylogenetic group A (31%; 
95% CI: 24.7-37.8), 78 to group B1 (42%; 95% CI: 34.4-48.9), 33 to group B2 (18%; 95% CI: 12.8-
23.6) and 19 to group D (10%; 95% CI: 6.6-15.2). The second method by Clermont et al., (2013) 
assigned 15 E. coli isolates to phylogenetic group A (8%; 95% CI: 4.9-12.7), 78 to group B1 (42%; 
95% CI: 34.4-48.9), 31 to group B2 (17%; 95% CI: 11.9-22.5) and seven to group D (4%; 95% CI: 
1.8-7.5). The remaining isolates that were assigned to A group by the first method were reassigned to 
either group C (n = 39 isolates) or Escherichia Clades III-IV (n = 4 isolates). Additionally nine 
isolates that were assigned to either group B1 (n = 1), B2 (n = 3) or D (n = 5) by the first method were 
reassigned to group E and three isolates, assigned to group D by the first method, were reassigned to 
group F. There were also two isolates grouped as B1 by the first method that were classed as unknown 
by the second method. 
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The agreement between the two methods was compared using a kappa statistic. The agreement was 
very good for the assignment of phylo-groups B1 (kappa = 0.890) and B2 (kappa = 0.884), but there 
was only fair and moderate agreement respectively for phylo-groups A (kappa = 0.289) and D (kappa 
= 0.470). However, when the assignment of group A by the first method was compared to the 
assignment of group A or C, by the second method, the agreement was also very good (kappa = 
0.924).  
 
3.5 Conjugation studies 
All MDR isolates (n = 61), including two ESBL- and three AmpC-producing isolates, were tested for 
the transfer of antimicrobial resistance genes to a recipient E. coli strain. In total, 23 isolates 
transferred resistance to the recipient strain including ESBL- and AmpC-producing E. coli.  The 
isolates that successfully transferred resistance determinants were negatively associated with phylo-
group A (OR 0.2; CI: 0.05-0.66; P = 0.005) and C (OR 0.12; CI: 0.02-0.57; P = 0.002) but positively 
associated with phylo-group B1 (OR 1.58; CI: 1.55-15.19; P = 0.004) (Table 3).  
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Table 3. Details of the conjugation experiments: multidrug resistance isolates that have transferred resistance 
profiles/antimicrobial resistance genes onto the recipient strain*. 
 
Donor resistance phenotype Transconjugate resistance phenotype blaCIT or blaCTX-M  gene1 transconjugate 
AMP, TET, TM AMP, TET, TM  
AMP, CHL, TET, TM AMP, TET, TM  
AMP, CHL, TET, TM AMP, CHL, TET, TM  
AMP, TET, TM TET  
AMP, CHL, TET, TM AMP, TET  
AMP, TET, TM AMP, TET, TM  
AMP, TET, TM AMP, TET, TM  
AMP, CIP, TET, TM AMP, TET, TM  
AMP, AC, CIP, CHL, NAL, TET, TM AMP blaCIT 
AMP, CHL, TET AMP, CHL, TET  
AMP, CHL, TET AMP, CHL, TET  
AMP, CHL, NAL, TET, TM AMP, TET, TM  
AMP, CIP, CHL, NAL, TET, TM AMP, CHL, TET, TM  
AMP, CHL, TET AMP, CHL, TET  
AMP, TET, TM AMP, TET, TM  
AMP, AUG, CHL, TM AMP, TM  
AMP, CHL, TET, TM AMP  
AMP, CIP, CHL, NAL, TET, TM AMP, CHL, TET, TM  
AMP, CHL, TET AMP, CHL, TET  
AMP, CHL, TET AMP, CHL, TET  
AMP, CHL, TET AMP, CHL, TET  
AMP, CHL, TET AMP, CHL, TET  
AMP, CHL, TET AMP, CHL, TET  
AMP, CIP, CHL, NAL, TET, TM AMP, CHL, TET, TM  
AMP, TET, TM AMP, TET, TM blaCTX-M 
*The recipient strain was rifampin-resistant, lactose-negative E. coli 26R793 (Karczmarczyk et al., 2011); AMP = ampicillin; AC = 
clavulanate-amoxicillin; CIP = ciprofloxacin; CHL = chloramphenicol; NAL = nalidixic acid; TET = tetracycline; TM = trimethoprim; 
1present in donor and transconjugate. 
 
 
 
3.6 Association between phylo-groups and antimicrobial resistance outcomes 
ESBL-producing E. coli belonged to phylo-group B2, whereas the 17 AmpC-producing E. coli 
belonged to groups A (n = 5), B1 (n = 8) or D (n = 4). One isolate carrying blaAmpC belonged to group 
B1 and two isolates to group A (including the ciprofloxacin and MDR isolate). The majority of the 
isolates in phylo-groups A, B1 and D were resistant to at least one antimicrobial, particularly a beta-
lactam, whereas group B2 isolates were unlikely to be antimicrobial resistant (P < 0.001) and did not 
contain isolates with either clavulanate-amoxicillin, 3GCR or MDR. On the other hand, group D 
isolates were likely to be antimicrobial resistant (P = 0.04), in particular to clavulanate-amoxicillin (P 
= 0.004) and 3GCR (P = 0.005). Ciprofloxacin resistant isolates were spread between the phylo-
groups (Figure 3; Table 4-2, Appendix II). 
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Figure 3. Percentage of isolates (n = 188) with each antimicrobial resistance outcome (n = 6) and phylo-group (error 
bars = 95% CI).  
 
95% confidence interval = 95% CI; phylo-groups A, B1, B2 or D (Doumith et al., 2012); ACR = clavulanate-amoxicillin resistance; CipR = 
ciprofloxacin resistant; BLR = beta-lactam antimicrobial resistant; 3GR = third generation cephalosporin resistant; AMR = any 
antimicrobial resistance; MDR = multidrug resistance; *significant (P < 0.05) 
 
3.7 Logistic regression of antimicrobial resistance, phylo-groups & questionnaire data 
The diet of all dogs in this study consisted of dry dog food supplemented either with tinned dog food, 
home-cooked meats, proprietary dog treats, table scraps or raw meat. In addition, a number of dogs 
regularly scavenged from the environment. The variables, obtained from questionnaire data, and the 
investigated outcomes were all categorical other than age (Table 4). Clavulanate-amoxicillin 
resistance (P = 0.003) and 3GCR (P = 0.002) were associated with dogs eating raw meat (chicken, 
red-meat and/or tripe). Multi-animal households were also at increased risk for faecal carriage of E. 
coli with 3GCR (P = 0.04) and in particular, multi-dog households were of borderline significance for 
beta-lactam resistance (P = 0.08). Consumption of proprietary dog treats appeared to be protective 
against ciprofloxacin (P = 0.003) and MDR (P = 0.001) E. coli (Table 5). Univariable models are 
included in the appendix of this chapter (Table 4-3, Appendix II). 
* * * 
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Table 4. The number and percentage of dogs with each categorical variable and outcome for 73 dogs. 
Variable ACR  CipR BLR 3GCR 
 
AMR 
 
MDR Phylo-
group  
A 
Phylo-
group  
B1 
Phylo-
group  
B2 
Phylo-
group  
D 
Phylo-
group  
C 
Phylo-
groups  
E, F, 
Clades 
Total 
dogs with 
variable  
Dog eats raw meat 6 (50) 4 (40) 10 (26) 6 (55) 11 (24) 7 (32) 7 (30) 9 (30) 1 (8) 5 (38) 7 (41) 3 (25) 15 (21) 
Dog eats animal carcass or faeces 9 (75) 5 (50) 22 (56) 7 (64) 25 (54) 12 (55) 15 (65) 13 (43) 7 (58) 8 (62) 12 (71) 2 (17) 42 (58) 
Dog eats tinned or cooked meat  1 (8) 2 (20) 7 (18) 3 (27) 10 (22) 4 (18) 1 (4) 6 (20) 2 (17) 2 (15) 1 (6) 1 (8) 16 (22) 
Dog fed treats 10 (83) 3 (30) 25 (64) 8 (73) 32 (70) 10 (46) 15 (65) 18 (60) 11 (92) 9 (69) 8 (47) 4 (33) 52 (71) 
Dog fed table scraps 7 (58) 6 (60) 19 (49) 6 (55) 21 (46) 10 (46) 12 (52) 13 (43) 3 (25) 6 (46) 7 (41) 1 (8) 37 (51) 
Multi-dog household 12 (100) 9 (90) 34 (87) 7 (64) 38 (84) 20 (91) 21 (91) 24 (80) 8 (67) 12 (92) 16 (94) 5 (42) 56 (77) 
Multi-animal household 6 (50) 6 (60) 17 (44) 1 (9) 21 (48) 10 (46) 12 (52) 12 (40) 5 (42) 7 (54) 8 (47) 4 (33) 30 (41) 
Owner works with farm animals 1 (8) 3 (30) 5 (13) 1 (9) 10 (23) 2 (9) 6 (26) 7 (23) 1 (8) 2 (15) 3 (18) 0  15 (21) 
Owner works in healthcare 4 (33) 2 (20) 12 (31) 4 (36) 16 (36) 5 (24) 8 (35) 8 (27) 6 (50) 7 (54) 6 (35) 3 (25) 25 (34) 
In-contact been hospitalised1 8 (67) 7  (70) 24 (62) 8 (73) 28 (62) 13 (59) 12 (52) 18 (60) 7 (33) 9 (69) 9 (53) 4 (33) 44 (60) 
In-contact received antimicrobials1 5 (42) 8 (80) 25 (64) 5 (45) 31 (69) 15 (68) 12 (52) 20 (67) 6 (50) 8 (62) 10 (59) 4 (33) 44 (60) 
Male 5 (42) 4 (40) 16 (41) 5 (45) 19 (41) 8 (36) 9 (39) 12 (41) 6 (50) 5 (38) 7 (41) 2 (17) 34 (47) 
Female 7 (58) 6 (60) 23 (59) 6 (55) 27 (59) 14 (64) 14 (61) 17 (57) 6 (50) 8 (62) 10 (59) 4 (30) 37 (51) 
Total dogs with outcome 12 (16) 10 (14) 39 (53) 11 (15) 46 (63) 22 (30) 23 (31) 30 (40) 12 (16) 13 (17) 17 (23) 12 (16) 73 (100) 
1In-contact person or pet within 12 months before enrolment. ACR = clavulanate-amoxicillin resistance; CipR = ciprolfloxacin resistance; BLR = beta-lactam resistance; 3GCR = third generation cephalosporin 
resistance; AMR = antimicrobial resistance to at least one disc; MDR = multidrug resistance (resistance to three or more antimicrobial classes); phylo-groups A-D are from (Doumith et al., 2012) and C, E, F and clades 
from (Clermont et al., 2013).
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Table 5. Final multivariable logistic regression models for the six antimicrobial resistance outcomes 
amongst faecal E. coli from 73 dogs. 
Resistance outcome and final model variables     
Clavulanate-amoxicillin (ACR) β  OR 95% CI P-value 
Dog eats raw meat1 2.25 9.57 2.0-45.68 0.003* 
In-contact had antimicrobials2 - 1.79 0.19 0.04-0.91 0.028* 
Ciprofloxacin resistance (CipR) β  OR 95% CI P-value 
Dog fed treats1 - 2.07 0.13 0.03-0.56 0.004* 
Beta-lactam resistance (BLR) β  OR 95% CI P-value 
Multi-dog household1  1.16 3.19 0.85-11.99 0.08 
Owner works with farm animals1  - 1.06 0.35 0.1-1.19 0.09 
3rd generation cephalosporin resistance (3GCR) β  OR 95% CI P-value 
Dog eats raw meat1 2.39 10.86 2.18-54.03 0.002* 
In contact had antimicrobials1 - 1.55 0.21 0.04-1.07 0.05 
Multi-animal household1  1.62 5.06 0.97-26.5 0.04 
Any antimicrobial resistance (AMR) β  OR 95% CI P-value 
Gender (Male is reference) 0.81 2.25 0.83-6.1 0.11 
Multidrug resistance (MDR) β  OR 95% CI P-value 
Dogs fed treats1 - 1.9 0.15 0.04-0.49 0.001* 
Owner works with farm animals1 - 1.5 0.23 0.04-1.3 0.07 
1 Reference category is the absence of the risk factor; 2Within 12 months of enrolment; β = coefficient; OR = odds ratio; 95% CI 
= 95% confidence interval; P values are from the likelihood ratio test; AMR = antimicrobial resistance to at least one 
antimicrobial; MDR = antimicrobial resistance to three or more antimicrobial classes; *significant at P < 0.05. 
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Association with a raw meat diet was also significant for phylo-groups B1 (P = 0.032) and D 
(P = 0.014) and of borderline significance (P = 0.056) for group B2 isolates. Multi-dog 
households were associated with phylo-groups A (P = 0.02) and C (P = 0.05), while having 
an owner working in healthcare was significant for carriage of group D (P = 0.015). Dogs 
rolling in, or eating animal carcasses or faeces were negatively associated with group B1 (P = 
0.018) and being fed treats was negatively associated with group C (P = 0.011) (Table 6). 
Univariable models are included in the appendix of this chapter (Table 4-4, Appendix II). 
 
Table 6. Final multivariable logistic regression models for the six-phylogeny outcomes amongst faecal E. coli 
from 73 dogs. 
Resistance outcome and final model variables     
Phylogenetic group A β  OR 95% CI P-value 
Multi-dog household1 2.00 7.4 0.89-61.21 0.020* 
Phylogenetic group B1 β  OR 95% CI P-value 
Dog eats raw meat1 1.38 3.9 1.08-14.64 0.032* 
Dog eats animal carcass or faeces1 - 1.26 0.28 0.1-0.83 0.018* 
Phylogenetic group B2 β  OR 95% CI P-value 
Dog eats raw meat1 1.17 3.2 0.94-11.0 0.056 
Phylogenetic group D β  OR 95% CI P-value 
Dog eats raw meat1 2.08 8.04 1.37-47.21 0.014* 
Owner works in healthcare1 1.88 6.57 1.24-34.82 0.015* 
Phylogenetic group C β  OR 95% CI P-value 
Multi-dog household1 1.84 6.29 0.68-57.9 0.054 
Dog fed treats1 - 1.58 0.21 0.06-0.72 0.011* 
Age (variable is continuous) - 0.018 0.98 0.96-1.01 0.075 
Phylogenetic groups E, F or Clades β  OR 95% CI P-value 
Dog eats raw meat 2.85 5.44 1.43-20.72 0.014* 
1 Reference category is the absence of the risk factor; β = coefficient; OR = odds ratio; 95% CI = 95% confidence interval; P 
values are from the likelihood ratio test; AMR = antimicrobial resistance to at least one antimicrobial; MDR = antimicrobial 
resistance to three or more antimicrobial classes; phylo-groups A, B1, B2 and D based on (Doumith et al., 2012); C, E, F and 
Clades based on (Clermont et al., 2013); *significant at P < 0.05. 
 
4. Discussion 
 
This study found a high level of antimicrobial and multidrug resistance amongst canine faecal 
E. coli from a group of healthy Labrador retrievers in the UK, in the absence of direct 
antimicrobial selective pressure and veterinary premises contact. However, the majority of the 
isolates were of commensal (B1 and A) phylogenetic backgrounds and detection of ESBL- 
and plasmid-mediated AmpC-producing E. coli was rare.  
 
The level of MDR was high (30% of dogs) compared to that in previous reports of healthy 
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dogs in the UK of 15% (Wedley et al., 2011). This discrepancy may be due to the five-year 
difference in sample collection between the studies as the prevalence of AMR may have 
increased in such populations over time. In addition, the dogs in this study were regularly in 
close contact, in confined environments, with many other dogs and humans at dog shows 
around the UK. Sharing of faecal E. coli isolates may occur within kennels (Harada et al., 
2011), within households between humans and pets (Damborg et al., 2009; Johnson et al., 
2008; Stenske et al., 2009) and probable transmission of MDR resistant faecal E. coli from 
humans to dogs (Stenske et al., 2009). Moreover, kenneled dogs can have a higher prevalence 
of AMR faecal E. coli than individually owned dogs (De Graef et al., 2004), possibly 
associated with antimicrobial selection pressure and/or exposure through diet, the 
environment or other dogs.  
 
Only one dog had faecal E. coli carrying a blaCTX-M gene and only three dogs carried blaAmpC. 
A similar prevalence (< 1% of faecal samples) was reported for healthy dogs in semi-rural 
Cheshire (Wedley et al., 2011). A larger UK wide study reported a slightly higher prevalence 
of 4% and 7% of ESBL- and AmpC-producing E. coli respectively (Wedley, 2012) but these 
dogs may have received antimicrobials or had other veterinary contact within 12 months of 
sampling, and may be more representative of the whole UK vet visiting dog population. 
Antimicrobial therapy with enrofloxacin or cefalexin has been reported to select for faecal E. 
coli carrying blaCTX-M or blaAmpC respectively (Damborg et al., 2011; Moreno et al., 2008) and 
the absence of antimicrobial therapy in dogs in the current study may explain the low 
prevalence. Ciprofloxacin resistance was uncommon, but when present corresponded with 
MDR. This finding has been previously reported amongst canine clinical isolates, where it 
was proposed that this was due to ‘last-line’ clinical use of fluoroquinolones in dogs (Platell 
et al., 2011). 
 
The majority of the isolates in this study belonged to phylo-group B1 followed by A, B2 and 
D, which concurs with (Tenaillon et al., 2010) who reviewed a number publications 
examining faecal E. coli from various animal species. Damborg et al., (2009) also reported a 
predominance of phylo-group B1 in 13 healthy dogs in Denmark. However, this 
predominance of group B1 followed by group A has been reported in farmed and wild 
herbivorous animals (Carlos et al., 2010; Escobar-Paramo et al., 2006), whereas omnivorous 
and carnivorous animals had a predominance of A followed by B1 (Escobar-Paramo et al., 
2006). The base diet of the dogs in this study was proprietary dry dog food, consisting of a 
combination of crude fibre and protein, equivalent to an omnivorous diet. We expected the 
phylogenic diversity to be similar to that reported for other domesticated omnivorous animals. 
High levels of crude dietary fibre found in some dog foods could impact the abundance of 
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certain phylo-groups (O'Brien and Gordon, 2011), although this variable was not examined in 
the current study. Escobar-Paramo et al., (2006) found increased prevalence of B1 and A and 
decreased B2 and D from domesticated animals compared to wild animals, which is in 
agreement with our findings. The authors proposed that this might be associated with high 
antimicrobial pressure in the farmed animals deselecting antimicrobial susceptible B2 strains, 
although the dogs in our study had not received antimicrobials. The secondary habitat of E. 
coli is soil, sediment and water (Savageau, 1983) where phylo-group B1 isolates are more 
likely to persist than the other groups (Walk et al., 2009). Given the propensity for dogs to 
drink, scavenge and orally explore their environments, these habits may predispose them to a 
predominance of B1 but many other factors may be involved. French pig-farmers were found 
to have a faecal E. coli phylogeny (Escobar-Paramo et al., 2004) more similar to their 
livestock than to other human populations (Escobar-Paramo et al., 2006). As dogs live in very 
close contact with humans it would be interesting to see if dog owners have a divergent 
phylogeny from non-dog owners and the general human population.  
 
Previous studies have reported that antimicrobial resistant E. coli from humans and dogs are 
less likely to be of phylo-group B2 (Johnson et al., 2009; Johnson et al., 2003; Platell et al., 
2010; Platell et al., 2011; Sato et al., 2014). Similarly, this study showed that group B2 
isolates tended to be more susceptible and in particular, less likely to be clavulanate-
amoxicillin, 3GCR or MDR. Phylo-group D was more likely to be antimicrobial resistant; in 
particular to clavulanate-amoxicillin and 3GCR. Other studies have reported a relationship 
between group D and fluoroquinolone resistance, 3GCR and MDR (Deschamps et al., 2009; 
Platell et al., 2011; Sato et al., 2014; Tamang et al., 2012). Phylo-group D was not associated 
with fluoroquinolone resistance in this study, although the low prevalence of this phylo-group 
and fluoroquinolone resistance may have precluded accurate statistical analysis. 
  
The analysis of AMR outcomes and phylogenetic groups with potential risk factors found a 
relationship between dogs fed raw diets (chicken, red meat and/or tripe) with clavulanate 
amoxicillin and 3GCR, as well as with phylo-groups B1, D and combined E, F and Clades. In 
addition multi-dog households were associated with 3GCR and phylogenetic group A, and 
dogs with owners working in either human or veterinary healthcare were more likely to have 
phylo-group D faecal E. coli isolates. In contrast, consumption of proprietary dog treats 
appeared to be protective against ciprofloxacin resistance and phylogenetic group C; group C 
was associated ciprofloxacin resistance on univariable analysis. Dogs fed Salmonella-
contaminated raw-meat diets have been reported to shed Salmonella in their faeces (Finley et 
al., 2007). Food, particularly chicken meat, has been reported as a possible source of 
antimicrobial resistant bacteria, including ExPEC, for humans and dogs (Johnson et al., 2009; 
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Johnson et al., 2007; Vincent et al., 2010). Both ESBL- and AmpC-producing and 
ciprofloxacin resistant E. coli have been isolated from chickens and pigs in Spain, and the 
predominant phylo-groups reported from chickens, pigs and cattle in the US, Spain and South 
Korea are B1, A and D (Cortes et al., 2010; Johnson et al., 2003; Johnson et al., 2007; Unno 
et al., 2009). Recommendations to feed raw meat diets are of some concern, as raw meats 
may be a source of AMR and/or pathogenic organisms that are potential animal and a public 
health risks.  
 
Sharing of faecal E. coli between household members correlates with increasing numbers of 
in-contact humans and pets (Johnson et al., 2008). This may include phylo-group A strains, 
which appear to be equally present in humans and animals (Tenaillon et al., 2010). 
Furthermore, people working in healthcare may represent reservoirs of antimicrobial resistant 
and/or pathogenic bacteria for their home and its occupants. Phylo-group D isolates may 
potentially cause extra-intestinal infections and, together with probable antimicrobial 
resistance, may be selected within healthcare environments.  
 
There was very good agreement between the two methods for assigning isolates to group B1 
and B2 and differences were mainly associated with the reassignment of the groups. The 
prevalence of group C in our study was high compared to the prevalence reported for a 
variety of pathogenic and commensal E. coli isolates of human, bird and non-human mammal 
origin (Clermont et al., 2013) but further studies will be required to confirm this finding in 
dogs. Phylo-groups E and F are potential ExPEC strains (Jaureguy et al., 2008; Tenaillon et 
al., 2010) and were re-assigned from group D or B2 with similar risk factors to group D. Four 
isolates were assigned to Escherichia Clades (Clermont et al., 2013). Escherichia Clades have 
been more commonly isolated from non-human mammals and birds than people and are 
unlikely to be pathogenic (Clermont et al., 2011a). They have not been reported previously in 
dogs but as they may emanate from an environmental source (Walk et al., 2009) it is not 
surprising to find them.  
 
Limitations of this study include the low number of observations for some outcomes, which 
reduced the power of the study. Selection and testing of more isolates may have increased the 
detection of antimicrobial resistance, in particular ESBL-producing E. coli. However, despite 
the small subgroups, we were able to identify strong associations between outcomes and risk 
factors. Another limitation was that the study only included one breed and had limited 
demographics. It is possible that samples from other breeds and other geographical 
populations would differ.  
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5. Conclusions 
 
The overall prevalence of AMR and MDR amongst canine faecal E. coli was higher than 
expected for a group of healthy non-vet-visiting and non- antimicrobial-treated dogs. 
However the level of ESBL and AmpC-producing E. coli was low and had not increased 
compared to earlier UK studies. The predominant faecal E. coli phylogenetic group in this 
group of dogs was group B1, and group B2 was less likely than the other groups to harbour 
antimicrobial resistance, in agreement with previous work. Certain risk factors were 
identified. In particular, raw meat diets were associated with increased detection of beta-
lactam resistance and phylo-group D, representing a potential animal welfare and zoonotic 
risk. Further strain characterisation, including virulence typing, may help to elucidate this 
further. It is likely that the canine faecal flora consists of a variety of organisms in addition to 
canine resident bacteria derived from in contact humans and animals, diet or the environment. 
Transient bacteria may act as a reservoir of antimicrobial resistant determinants for resident 
bacteria. Additionally, selective pressure through antimicrobial therapy may facilitate 
establishment as permanent residents of the gut flora. Gut diversity is likely to be dynamic 
and maybe cyclical. Future research should include longitudinal studies with genotyping to 
better determine and understand these changes. 
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Summary 
 
Background: The intestinal E. coli population structure in healthy humans and other animals 
is diverse with differing phenotypes and genotypes over time. Risk factors for antimicrobial 
resistant (AMR) faecal E. coli include antimicrobial therapy and veterinary admission but few 
longitudinal studies have examined commensal isolates in healthy dogs under normal 
exposures.  
Objectives: The main aim of the study was to characterise the population structure and AMR 
profiles of E. coli in healthy non-vet visiting and non-antimicrobial treated dogs over three 
months and to examine potential risk factors of carriage.  
Methods: Faecal samples were collected from 28 dogs; daily for seven days, weekly for four 
weeks, and monthly for two months. Isolates were identified using phenotypic and 
biochemical methods and PCR assay for the uidA gene. Disc diffusion susceptibility tests 
were determined for a range of antimicrobials, including combination disc tests for 
phenotypic ESBL- and AmpC-production. A selection of isolates from three dogs was strain 
typed using Pulsed Field Gel Electrophoresis (PFGE). Survival analysis was calculated for 
resistance outcomes and multilevel, multivariable models were used to examine potential risk 
factors of carriage. 
Results: AMR to at least one antimicrobial, MDR, AmpC- and ESBL-producing E. coli were 
detected in 45%, 14%, 20% and 4% of samples (n = 341), respectively. AMR to at least one 
antimicrobial and AmpC-producing E. coli could be persistent, whereas MDR and ESBL-
producing isolates were usually intermittent and/or transient. The mean survival of isolates 
with AMR, MDR, ESBL and AmpC-production was 58, 24, 29 and 18 days, respectively. 
Marked genetic diversity was demonstrated on an individual animal basis. There was frequent 
change of resistance phenotype and genotype, however resident clones were detected. Owners 
working with farm animals were associated with AMR to any antimicrobial, eating raw meat 
was associated with MDR and ESBL/AmpC-production and the consumption of dog treats 
was associated with MDR faecal E. coli. 
Conclusions: AMR was common and persistent. MDR- and AmpC-production was less 
frequent, transient or intermittent. ESBL-production was rare and transient, suggesting 
exogenous exposure, and eating raw meat was associated with MDR and ESBL/AmpC 
production. The E. coli population structure was diverse with frequent change of resistance 
phenotype and genotype over time. These findings highlight the diversity of gut E. coli under 
natural conditions and potential risk factors that should be taken into account when examining 
the impact of antimicrobial therapy.  
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3. Introduction 
 
Antimicrobial resistance (AMR), particularly multi-drug resistance (MDR), is increasing 
amongst E. coli from people and other animals (Ewers et al., 2012; Gould, 2009; Hunter et 
al., 2010). Of major concern is the emergence and dissemination of ESBL-producing E. coli 
that are resistant to a wide range of beta-lactam antimicrobials, including oxyimino-
cephalosporins (Gould, 2008). Additionally, AmpC-producing E. coli that are common 
amongst animal isolates, are resistant to cephamycins and not inhibited by clavulanic acid 
(Jacoby, 2009; Li et al., 2007; Thomson, 2010). Genes encoding these enzymes can be spread 
between bacteria by horizontal transmission on mobile genetic elements (Li et al., 2007), and 
due to genetic linkage with other antimicrobial resistance determinants, isolates are 
commonly MDR (Gould, 2009; Paterson and Bonomo, 2005). MDR, ESBL- and AmpC- 
producing E. coli have been detected in healthy and hospitalised dogs (Gibson et al., 2011b; 
Guo et al., 2013; Wedley, 2012; Wedley et al., 2011) and in canine clinical samples (O'Keefe 
et al., 2010; Sanchez et al., 2002; Sidjabat et al., 2006). 
 
Colonisation of the hosts’ large intestine is a prerequisite for extra-intestinal infections with 
E. coli (Martindale et al., 2000). Gastrointestinal E. coli may include both commensal and 
ExPEC (extra-intestinal pathogenic E. coli) strains. ExPEC strains are more likely to reside 
within phylogenetic group B2, and to a lesser extent group D (Picard et al., 1999). ExPEC are 
more likely than commensal strains to carry a range of virulence genes that may be involved 
in pathogenesis (Russo and Johnson, 2003). In particular, virulence genes may encode 
colonisation factors, such as P fimbriae that facilitate gut colonisation by resident E. coli 
strains. Resident strains are adapted to the gut environment and can persist for extended 
periods, and in humans they are often of phylo-group B2 (Nowrouzian et al., 2001; 
Nowrouzian et al., 2006; Sears et al., 1950; Sears et al., 1956). Transient strains are only 
present for a few days to weeks but may act as a reservoir of AMR determinants for resident 
bacteria (Wellington et al., 2013), or antimicrobial selective pressures may lead to longer 
persistence in the gut (Dethlefsen et al., 2007; Edlund and Nord, 2000).  
 
Longitudinal studies in people, horses, cattle and dogs have reported the intestinal E. coli 
population structure to be diverse and in a state of flux (Anderson et al., 2006; Damborg et 
al., 2009; Schlager et al., 2002). Schlager et al., (2002) examined faecal E. coli from female 
children, in the absence of antimicrobial pressure, and reported a change of resident clone on 
a weekly basis in approximately 60% of cases. Anderson et al., (2006) also reported a 
changing dominant subtype on a monthly basis in horses, cattle and adult humans (Anderson 
et al., 2006). This latter study also reported greater diversity amongst E. coli populations, with 
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respect to AMR phenotypes and genotypes, in farm animals compared to humans. Damborg 
et al., (2009) reported either long-term or intermittent detection of one or two resident E. coli 
strains in the majority of people and dogs, however there was high individual diversity with 
frequent detection of different clones, particularly in dogs. Overall faecal E. coli population 
dynamics can differ between individuals and between host species; possibly associated with 
particular host factors such as signalment, diet and health status (Anderson et al., 2006). 
 
The intestinal microbiota has a protective barrier function for the host (Vollaard and Clasener, 
1994). Disruption of the microbiota and selection of AMR may ensue following exposure to 
certain factors including disease, diet and medications (Katouli, 2010; Stecher and Hardt, 
2008; Vincent et al., 2010). In particular, antimicrobial therapy can disturb the intestinal 
microbial flora and select for AMR (Edlund and Nord, 2000; Jernberg et al., 2010). Both 
antimicrobial therapy and veterinary clinic admission are reported risk factors for the 
detection of MDR, ESBL and AmpC-producing E. coli in dogs (Damborg et al., 2011; Gibson 
et al., 2011a, b; Moreno et al., 2008; Stenske et al., 2009). Additionally, the environment 
(Wellington et al., 2013), in-contact humans or pets (Damborg et al., 2009; Johnson et al., 
2008; Sidjabat et al., 2006) and farm-animal meat (Johnson et al., 2009; Johnson et al., 2007; 
Vincent et al., 2010) are possible sources of AMR E. coli or ExPEC strains.  
 
Shedding of AMR faecal E. coli has been reported in dogs and horses receiving antimicrobial 
therapy (Damborg et al., 2011; Damborg et al., 2012; Gronvold et al., 2010; Johns et al., 
2012; Lawrence et al., 2013; Trott et al., 2004). Hospitalisation in addition to antimicrobial 
therapy increased the duration of shedding in horses in one study (Johns et al., 2012). Faecal 
shedding of AMR bacteria and/or determinants leads to environmental contamination and 
potential dissemination to in-contact humans or pets (Johnson et al., 2009; Johnson et al., 
2001). However, few studies have examined temporal faecal shedding of antimicrobial 
resistant E. coli in healthy dogs in the community. 
 
E. coli community profiles have been commonly investigated to detect antimicrobial selection 
pressure on the gastrointestinal flora (Gronvold et al., 2010), however study construction and 
interpretation should be based on knowledge and understanding of the normal diversity that 
occurs in healthy individuals over time. This study was performed to characterise the 
diversity of the canine faecal E. coli population structure and AMR shedding patterns in the 
absence of direct antimicrobial pressure or veterinary premise contact but with normal day-to-
day exposures. This study may act as a baseline for further risk factor associated studies in 
dogs. 
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2. Methods 
2.1 Study population 
 
A convenience sample (n = 28 dogs) of staff-owned healthy dogs was recruited from the 
University of Liverpool, Leahurst Campus, between October 2011 and May 2012. Exclusion 
criteria included antimicrobial therapy or veterinary admission within three months of 
enrolment. Dogs were excluded during the study if they became ill, were prescribed systemic 
antimicrobials or attended veterinary premises. Before enrolment, all dog owners read the 
study information sheets and gave written informed consent. Owners were asked to provide a 
fresh faecal sample from their dog once daily for seven days (days 0, 1, 2, 3, 4, 5, & 6), 
followed by once weekly for four weeks (days 13, 20, 27 & 34) and then once monthly for 
two months (days 62 & 90). Labelled sterile faecal pots (n = 13) were provided for the owner 
of each dog at the time of enrolment. Samples were either delivered in person or by first-class 
post. Email and phone text reminders were sent before each weekly and monthly sample was 
due. A two-page questionnaire for potential risk factors for the carriage of AMR bacteria was 
administered at the start and end of the study. Questionnaires were returned in person, by 
first-class post or by email and consisted of closed questions with tick box responses and 
space for additional information (Appendix III). A “Don’t Know” response was included for 
all questions to enable the respondent to avoid answering incorrectly if they were uncertain. 
Data were collected regarding patient signalment, diet, the presence and type of in-contact 
pets, previous medical history of the household (including antimicrobial therapy or hospital 
contact of humans and pets) and whether owners worked with farm animals or in healthcare. 
All questionnaire-derived information was available as potential explanatory variables for 
inclusion in the multivariable modelling of antimicrobial resistance outcomes. The University 
of Liverpool, School of Veterinary Science Ethics-Committee approved the study protocol in 
October 2011.  
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2.2 Specimen collection and bacterial isolation 
 
Faecal samples were mixed with an equal volume of brain heart infusion broth containing 5% 
glycerol (BHI-G) on receipt. Each faecal homogenate was streaked onto one eosin methylene 
blue agar (EMBA) plate without antimicrobials, one EMBA plate impregnated with 1 µg/ml 
ceftazidime (CZ) and one EMBA plate impregnated with 1 µg/ml cefotaxime (CX) (Liebana 
et al., 2006), to obtain single colonies. In addition, to detect antimicrobial resistant isolates, 
one EMBA plate and one MacConkey agar (MAC) plate were inoculated with the faecal 
homogenate for confluent bacterial growth with seven antimicrobial discs (10 µg ampicillin, 
30 µg clavulanate-amoxicillin, 1 µg ciprofloxacin, 30 µg chloramphenicol, 30 µg nalidixic 
acid, 30 µg tetracycline and 2.5 µg trimethoprim) (Bartoloni et al., 2006; Bartoloni et al., 
1998). A further 500 µL of faecal homogenate was enriched in 4.5 ml of buffered peptone 
water.  All plates and broths were incubated aerobically for 18-20 hours at 37°C. If there had 
been no growth on the EMBA plates impregnated with third generation cephalosporins, the 
enriched broths were streaked onto the same selective media and incubated aerobically for 18 
to 20 hours at 37°C. Three random colonies, whose morphology resembled E. coli, were 
selected from the plain EMBA plate. Where present, one colony growing within the zone of 
inhibition around each antimicrobial disc on both the EMBA and MAC plates and/or from the 
CX and/or CZ plates were also selected. These colonies were sub-cultured onto nutrient agar 
and incubated aerobically for 18 to 20 hours at 37°C. Gram stains and biochemical tests 
(catalase production, lack of oxidase, lactose fermentation, indole production and inability to 
use citrate as a carbon source) to confirm E. coli were performed on fresh overnight cultures. 
PCR assays for the uidA gene (McDaniels et al., 1996) were performed to confirm that the 
isolates were E. coli before further characterisation. All antimicrobial discs were obtained 
from MAST Group Ltd., Liverpool, UK, the media from LabM Ltd, Bury, UK, and the CX 
and CZ powder from Sigma-Aldrich Company Ltd, Gillingham, UK. 
 
2.2 Antimicrobial susceptibility testing 
 
Antimicrobial susceptibility disc diffusion testing was performed on all E. coli isolates 
according to British Society for Antimicrobial Chemotherapy guidelines (BSAC; Version 
11.1 May 2012) (Andrews, 2007). Iso-Sensitest agar plates were inoculated, with isolates 
homogenised in sterile distilled water (1:10 dilution of a 0.5 McFarland standard), for semi-
confluent bacterial growth and the same panel of seven antimicrobial discs were applied. 
After the plates were incubated aerobically at 37°C for 18 to 20 hours, the zone diameters 
around each disc were measured in millimeters and recorded. E. coli ATCC® 25922 (LGC 
Standards, Teddington, UK), was used as a control.  
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2.3 Screening for phenotypic AmpC- and ESBL-producing E. coli 
 
Isolates that grew on media containing third generation cephalosporins were tested for the 
production of ESBL enzymes. An Iso-Sensitest agar plate was inoculated for confluent 
bacterial growth and three pairs of cephalosporin discs (with and without clavulanic acid) 
were placed on the surface of the agar plate: 30 µg ceftazidime and 30 µg ceftazidime plus 10 
µg clavulanic acid; 30 µg cefotaxime and 30 µg cefotaxime plus 10 µg clavulanic acid; and 30 
µg cefpodoxime and 30 µg cefpodoxime plus 10 µg clavulanic acid. The plates were 
incubated aerobically at 37°C for 18 to 20 hours and zone diameters around each disc were 
measured and recorded. ESBL production was confirmed when the zone around the 
cephalosporin disc was expanded in the presence of the clavulanic acid by a minimum of 5 
mm by one or more of the antimicrobial pairs, according to the manufacturer’s instructions 
(Extended Spectrum Beta-Lactamase Set D52C, MAST Group Ltd., Liverpool, UK) (M'Zali 
et al., 2000). E. coli isolates resistant to third generation cephalosporins or clavulanate-
amoxicillin were tested for production of AmpC enzyme. An Iso-Sensitest agar plate was 
inoculated for confluent bacterial growth and three discs applied: 10 µg cefpodoxime plus 
AmpC inducer (A); 10 µg cefpodoxime plus AmpC inducer and ESBL inhibitor (B); 10 µg 
cefpodoxime plus AmpC inducer, ESBL inhibitor and AmpC inhibitors (C). The plates were 
incubated aerobically at 37°C for 18 to 20 hours and zone diameters around each disc were 
measured and recorded. AmpC production was confirmed when the zone of inhibition around 
disc C was greater than that for discs A and B by a minimum of 5 mm, according to the 
manufacturer’s instructions (AmpC detection set D69C, MAST Group Ltd., Liverpool, UK) 
(Halstead et al., 2012). E. coli ATCC® 25922 (LGC Standards, Teddington, UK) was used as 
a control. 
 
2.4 Macro-restriction pulsed field gel electrophoresis (PFGE)  
 
PFGE was performed on a selection of isolates from 21 samples (n = 3 dogs) to compare 
phenotypic resistance outcome with genotype. XbaI digested genomic DNA was analysed in 
1% agarose gels in 0.5 x Tris-boric acid (TBE) buffer at 14°C in a CHEF-DRIII PFGE system 
in accordance with (Ribot et al., 2006). Banding patterns were assessed for each dog to 
examine individual genetic diversity over time. 
 
2.5 Statistical analysis 
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All questionnaire derived information and microbiological data were entered into a 
spreadsheet program (Microsoft Excel for Mac 2008, Microsoft Corporation) and the dataset 
was reviewed and checked for coding of all variables. Independent (risk factor) variables 
were created from information obtained from the owner questionnaires. Except for the age of 
the dog, all variables were dichotomous or categorical in nature. The variable body weight 
was divided into three categories: small (< 11 kg), medium (11 - 20 kg) and large (> 20kg) 
(Table 1).  
 
Microbiological data were collapsed to the sample level and categorised for time of sample 
collection. Initial data analysis included calculation of the percentage, with 95% confidence 
intervals, of samples with antimicrobial resistance to each tested antimicrobial and in 
addition, antimicrobial resistance to at least one tested antimicrobial (AMR), multidrug 
resistance (MDR; resistance to three or more antimicrobial classes) and the presence of either 
extended-spectrum beta-lacatmase (ESBL) or AmpC-producing E. coli (AmpC). 
 
Kaplan Meier plots were utilised to calculate the duration of shedding of antimicrobial 
resistant faecal E. coli for the four outcomes: AMR, MDR, ESBL and AmpC. The survival 
time was the time in days from the appearance of the resistance outcome until the first 
occurrence of two consecutive negative samples. If the end event (loss of resistance outcome 
for two consecutive samples) did not occur before the dog left of completed the study it was 
censored. The first six samples were considered together so that the minimum duration was 
seven days. Kaplan-Meier plots were created to determine the mean and median duration of 
each outcome. The Log-rank test was used to detect differences between the resistance 
outcomes (significance P < 0.05). 
 
To examine the effect of independent variables on the presence of resistance, data were 
analysed using a multilevel logistic regression models with a binomial distribution and logit 
link. Due to the inclusion of multiple dogs from some owners and repeated samples over 
time, data were clustered within household (level three) and within dogs (level two units) and 
this clustering was accounted for by inclusion of second- and third-level random intercept 
terms in all models. Faecal samples were considered the level one unit of interest. Three 
binary outcomes were investigated: AMR, MDR and the presence of either ESBL- or AmpC-
producing E. coli (ESBL/AmpC).  
 
Spearman’s rho was used to test for correlation amongst the independent variables. For any 
pair of variables with a correlation coefficient of ≥ 0.7 only the variable with the smallest P-
value was considered for further analysis. Initially all variables were analysed in a univariable 
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multilevel model. All variables that showed some association with the presence of resistant E. 
coli on univariable analysis (P-value < 0.25) were considered for incorporation into a final 
multivariable model for that outcome. The final models were constructed by a manual 
backwards stepwise procedure where variables with a Wald P-value < 0.05 were retained in 
the model. First order interaction terms were tested for biologically plausible variables 
remaining in the final models. Multilevel models were analysed using the MLwiN statistical 
software package (MLwiN Version 2.28 Centre for Multilevel Modelling, University of 
Bristol). Univariable and multivariable calculations were performed using penalised quasi-
likelihood estimates (2nd order PQL for all outcomes). Calculating and graphing the residual 
+/- 1.96 SD x rank (caterpillar plots) was performed for each household and dog to check for 
outliers (Figures 5-1 to 5-6, Appendix III). If present, outliers were removed and the models 
were rerun to assess the effects. Tests for correlation (Spearman’s rho) and survival analysis 
were performed using SPSS software package (SPSS 20.0 for Mac, SPSS Inc, Chicago, 
Illinois). 
 
3. Results 
3.1 Study population 
In total, 28 dogs, 18 male and ten female, were recruited from 21 households for this study; 
the average age was 81 months and ranged from 5 - 146 months. The main diet of all dogs 
consisted of dry complete dog food and the majority of the dog owners worked in veterinary 
health care; owners from 10 households worked in veterinary clinical practice. Five dogs did 
not complete the study; two dogs left the study after seven days, one dog after 14 days, one 
after 21 days and one after 35 days.  One dog left the study due to enteritis, two dogs were 
prescribed antimicrobials and two owners withdrew for personal reasons. Overall there were 
341 faecal samples provided during a 90-day period (Table 1).  
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Table 1. The variables and outcomes considered for inclusion in the final multivariable model, with the 
number and percentage (%) of dogs. 
Variable AMR MDR AmpC/ESBL 
 
Total  
Agea (mean age in months) 83  82  86  81  
Purebred REF 19 (68) 14 (50) 13 (46) 21 (75) 
Crossbreed  6 (21) 5 (19) 5 (18) 7 (25) 
Weight (< 11kg) REF 11 (40) 9 (32) 6 (21) 13 (46) 
Weight (11-20kg) 6  (21) 4 (14) 5 (18) 6 (21) 
Weight (> 20kg)  8 (29) 6 (21) 7 (25) 9 (32) 
Male REF 17 (61) 13 (46) 13 (46) 18 (64) 
Female 8 (29) 6 (21) 5 (18) 10 (36) 
Eat tinned meat 6 (22) 4 (15) 3 (11) 6 (22) 
Eat raw meat 5 (19) 5 (19) 5 (19) 5 (19) 
Eat treats 18 (67) 15 (56) 14 (52) 19 (71) 
Eat table scraps 19 (70) 15 (56) 14 (52) 20 (74) 
Eat or roll carcass 5 (19) 5 (19) 4 (15) 6 (22) 
Eat animal faeces 12 (44) 10 (37) 10 (37) 14 (52) 
Multi-dog household 17 (63) 14 (52) 15 (56) 18 (67) 
Multi-animal household (not dog) 6 (22) 6 (22) 5 (19) 7 (26) 
Owner works with farm animals 7 (26) 6 (22) 6 (22) 7 (26) 
Owner works in health care 20 (74) 16 (60) 15 (56) 22 (81) 
In-contact human or pet received systemic 
antimicrobialsb 
10 (37) 9 (33) 10 (37) 11 (41) 
In-contact human or pet admitted to hospital or 
veterinary premiseb  
11 (41) 10 (37) 9 (33) 12 (44) 
AMR = antimicrobial resistance to at least one tested antimicrobial; MDR = multidrug resistance (resistance to three or more 
antimicrobial classes); ESBL = extended spectrum beta-lactamase producing E. coli; AmpC = AmpC enzyme producing E. coli. 
aAge was the only categorical value and is represented by the mean age of dogs in each treatment group rather than the number 
and percentage of dogs; REF = the reference category for non-dichotomous variables; bWithin 12-months of enrolment. 
 
3.2 Prevalence of antimicrobial resistance  
Overall AMR, MDR, AmpC- and ESBL-producing E. coli were detected in at least one 
sample, in 25, 19, 18 and eight dogs respectively. From 341 samples, AMR E. coli were 
detected in 152 samples (45%; 95% CI: 39.4-50), MDR in 48 samples (14%; 95% CI: 10-8-
18.2), AmpC-producing E. coli in 68 samples (20%; 95% CI: 16-24.5) and ESBL-producing 
E. coli in only 15 samples (4%; 95% CI: 2.7-7) (Figure 1).  
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Figure 1. Percentage of samples (n = 341) with antimicrobial resistant E. coli (error bars = 95% CI) 
 
Amp = ampicillin; AC = clavulanate-amoxicillin; Cip = ciprofloxacin; Chl = chloramphenicol; Tet = tetracycline; TM = 
trimethoprim; AMR = resistance to at least one tested antimicrobial; MDR = multidrug resistance 
 
3.3 Changes in antimicrobial resistance over time 
E. coli isolates with AMR to at least one antimicrobial were not detected in any sample from 
three dogs, however only one of these dogs completed the study and there was no 
commonality amongst questionnaire data for these dogs (one Labrador cross, one Pug and one 
Shih Tzu). E. coli isolates with AMR to at least one antimicrobial were detected in every 
sample submitted from three dogs that completed the study. Ampicillin resistance with or 
without resistance to other antimicrobials was the most common resistance phenotype. Two 
dogs that completed the study had stable resistance to ampicillin in every isolate in every 
sample. Both dogs (one Chihuahua and one Cocker Spaniel) lived in single-animal 
households, ate only proprietary dog food or cooked meat, rarely ate treats or table scraps and 
only one dog rarely ate animal faeces. Both dog owners were veterinarians, one small animal 
and one farm animal.  
Other resistance phenotypes, particularly MDR, were generally intermittent and/or transient 
over time. AmpC-producing E. coli however, could be also be detected long term in a small 
number of dogs whereas ESBL-producing E. coli were infrequently isolated and transient 
(Figure 2).
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Figure 2. Faecal carriage of a) any resistance (AMR), b) multidrug resistance (MDR), c) ESBL-producing 
and d) AmpC-producing E. coli in 28 healthy community dogs.  
a) AMR 
 
Sample time points were days 0,1,2,3,4,5,6,13 (week 1), 20 (week 2), 27 (week 3), 34 (week 4), 62 (month 1) and day 90 (month 
2). After week 4 (34 days) detection is still expressed as seven day intervals: Black bars represent positive detection, white bars 
represent negative detection, grey solid bars follow positive detection and are expected to be positive but samples were not 
examined during this period; textured grey bars follow negative detection and are expected to be negative but samples were not 
examined during this period; * dogs that did not complete the study 
 
 
 
 
 
b) MDR 
 
Sample time points were days 0,1,2,3,4,5,6,13 (week 1), 20 (week 2), 27 (week 3), 34 (week 4), 62 (month 1) and day 90 (month 
2). After week 4 (34 days) detection is still expressed as seven day intervals: Black bars represent positive detection, white bars 
represent negative detection, grey solid bars follow positive detection and are expected to be positive but samples were not 
examined during this period; textured grey bars follow negative detection and are expected to be negative but samples were not 
examined during this period; * dogs that did not complete the study 
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c) ESBL-producing E. coli  
 
Sample time points were days 0,1,2,3,4,5,6,13 (week 1), 20 (week 2), 27 (week 3), 34 (week 4), 62 (month 1) and day 90 (month 
2). After week 4 (34 days) detection is still expressed as seven day intervals: Black bars represent positive detection, white bars 
represent negative detection, grey solid bars follow positive detection and are expected to be positive but samples were not 
examined during this period; textured grey bars follow negative detection and are expected to be negative but samples were not 
examined during this period; * dogs that did not complete the study 
 
 
 
 
d) AmpC-producing E. coli 
 
Sample time points were days 0,1,2,3,4,5,6,13 (week 1), 20 (week 2), 27 (week 3), 34 (week 4), 62 (month 1) and day 90 (month 
2). After week 4 (34 days) detection is still expressed as seven day intervals: Black bars represent positive detection, white bars 
represent negative detection, grey solid bars follow positive detection and are expected to be positive but samples were not 
examined during this period; textured grey bars follow negative detection and are expected to be negative but samples were not 
examined during this period; * dogs that did not complete the study 
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3.4 Survival analysis 
Kaplan-Meier survival analysis was performed for 25 dogs with any AMR resistance; 20 dogs 
with MDR; 18 dogs carrying AmpC-producing E. coli; and eight dogs carrying ESBL-
producing E. coli. The median survival time for MDR, ESBL and AmpC-producing E. coli 
was 14 days and the mean ranged from 18 – 29 days. Due to the large number of dogs with 
AMR detected at the end of the study, the median survival time could not be calculated but 
the mean survival time was 58 days. There was a significant difference between the survival 
time of AMR and the other three outcomes (Figure 3; Table 2). 
 
Figure 3. Kaplan-Meier plot of survival analysis for AMR, MDR, ESBL and AmpC-producing E. coli 
(n = 28 dogs) 
 
AMR = resistance to at least one tested antimicrobial, MDR = multidrug resistance; ESBL = presence of ESBL-producing E. 
coli; AmpC = presence of AmpC producing E. coli; dogs were censored for an outcome if they did not have two consecutive 
negative samples before the end of the study or before they left the study 
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Table 2. Mean and median duration of carriage (days) of AMR, MDR, ESBL and AmpC before two 
consecutive negative samples (n = 28 dogs) 
Outcome Mean 95% CI Median 95% CI 
AMR* 58 
 
42-75 
 
⎯ 
 
⎯ 
MDR 24 
 
15-33 
 
14 
 
7-21 
AmpC 29 
 
13-44 
 
14 
 
4.5-23.5 
ESBL 18 
 
6-30 
 
14 
 
6-22 
Total 38 
 
29-47 
 
14 
 
8-20 
95% CI = 95% confidence interval; AMR = any antimicrobial resistance; MDR = multidrug resistance; AmpC = AmpC 
producing E. coli; ESBL = ESBL-producing E. coli; ‘⎯’ = cannot be calculated as > 50% of dogs censored; *significant 
difference (Log-Rank Test; P = 0.006) 
 
3.5 Genetic diversity over time assessed by PFGE in three dogs 
Marked genetic diversity was demonstrated on an individual animal basis. For example a total 
of 21 and 12 different strains were detected in only six samples over 90-days from two dogs 
(dogs 16 and 28 respectively). In addition, 40 genotypes, 10 recurrent, were detected from 
nine samples during a three-week period from one dog (dog 17). Dog 16 and 28 had five 
recurrent genotypes each (Table 3). The original antimicrobial susceptible strains were not 
detected throughout the study however they were replaced by new susceptible strains that 
were then detected in consecutive samples. There were also susceptible strains that appeared 
to gain or lose resistance traits, and the same strains had both identical and different 
antimicrobial resistance phenotypes within and between samples. ESBL-production was 
detected in dogs 16 and 28. Detection of the identical strain and ESBL-resistance phenotype 
occurred for both dogs, but only in one consecutive sample. In addition, ESBL production 
and phenotypic resistance (ampicillin & tetracycline for dog 16 and ampicillin for dog 28), 
were detected in strains that were previously antimicrobial susceptible.  
AmpC-production was detected in all samples from dog 17 (Table 4). The most common 
resistance phenotype (ampicillin & clavulanate-amoxicillin) and genotype were detected in all 
but the final sample. The second most common AmpC resistance phenotype (ampicillin, 
clavulanate-amoxicillin & tetracycline) was detected with at least three different genotypes, 
but only one genotype was detected in a consecutive sample. One other of the three-ampC 
genotypes was detected again in the last sample but it had a new resistance phenotype 
(ampicillin & tetracycline).  An AmpC-producing isolate with the resistance phenotype 
ampicillin, clavulanate-amoxicillin & tetracycline was also present in the last sample, but it 
had a different genotype; a genotype that had been detected in earlier samples with ampicillin, 
tetracycline and trimethoprim resistance, but without AmpC production. MDR (ampicillin, 
chloramphenicol, nalidixic acid, tetracycline and trimethoprim/ampicillin, ciprofloxacin, 
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chlormphenicol, nalidixic acid and trimethoprim) was also detected for two different ampC-
producing genotypes but from only one sample each.
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Table 3. Resistance phenotypes compared to genotypes over different sampling time points for dogs number 16 and 28. 
Sample code dog 16 Resistance phenotype PFGE ESBL or AmpC Sample code dog 16 Resistance phenotype PFGE ESBL or AmpC 
Day 1  A  Week 4 Tet Q  
Day 1  B  Week 4  H4  
Week 1  C1  Month 1  T5  
Week 1 Amp, Tet D2 ESBL Month 1  H4  
Week 1 Amp, Cip, Chl, Nal, Tet, Tm E  Sample code dog 28 Resistance phenotype PFGE ESBL or AmpC 
Week 1 Amp, Chl, Tet F3  Day 1  a  
Week 1 Amp, Tet, Tm G  Day 1  b  
Week 1 Amp, Chl, Tet, Tm C1 ESBL  Day 4  c  
Week 2  H4  Week 1  d1  
Week 2 Amp, Nal, Tet, Tm J  Week 1 Amp, Tet, Tm e2  
Week 2 Amp ⎯  Week 1 Amp, Tet, Tm f  
Week 2 Amp, Tm ⎯  Week 1 Amp, AC g ESBL  
Week 2 Amp, Nal, Tm ⎯  Week 1 Amp h ESBL  
Week 2 Amp, AC, Chl, Nal, Tet, Tm ⎯  Week 2 Amp d1 ESBL 
Week 2 Amp, Chl, Nal, Tet ⎯  Week 2 Amp i  
Week 2 Amp, Tet I  Week 3   J3  
Week 2 Amp, Tet K  Week 3 Amp, Nal, Tet, Tm e2  
Week 2 Amp, Tet D2 ESBL  Week 3 Amp, Tet, Tm ⎯  
Week 3   L  Week 3 Amp, Nal, Tet ⎯  
Week 3  P  Week 3 Amp d1 ESBL  
Week 3  H4  Week 3 Amp J3 ESBL  
Week 3 Tet F3  Week 4  j3  
Week 3 Nal N  Week 4 Amp, Tet, Tm k4  
Week 3 Amp, Tet O  Week 4 Amp, AC, Cip, Nal, Tet, Tm l5 AmpC 
Week 3 Amp, Na, Tet, Tm ⎯  Week 4 Amp, Cip, Nal, Tet, Tm l5 AmpC 
Week 3 Chl, Tet R  Week 4 Amp, AC, Nal, Tet, Tm k4 AmpC 
Week 3 Amp, Tm ⎯  Week 4 Amp, AC, Cip, Chl, Nal, Tet, Tm ⎯  
Week 3 Amp, Chl, Nal, Tet, Tm S      
Week 3 Amp, Tet, Tm M      
Week 3 Amp, Tet, Tm T5      
Week 3 Amp, AC U AmpC     
Week 3 Amp, AC, Cip, Na, Tet, Tm P AmpC     
Day 1 = baseline; Day 4 = four days; Week 1 = 14 days; Week 2 = 21 days; Week 3 = 28 days; Week 4 = 35 days; Month 1 = 65 days; Amp = ampicillin; AC = clavulanate-amoxicillin; Cip = 
ciprofloxacin; Chl = chloramphenicol; Nal = nalidixic acid; Tet = tetracycline; Tm = trimethoprim; blank = no resistance detected ‘⎯ ‘= PFGE type not identified; 1-5repeated genotypes; 
genotypes A - U (dog 16) and a - l (dog 28) 
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Table 4. Resistance phenotypes compared to genotypes over different sampling time points for dog number 17 
Sample code dog 17 Resistance phenotype PFGE ESBL or AmpC Sample code dog 17 Resistance phenotype PFGE ESBL or AmpC 
Day 1 Tet 1  Day 5 Amp, Chl, Nal, Tet, Tm 20g  
Day 1 Amp, AC 2a AmpC Day 5 Amp, Chl, Nal, Tet, Tm 2a AmpC 
Day 1 Amp, Cip, Chl, Nal, Tet, Tm 3b  Day 5 Amp, Tet 26  
Day 1 Amp, Chl, Tet 4  Day 5 Amp, Cip, Chl, Nal, Tet, Tm 3b  
Day 1 Tm 5  Day 5 Amp, Chl, Tet, Tm 25j  
Day 1 Amp 6c  Day 5 Tet, Tm 27  
Day 1 Amp, Tet ⎯  Day 5 Amp, AC, Tet ⎯ AmpC 
Day 1 Amp, Tet, Tm 7  Day 5 Amp, AC 2a AmpC 
Day 1 Amp, AC 8 AmpC Day 6 Tet ⎯  
Day 1 Amp, Nal, Tet, Tm ⎯  Day 6 Amp, AC 2a AmpC 
Day 2 Tet 9d  Day 6 Amp, Chl, Tet ⎯  
Day 2 Amp, AC 2a AmpC Day 6 Amp, Tet 28  
Day 2 Amp, Cip, Nal, Tt, Tm 10  Day 6 Amp, Chl, Tm 29  
Day 2 Amp, Chl, Tet 6c  Day 6 Amp, AC, Tet ⎯ AmpC 
Day 2 Amp, Nal, Tet, Tm 11  Day 6 Chl, Nal, Tet, Tm ⎯  
Day 2 Amp, AC, Tet, Tm 12  Day 6 Tet, Tm 30  
Day 2 Chl, Tm 13  Day 7 Amp, AC, Tet 23h AmpC 
Day 2 Amp, AC, Tet 14e AmpC Day 7 Amp, AC 2a AmpC 
Day 2 Amp, Cip, Chl, Nal, Tet, Tm 3b  Day 7 Cip, Nal, Tet ⎯  
Day 2 Chl, Tet 15  Day 7 Amp, Chl, Nal, Tet, Tm 20g  
Day 2 Amp, Nal, Tet 16  Day 7 Amp, Tet 31  
Day 2 Amp, Tet, Tm 17  Day 7 Tm 32  
Day 3 Amp, Tet, Tm 18f  Day 7 Amp, Tet ⎯  
Day 3 Amp, AC 2a AmpC Day 7 Amp, Cip, Chl, Nal, Tm 33 AmpC 
Day 3 Amp, Chl, Tet 6c  Day 7 Chl 34  
Day 3 Cip, Nal ⎯  Day 7 Amp, Tet, Tm 35  
Day 3 Amp, Nal, Tet ⎯  Day 7 Amp, AC, Tet ⎯ AmpC 
Day 3 Tet 9d  Week 1 Amp, Tet ⎯  
Day 3 Amp, AC, Tet ⎯ AmpC Week 1 Chl, Tet 36  
Day 4 Amp, AC, Chl, Tm 19  Week 1 Chl, Tet, Tm ⎯  
Day 4 Amp, AC 2a AmpC Week 1 Amp, Nal, Tet, Tm 37  
Day 4 Amp, Chl, Nal, Tet, Tm 20g  Week 1 Tet 38  
Day 4 Amp, Chl, Tet 6c  Week 1 Amp, AC, Tet ⎯ AmpC 
Day 4 Cip, Chl, Nal, Tet, Tm 21  Week 1 Amp, AC 2a AmpC 
Day 4 Tet 22  Week 2 Amp, Tet, Tm 18f  
Day 4 Chl, Tm ⎯  Week 2 Amp, Tet 14e AmpC 
Day 4 Amp, AC, Tet 23h AmpC Week 2 Amp, AC, Chl, Tet 39  
Day 4 Cip, Nal, Tet 24i  Week 2 Chl, Nal, Tet, Tm ⎯  
Day 4 Nal, Tet ⎯  Week 2 Amp, Chl, Tet ⎯  
Day 4 Tet, Tm 25j  Week 2 Tet ⎯  
Day 5 Amp, AC 2a AmpC Week 2 Amp, Tet, Tm 40  
Day 5 Cip, Nal, Tet 24i  Week 2 Amp, AC, Tet 18f AmpC 
 
 
 
 
Day 1 = baseline; Week 1 = 14 days; Week 2 = 21 days; Amp = ampicillin; AC = clavulanate-amoxicillin; Cip = ciprofloxacin; Chl = chloramphenicol; Nal = nalidixic acid; Tet = tetracycline; Tm = trimethoprim; 
blank = no resistance detected; ‘⎯’ = PFGE type not identified; a-jrepeated genotypes; genotypes 1 - 40
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3.6 Univariable multilevel analysis 
 
Only two variables were statistically significant (P < 0.05) in the univariable models: an 
owner working with farm animals (P = 0.035) for AMR and dogs eating raw meat for MDR 
(P < 0.001) and ESBL/AmpC-producing E. coli (P = 0.015). Variables with P ≤ 0.25 were 
considered in multivariable models (Table 5-1, Appendix III).   
 
3.7 Multivariable multilevel analysis 
 
Dogs with owners working with farm animals were at increased risk for the detection of 
AMR faecal E. coli. Dogs eating raw meat were at increased risk for the detection of MDR 
and ESBL/AmpC-producing faecal E. coli and of borderline significance for AMR E. coli. In 
addition, dogs being fed treats were at increased risk for the detection of MDR and living in a 
multi-dog household was of borderline significance for ESBL/AmpC-producing faecal E. 
coli. The variance partition coefficients (VPC) for household were 40% and 49% for 
outcomes AMR and ESBL/AmpC respectively, and for dog the VPC for ESBL/AmpC was 
56%. This suggests that there was substantial clustering within household or dog for these 
outcomes as expected (Table 5). 
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Table 5. Multilevel, multivariable final models for outcomes AMR, MDR and ESBL/AmpC-producing E. 
coli 
Resistance outcome and final model variables     
Antimicrobial resistance (AMR) β  OR 95% CI P-value 
Dogs fed raw meat1 2.6 14.1 0.9-218 0.06 
Owner works with farm animals1 1.9 6.4 1.7-33.7 0.02* 
Household variance (SE); dog variance (SE) 2.192 (0.896); 0.000 
Multidrug resistance (MDR) β  OR 95% CI P-value 
Dogs fed treats1 1.4 4.1 1.4-11.9 0.01* 
Dogs fed raw meat1 4.2 67.5 8.5-537.4 0.000* 
Household variance (SE); dog variance (SE) 0.000; 0.000 
ESBL/AmpC-producing E. coli  β  OR 95% CI P-value 
Dogs fed raw meat1 4.5 91.7 2.9-2937.7 0.011* 
Multi-dog household1 2.6 18.12 1.0-198.4 0.051 
Household variance (SE); dog variance (SE) 3.214 (1.94); 4.26 (0.642) 
1 Reference category is absence of risk factor; β = coefficient; OR = odds ratio; 95% CI = 95% confidence interval; P values are 
from the Wald chi-squared test; AMR = antimicrobial resistance to at least one tested antimicrobials; MDR = antimicrobial 
resistance to three or more antimicrobial classes; significant at P < 0.05 
 
4. Discussion 
 
This study was performed to examine the natural diversity of faecal E. coli populations, with 
respect to AMR phenotype and genotype, under natural conditions in healthy dogs. In 
addition, to assess the detection of AMR E. coli over time and to investigate the relationship 
of these findings to potential risk factors for carriage.  
 
AMR to one antimicrobial was very common (45% of samples); three dogs also carried AMR 
E. coli in every sample and only one dog did not have AMR E. coli in any sample over the 
entire study period. The most common type of resistance was to beta-lactam antimicrobials 
(ampicillin and clavulanate-amoxicillin) that are commonly sold for use in both food and non-
food producing animals in the UK (VMD, 2012). These dogs had not recently received 
antimicrobial therapy, but the majority of owners worked in veterinary healthcare with 
companion and farm animals. Healthcare and farm animal contact may be risk factors for the 
carriage of AMR E. coli in humans (Ben-Ami et al., 2009; Price et al., 2007) and strains may 
be shared within households, including pets (Johnson et al., 2008). Hence the frequency of 
resistance may be lower in the general population of dogs not owned by veterinary healthcare 
workers.  
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Sole ampicillin resistance was detected in every isolate in every sample over three months in 
two unrelated dogs. This resistance phenotype is common amongst canine faecal E. coli 
(Hamilton et al., 2013; Procter et al., 2013; Wedley et al., 2011) and may not exert a fitness 
cost to such isolates. Long-term gut colonisation with ampicillin resistant faecal E. coli, in the 
absence of direct antimicrobial pressure, has also been reported for Swedish infants (Karami 
et al., 2008). In addition the stability of the E. coli population in these dogs may be associated 
with a lack of other potential risk factors that could disturb gut flora or select for AMR 
compared to other dogs in the study. 
 
MDR was less common (14% of samples) and only detected intermittently and/or transiently, 
and not in any sample from seven of the dogs. These findings may be associated with the 
absence of antimicrobial selective pressure and the potential fitness cost of carrying multiple 
resistance determinants on mobile genetic elements, or mutations. Additionally the isolates 
may lack virulence factors associated with gut adherence. In humans, strains possessing the 
adhesion factor P fimbriae were more likely to persist in the colon (Nowrouzian et al., 2006). 
Clavulanate-amoxicillin resistance was common (~ 20% samples) and correlated well with 
the detection of AmpC-producing E. coli. Plasmid-mediated AmpC producing E. coli are 
frequently detected in animal samples and may be selected for by the frequent use of 
potentiated beta-lactam antimicrobials in animal populations (Li et al., 2007). AmpC 
producing E. coli were found to be either intermittently or transiently shed or could be carried 
long term in some animals. Whereas ESBL producing E. coli were uncommon, and usually 
only detected short term, suggesting acquisition from an endogenous source. A similar study 
detected ESBL-producing E. coli from only two samples from one dog over six months 
(Damborg et al., 2009). 
 
The first seven faecal samples were collected on a daily basis. During this period 
approximately one quarter of dogs had intermittent AMR, one quarter had transient AMR, 
one quarter had constant AMR and one quarter had no resistance; this trend continued for the 
remainder of the study. Marked diversity in AMR profiles of faecal E. coli have even been 
detected during a 24-hour period in humans and farm animals (Anderson et al., 2006), 
highlighting the insensitivity of single point sampling. Also in agreement with our study, high 
diversity was reported within individual humans, horses and cattle when sampling monthly 
for six-months; the majority of AMR phenotypes were detected from only one sample 
(Anderson et al., 2006). AMR faecal E. coli were shed for an average of 58 days in the 
current study, approximately double the duration of the other resistance phenotypes (AmpC = 
29 days; MDR = 24 days; ESBL = 18 days). Although AMR (resistance to at least one 
antimicrobial) included all resistance phenotypes, many AMR E. coli isolates were not MDR, 
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ESBL- or AmpC-producing. Therefore AMR to one or two antimicrobials, in the absence of 
antimicrobial pressure, may exert less fitness cost than the other phenotypes if adaptation 
and/or compensatory mechanisms have not occurred (Andersson and Hughes, 2010; Morosini 
et al., 2000; Schrag et al., 1997). Horses were also found to shed AMR longer than either 
MDR or ESBL-producing E. coli. While ESBL shedding in horses was similar to the dogs in 
this study, the duration of AMR and MDR shedding was much longer in the horses, half of 
which had been recently hospitalised and received antimicrobials (Maddox, 2010). 
Hospitalisation together with antimicrobial therapy may prolong shedding of AMR in horses 
(Johns et al., 2012), where as the dogs in this study had not received antimicrobials or been 
admitted to veterinary premises within three months of enrolment.  
 
Genotyping of isolates from three dogs in this study revealed high inter-individual variation 
between the dogs with new strains detected on a weekly basis. Similar diversity has been 
reported in female children (Schlager et al., 2002). In two dogs, 12 and 21 distinct E. coli 
strains were detected over three months and in another dog, 40 distinct E. coli strains were 
detected over a three-week period. While high diversity amongst faecal E. coli has been 
previously reported for horses, cattle and dogs when compared to humans (Anderson et al., 
2006; Damborg et al., 2009), only a maximum of 10 distinct strains were detected over a six-
month sampling period from a group of 13 dogs (Damborg et al., 2009). The difference 
between the two studies may be associated with different sampling methods and criteria. The 
previous study only tested one random colony, from non-selective media, per sample, 
whereas this study tested three random colonies. This increased the sensitivity to detect 
potentially highly prevalent susceptible clones (Damborg et al., 2009), in our study. The 
direct plating method (Bartoloni et al., 2006) was employed by both studies to improve 
detection of less prevalent AMR strains (Damborg et al., 2009), however the previous study 
only genotyped select isolates according to their study criteria.  
 
Resident clones are defined as strains detected from individual hosts on at least two separate 
occasions at least three weeks apart (Damborg et al., 2009), or strains persisting for at least 
three weeks (Karami et al., 2008). Long-term carriage or intermittent shedding of one or two 
resident E. coli clones from 69% of dogs (n = 13) was reported over a six-month period 
(Damborg et al., 2009). If similar criteria are applied in this study, two resident strains were 
detected from consecutive samples in one of the two dogs assessed over three months; one 
strain was a susceptible isolate that was detected on three consecutive weeks and again 30 
days later. Potentially this isolate may have possessed virulence factors that facilitated gut 
adherence, possibly of phylo-group B2; phylo-group B2 isolates are less likely to be AMR 
than other phylo-groups (Johnson et al., 2009; Nowrouzian et al., 2006; Platell et al., 2010; 
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Platell et al., 2011; Sato et al., 2014). The third dog was only assessed for three weeks, 
however an AmpC-producing strain with ampicillin and clavulante-amoxicillin resistance was 
present at baseline and detected in all consecutive samples apart from the last sample, 
whereas MDR AmpC-producing E. coli were only detected on single occasions. It seems 
likely that this isolate was a gut resident.  
 
Entirely new genotypes were frequently identified during the study in the three dogs, 
suggesting endogenous acquisition. Potential sources include the environment (Wellington et 
al., 2013), farm-animal meat (Johnson et al., 2009; Johnson et al., 2007; Vincent et al., 2010), 
or in-contact humans or pets (Damborg et al., 2009; Johnson et al., 2008; Stenske et al., 
2009). In addition, recurring genotypes gained/changed antimicrobial resistance phenotype 
during the study, suggesting exchange of antimicrobial resistance determinants between 
strains by horizontal gene transfer within the gastrointestinal tract. Transfer of antimicrobial 
resistance genes may occur under natural conditions in the gastrointestinal tract (Lester et al., 
2006; Levy et al., 1988). Transmission of plasmid-encoded ampicillin resistance to a co-
residing antimicrobial susceptible bowel isolate has been reported in a Swedish infant, in the 
absence of antimicrobial pressure (Karami et al., 2008). Alternatively, identical genotypes 
with different AMR phenotypes may have been present concurrently but were undetectable 
due to small numbers. 
 
A number of variables were found to be associated with AMR, MDR and ESBL or AmpC-
producing E. coli. Dogs with owners working with farm animals were more likely to have 
AMR faecal E. coli, while eating raw meat was a risk factor for having MDR, ESBL- or 
AmpC-producing E. coli. Contact with farm animals has been recognised as a risk factor for 
human carriage of AMR bacteria (Price et al., 2007; Silbergeld et al., 2008; Weese et al., 
2005). Food, particularly chicken meat, has been reported as a possible source of AMR 
bacteria (including ExPEC) for humans and dogs (Johnson et al., 2009; Johnson et al., 2007; 
Vincent et al., 2010). Faecal contamination of carcasses during processing is important for the 
dissemination of ESBL-producing E. coli, that along with AmpC-producing E. coli, have 
been isolated from the faeces of cattle, chickens and pigs in the UK (Horton et al., 2011). 
Raw meats may therefore be a source of antimicrobial resistant and/or pathogenic organisms 
that are potential animal and public health risks. In addition, dogs that were regularly fed dog 
treats were at increased risk for MDR E. coli, and multi-dog households for ESBL or AmpC-
producing E. coli. Details of the type of treats fed to the dogs in this study was not available, 
however dog treats derived from animal parts, such as pig ears are popular and may be a 
potential source of AMR bacteria (White et al., 2003). Sharing of E. coli between household 
members correlates with increasing numbers of in-contact humans and pets (Johnson et al., 
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2008) and ESBL- and AmpC- enzymes are encoded by genes that are usually plasmid-
mediated, facilitating horizontal dissemination amongst bacterial populations (Jacoby, 2009; 
Thomson, 2010). 
  
Limitations of this study included the small number of observations for some variables and 
outcomes that reduced the power of the study and resulted in very large confidence intervals. 
Nevertheless, after accounting for clustering within dog and within household, statistically 
significant associations were found. Another limitation was the enrolment of a convenience 
sample of dogs, where the majority of owners worked in veterinary healthcare. This may have 
increased the detection of AMR and negated the exclusion criteria of veterinary admission, 
however this information was included in the models. In addition, testing more colonies and 
genotyping all isolates from all dogs would have allowed better assessment of diversity and 
stability of canine faecal E. coli; individually, within households and overall. Finally, further 
characterisation of resistance determinants and phylogenetic typing would help to further 
explain the findings of this study. 
 
5. Conclusions 
 
There was a high prevalence of antimicrobial resistant faecal E. coli, including AmpC-
producing E. coli, detected in this group of non-antimicrobial treated and non vet-visiting 
dogs over three months. Fewer samples had MDR or ESBL-producing E. coli. AmpC 
producing E. coli could be detected long term in some dogs, whereas ESBL-producing 
isolates tended to be transient. However, from survival analysis, the median duration of 
carriage for MDR, ESBL- or AmpC-producing E. coli was two weeks. This represents a 
potential source of antimicrobial resistant E. coli for contamination of the environment or for 
in-contact individuals. There was high individual diversity in most cases with changing AMR 
phenotypes and genotypes on a daily, weekly and monthly basis. However there were also 
some dogs with recurrent, possibly resident, strains or stable E. coli populations over the 
entire study period. Multi-level, multivariable regression analysis found certain variables to 
be associated with antimicrobial resistance and it is likely that there are external sources of 
AMR bacteria for dogs including diet, environment and in-contact humans and animals. 
E. coli colonisation of the canine gut is likely to be multifactorial including AMR phenotype, 
genotype, fitness and phylo-type. More in-depth characterisation of these isolates with 
phylogenetic grouping and fitness assays may help to further elucidate these results. 
Ultimately longitudinal studies investigating the effects of other risk factors, such as 
antimicrobial therapy, will need to account for the normal diversity detected amongst canine 
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faecal E. coli populations under natural conditions. Allowing for the effects of the risk factors 
identified in this study will facilitate interpretation of such investigations.
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Summary 
 
Background: Coagulase-positive (CoPS) and coagulase-negative (CoNS) staphylococci are 
normal commensals of the skin and mucosa, but are also opportunist pathogens. Meticillin-
resistant (MR) and multidrug-resistant (MDR) isolates are increasing in veterinary healthcare. 
Reported risk factors for infections with or carriage of such bacteria include antimicrobial 
therapy and health care contact.  
Objectives: The main aim of the study was to examine staphylococcal populations and 
antimicrobial resistance profiles following therapy with one of five different antimicrobials 
(cefalexin, clavulanate-amoxicillin, cefovecin, clindamycin, or a fluoroquinolone), authorised 
for use in dogs in the UK. Additionally, to investigate potential risk factors for resistance, and 
the longevity of any change. 
Methods: Swab samples (one nasal, one perineal) were collected from 127 dogs attending 
veterinary consultations in the UK: before treatment (D0), treatment end (End), and one 
month (M1) and three months (M3) after the end of treatment. Staphylococci were isolated 
and identified using phenotypic and biochemical methods. Disc diffusion antimicrobial 
susceptibility tests were determined for a range of antimicrobials and PCR assays detected the 
mecA gene. CoPS were assigned to species by matrix-assisted laser desorption ionisation 
time-of-flight mass spectrometry (MALDI-TOF-MS) and PCR of the nuc gene. Questionnaire 
data and treatment group/sample time were used as independent variables. 
Results: The percentage of samples with MRS, MDR and ciprofloxacin resistant 
staphylococci, increased following beta-lactam (particularly cephalosporin), or 
fluoroquinolone therapy; this was significant on multilevel, multivariable analysis for 
fluoroquinolone therapy. Furthermore, the percentage of samples with CoPS decreased and 
CoNS increased after all treatments. By one month after the end of therapy, there was no 
significant difference in resistance compared to baseline and by three months the percentage 
of samples had returned to pre-treatment levels.  
Conclusions: Antimicrobial resistant staphylococci were prevalent in this population of dogs. 
In particular, treatment with a fluoroquinolone was associated with the detection of such 
bacteria. These findings are of concern due to the potential for resistant opportunistic 
infection and zoonotic and environmental transmission. In addition, MR-CoNS may be a 
source of the mecA gene for CoPS. Implementation of antimicrobial prescribing guidelines 
may facilitate prudent use of antimicrobials and reduce the development and spread of 
resistance. 
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8. Introduction 
 
Staphylococci are normal mucosal and skin commensals of humans and other animals (Kloos, 
1980). The main coagulase positive Staphylococcus (CoPS) of humans is S. aureus (Mainous 
et al., 2006) and the main CoPS of dogs is S. pseudintermedius (Berg et al., 1984). Prior to re-
classification of the S. intermedius group (SIG) in 2007, S. pseudintermedius were referred to 
as S. intermedius (Bannoehr et al., 2007). The prevalence of mucosal S. pseudintermedius 
carriage in healthy dogs has been reported to be between 37% to 92% in different studies 
(Devriese and De Pelsmaecker, 1987; Fazakerley et al., 2010; Griffeth et al., 2008; 
Hanselman et al., 2009; Paul et al., 2012; Rubin et al., 2011; Schmidt et al., 2014), with 
increased carriage in dogs with atopic dermatitis or pyoderma (Fazakerley et al., 2010; 
Saijonmaa-Koulumies and Lloyd, 1995). Fewer healthy dogs carry S. aureus (4% to 12%) 
(Boost et al., 2007; Fazakerley et al., 2010; Griffeth et al., 2008; Kottler et al., 2010; Loeffler 
et al., 2005; Schmidt et al., 2014; Wedley et al., 2014) and isolates are likely to originate from 
in-contact humans (Weese and van Duijkeren, 2010). In addition, coagulase negative 
staphylococci (CoNS) are common mucosal commensals of dogs (Schmidt et al., 2014). 
Commensal staphylococci are also opportunistic pathogens with mucosal isolates often being 
the source of infection (von Eiff et al., 2002). The most frequent cause of canine pyoderma is 
S. pseudintermedius (Ihrke, 1987; Medleau et al., 1986). 
 
The frequency of antimicrobial resistance (AMR), particularly multi-drug resistance (MDR) 
in canine staphylococcal infections is increasing, severely limiting therapeutic options. 
Meticillin resistant staphylococci (MRS) are associated with the carriage of the mecA gene, 
which encodes an altered penicillin binding protein (PBP2a) and confers resistance to all beta-
lactam antimicrobials (Hartman and Tomasz, 1984). The mecA gene is carried on a large 
mobile genetic element (MGE), the staphylococcal cassette chromosome mec (SCCmec) that 
can be transferred horizontally between staphylococci (Black et al., 2009). CoNS may be the 
original source of the mecA gene (Tsubakishita et al., 2010) and may act as reservoirs of this 
gene for CoPS (Barbier et al., 2010; Descloux et al., 2008; Smyth et al., 2011). Resistance 
determinants for other antimicrobials may also be carried on SCCmec (Hiramatsu et al., 
2001), or other mobile genetic elements, and chromosomal mutations may occur also giving 
rise to resistance. Hence these isolates are commonly MDR and often, fluoroquinolone 
resistant (Descloux et al., 2008). Co-selection of fluoroquinolone resistant MRS isolates by 
beta-lactams or fluoroquinolones may lead to the rapid emergence and persistence of these 
strains (Descloux et al., 2008; Weber et al., 2003; Westh et al., 2004). 
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Antimicrobial therapy, frequent veterinary premise contact and hospital admission have been 
frequently reported as risk factors for the mucosal carriage of or infection with MRS in dogs 
(Eckholm et al., 2013; Faires et al., 2010; Huerta et al., 2011; Lehner et al., 2014; Nienhoff et 
al., 2011; Soares Magalhaes et al., 2010; Weese et al., 2012; Windahl et al., 2012). Similar 
risk factors have been reported or proposed for meticillin resistant S. aureus (MRSA) and 
meticillin resistant coagulase negative staphylococci (MR-CoNS) carriage in humans (Barbier 
et al., 2010; Soares Magalhaes et al., 2010). Meticillin resistant S. pseudintermedius  (MRSP) 
have been detected from 0 to 4.5% of healthy dogs (Griffeth et al., 2008; Hanselman et al., 
2008; Hanselman et al., 2009; Kania et al., 2004; Murphy et al., 2009; Schmidt et al., 2014; 
Vengust et al., 2006; Wedley et al., 2014) and from the mucosa and/or skin of between 3.5 to 
66% of dogs with skin infections and/or veterinary hospital admission from Germany, the 
USA or Japan (Beck et al., 2012; Griffeth et al., 2008; Kania et al., 2004; Kawakami et al., 
2010; Nienhoff et al., 2011; Onuma et al., 2012; Sasaki et al., 2007). In addition, transfer of 
isolates between individuals within households and veterinary clinics, and environmental 
contamination has been reported (Gomez-Sanz et al., 2013; Laarhoven et al., 2011; Paul et al., 
2011; Singh et al., 2013; van Duijkeren et al., 2011). 
 
There are a limited number of antimicrobials authorised for use in companion animals in the 
UK, mostly broad-spectrum and therefore active against both Gram-positive and Gram-
negative bacteria (Hughes et al., 2012; Li et al., 2007; Mateus et al., 2011). The majority of 
these antimicrobials are usually administered in an oral form, however cefovecin is a long-
acting subcutaneous preparation of a semi-synthetic third generation cephalosporin, 
authorised to use every 14-day (Stegemann et al., 2006). It has reported efficacy in the 
treatment of canine pyoderma (Summers et al., 2012). Veterinary authorised 
fluoroquinolones, including enrofloxacin and marbofloxacin, are broad-spectrum 
antimicrobials that have also been used frequently in dogs to treat pyoderma (Guardabassi et 
al., 2004; Ihrke et al., 1999). 
 
The majority of the previous studies examining risk factors for MRS in dogs either found no 
association with antimicrobial therapy, or reported in association with antimicrobial therapy 
in general, with or without veterinary premise admission, and did not examine the recovery 
period. The aim of this study was to examine the impact of antimicrobial therapy on the 
canine mucosal staphylococci, by investigating changes in antimicrobial resistance and 
community staphylococcal profiles during and after treatment. In addition, to compare 
therapy with one of five, commonly used and important antimicrobials authorised for the use 
in dogs in the UK without the confounding factor of veterinary premise admission.  
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2. Methods 
2.1 Study Population 
 
A convenience sample of dogs attending veterinary consultations at three centres including 
first opinion and referral practice, in the North West of England between June 2011 and 
September 2012 were recruited for the study if they met the inclusion and exclusion criteria. 
Inclusion criteria included diagnosis of a bacterial infection (skin, soft tissue, urinary tract, 
dental, respiratory tract, orthopaedic, gastrointestinal, ocular) requiring systemic antimicrobial 
therapy with one of five different antimicrobials authorised for use in dogs in the UK 
(cefalexin [CFX], clavulanate-amoxicillin [AC], cefovecin [CVN], clindamycin [CD], or a 
fluoroquinolone [enrofloxacin or marbofloxacin; FL]). Exclusion criteria included 
antimicrobial therapy or veterinary admission within three months of enrolment and dogs 
aged less than 12 months old. Dogs were excluded during the study if they were prescribed a 
further course of systemic antimicrobial.  
 
The veterinarian in charge of the case determined if the dog required systemic antimicrobials 
and decided on and implemented the treatment plan (type of antimicrobial, dose, frequency 
and duration of therapy). Before enrolment, all dog owners read the study outline and gave 
written informed consent. Samples were collected before starting treatment (D0), at the end of 
treatment (End) and at one (M1) and three months (M3) after the end of treatment. Veterinary 
personnel were responsible for client follow-up and scheduled re-examinations coinciding 
with the re-sample date. A questionnaire regarding potential risk factors for the carriage of 
antimicrobial resistant bacteria was administered at the start of the study and at the time of 
each follow-up sample. The questionnaire was either completed during the consultation or 
returned by first-class post. The two-page questionnaire used in this study consisted of closed 
questions with tick box responses and space for additional information (Appendix IV). A 
“Don’t Know” response was included for all questions to enable the respondent to avoid 
answering incorrectly if they were uncertain. Data were collected regarding patient 
signalment, diet, previous veterinary history (including previous antimicrobial therapy and 
veterinary admission), the presence, number and type of in-contact pets, previous medical 
history of the household (including antimicrobial therapy or hospitalisation of humans or 
other pets) and whether any household member worked with farm animals or in healthcare. 
The attending veterinary surgeon also completed a one-page questionnaire confirming the 
reason for the visit, the prescribed antimicrobial and therapeutic regime and any previous 
antimicrobial therapy the dog had received in the last 12 months. All questionnaire-derived 
information was available as potential explanatory variables for inclusion in the multivariable 
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modelling of various antimicrobial resistance outcomes. The University of Liverpool, School 
of Veterinary Science Ethics-Committee approved the study protocol in June 2011.  
 
2.2 Specimen collection and bacterial isolation 
 
One nasal swab and one perineal swab were collected from each dog (Copan Eswab LQ 
Amies Minitip Nylon Flocked Applicator, Appleton Woods, Birmingham, UK) at each 
sample point. A sterile swab was inserted 5mm into one nostril and a further swab rubbed on 
the skin of the perineum for 3 to 5 seconds before being placed in Amies transport media, 
stored at 4˚C, and processed within 36 hours of collection. Swabs were incubated aerobically 
overnight at 37˚C in nutrient broth with 6.5% sodium chloride. The broth was streaked onto 
mannitol salt agar (MSA), oxacillin resistance screening agar (ORSA) supplemented with 2 
µg/ml of oxacillin and Columbia 5% horse blood agar (CAB) to obtain single colonies, and 
incubated aerobically overnight at 37˚C. Where present, isolates with a staphylococcal 
phenotype were selected from all plates, sub-cultured onto CAB and incubated aerobically 
overnight at 37˚C. Fresh staphylococcal cultures on CAB were subject to Gram stain (Sigma-
Aldrich Company Ltd., Gillingham, UK), tested for catalase (Sigma-Aldrich Company Ltd., 
Gillingham, UK) and free coagulase production (Rabbit plasma, Pro-Lab, Bromborough, UK) 
according the manufacturer’s instructions. Testing for free coagulase production was repeated 
if there was discrepancy between this result and species assignment. Isolates were stored at -
80˚C in Microbank vials (Pro-Lab, Bromborough, UK) for further processing. All media were 
obtained from LabM Ltd, Bury, UK. 
 
2.3 Antimicrobial susceptibility testing 
 
Disc diffusion testing was performed in accordance with accepted standards (CLSI, 2008) as 
described previously (Schmidt et al., 2014) with the following discs: 1 µg oxacillin (OX), 
1 µg ciprofloxacin (CIP), 10 µg gentamicin (GM), 10 µg fusidic acid (FA), 30 µg cefalexin 
(CFX), 30 µg cefovecin (CVN), 25 µg trimethoprim-sulfamethoxazole (TS), 10 µg 
tetracycline (Tet), 2 µg clindamycin (CD) and 5 µg vancomycin (Va).  All discs were 
purchased from MAST Group Ltd., Liverpool, UK, except for CVN, which were obtained 
from Oxoid, Basingstoke, UK.  The reference strain S. aureus ATCC®25923 (LGC 
Standards, Teddington, UK) was used for quality control for zone diameter determinations. 
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2.4 Species identification using MALDI-TOF-MS 
 
All coagulase positive, all CoNS with phenotypic oxacillin resistance, and CoNS from ten 
randomly selected dogs from each antimicrobial treatment group, were subject to matrix-
assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF-MS) 
according to the manufacturer’s protocol. Raw spectra were analysed by the MALDI Biotyper 
2.0 software programme with default settings (Bruker Daltonics, Bremen, Germany). The 
extraction method was performed as previously described (Alatoom et al., 2011) on overnight 
colonies grown on CAB at 37°C and all isolates were tested in duplicate. The bacterial test 
standard (E. coli DH5 alpha, Bruker, Bremen, Germany) was used for calibration before each 
experiment and included in duplicate on each target plate. The mass peak profiles were 
matched to the reference database and a score generated based on similarity. A positive 
identification to species level was made for single result > 2.0 or duplicate results > 1.8 
(Carpaij et al., 2011). All staphylococcal speciation results are not reported in this thesis. 
 
2.5 Detection of antimicrobial resistance genes and species identification 
 
DNA extraction was performed as previously described (Schmidt et al., 2014). PCR assays 
were performed to detect the presence of mecA gene in staphylococcal isolates that were 
phenotypically resistant to oxacillin. PCR assays to detect the presence of the nuc genes of S. 
pseudintermedius, S. aureus and S. schleiferi were performed on CoNS isolates identified as 
either S. pseudintermedius or S. aureus by MALDI-TOF-MS using Qiagen® Multiplex PCR 
Mix (Qiagen, Crawley, UK), according to the manufacturer’s instructions with minor 
modifications (Schmidt et al., 2014). PCR products were analysed by agarose gel (1.5%) 
electrophoresis and the DNA fragments were visualised under UV light after peqGREEN 
(peqlab, Fareham, UK) staining (Table 3-1, Appendix I). 
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2.6 Statistical analysis 
 
All questionnaire derived information and microbiological data were entered into a 
spreadsheet program (Microsoft Excel for Mac 2008, Microsoft Corporation) and the dataset 
was reviewed and checked for coding of all variables. Independent (risk factor) variables 
were created from information obtained from the owner and veterinary surgeon 
questionnaires. Except for the age of the dog, all variables were dichotomous or categorical in 
nature. The variables treatment duration and body weight were divided into three categories: 
≤ 1 week, > 1 week and ≤ 3 weeks, and > 3 weeks and small (< 11 kg), medium (11-20 kg) 
and large (> 20kg) respectively. The variable recruitment site was divided into two categories: 
first opinion and referral consultations. Microbiological data were collapsed to the sample 
level and categorised for time of sample collection. The baseline samples were always at day 
zero (D0) and the end of therapy sample (End) varied depending on the length of the 
prescription. M1 and M3 time points were always at one month (M1) or three months (M3) 
after End for individual dogs.  
 
Initial data analysis included Pearson’s chi-square tests for the categorical variables and a 
one-way between-groups analysis of variance (ANOVA) for age to investigate differences 
between treatment groups at baseline (D0) (Table 2). In addition logistic regression was used 
to test for differences in antimicrobial resistance outcomes between treatment groups at 
baseline (D0) after accounting for the other independent variables (Tables 6-7 to 6-9, 
Appendix IV). 
 
Phenotypic resistance to oxacillin, ciprofloxacin or multidrug resistance (MDR; resistance to 
three or more antimicrobial classes), the presence of CoNS or CoPS isolates and the presence 
of phenotypic oxacilllin resistant isolates carrying the mecA gene (MRS) were considered as 
six separate binary outcomes. The percentage of samples, with 95% confidence intervals, 
were calculated for each treatment group and treatment overall (CFX, AC, CVN, CD, FL, 
Total) at each time point (D0, E, M1, M3) for each of the six outcome measures. To examine 
the effect of treatment group and time of sample, and other independent variables on the 
presence of resistance, data were analysed using a multilevel logistic regression models with a 
binomial distribution and logit link. Due to repeated samples over time, data were clustered 
within dogs (level two units) and this clustering was accounted for by inclusion of dog as a 
random intercept in all models. Swab samples were considered the level one unit of interest. 
In order to make allowance for all dogs not having received any therapy at baseline (D0), all 
dogs at baseline were classed as baseline untreated. Ultimately, in addition to no treatment at 
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baseline (n = 1), there were 15 categories created to account for the different combinations of 
time (n = 3) and treatment group (n = 5). 
 
Initially all variables were analysed in univariable multilevel models. All variables that 
showed some association with each outcome on univariable analysis (P-value < 0.25) were 
considered for incorporation into a final multilevel, multivariable model. Treatment group and 
the time of sample were always retained in the final models. For any pair of variables with a 
correlation coefficient of ≥ 0.7 only the variable with the smallest P-value was considered for 
further analysis. The final models were constructed by a manual backwards stepwise 
procedure where variables with a Wald P-value < 0.05 were retained in the model. Once a 
final multivariable model was produced all variables that were significantly (P < 0.05) 
different between treatment groups at day 0 were forced back into the model to assess their 
effect on the remaining variables, in particular treatment group (Table 1).  
   
Multilevel models were analysed using the MLwiN statistical software package (MLwiN 
Version 2.28 Centre for Multilevel Modelling, University of Bristol). Univariable and 
multivariable calculations were performed using penalised quasi-likelihood estimates (2nd 
order PQL for all outcomes). First order interaction terms were tested for biologically 
plausible variables remaining in the final models. The residuals +/- 1.96 SD x rank (caterpillar 
plots) were calculated and graphed for each dog to check for outliers (Figures 6-1 to 6-6, 
Appendix V). If present, outliers were removed and the models were rerun to assess the 
effects. Tests for correlation (Spearman’s rho), Pearson’s chi-square and logistic binary 
regression were performed using SPSS software package (SPSS 20.0 for Mac, SPSS Inc, 
Chicago, Illinois).  
 
3. Results  
3.1 Study population 
  
One hundred and twenty-seven dogs were enrolled in this study from three centres: 1 (n = 
43), 2 (n = 52) and 3 (n = 32) and included first opinion (n = 72) and referral consultations (n 
= 55). The dogs were treated with one of the following antimicrobials: cefalexin (n = 32), 
clavulanate-amoxicillin (n =29), cefovecin (n = 26), clindamycin (n = 28), or a 
fluoroquinolone (n = 13). Treatment was prescribed for ≤ 1 week in 33 dogs, > 1 week and ≤ 
3 weeks in 48 dogs, and > 3 weeks in 46 dogs. The dogs were aged from 12 to 204 months 
(mean = 62 months) with 75 male and 52 female, 21 small, 16 medium and 90 large (> 20kg) 
dogs enrolled in this study. Owners of 24 dogs worked in health care environments. This 
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included four owners in veterinary healthcare, 18 owners in human healthcare (hospital, GP 
surgery, community nursing, paramedical, pharmaceutical, research and nursing home staff), 
and two owners in undefined healthcare (Table 1).  
 
Table 1. The baseline (D0) variables considered for inclusion in the final multivariable model, with the 
number and percentage (%) of samples in each treatment group and variable category. 
Variable CFX AC CVN CD 
 
Fl 
 
Total 
dogs 
P-value  
Mean agea (months) 44  50 68 79 83 62 0.016* 
Weight       0.003* 
Small (< 11kg) 1 (5) 3 (14) 4 (19) 10 (48) 3 (14) 21 (17)  
Medium (11-20kg) 4 (25) 3 (19) 0 7 (44) 2 (13) 16 (13)  
Large (> 20kg) REF 26 (29) 23 (26) 22 (24) 11 (12) 8 (9) 90 (71)  
Gender       0.925 
Male REF 18 (24) 17 (23) 14 (19) 17 (23) 9 (12) 75 (59)  
Female 13 (25) 12 (23) 12 (23) 11 (21) 4 (8) 52 (41)  
Treatment duration       0.000* 
1 week REF 5 (15) 17 (52) 0 10 (30) 1 (3) 33 (26)  
>1 and < 3 weeks 12 (25) 9 (19) 10 (21) 11 (23) 6 (13) 48 (38)  
> 3 weeks 14 (30) 3 (7) 16 (35) 7 (15) 6 (13) 46 (173)  
Recruitment site       0.000* 
First opinion practice REF 23 (32) 28 (39) 4 (6) 17 (24) 0 72 (57)  
Referral consultation 8 (15) 1 (2) 22 (40) 11 (20) 13 (24) 55 (43)  
A diagnosis of pyoderma was made at 
enrolment 
27 (33) 3 (4) 25 (31) 15 (18) 12 (15) 82 (65) 0.000* 
Previous systemic antimicrobial 
treatment1 
15 (26) 10 (17) 15 (26) 9 (16) 9 (16) 58 (46) 0.031* 
Previous beta-lactam antimicrobial 
treatment1 
11 (29) 7 (18) 7 (18) 6 (16) 7 (18) 38 (30) 0.111 
Previous hospital admission1  4 (16) 3 (12) 6 (24) 8 (32) 4 (16) 25 (20) 0.287 
In-contact human or pet received 
antimicrobials2 
7 (25) 6 (22) 4 (14) 6 (21) 5 (18) 28 (22) 0.720 
In-contact human or pet admitted to 
hospital or veterinary premises1  
16 (40) 12 (30) 5 (13) 6 (15) 1 (2.5) 40 (31) 0.015* 
Owner works in healthcare  5 (21) 2 (8) 5 (21) 9 (38) 3 (13) 24 (19) 0.133 
Multi-dog household  17 (30) 15 (27) 12 (21) 8 (14) 4 (7) 56 (44) 0.241 
Enrolled dog regularly eats animal 
stools  
7 (18) 5 (13) 8 (21) 10 (26) 8 (21) 38 (30) 0.025* 
CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fl = fluoroquinolone. aAge was the only 
continuous variable and is represented by the mean age of dogs in each treatment group; REF = the reference category for non-
dichotomous variables; 1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of 
enrolment; *significant at P < 0.05. 
 
One hundred and twenty-seven dogs provided samples at Day 0 and End, 106 dogs provided 
samples at M1 and 103 dogs provided samples at M3 with a total of 463 samples (Table 2). 
Missing samples from M1 (n = 21) were due to prescription of further antimicrobials (n = 6), 
euthanasia or death due to unrelated reasons (n = 2), or owner non-compliance (n = 13). 
Missing samples from M3 (n = 24) were due to prescription of further antimicrobial courses 
(n = 10), euthanasia or death due to unrelated reasons (n = 3), re-homing (n = 3) or owner 
non-compliance (n = 8). 
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Table 2. The number of samples provided at each time point in each treatment group. 
Antimicrobial treatment group 
Time point CFX AC CVN CD Fl Total 
D0 31 29 26 28 13 127 
End 31 29 26 28 13 127 
M1 26 27 20 24 9 106 
M3 24 25 21 24 9 103 
Total 112 110 93 104 44 463 
CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fl = fluoroquinolone; D0 = baseline day 
zero; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy; two swabs per sample. 
 
3.2 Descriptive statistics 
 
3.2.1 Staphylococcal species & antimicrobial resistance during the study period  
CoNS isolates were detected in 272 samples (59%; 95% CI: 54 - 63) from 118 dogs  (93%; 
95% CI: 87-96.2), including five dogs (4%) with S. schleiferi subsp schleiferi. CoPS isolates 
were detected in 289 samples (62%; 95% CI: 57.9 – 66.7) from 111 dogs  (87%; 95% CI: 
80.5-92.2), including S. aureus, detected in at least one sample from 27 dogs (21%), and 
S. schleiferi subsp coagulans, detected in at least one sample from nine dogs (7%). All 
S. schleiferi isolates were oxacillin susceptible at all time points. 
 
Phenotypic oxacillin resistant staphylococci were detected in 135 samples (29%; 95% CI: 
29.2 – 33.5) from 86 dogs (68%; 95% CI: 59.2-75.2), with 27 samples (6%; 95% CI: 4 – 8.4) 
from 18 dogs (14%; 95% CI: 9-21) having phenotypic oxacillin resistant CoPS. Oxacillin 
resistant mecA positive staphylococci (MRS) were detected in 118 samples (26%; 95% CI: 
21.7 - 29.6) from 80 dogs (63%; 95% CI: 54.3 – 70.9). Eighteen of these samples (4%; 95% 
CI: 2.5-6) from 13 dogs (10%; 95% CI: 6.1 – 16.7) were meticillin resistant coagulase 
positive staphylococci (MR-CoPS); 11 dogs carried MRSP and two dogs carried MRSA. 
MRS isolates that were MDR were detected in 80 samples (17%; 95% CI: 14 - 21) from 59 
dogs (46.5%; 95% CI: 38-55) and MRS with ciprofloxacin resistance were detected in 49 
samples (11%; 95% CI: 8.1 - 13.7) from 44 dogs (35%; 95% CI: 26.9-43.3) at any time point.  
 
Overall MDR staphylococci were detected in 128 samples (28%; 95% CI: 23.8 - 31.9) from 
77 dogs (61%; 95% CI: 51.9 – 68.7) and 49 samples (11%; 95% CI: 8.1 – 13.7) from 33 dogs 
(26%; 95% CI: 19 – 34.2) had MDR CoPS isolates. Ciprofloxacin resistant isolates were 
detected in 81 samples (18%; 95% CI: 14.3 - 21.2) from 60 dogs (47%; 95% CI: 38.3-55.9) 
and 25 samples (5%; 95% CI: 3.7 – 7.8) from 17 dogs (13%; 95% CI: 8.5-20.5) had 
ciprofloxacin resistant CoPS isolates. MDR isolates with ciprofloxacin resistance were 
detected in 78 samples (17%; 95% CI: 13.7 - 20.5) from 57 dogs (45%; 95% CI: 36.5 – 53.6) 
at any time point.  
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3.2.2 Changes in species and antimicrobial resistance following therapy 
There was an overall trend for the percentage of samples with antimicrobial resistant mucosal 
staphylococci (phenotypic oxacillin resistance [Figure 1], MRS [Figure 2], ciprofloxacin 
resistance [Figure 3] or MDR [Figure 4]), to increase following antimicrobial therapy with 
beta-lactams or fluoroquinolones. In addition, the percentage of samples with CoPS (Figure 
5) decreased and CoNS (Figure 6) increased following most therapies. However by M3, the 
percentage of samples positive for each of these outcomes had returned to pre-treatment 
levels in the majority of treatment groups and outcomes. A similar tendency for increase 
following treatment and recovery by M3 was noted for the detection of phenotypic oxacillin 
resistant CoPS, MR-CoPS, MR-MDR staphylococci and MRS or MDR staphylococci with 
concurrent ciprofloxacin resistance (Tables 6-1 to 6-6, Appendix IV). 
 
Figure 1. The percentage of samples with phenotypic oxacillin resistant staphylococci at each time point for 
each treatment group and treatment overall (error bars = 95% CI) 
 
95% CI = 95% confidence interval; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fluro 
= fluoroquinolone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy 
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Figure 2. The percentage of samples with phenotypic oxacillin resistant, mecA gene positive, staphylococci 
(MRS) at each time point in each treatment group (error bars = 95% CI) 
 
95% CI = 95% confidence interval; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fluro 
= fluoroquinolone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy; 
MRS = meticillin resistant staphylococci 
 
Figure 3. The percentage of samples with ciprofloxacin resistance at each time point in each treatment 
group (error bars = 95% CI) 
 
95% CI = 95% confidence interval; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fluro 
= fluoroquinolone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy 
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Figure 4. The percentage of samples with MDR at each time point in each treatment group (error bars = 
95% CI) 
 
95% CI = 95% confidence interval; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fluro 
= fluoroquinolone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy; 
MDR = multidrug resistance (resistance to ≥ 3 antimicrobial classes)  
 
Figure 5. The percentage of samples with CoPS at each time point in each treatment group (error bars = 
95% CI) 
 
95% CI = 95% confidence interval; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fluro 
= fluoroquinolone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy; 
CoPS = coagulase positive staphylococci 
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Figure 6. The percentage of samples with CoNS at each time point in each treatment group (error bars = 
95% CI) 
 
95% CI = 95% confidence interval; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fl = 
fluoroquinonlone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy; 
CoNS = coagulase negative staphylococci 
 
3.3 Multilevel, univariable analysis 
 
The overall variable of treatment and time was associated with all outcomes (P < 0.25) other 
than CoNS, and was statistically significant for decreased CoPS detection (P < 0.001). In 
particular, fluoroquinolone therapy at end was significant for all antimicrobial resistance 
outcomes (P < 0.01). In addition univariable analysis found multi-dog household to be 
significant for increased detection of phenotypic oxacillin resistant, MRS or MDR 
staphylococci or CoNS (P < 0.05). Similarly, recruitment from referral services rather than 
first opinion clinics increased the risk to detect phenotypic oxacillin resistant (P = 0.04) or 
MDR staphylococci (P = 0.001) or CoPS (P = 0.005). An initial ‘diagnosis of pyoderma’ 
increased the risk to detect phenotypic oxacillin resistant (P = 0.02) or MDR staphylococci 
(P = 0.001) and CoPS (P = 0.002), while female dogs were more likely than male dogs to 
harbour MDR staphylococci or CoNS (P < 0.05). Increasing age (P = 0.01) or smaller breed 
dogs (P = 0.006) were at increased risk for the detection of ciprofloxacin resistant 
staphylococci, while previous admission to veterinary premises decreased the risk of CoPS 
detection (P = 0.01) and increasing treatment length (P = 0.02) was a risk for CoPS detection. 
Finally MDR was more likely if the owner or in-contact dog had been admitted to hospital 
(P = 0.004), the dog had received beta-lactam antimicrobials prior to enrolment (P = 0.04), or 
if the dog regularly ate animal stools (P = 0.01). A number of other variables were associated 
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(P < 0.25) with each outcome and were considered for inclusion in the final model (Tables 6-
10 and 6-11; Appendix IV). 
 
2.3 Multilevel, multivariable analysis 
 
Treatment and time overall was only significant for the outcome CoPS, however therapy with 
a fluoroquinolone was a risk for increased detection of phenotypic oxacillin resistant, MRS, 
ciprofloxacin resistant or MDR staphylococci at the end of therapy compared to all samples at 
baseline. By M1 there was no significant difference from baseline for the majority of 
treatment groups and outcomes. There was increased risk for the detection of MDR 
staphylococci three months after the end of therapy with cefalexin however the aetiology of 
this finding is unknown. Although cefalexin therapy at the end was a borderline risk for the 
detection of MDR there was no association at M1. All treatment groups other than 
clavulanate-amoxicillin were negatively associated with the detection of CoPS staphylococci 
and this effect continued to M1 for the treatment CD. There was no significant difference at 
M1 for CFX, AC, CVN or FL treatment groups and M3 for CD treatment group compared to 
baseline. Other variables were found to be significant for various outcomes including living in 
a multi-dog household, which was a risk for the detection of phenotypic oxacillin resistant 
staphylococci or MRS. Small and medium dogs were more likely to harbour ciprofloxacin 
resistant staphylococci than large dogs. In addition, female dogs, dogs that regularly ate 
animal stools and dogs that lived with owners or in-contact pets that had been hospitalised 
were at increased risk for the detection of MDR staphylococci. Previous veterinary admission 
reduced the risk of detecting CoPS, while conversely living with an owner working in 
healthcare increased the risk of detecting CoPS and decreased the risk for detecting CoNS. A 
‘diagnosis of pyoderma’ also increased the risk to detect CoPS. The variance partition 
coefficient (VPC) varied between 8% and 35% for the models, suggesting that there was 
clustering within dog, particularly for the outcome CoPS (Table 3 and 4).  
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Table 3. Multilevel multivariable results for outcomes phenotypic oxacillin resistance, oxacillin resistance and carriage of the mecA gene (MRS) and ciprofloxacin resistant 
staphylococci in samples from 127 dogs. 
Variables Phenotypic oxacillin resistance Oxacillin resistant & carriage of mecA gene (MRS) Ciprofloxacin resistance 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Time D0  REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Time End and CFX  2.03 0.83-4.98 0.121 2.23 0.86-5.77 0.100 1.56 0.53-4.63 0.421 
Time End and AC  0.95 0.33-2.72 0.927 0.98 0.31-3.12 0.977 0.68 0.17-2.70 0.584 
Time End and CVN  1.94 0.70-5.34 0.201 2.42 0.84-6.95 0.100 2.36 0.80-6.92 0.118 
Time End and CD  0.70 0.23-2.16 0.540 0.63 0.18-2.21 0.466 0.29 0.06-1.46 0.133 
Time End and FL  4.56 1.24-16.73 0.022* 9.09 2.22-37.23 0.002* 4.98 1.39-17.80 0.013* 
Time M1 and CFX  1.06 0.36-3.07 0.918 1.70 0.59-4.93 0.328 2.43 0.84-7.02 0.102 
Time M1 and AC  0.60 0.18-2.02 0.412 0.55 0.14-2.22 0.399 0.23 0.03-2.07 0.190 
Time M1 and CVN  1.47 0.45-4.81 0.521 1.27 0.34-4.72 0.717 1.03 0.24-4.34 0.968 
Time M1 and CD  1.81 0.65-5.03 0.257 1.39 0.45-4.30 0.571 1.00 0.31-3.27 0.994 
Time M1 and FL  2.47 0.56-10.81 0.231 3.22 0.69-15.01 0.137 4.27 0.95-19.23 0.059 
Time M3 and CFX  2.03 0.77-5.36 0.155 2.09 0.74-5.91 0.163 1.24 0.35-4.38 0.740 
Time M3 and AC  0.69 0.20-2.35 0.556 1.22 0.38-3.94 0.744 0.83 0.21-3.33 0.792 
Time M3 and CVN  1.19 0.37-3.84 0.771 1.06 0.29-3.89 0.931 0.58 0.11-3.06 0.519 
Time M3 and CD  1.12 0.38-3.34 0.833 1.06 0.32-3.47 0.928 1.30 0.42-4.00 0.644 
Time M3 and FL  3.25 0.69-15.18 0.134 0.47 0.04-4.99 0.530 1.60 0.28-9.36 0.599 
Time treatment overall  ⎯ ⎯ 0.418 ⎯ ⎯ 0.207 ⎯ ⎯ 0.082 
Weight (large) REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Weight (small) ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ 3.04 1.45-6.36 0.003* 
Weight (medium) ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ 2.48 1.11-5.52 0.026* 
Weight overall ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ 0.005* 
Multi-dog household 0.56 0.34-0.93 0.026* 0.56 0.31-0.99 0.045* ⎯ ⎯ ⎯ 
Level 2 (dog) Variance [standard error] VPC (%) 0.331 (0.237) 9% ⎯ ⎯ 0.573 (0.299) 15% ⎯ ⎯ 0.349 (0.311) 10% ⎯ ⎯ 
OR = odds ratio; 95% CI = 95% confidence interval; VPC = variance partition coefficient; P values are from the Wald chi-squared test; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; 
CD = clindamycin; FL = fluoroquinolone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy; significant at P < 0.05
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Table 4. Multilevel multivariable results for outcomes multidrug resistant staphylococci or the presence of CoPS or CoNS in samples from 127 dogs. 
Variables Multidrug resistance (MDR) CoPS CoNS 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Time D0  REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Time End and CFX  2.41 0.89-6.56 0.085 0.15 0.05-0.46 0.001* 1.05 0.45-2.46 0.911 
Time End and AC  0.40 0.08-2.04 0.270 1.22 0.37-4.02 0.745 1.96 0.76-5.06 0.162 
Time End and CVN  1.73 0.57-5.19 0.331 0.12 0.03-0.41 0.001* 1.21 0.46-3.21 0.704 
Time End and CD  0.63 0.18-2.23 0.478 0.03 0.01-0.10 0.000* 1.54 0.59-4.04 0.375 
Time End and FL  7.03 1.76-28.13 0.006* 0.20 0.04-0.98 0.047* 2.94 0.71-12.22 0.137 
Time M1 and CFX  1.47 0.48-4.50 0.503 0.54 0.16-1.85 0.327 2.29 0.84-6.21 0.105 
Time M1 and AC  0.42 0.08-2.11 0.290 0.67 0.20-2.21 0.513 0.90 0.37-2.20 0.814 
Time M1 and CVN  1.56 0.45-5.40 0.480 0.53 0.12-2.38 0.405 1.41 0.46-4.31 0.552 
Time M1 and CD  1.60 0.53-4.77 0.403 0.17 0.05-0.59 0.005* 0.79 0.29-2.16 0.648 
Time M1 and FL  3.63 0.80-16.53 0.096 1.71 0.11-25.98 0.699 1.95 0.44-8.73 0.381 
Time M3 and CFX  2.97 1.06-8.36 0.039* 1.13 0.29-4.45 0.857 1.24 0.49-3.15 0.650 
Time M3 and AC  1.06 0.30-3.78 0.927 1.71 0.44-65.59 0.435 1.00 0.38-2.58 0.993 
Time M3 and CVN  1.22 0.36-4.19 0.749 0.48 0.11-2.17 0.339 0.77 0.27-2.22 0.627 
Time M3 and CD  0.72 0.20-2.59 0.619 0.45 0.13-1.59 0.214 1.22 0.45-3.32 0.703 
Time M3 and FL  1.74 0.33-9.07 0.513 0.23 0.03-1.59 0.136 2.89 0.52-16.16 0.226 
Time treatment overall  ⎯ ⎯ 0.113 ⎯ ⎯ 0.000* ⎯ ⎯ 0.814 
Pyoderma diagnosis ⎯ ⎯ ⎯ 4.59 1.86-11.33 0.001* ⎯ ⎯ ⎯ 
Gender (male REF) 2.01 1.16-3.50 0.013* ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ 
Dog eats animal faeces 2.19 1.22-3.92 0.009* ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ 
Owner works in healthcare  ⎯ ⎯ ⎯ 2.83 1.09-7.38 0.033* 0.55 0.31-0.96 0.036* 
In-contact been hospitalised2 2.35 1.26-4.35 0.007* ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ 
Previous vet admission1 ⎯ ⎯ ⎯ 0.30 0.13-0.66 0.003* ⎯ ⎯ ⎯ 
Level 2 (dog) Variance [standard error] VPC (%) 0.298 (0.263) 8% ⎯ ⎯ 1.778 (0.491) 35% ⎯ ⎯ 0.299 (0.198) 8% ⎯ ⎯ 
1 Within  12 months but more than three months as per enrolment criteria; 2Within 12 months of enrolment; OR = odds ratio; 95% CI = 95% confidence interval; VPC = variance partition coefficient; P values are from 
the Wald chi-squared test; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fl = fluoroquinonlone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = 
three months after therapy; CoPS = coagulse positive staphylococci; CoNS = coagulase negative staphylococci; significant at P < 0.05
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3. Discussion 
 
The aim of this study was to examine the effect of routine antimicrobial therapy on canine 
mucosal staphylococci and to compare five different antimicrobials, authorised for use in 
dogs in the UK. The percentage of samples with antimicrobial resistant staphylococci 
increased and the percentage of samples with CoPS decreased at the end of therapy for the 
majority of the treatment groups. However, for the majority of the examined outcomes and 
treatment groups, the sample prevalence returned to pre-treatment levels by three months 
following the end of therapy. In addition, fluoroquinolone therapy was found to be a risk 
factor for the detection of antimicrobial resistance amongst canine mucosal staphylococci.  
 
CoNS were detected in 93% of dogs in this study in agreement with the prevalence reported 
for healthy dogs (Schmidt et al., 2014). The CoNS in this study included S. schleiferi subsp. 
schleiferi, previously reported from humans and dogs (Kloos and Bannerman, 1994; May et 
al., 2005). Interestingly coagulase negative S. aureus, previously reported from humans and 
cattle (Malinowski et al., 2009; Obaid et al., 1999), and coagulase negative 
S. pseudintermedius were detected, including MRSP isolates. This finding has not been 
previously reported for S. pseudintermedius and highlights the importance of species 
determination, particularly of clinical isolates. CoPS were detected in 87% of dogs and S. 
pseudintermedius in 83%, which is double the prevalence reported for healthy non-vet 
visiting and non-antimicrobial treated dogs using the same methodology (Schmidt et al., 
2014). This may be due to consecutive sampling, but 65% of the dogs were diagnosed with 
pyoderma and skin disease, including atopic dermatitis, which may be associated with 
increased detection of S. pseudintermedius (Fazakerley et al., 2010; Onuma et al., 2012; 
Saijonmaa-Koulumies and Lloyd, 1995). 
 
The percentage of dogs carrying MRS in this population (~ 60%) was high compared to a 
group of healthy non-vet visiting and non-antimicrobial treated Labrador retrievers (42%) or 
healthy vet-visiting dogs (6%) in the UK (Schmidt et al., 2014; Wedley et al., 2014). A higher 
prevalence of MRS was also reported in dogs with recurrent pyoderma and long-term 
antimicrobial therapy compared to healthy dogs (Huerta et al., 2011). In addition, MR-CoPS 
mainly MRSP, were detected in 10% of dogs in this study, whereas no MR-CoPS were 
detected in previous studies of healthy dogs in the UK (Schmidt et al., 2014; Wedley et al., 
2014). A similar prevalence of MRSP (7.4%) was reported in dogs admitted to a small animal 
hospital in Germany and antimicrobial therapy and hospitalisation were identified as separate 
risk factors (Nienhoff et al., 2011). 
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Ciprofloxacin resistant and MDR staphylococci were also prevalent, detected in 47% and 
61% of dogs respectively. Similarly, fluoroquinolone resistant staphylococci were more 
frequently detected in dogs with recurrent pyoderma and long-term antimicrobial therapy than 
in healthy dogs (Huerta et al., 2011). In addition, ciprofloxacin resistant and MDR CoPS 
isolates were detected in 13% and 26% of dogs in this study, including MRSP isolates that are 
often resistant to four or more antimicrobial classes (Descloux et al., 2008; Perreten et al., 
2010). 
 
Antimicrobial therapy has been associated with increased infection with or carriage of 
antimicrobial resistant staphylococci, including MRS and MDR isolates in humans and dogs 
(Eckholm et al., 2013; Huerta et al., 2011; Jarlov et al., 1996; Nienhoff et al., 2011; Soares 
Magalhaes et al., 2010; Terpstra et al., 1999; Weese et al., 2012; Westh et al., 2004). 
Fluoroquinolone therapy was found to be a risk factor for the detection of phenotypic 
oxacillin resistant staphylococci, MRS, MDR staphylococci and ciprofloxacin resistant 
staphylococci in this study. Other studies have reported the selection of MRSA or meticillin 
resistant S. epidermidis (MRSE) in humans and MRSA in dogs by fluoroquinolones (Faires et 
al., 2010; Graffunder and Venezia, 2002; Weber et al., 2003). Phenotypic oxacillin resistant, 
MRS or MDR-staphylococci were concurrently ciprofloxacin resistant in half of the dogs 
with each of these resistance outcomes, which may explain selection by fluoroquinolones. 
Co–selection of MRSA by fluoroquinolones is a significant problem in human hospitals 
(Westh et al., 2004). 
 
Conversely, it was surprising that beta-lactam therapy was not significantly associated with 
the investigated resistance outcomes, particularly as the percentage of samples with MRS 
increased following therapy with cefalexin and cefovecin. Beck et al., (2012) did not find an 
association between previous beta-lactam therapy and MRSP in dogs however other studies 
have reported beta-lactam therapy as a risk factor for MRSA infection in humans and dogs 
(Aldeyab et al., 2008; Faires et al., 2010). In addition, clavulanate-amoxicillin, a broad-
spectrum-beta-lactam antimicrobial appeared to have less effect on the detection of MRS than 
either of the cephalosporins. The majority of the dogs in the clavulanate-amoxicillin group 
received one week or less of treatment compared to the other two groups, where the majority 
of dogs received three or more weeks of cephalosporin treatment. Although there was a 
significant difference for treatment duration between treatment groups at baseline, there was 
no statistical association between treatment duration and any resistance outcome. Lack of 
statistical significance may have been associated with the power of the study; however the 
fluoroquinolone treatment group had the smallest number of observations. Larger studies are 
required to validate these findings. 
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Clindamycin therapy did not select for MRS or MDR staphylococci, however it did reduce 
the detection of CoPS for an extended period compared to the other tested antimicrobials. 
Prolonged aberrations in gut microbiota have been reported following therapy with 
clindamycin in humans (Jernberg et al., 2010). Although extended courses of antimicrobials 
would be expected to prolong selection pressure (Huttner et al., 2013), duration of therapy 
was not significantly associated with antimicrobial resistance on multivariable analysis in this 
study. However, due to the small number of observations, it cannot be excluded.  
 
At one and three months following the end of therapy, there was no significant difference 
between resistance outcomes compared to baseline for the majority of the outcomes and 
treatment groups. The mechanism of increased antimicrobial resistance following therapy and 
subsequent recovery was not investigated in this study, but is likely to be multi-factorial. 
Staphylococci contain a number of mobile genetic elements (MGEs) that may be involved in 
horizontal transference of antimicrobial resistance determinants between isolates (Forbes and 
Schaberg, 1983). SCCmec cassettes carry the mecA gene, and possibly other antimicrobial 
resistance determinants (Hiramatsu et al., 2001; Holden et al., 2004) but are generally less 
mobile than other MGEs (Lindsay and Holden, 2006). Furthermore chromosomal mutations, 
giving rise to clinically relevant fluoroquinolone resistance, may take time to accumulate 
(Hacker and Carniel, 2001). Therefore selection and co-selection of pre-existing, possibly 
undetected, antimicrobial resistant strains by fluoroquinolones may have occurred. 
Additionally, the use of fluoroquinolones, which are broad-spectrum antimicrobials, may 
have resulted in vacant mucosal niches that could be filled by exogenous strains acquired 
from the environment or in-contact humans or pets.  
 
However, as co-selection of ciprofloxacin resistant MRS isolates by beta-lactam 
antimicrobials was not found to be significant, perhaps other mechanisms were involved. 
S. aureus isolates have been shown to up-regulate adhesion factors in response to 
fluoroquinolones, promoting colonisation by resistant strains (Weber et al 2004). This may 
occur in other MRS species and further studies are required to investigate this possibility. In 
addition, fluoroquinolones may affect mutational rates, bacterial SOS response (Mamber et 
al., 1993) or repress mecA regulator genes resulting in up-regulated mecA gene expression 
(Venezia et al., 2001). The recovery phase may represent re-establishment of the original 
susceptible isolates or newly acquired exogenous antimicrobial susceptible isolates at the 
expense of the antimicrobial resistant isolates. Antimicrobial resistant isolates may be less fit 
than antimicrobial susceptible isolates, in the absence of antimicrobial pressure, if 
compensatory mechanisms have not occurred (Andersson and Hughes, 2010; Lenski, 1998). 
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In addition to antimicrobial therapy, a number of other factors were found to increase the risk 
of antimicrobial resistance or change the population structure. These included multi-dog 
household for phenotypic oxacillin resistance and MRS. Sharing of staphylococci including 
MRSP, has been reported between in-contact individuals and pets (Gomez-Sanz et al., 2013; 
Huebner and Goldmann, 1999; Laarhoven et al., 2011) and correlates with the number of in-
contacts (Walther et al., 2012). Other findings included females being more likely to carry 
MDR isolates than males, while other studies have reported male gender more commonly 
associated with MRS (Huerta et al., 2011; Weese et al., 2012). Additionally, dogs eating 
animal stools or living with humans or pets with hospital contact increased the risk of 
detecting MDR staphylococci. Exposure to swine manure was a risk for MRSA infections in 
humans (Casey et al., 2013), suggesting that animal stools could be source of antimicrobial 
resistant Gram-positive bacteria for dogs. Hospital contact is a reported risk factor for the 
detection of MRS in dogs (Eckholm et al., 2013; Hamilton et al., 2013; Nienhoff et al., 2011) 
and humans (Guclu et al., 2007; Huebner and Goldmann, 1999; Salgado et al., 2003). MRS 
are often MDR (Diekema et al., 2001; Kern and Perreten, 2013; Perreten et al., 2010) and 
isolates could be shared with in-contact dogs.  
 
A diagnosis of pyoderma prior to therapy was associated with increased CoPS, mainly 
S. pseudintermedius, which has been isolated more frequently in dogs suffering with 
pyoderma than from healthy dogs (Beck et al., 2012; Onuma et al., 2012; Saijonmaa-
Koulumies and Lloyd, 1995). Additionally, along the same lines, we found that dogs with 
owners working in health care were more likely to harbour CoPS than CoNS. Dogs in-contact 
with human health-care workers or facilities were more likely to harbour S. aureus or MRSA 
(Kottler et al., 2010; Lefebvre and Weese, 2009; Soares Magalhaes et al., 2010). The majority 
of the dog owners working in healthcare in this study worked in the human health care sector, 
which may account for the predominance of CoPS in this subset of dogs. Approximately half 
of these dogs carried S. aureus, MRSA in one dog.  
 
Limitations of this study included small treatment groups, which reduced the power of the 
study although the smallest treatment group, fluoroquinolones were found to be a risk factor 
for a number of outcomes. The recruitment of a clinically-led sample of dogs rather than a 
fully randomised sample may have introduced sampling bias; however antimicrobial selection 
and treatment length is based on a number of important individual case factors (diagnosis, 
culture and susceptibility testing, compliance, cost, contraindications or previous adverse 
events, drug cascade and UK authorisation) and all antimicrobials under investigation in this 
study were not appropriate for all cases. In addition, sampling only one nostril per dog may 
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have reduced the sensitivity to detect staphylococci, however we also sampled the perineum. 
There were 16 samples missing from M1 and M3 time points due to the exclusion of dogs for 
receiving further antimicrobial therapy. The majority of these dogs were diagnosed with 
pyoderma and recurrent infections may occur with ongoing underlying disease. While 
antimicrobial resistance to the initial prescription was possible, and may be a source of bias, 
this information was not available. In addition, the non-randomisation to treatment groups led 
to significant differences of the baseline variables between treatment groups and may have 
introduced bias. However, the significant variables were all retested in the final models to 
ensure they did not alter the results.  After accounting for the baseline variables there was no 
significant difference in baseline resistance outcomes across treatment groups. However there 
was a high level of antimicrobial resistance at baseline. This may have been associated with 
chronic skin infection, previous veterinary premise contact and antimicrobial treatment; 55 
dogs were recruited during referral consultations. High baseline resistance made it harder to 
identify change following therapy and may have extended the detection of resistance. 
 
3. Conclusions 
 
Overall this study demonstrated changes in antimicrobial resistance profiles and population 
structure of mucosal staphylococci following routine antimicrobial therapy in dogs. However, 
the percentage of samples with antimicrobial resistant staphylococci, CoPS and CoNS were 
similar to pre-treatment levels by three months after the end of therapy. As the infecting 
isolate often originates from the individuals own mucosal flora, carriage of resistant 
staphylococci is a risk for resistant infections. This is of particular concern in dogs that are 
immune suppressed or predisposed to recurrent pyoderma. Additionally, staphylococci can be 
shared and contaminate environments or clothing, representing potential risks for in-contact 
individuals. This study provides important information that can be used to design and 
implement antimicrobial prescribing guidelines and stewardship programs to help limit the 
development and dissemination of antimicrobial resistance. Larger studies are indicated to 
validate and build on the findings of this study. Further characterisation and fitness assays of 
staphylococcal isolates may help to elucidate changes in population structure following 
therapy and during recovery.
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Summary 
 
Background: Antimicrobial resistant, particularly multidrug resistant (MDR) and/or 
extended spectrum beta-lactam (ESBL) producing E. coli are increasingly detected in both 
healthy and sick dogs. This creates potential animal welfare and public health issues. 
Reported risk factors include antimicrobial therapy and health care contact.   
Objectives: The main aim of the study was to examine the antimicrobial resistance profiles of 
faecal E. coli undergoing treatment with one of five different antimicrobials (cefalexin, 
clavulanate-amoxicillin, cefovecin, clindamycin, or a fluoroquinolone), authorised to treat 
dogs in UK. In addition, to investigate potential risk factors for resistance and the longevity of 
any change. 
Methods: Faecal samples were collected from 127 dogs attending veterinary consultations in 
the UK: before antimicrobial therapy (D0), end of therapy (End), and one month (M1) and 
three months (M3) after the end of therapy. E. coli were isolated and identified using 
phenotypic, biochemical and genotypic methods. Disc diffusion antimicrobial susceptibility 
tests were used to determine resistance to a range of antimicrobials and to detect phenotypic 
ESBL- and AmpC-production. PCR assays investigated the carriage of relevant antimicrobial 
resistance genes. Questionnaire data and treatment group/time point were independent 
variables for resistance outcomes.  
Results: At the end of therapy, multivariable, multilevel modelling found treatment with 
cephalosporins to be significant for the detection of third generation cephalosporin and 
ciprofloxacin resistance and phenotypic AmpC-producing E. coli; cefovecin and clavulanate-
amoxicillin treatment significant for MDR and fluoroquinolones significant for ciprofloxacin 
resistance, compared to all samples at baseline. Living in a multi-dog household and a 
‘diagnosis of pyoderma’ were associated with the detection of extended spectrum beta 
lactamase (ESBL)-producing E. coli.  
Conclusions: Antimicrobial therapy impacts on the gastro-intestinal flora of some dogs. 
There is a period of at least one month following the end of therapy where treated dogs may 
have antimicrobial resistant faecal E. coli. These findings are of concern due to the potential 
for resistant opportunistic infections, zoonotic and/or environmental spread and transmission 
of antimicrobial resistant determinants to pathogens within the gut. Implementation of 
antimicrobial guidelines may promote rationale antimicrobial use and help limit the 
development and spread of resistance. 
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1. Introduction
During the last several years there has been the development and global spread of multidrug 
resistance and even pan-drug resistance, amongst clinical and commensal bacteria of humans 
and other animals (Ewers et al., 2012; Gould, 2009; Hunter et al., 2010). Specifically, 
extended spectrum beta-lactamase (ESBL) and AmpC-producing Gram-negative bacteria, 
including Escherichia coli, have emerged (Gould, 2008) and are increasingly detected from 
animal samples (Li et al., 2007). 
ESBL enzymes hydrolyse oxyimino-cephalosporins but can be inhibited by clavulanic acid 
whereas AmpC enzymes additionally hydrolyse cephamycins and are not inhibited by 
clavulanic acid (Bradford, 2001; Li et al., 2007; Thomson, 2010). Genes encoding ESBL and 
plasmid-mediated AmpC enzymes are carried on mobile genetic elements so can be readily 
spread between bacteria by horizontal transmission (Li et al., 2007). AmpC-production may 
also be chromosomally mediated (Woodford et al., 2007). ESBL- and plasmid-mediated 
AmpC-producers are commonly multidrug resistant (MDR; resistance to three or more 
antimicrobial classes) because of linkage to other antimicrobial resistance determinants on 
plasmids (Gould, 2009; Paterson and Bonomo, 2005). This may result in co-selection by 
therapy with non-oxyimino-cephalosporins (Livermore and Hawkey, 2005) or unrelated 
antimicrobials such as fluoroquinolones (Jiang et al., 2008). 
MDR severely limits therapeutic options for patients resulting in increased morbidity, 
mortality and costs (Hawkey and Jones, 2009). The gastrointestinal tract of humans and 
animals is the most important reservoir of antimicrobial resistant (AMR) Gram-negative 
organisms; the usual source for nosocomial infections (Johnson and Russo, 2002; Livermore 
and Hawkey, 2005; Wellington et al., 2013). MDR, ESBL- and AmpC-producing E. coli have 
been detected in the rectum or faeces of healthy and hospitalised dogs (Gibson et al., 2011a, 
b; Guo et al., 2013; Wedley, 2012; Wedley et al., 2011), and have been reported to cause 
opportunistic infections (O'Keefe et al., 2010; Sanchez et al., 2002; Sidjabat et al., 2006). In 
addition to the animal welfare concern, due to the close relationship of companion animals 
with their owners, there is also a potential public health issue (Ewers et al., 2012). Although 
E. coli isolates may be shared within households between humans and pets, the risk appears to 
be zoonotic and anthroponotic (Damborg et al., 2009; Johnson et al., 2008). 
A stable intestinal microflora is required for health with important functions in nutrition, 
development, metabolism, immune response and pathogen resistance (Dethlefsen et al., 
2007). A disruption of this microbiota can occur due to many factors, including diet and 
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disease, but antimicrobial therapy is the most common and considerable cause (Dethlefsen et 
al., 2007; Edlund and Nord, 2000; Jernberg et al., 2007). In humans, even short-term 
antimicrobial therapy may lead to long-term aberration of bacterial populations and prolonged 
antimicrobial resistance. Ciprofloxacin, cephalosporins and clindamycin have all been 
associated with the detection of antimicrobial resistant Enterobacteriaceae in the intestinal 
microbiota of humans (Jernberg et al., 2010). The extent and duration of the effect on 
commensal bacterial populations in humans is reported to depend on the pharmacokinetics, 
the spectrum of activity, the dose and the duration of the antimicrobial, and the level of 
antimicrobial resistance present before treatment (Edlund and Nord, 2000; Jernberg et al., 
2010; Turnbaugh et al., 2009). 
 
In dogs, treatment with beta-lactam antimicrobials and fluoroquinolones can select for 
antimicrobial resistant intestinal E. coli (Boothe and Debavalya, 2011; Damborg et al., 2011; 
Gibson et al., 2011a, b; Gronvold et al., 2010; Lawrence et al., 2013; Moreno et al., 2008; 
Trott et al., 2004). There are a limited number of antimicrobials, mostly broad-spectrum, that 
are authorised for use in companion animals in the UK. Amongst these, beta-lactam and 
fluoroquinolone antimicrobials are commonly used and are critically important for the 
treatment of various bacterial infections in companion animals (Hughes et al., 2012; Li et al., 
2007; Mateus et al., 2011; Sato et al., 2013). The majority of these antimicrobials are usually 
administered in an oral form and active drug that reaches the colon can disturb the microflora 
(Edlund and Nord, 2000). Cefovecin is a long-acting subcutaneous preparation of semi-
synthetic third generation cephalosporin and treatment may be recommended to improve 
owner compliance (Hughes et al., 2012). Cefovecin is authorised in Europe for administration 
every 14 days, to treat skin and urinary tract infections, associated with a number of Gram-
positive and Gram-negative bacteria in dogs (EMA, 2014). However, its spectrum of activity 
is narrower than other parenteral third-generation cephalosporins (Hughes et al., 2012). The 
majority of cefovecin is excreted unchanged in the urine, but unchanged drug also occurs in 
the bile (Stegemann et al., 2006) and may expose intestinal microflora (Edlund and Nord, 
2000). Clindamycin is also commonly used to treat bacterial pyoderma and dental disease, 
and while it is not effective against Gram-negative aerobes, unlike fluoroquinolones, it has 
potent activity against anaerobes (Edlund and Nord, 2000; Jernberg et al., 2010; NOAH, 
2014). 
 
A number of small case control longitudinal studies, examining the in-vivo effects of single 
antimicrobial agents on the gastrointestinal flora, have been performed in animals. Trott et al., 
(2004) reported the shedding of MDR faecal E. coli for up to 27 days following 21 days of 
enrofloxacin in a dog model; Cavaco et al., (2008) reported the selection of CTX-M ESBL-
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producing faecal E. coli for up to 22 days following a three-day course of amoxicillin or 
oxyimino-cephalosporins in pigs; Gronvold et al., (2010) reported the selection of 
antimicrobial resistant faecal E. coli for up to two weeks after seven days of amoxicillin in 
dogs; Singer et al., (2008) reported the selection of MDR, AmpC-producing faecal E. coli for 
four days following five-days of ceftiofur treatment in dairy cows; Boothe and Debavalya, 
(2011) reported the selection of enrofloxacin resistant and MDR faecal E. coli for at least 21 
days following seven-days of enrofloxacin treatment in dogs and Lawrence et al., (Lawrence 
et al., 2013) reported the selection of beta-lactam resistant, AmpC-producing faecal E. coli at 
28 days following a single injection of cefovecin in laboratory Beagles. 
 
In humans, previous therapy with broad-spectrum antimicrobials, particularly oxyimino-
cephalosporins, is a risk factor for acquiring infections with antimicrobial resistant bacteria 
(Wellington et al., 2013), and one of the most useful interventions has been to restrict the use 
of these antimicrobials (Livermore and Hawkey, 2005). However other authors have 
questioned whether this therapy is more likely to select for resistance than the use of other 
broad-spectrum agents and possibly antimicrobial diversification, rather than restriction, may 
be a more appropriate strategy (Gould, 2008, 2009).  
The aim of this study was to ascertain the impact of antimicrobial therapy on the canine 
gastrointestinal flora by investigating changes in the antimicrobial resistance profiles of faecal 
E. coli over time and to examine the effects of five commonly used and important 
antimicrobials, authorised for the use in dogs in the UK. This information will help to 
elucidate the relationship between treatment and the selection and maintenance of 
antimicrobial resistance amongst canine commensal bacteria, and ultimately aid with the 
formulation and implementation of strategies to help reduce the burden of antimicrobial 
resistance in dogs. Considerable inter-individual gastrointestinal flora variability has been 
reported for both humans and dogs (Dethlefsen et al., 2008; Gronvold et al., 2010; Turnbaugh 
et al., 2009), which suggests that the impact of antimicrobial therapy is best assessed on an 
individual basis (Engelbrektson et al., 2006; Jernberg et al., 2010). Therefore the dogs 
enrolled in this study were used as their own controls. 
 
2. Methods 
2.1 Study population 
 
A convenience sample of dogs attending veterinary consultations at three centres including 
first opinion and referral practice, in the North West UK between June 2011 and September 
2012 were recruited for the study. Inclusion criteria included diagnosis of a bacterial infection 
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(skin, soft tissue, urinary tract, dental, respiratory tract, orthopaedic, gastrointestinal, ocular) 
requiring systemic antimicrobial therapy with one of five different antimicrobials authorised 
for use in dogs in the UK (cefalexin [CFX], clavulanate-amoxicillin [AC], cefovecin [CVN], 
clindamycin [CD], or a fluoroquinolone [enrofloxacin or marbofloxacin; FL]). Exclusion 
criteria included antimicrobial therapy or veterinary admission within three months of 
enrolment and dogs aged less than 12 months old. Dogs were excluded during the study if 
they were prescribed a further course of systemic antimicrobials.  
 
The veterinarian in charge of the case selected and implemented the treatment plan (type of 
antimicrobial, dose, frequency and duration of therapy). Before enrolment, all dog owners 
read the study outline and gave written informed consent. Owners were asked to provide a 
fresh faecal sample from their dog before starting treatment (D0), at the end of treatment 
(End) and at one (M1) and three months (M3) after the end of treatment. Labelled faecal pots 
and first-class return-post envelopes were provided at the time of the initial consultation and 
at each re-examination and/or posted to the client the week before the next sample was due. 
Veterinary personnel were responsible for client follow-up. This consisted of re-examinations 
coinciding with the sample due date or by telephone and postal (see above) reminders one 
week before the sample was due. A questionnaire regarding potential risk factors for the 
carriage of antimicrobial resistant bacteria was administered at the start of the study and at the 
time of each faecal sample. The questionnaire was either completed during the consultation or 
returned with the sample by first-class post.  
 
The two-page questionnaire used in this study consisted of closed questions with tick box 
responses and space for additional information. A “Don’t Know” response was included for 
all questions to enable the respondent to avoid answering incorrectly if they were uncertain. 
Data were collected regarding patient signalment, diet and previous veterinary history 
(including previous antimicrobial therapy and veterinary admission), the presence, number 
and type of in-contact pets, previous medical history of the household (including 
antimicrobial therapy or hospitalisation of owners or other pets) and whether any household 
member worked with farm animals or in healthcare (Appendix V). The attending veterinary 
surgeon also completed a one-page questionnaire confirming the reason for the visit, the 
prescribed antimicrobial and therapeutic regime and any previous antimicrobial therapy the 
dog had received in the last 12 months. All questionnaire-derived information was available 
as potential explanatory variables for inclusion in the multivariable modelling of various 
antimicrobial resistance outcomes. The University of Liverpool, School of Veterinary Science 
Ethics-Committee approved the study protocol in June 2011.  
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2.2  Specimen collection and bacterial isolation 
 
Faecal samples were mixed with an equal volume of brain heart infusion broth with 5% 
glycerol (BHI-G) on receipt. Each faecal homogenate was streaked, to obtain single colonies, 
onto one eosin methylene blue agar (EMBA) plate without antimicrobials, and one EMBA 
plate impregnated with 1 µg/ml ceftazidime (CZ) and one EMBA plate impregnated with 
1 µg/ml cefotaxime (CX) (Liebana et al., 2006). In addition, to detect antimicrobial resistant 
isolates, one EMBA plate and one MacConkey agar (MAC) plate were inoculated with the 
faecal homogenate for confluent bacterial growth with seven antimicrobial discs: 10 µg 
ampicillin, 30 µg clavulanate-amoxicillin, 1 µg ciprofloxacin, 30 µg chloramphenicol, 30 µg 
nalidixic acid, 30 µg tetracycline and 2.5 µg trimethoprim, (Bartoloni et al., 2006). A further 
500 µL of faecal homogenate was enriched in 4.5 ml of buffered peptone water.  All plates 
and broths were incubated aerobically for 18 to 20 hours at 37°C. If there was no growth on 
the EMBA plates impregnated with third generation cephalosporins, the enriched broths were 
streaked onto the same selective media and incubated aerobically for 18 to 20 hours at 37°C. 
Ten random colonies, whose morphology resembled E. coli, were selected from the plain 
EMBA plate and where present, one colony growing within the zone of inhibition around 
each antimicrobial disc on both the EMBA and MAC plates and/or from the CX and/or CZ 
plates. The selected colonies were sub-cultured onto nutrient agar and incubated aerobically 
for 18 to 20 hours at 37°C. Gram stain and biochemical tests to confirm E. coli were 
performed (catalase production, lack of oxidase, lactose fermentation, indole production and 
inability to use citrate as a carbon source) on fresh overnight cultures. All antimicrobial discs 
were obtained from MAST Group Ltd., Liverpool, UK, and media from LabM Ltd, Bury, UK 
and the CX and CZ powder from Sigma-Aldrich Company Ltd, Gillingham, UK. 
 
2.3 Antimicrobial susceptibility testing 
 
Antimicrobial susceptibility disc diffusion testing was performed on all E. coli isolates 
according to British Society for Antimicrobial Chemotherapy guidelines (BSAC; Version 
11.1 May 2012) (Andrews, 2007). Iso-Sensitest agar plates were inoculated, with isolates 
homogenised in sterile distilled water (0.5 McFarland standard), for semi-confluent bacterial 
growth and the same panel of seven antimicrobial discs detailed in section 2.3 were applied. 
After the plates were incubated aerobically at 37°C for 18 to 20 hours, the zone diameters 
around each disc were measured in millimeters and recorded. E. coli ATCC® 25922 (LGC 
Standards, Teddington, UK), cultured overnight on nutrient agar at 37°C, was used as a 
control.  
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2.4 Screening for phenotypic AmpC- and ESBL-producing E. coli 
 
Isolates that were resistant to third generation cephalosporins were tested for the production 
of extended spectrum beta-lactamase enzymes (ESBL). An Iso-Sensitest agar plate was 
inoculated for confluent bacterial growth and three pairs of cephalosporin discs (with and 
without clavulanic acid) were placed on the surface of the agar plate: 30 µg ceftazidime and 
30 µg ceftazidime plus 10 µg clavulanic acid; 30 µg cefotaxime and 30 µg cefotaxime plus 
10 µg clavulanic acid; and 30 µg cefpodoxime and 30 µg cefpodoxime plus 10 µg clavulanic 
acid. The plates were incubated aerobically at 37°C for 18 to 20 hours and zone diameters 
around each disc were measured and recorded. ESBL production was confirmed when the 
zone around the cephalosporin disc was expanded in the presence of the clavulanic acid by a 
minimum of 5 mm by ≥ 1 of the antimicrobial pairs, according to the manufacturer’s 
instructions (Extended Spectrum Beta-Lactamase Set D52C, MAST Group Ltd., Liverpool, 
UK) (M'Zali et al., 2000). E. coli isolates that were resistant to third generation 
cephalosporins or clavulanate-amoxicillin were tested for production of AmpC enzyme. An 
Iso-Sensitest agar plate was inoculated for confluent bacterial growth and three discs applied: 
10 µg cefpodoxime plus AmpC inducer (A); 10 µg cefpodoxime, AmpC inducer plus ESBL 
inhibitor (B); 10 µg cefpodoxime, AmpC inducer, ESBL inhibitor plus AmpC inhibitors (C). 
The plates were incubated aerobically at 37°C for 18 to 20 hours and zone diameters around 
each disc were measured and recorded. AmpC production was confirmed when the zone of 
inhibition around disc C was greater than the zone of inhibition around discs A and B by a 
minimum of 5 mm, according to the manufacturer’s instructions (AmpC detection set D69C, 
MAST Group Ltd., Liverpool, UK) (Halstead et al., 2012). E. coli ATCC® 25922 (LGC 
Standards, Teddington, UK) cultured overnight on CAB at 37°C was used as a control. 
 
2.5 E. coli confirmation and characterisation of antimicrobial resistance genes 
 
Cell lysates were prepared by adding approximately three colonies of each isolate to 500 µl of 
sterile distilled water (0.5 McFarland standards) and vortexed. The suspensions were then 
heated at 100°C for 10 minutes and the supernatants were stored at 4°C. PCR assays for the 
uidA gene (McDaniels et al., 1996) were performed to confirm that the isolates were E. coli 
before further characterisation. E. coli isolates positive for ESBL production by the double 
disc method (MAST Group Ltd., Liverpool, UK) and isolates resistant to either CX and/or CZ 
and positive for AmpC production were tested for the presence of blaCTX-M (Batchelor et al., 
2005), blaSHV, blaTEM and blaOXA (Dallenne et al., 2010) genes. If positive for blaCTX-M, 
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isolates were tested for the presence of CTX-M group 1, 2 and 9 genes (Batchelor et al., 2005; 
Hopkins et al., 2006). Isolates identified as phenotypic AmpC producers by the AmpC 
detection set (MAST Group Ltd., Liverpool, UK) were tested for the presence of blaAmpC gene 
carriage (Perez-Perez and Hanson, 2002). All PCR assays were performed with 5 µL of 
bacterial DNA, 5 pmol of each primer, 4 µL of 5x FIREPol® Master Mix (12.5 mM MgCl2) 
and water, made up to a total reaction volume of 25 µL.  In addition, 0.5 µl of FIREPol® 
DNA Polymerase 5 U/µl (Solis-Biodyne, Tartu, Estonia) was added per reaction (total 
volume 25 µL) for multiplex assays. Positive control strains were included and molecular 
grade water (Sigma-Aldrich Company Ltd., Gillingham, UK) was used as the negative 
control. PCR products were analysed by agarose gel (1.5%) electrophoresis and the DNA 
fragments were visualised under UV light after peqGREEN (peqlab, Fareham, UK) staining 
(Table 4-1; Appendix II). 
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2.6 Statistical analysis 
 
All questionnaire derived information and microbiological data were entered into a 
spreadsheet program (Microsoft Excel for Mac 2008, Microsoft Corporation) and the dataset 
was reviewed and checked for coding of all variables. Independent (risk factor) variables 
were created from information obtained from the owner and veterinary surgeon 
questionnaires. Except for the age of the dog, all variables were dichotomous or categorical in 
nature. The variables treatment duration and body weight were divided into three categories: 
≤ 1 week, > 1 week and ≤ 3 weeks and > 3 weeks and small (< 11 kg), medium (11-20 kg) 
and large (> 20 kg) respectively. The variable recruitment site was divided into two 
categories: first opinion and referral consultations (Table 1).  
 
Microbiological data were collapsed to the sample level and categorised for time of sample 
collection. The baseline samples were always at day zero (D0) and the end of therapy sample 
(End) varied depending on the length of the prescription. Due to reduced owner compliance 
towards the end of the study, M1 and M3 time points represent a range of days over which 
samples were received for processing following the end of therapy; M1 = 21 to 60 days 
(mean = 35.38, median 33 and mode 28) and M3 = 61 to 150 days (mean = 100.97, 
median = 97, mode = 84), hence these were categorised as month 1 (M1) and month 3 (M3) 
samples. 
 
Initial data analysis included Pearson’s chi-square tests for the categorical variables and a 
one-way between-groups analysis of variance (ANOVA) for age to investigate differences 
between treatment groups at baseline (D0) (Table 2). In addition logistic regression was used 
to test for differences in antimicrobial resistance outcomes between treatment groups at 
baseline (D0) after accounting for the other independent variables (Table 7-8 to 7-11, 
Appendix V). The percentage of samples, with 95% confidence intervals, were calculated for 
each treatment group and treatment overall (CFX, AC, CVN, CD, FL, Total) at each time 
point (D0, E, M1, M3) for each of the five outcome measures. 
 
To examine the effect of treatment group and time of sample and other independent variables 
on the presence of resistance, data were analysed using a multilevel logistic regression models 
with a binomial distribution and logit link. Due to repeated samples over time, data were 
clustered within dogs (level two units) and this clustering was accounted for by inclusion of 
dog as a random intercept in all models. Faecal samples were considered the level one unit of 
interest. In order to make allowance for all dogs not having received any therapy at baseline 
(D0), all dogs at baseline were classed as baseline untreated. Ultimately, in addition to no 
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treatment at baseline (n = 1), there were 15 categories created to account for the different 
combinations of time (n = 3) and treatment group (n = 5). 
 
Resistance to ciprofloxacin or to third generation cephalosporins (CZ, CPD or CX; including 
ESBL- and/or AmpC-producing E. coli), multidrug resistance (MDR; resistance to ≥ 3 
antimicrobial classes) the presence of phenotypic ESBL-producing E. coli and the presence of 
AmpC-producing E. coli were considered as five separate binary outcomes.  
 
Initially all variables were analysed in a univariable multilevel model. All variables that 
showed some association with the presence of resistant E. coli on univariable analysis (a P-
value < 0.25) were considered for incorporation into a final multilevel, multivariable model 
for that outcome. In addition treatment group and the time of sample were always retained in 
the final models. For any pair of variables with a correlation coefficient of ≥ 0.7 only the 
variable with the smallest P-value was considered for further analysis. The final models were 
constructed by a manual backwards stepwise procedure where variables with a Wald P-value 
< 0.05 were retained in the model.  Once a final multivariable model was produced all 
variables that were significantly (P < 0.05) different between treatment groups at day 0 were 
forced back into the model to assess their effect on the remaining variables, in particular 
treatment group (Table 2).    
 
Multilevel models were analysed using the MLwiN statistical software package (MLwiN 
Version 2.28 Centre for Multilevel Modelling, University of Bristol). Univariable and 
multivariable calculations were performed using penalised quasi-likelihood estimates (2nd 
order PQL for all outcomes other than phenotypic ESBL which was 1st order MQL). First 
order interaction terms were tested for biologically plausible variables remaining in the final 
models. The residuals +/- 1.96 SD x rank (caterpillar plots) were calculated and graphed for 
each dog to check for outliers. Tests for correlation (Spearman’s rho), Pearson’s chi-square 
and logistic binary regression were performed using SPSS software package (SPSS 20.0 for 
Mac, SPSS Inc, Chicago, Illinois). 
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3. Results  
3.1 Study population  
 
One hundred and twenty-seven dogs were enrolled in this study from three centres: practice 1 
(n = 44), practice 2 (n = 50) and practice 3 (n = 33) and included first opinion (n = 73) and 
referral consultations (n = 54). The dogs were treated with the following antimicrobials: 
cefalexin (n = 32; CFX), clavulanate-amoxicillin (n = 29; AC), cefovecin (n = 27; CVN), 
clindamycin (n = 29; CD), or a fluoroquinolone (n = 14; FL). Treatment was prescribed for 
≤ 1 week in 34 dogs, > 1 week and ≤ 3 weeks in 47 dogs and > 3 weeks in 46 dogs. The dogs 
were aged between 12 to 204 months (mean = 62 months), there were 75 male and 52 female, 
and 20 small, 16 medium and 91 large dogs enrolled in this study (Table 1). One hundred and 
twenty-seven dogs provided samples at Day 0 and End, 105 dogs provided samples at M1 and 
98 dogs provided samples at M3. There were a total of 457 samples, 115 samples in the CFX 
treatment group, 107 samples in AC treatment group, 85 samples in the CVN treatment 
group, 107 samples in the CD treatment group and 43 samples in the FL treatment group 
(Table 2). Missing samples from M1 (n = 22) were due to prescription of further 
antimicrobial therapy (n = 7), euthanasia due to unrelated reasons (n = 3), or owner non-
compliance (n = 12). Missing samples from M3 (n = 29) were due to prescription of further 
antimicrobial therapy (n = 12), euthanasia due to unrelated reasons (n = 4), re-homing (n = 3) 
or owner non-compliance (n = 10).  
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Table 1. The baseline (D0) variables considered for inclusion in the final multivariable model, with the 
number and percentage (%) of samples in each treatment group and variable category. 
Variable CFX AC CVN CD 
 
Fl 
 
Total  P-value  
Mean agea (months)  44  50 68 79 83 62 0.016* 
Weight       0.002* 
Small (< 11 kg) 1 (5) 2 (10) 3 (15) 10 (50) 4 (20) 20 (16)  
Medium (11-20 kg) 4 (25) 3 (19) 0 7 (44) 2 (13) 16  (13)  
Large (> 20 kg) REF 27 (30) 23 (25) 21 (23) 12 (13) 8 (9) 91 (72)  
Gender       0.784 
Male REF 19 (25) 17 (23) 12 (16) 17 (23) 10 (13) 75 (59)  
Female 13 (25) 11 (21) 12 (23) 12 (23) 4 (8) 52 (41)  
Treatment duration       0.000* 
1 week REF 6 (18) 16 (47) 0 10 (29) 2 (6) 34  (27)  
> 1 and < 3 weeks 12 (26) 9 (19) 9 (19) 11 (23) 6 (13) 47  (37)  
> 3 weeks 14 (30) 3 (7) 15 (33) 8 (17) 6 (13) 46  (36)  
Recruitment site       0.000* 
First opinion practice REF 24 (33) 27 (37) 4 (17) 17 (23) 1 (1) 73 (57)  
Referral consultation 8 (15) 1 (2) 20 (83) 12 (22) 13 (24) 54 (43)  
A diagnosis of pyoderma was 
made at enrolment 
28 (35) 3 (4) 23 (28) 16 (20) 11 (14) 81 (64) 0.000* 
Previous systemic antimicrobial 
treatment1 
16 (26) 10 (16) 17 (28) 10 (16) 8 (13) 61 (48) 0.048* 
Previous beta-lactam antimicrobial 
treatment1 
11 (28) 7 (18) 9 (23) 7 (18) 6  (15) 40 (31) 0.408 
Previous hospital admission1  17 (42) 12 (29) 5 (12) 6 (15) 1 (2) 41 (32) 0.007* 
In-contact human or pet received 
antimicrobials2 
7 (26) 5 (19) 4 (15) 7 (26) 4 (15) 27 (21) 0.911 
In-contact human or pet admitted 
to hospital or veterinary premises2 
4 (15) 3 (12) 6 (23) 8 (31) 5 (19) 26 (20) 0.210 
Owner works in healthcare  5 (21) 2 (8) 4 (17) 10 (42) 3 (13) 24 (19) 0.078 
Multi-dog household  18 (15) 15 (26) 12 (21) 8 (14) 4 (7) 57 (45) 0.123 
Enrolled dog regularly eats animal 
stools  
7 (18) 5 (13) 8 (21) 11 (29) 7 (18) 38 (30) 0.083 
CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fl = fluoroquinolone. aAge was the only 
categorical value and is represented by the mean age of dogs in each treatment group; REF = the reference category for non-
dichotomous variables; 1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of 
enrolment; *significant at P < 0.05 
 
Table 2. The number of faecal samples provided at each time point in each treatment group. 
Antimicrobial treatment group 
Time point CFX AC CVN CD FL Total 
D0 32 28 24 29 14 127 
End 32 28 24 29 14 127 
M1 27 26 19 26 7 105 
M3 24 25 18 23 8 98 
Total 115 107 85 107 43 457 
CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; FL = fluoroquinolone; D0 = baseline day 
zero; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy 
 
3.2 Descriptive statistics 
 
3.2.1 Prevalence of antimicrobial resistance during the full study period 
During the full study period, at least one antimicrobial resistant E. coli isolate was detected in 
287 samples (63%, 95% CI: 58.3 – 67.1) from 115 dogs (91%, 95% CI: 84.2 - 94.5). Only 10 
dogs (8%, 95% CI: 4.3 – 13.9) had no antimicrobial resistant faecal E. coli detected in any of 
their samples (four dogs in CD group, three dogs in AC group, two dogs in CFX group and 
one dog in FL group). There was no commonality between these dogs and and tested 
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independent variable. MDR E. coli were identified in 149 (n = 457) samples (33%; 95% CI: 
28.5 - 37.0) from 80 dogs (63%; 95% CI: 54.3 – 70.9) (Tables 7-1 to 7-5; Appendix V).  
Multiple (greater than one) MDR phenotypes were detected in 48 of the 149 samples (32.2%; 
95% CI: 25.2 – 40.1): 32 samples with two phenotypes, 10 samples with three phenotypes, 
five samples with four phenotypes and one sample with five MDR phenotypes. Resistance to 
ampicillin, tetracycline and trimethoprim was the most common MDR pattern (Table 3).  
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Table 3. The ten most frequent multidrug-resistant phenotypes identified among the 149 faecal samples 
with MDR E. coli. 
Resistance phenotype 
Number of 
antimicrobial 
classes 
Number of 
samples 
Percentage of samples 
(95% CI) 
AMP, TET, TM 3 47 31.5 (24.6 – 39.4) 
AMP, AC, TET, TM 3 21 14.1 (9.4 – 20.6) 
AMP, AC, CIP, NAL, TET, TM 4 20 13.4 (8.9 – 19.8) 
AMP, CIP, NAL, TET, TM 4 16 10.7 (6.7 – 16.7) 
AMP, CHL, TET, TM 4 13 8.7 (5.2 – 14.4) 
AMP, NAL, TET, TM 4 11 7.4 (4.2 – 12.7) 
AMP, CHL, TET 3 11 7.4 (4.2 – 12.7) 
AMP, CHL, TM 3 10 6.7 (3.7 – 11.9) 
AMP, AC, CIP, CHL, NA, TET, TM 5 9 6 (3.2 – 11.1) 
AMP, CIP, NAL, TET, TM 4 8 5.4 (2.7 – 0.2) 
95% CI = 95% confidence intervals; AMP = ampicillin; AC = clavulanate-amoxicillin; CIP = ciprofloxacin; 
CHL = chloramphenicol, NAL = nalidixic acid, TET = tetracycline; TM = trimethoprim 
 
Overall, 20% (95% CI: 16.3 – 23.6) of samples from 49 dogs (39%; 95% CI: 30.6 – 47.3) and 
35% (95% CI: 30.4 – 39) of samples from 79 dogs (62%; 95% CI: 53.5 – 70.2) had at least 
one ciprofloxacin resistant or 3GCR E. coli isolated, respectively. Phenotypic ESBL-
producing E. coli were detected in 59 samples (11%, 95% CI: 8.2 – 13.9) from 39 dogs (31%, 
95% CI: 23.4 – 39.2) and ESBL-producing E. coli carrying blaCTX-M (mainly group 1) in 34 
samples (7.4%; 95% CI: 5.4 – 10.2). Additionally, third generation cephalosporin resistant E. 
coli that carried blaTEM and/or blaOXA were detected in 54 samples (12%; 95% CI: 9.2 – 15.1), 
in conjunction with blaCTXM in 11 samples. Only one sample carried blaSHV along with blaTEM 
and blaOXA. MDR ESBL-producing E. coli were detected in 33 samples (7.2%; 95% CI: 5.2 – 
10) and ciprofloxacin resistant ESBL-producing E. coli were detected in 21 samples (4.6%; 
95% CI: 3.0 – 6.9).  
 
Phenotypic AmpC-producing E. coli were detected in 159 samples (35%, 95% CI: 30.6 –
39.3) from 81 dogs (64%, 95% CI: 55.1 – 71.6) and AmpC-producing E. coli carrying AmpC 
genes, mainly blaCIT but also blaDHA-1 and blaMOX, in 133 samples (29.1%; 95% CI: 25.1, 
33.4). MDR AmpC-producing E. coli were detected in 50 samples (11%; 95% CI: 8.4 – 
14.1), while ciprofloxacin resistant AmpC-producing E. coli were only detected in 27 samples 
(5.9%; 95% CI: 4.1 – 8.5).  
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3.2.2 Changes in antimicrobial resistance following therapy 
There was an overall tendency for the percentage of samples with antimicrobial resistant 
faecal E. coli, to increase following antimicrobial therapy and to gradually decrease to pre-
treatment levels by M3. In particular, the percentage of samples with MDR, 3GCR or 
phenotypic ESBL-producing E. coli increased following therapy, particularly with beta-
lactam antimicrobials, and reduced to pre-treatment levels by M3 for all treatment groups 
(Figures 1, 2 and 3). MDR ESBL-producing E. coli also increased following therapy with 
beta-lactam or fluoroquinolone antimicrobials but decreased to pre-treatment levels by M1 for 
the majority of the groups (CFX, CVN and FL). The number of samples with ESBL 
producing E. coli carrying blaCTX-M increased following therapy in all treatment groups and 
gradually decreased to or below pre-treatment levels by M3 (Tables 7.1-7.2; Appendix V). 
 
Ciprofloxacin resistance increased after therapy, particularly following CFX, CVN or FL, and 
then gradually reduced to pre-treatment levels by M3 for all groups (Figure 4). Similar trends 
occurred for the detection of ciprofloxacin resistant ESBL- or AmpC-producing E. coli, 
however pre-treatment levels were reached by M1. The percentage of samples with 
phenotypic AmpC-producing E. coli, AmpC-producing E. coli carrying blaAmpC and MDR 
AmpC-producing E. coli increased following therapy with beta-lactam antimicrobials, but 
again decreased to pre-treatment levels for all treatment groups by M3 (Figure 5). In fact, pre-
treatment levels were reached by M1 for CVN with all AmpC outcomes, for AC with blaAmpC 
and for CFX with MDR AmpC-producing E. coli (Tables 7.1-7.3; Appendix V).  
 
Figure 1. The percentage of samples with MDR E. coli at each time point for each treatment group and 
treatment overall (error bars = 95% CI). 
95% CI = 95% confidence interval; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fluro 
= fluoroquinolone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy 
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Figure 2. The percentage of samples with third generation cephalosporin resistant E. coli at each time point 
in each treatment group (error bars = 95% CI). 
95% CI = 95% confidence interval; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fluro 
= fluoroquinolone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy 
 
Figure 3. The percentage of samples with phenotypic ESBL-producing E. coli at each time point in each 
treatment group (error bars = 95% CI). 
95% CI = 95% confidence interval; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fluro 
= fluoroquinolone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy 
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Figure 4. The percentage of samples with ciprofloxacin resistant E. coli at each time point in each treatment 
group (error bars = 95% CI). 
95% CI = 95% confidence interval; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fluro 
= fluoroquinolone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy 
 
Figure 5. The percentage of samples with phenotypic AmpC-producing E. coli at each time point in each 
treatment group (error bars =  
95% CI). 
95% CI = 95% confidence interval; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fluro 
= fluoroquinolone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy 
 
3.3 Multilevel, univariable analysis  
 
Univariable analysis found a number of explanatory variables to be either significant for or 
associated with each of the five outcomes: ciprofloxacin resistance (CipR), third-generation 
cephalosporin resistance (3GCR), multidrug resistance (MDR), AmpC-producing E. coli 
(AmpC) and ESBL-producing E. coli (ESBL). The variables of interest, treatment group 
(CFX, AC, CVN, CD & FL) at different time points (End, M1 & M3) were compared to the 
respective baseline outcome detected in all samples from all treatment groups. The overall 
treatment and time variable was significant for MDR (P = 0.009) and 3GCR and AmpC (P < 
0.001).  Living in a multi-dog household was significant for 3GCR (P = 0.001), ESBL 
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(P = 0.004) and AmpC models (P = 0.01). A ‘diagnosis of pyoderma’ was significant for 
CipR (P = 0.012), 3GCR (P = 0.008) and ESBL models (P = 0.009). Differences in body 
weight were significant for 3GCR (P = 0.002) and AmpC models (P < 0.001) and age 
(3GCR; P = 0.004), duration of treatment (CipR; P = 0.034), eating animal stools (CipR; P = 
0.016), gender (3GCR; P = 0.004) and owner working in healthcare (MDR; P = 0.021) were 
significant for one outcome each (outcome and P-value in parenthesis). Although recruitment 
from referral consultations compared to first opinion practice was only close to significance 
for 3GCR (P = 0.16) and AmpC (P = 0.11) in the univariable models, this variable was 
included in the final models for these outcomes (Tables 7-5 and 7-6, Appendix V). 
 
3.4 Multilevel, multivariable analysis 
 
Overall treatment groups and time points were significant for 3GCR, AmpC (P < 0.001), and 
MDR (P = 0.045) and borderline significant for CipR (P < 0.092). There was significantly 
increased risk of MDR following treatment with AC or CVN when compared to all baseline 
samples, but M1 and M3 samples did not have significantly more MDR than the baseline 
samples. The beta-lactam treatment groups were more likely to be associated with the 
outcomes 3GCR and AmpC after therapy when compared to baseline, but the risk was greater 
for treatment with CFX or CVN. In addition there was increased risk for the detection of 
ciprofloxacin resistant E. coli in samples following therapy with CFX, CVN or a 
fluoroquinolone. Although the odds ratios were still increased at M1 for the majority of 
outcomes in nearly all treatment groups these were not significantly different to baseline with 
the exception of AC group and 3GCR.  
 
In addition to the treatment group and time points the only other explanatory variables 
retained in the final models were living in a multi-dog household (positively associated with 
3GCR and ESBL), recruitment from referral consultations compared to first opinion practice 
(associated with 3GCR and AmpC resistance), eating animal stools (associated with CipR), 
owner working in healthcare (associated with MDR), a ‘diagnosis of pyoderma’ (associated 
with ESBL), and body weight (associated with AmpC); dogs of small or medium weight were 
less likely than large dogs to harbour AmpC-producing faecal E. coli (Table 5 and 6).  
 
All explanatory variables that were significantly different between treatment groups at 
baseline (P < 0.05), and not already present in the final models, were tested in the final 
models. A ‘diagnosis of pyoderma’ was significant in the univariable models (P = 0.008) for 
3GCR. When this variable was forced back into the final model, although it did not reach 
significance (P = 0.108), it narrowed the confidence intervals for cephalosporin therapy, 
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decreased the variance and resulted in AC treatment group being significant (P = 0.04) for 
this outcome. The variance partition coefficient ranged from 27% to 45% for the different 
resistance outcomes suggesting that there was substantial clustering within dog. There was no 
difference between any of the final models compared to models where potential outliers had 
been excluded (Figures 7-1 to 7-5, Appendix V).  
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Table 5. Multilevel multivariable results for outcomes ciprofloxacin resistance (CipR) and multidrug 
resistance (MDR) in 457 faecal samples from 127 dogs. 
Variables CipR MDR 
 OR 95% CI P-value OR 95% CI P-value 
Time D0  REF ⎯ ⎯ REF ⎯ ⎯ 
Time End and CFX  5.14 1.59-16.58 0.006* 1.67 0.55-5.03 0.365 
Time End and AC  1.35 0.26-7.07 0.720 4.97 1.54-15.98 0.007* 
Time End and CVN  6.97 1.91-25.48 0.003* 8.02 2.10-30.59 0.002* 
Time End and CD  0.69 0.10-4.91 0.714 1.59 0.44-5.69 0.479 
Time End and FL  5.57 1.21-25.74 0.028* 0.77 0.15-4.00 0.759 
Time M1 and CFX  2.02 0.46-8.81 0.352 2.14 0.66-6.94 0.204 
Time M1 and AC  2.08 0.46-9.3 0.340 0.58 0.13-2.51 0.465 
Time M1 and CVN  0.80 0.11-5.73 0.820 1.59 0.34-7.32 0.553 
Time M1 and CD  0.30 0.02-4.12 0.368 1.75 0.47-6.43 0.401 
Time M1 and FL  2.70 0.32-22.87 0.363 1.82 0.23-14.09 0.567 
Time M3 and CFX  0.44 0.03-5.63 0.528 0.66 0.16-2.80 0.578 
Time M3 and AC  1.00 0.15-6.94 0.996 2.02 0.57-7.23 0.278 
Time M3 and CVN  2.52 0.51-12.39 0.254 1.24 0.25-6.11 0.792 
Time M3 and CD  0.44 0.03-6.02 0.536 0.36 0.07-1.79 0.212 
Time M3 and FL  2.88 0.36-22.96 0.317 0.28 0.02-4.53 0.373 
Time treatment overall ⎯ ⎯ 0.092 ⎯ ⎯ 0.045 
Owner works in healthcare  ⎯ ⎯ ⎯ 3.61 1.32-9.88 0.012* 
Dog eats animal stools 2.89 1.20-7.00 0.018* ⎯ ⎯ ⎯ 
Level 2 (dog) Variance [standard 
error] VPC (%) 
1.58 [0.64] 
32% ⎯ ⎯ 
2.7 [0.66] 
45% ⎯ ⎯ 
OR = odds ratio; 95% CI = 95% confidence interval; VPC = variance partition coefficient; P values are from the Wald chi-
squared test; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; Fl = fluoroquinolone; Day 0 
= baseline; End = end of therapy; M1 = one month after therapy; M3 = three months; *significant at P < 0.05
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Table 6. Multilevel multivariable results for outcomes third generation cephalosporin resistance (3GCR), presence or absence of ESBL- or  AmpC-producing E. coli in 457 faecal 
samples from 127 dogs. 
Variables 3GCR ESBL AmpC 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Time D0  REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Time End and CFX  10.04 3.39-29.75 0.000* 1.59 0.52-4.84 0.418 8.84 3.08-25.37 0.000* 
Time End and AC  2.86 0.85-9.67 0.091 1.31 0.22-7.59 0.765 2.81 0.95-8.28 0.061 
Time End and CVN  11.31 2.89-44.31 0.000* 2.54 0.78-8.26 0.121 9.31 2.72-31.89 0.000* 
Time End and CD  0.93 0.25-3.49 0.917 0.42 0.05-3.51 0.426 0.78 0.22-2.73 0.693 
Time End and FL  0.58 0.10-3.3 0.537 2.37 0.49-11.53 0.286 0.47 0.09-2.59 0.389 
Time M1 and CFX  2.54 0.81-7.97 0.111 0.51 0.11-2.48 0.406 2.76 0.95-8.02 0.063 
Time M1 and AC  3.86 1.13-13.14 0.031* 3.01 0.69-13.14 0.143 1.59 0.51-4.92 0.420 
Time M1 and CVN  1.50 0.38-5.95 0.561 2.07 0.55-7.72 0.281 1.85 0.56-6.11 0.313 
Time M1 and CD  0.64 0.14-2.86 0.562 0.57 0.07-4.59 0.594 1.04 0.29-3.7 0.956 
Time M1 and FL  0.69 0.08-5.58 0.724 0.86 0.07-10.42 0.906 0.42 0.03-5.83 0.517 
Time M3 and CFX  0.77 0.20-2.98 0.704 0.93 0.23-3.77 0.914 0.62 0.17-2.26 0.471 
Time M3 and AC  1.15 0.30-4.41 0.835 0.67 0.07-6.49 0.731 0.42 0.11-1.71 0.227 
Time M3 and CVN  3.48 0.86-13.99 0.079 0.76 0.13-4.37 0.759 1.83 0.54-6.24 0.334 
Time M3 and CD  0.48 0.09-2.55 0.390 0.65 0.08-5.18 0.686 0.28 0.04-1.85 0.185 
Time M3 and FL  0.90 0.12-7.09 0.923 1.13 0.11-11.22 0.916 0.96 0.13-7.21 0.972 
Time treatment overall  ⎯ ⎯ 0.000* ⎯ ⎯ 0.773 ⎯ ⎯ 0.000* 
Weight (large) REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Weight (small) ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ 0.48 0.17-1.35 0.165 
Weight (medium) ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ 0.12 0.03-0.5 0.004* 
Weight overall ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ 0.009* 
Diagnosis of pyoderma ⎯ ⎯ ⎯ 3.63 1.18-11.13 0.024* ⎯ ⎯  
First opinion  REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Referral consultation 2.61 1.09-6.24 0.031* ⎯ ⎯ ⎯ 2.21 1.06-4.62 0.035* 
Multi-dog household 3.78 1.64-8.74 0.002* 2.71 1.24-5.93 0.012* ⎯ ⎯ ⎯ 
Level 2 (dog) Variance [standard error] VPC (%) 2.44 [0.6] 43% ⎯ ⎯ 1.190 [0.5] 27% ⎯ ⎯ 1.79 [0.48] 35% ⎯ ⎯ 
OR = odds ratio; 95% CI = 95% confidence interval; VPC = variance partition coefficient; P values are from the Wald chi-squared test; CFX = cefalexin, AC = clavulanate-amoxicillin; CVN = cefovecin; 
CD = clindamycin; Fl = fluoroquinolone; Day 0 = baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy; *significant at P < 0.05
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4. Discussion  
The aim of this study was to examine the impact of routine antimicrobial therapy on the 
faecal E. coli of dogs attending veterinary outpatient clinics. Treatment with one of five 
different systemic antimicrobials, authorised to treat dogs in the UK, was investigated. 
Systemic antimicrobial therapy is known to select for antimicrobial resistant bacteria in the 
gastrointestinal tract in humans and other animals (Jernberg et al 2010; Singer et al., 2008; 
Grønvold et al., 2010), and was demonstrated in this study with a significant increase in 
samples carrying resistant E. coli following therapy. For overall antimicrobial treatment, there 
was approximately a 10 to 20% increase in samples with 3GCR, ciprofloxacin resistance, 
MDR, phenotypic ESBL-producing E. coli and phenotypic and genotypic (blaAmpC) AmpC-
producing E. coli after therapy. In addition, the percentage of samples with either MDR, 
ciprofloxacin resistant or CTX-M carrying ESBL-producing E. coli doubled immediately 
following treatment.  
 
Multivariable, multilevel modelling found treatment with beta-lactam antimicrobials, in 
particular cephalosporins, to be statistically significant for the detection of 3GCR, 
ciprofloxacin resistance and phenotypic AmpC-producing E. coli, and cefovecin and 
clavulanate-amoxicillin to be significant for MDR, compared to all samples at baseline. 
AmpC-producing E. coli are resistant to oxyimino-cephalosporins (Livermore and Hawkey, 
2005) and therefore likely to be selected by therapy with these antimicrobials. Cefalexin was 
a risk factor for rectal carriage of MDR, predominantly AmpC- producing E. coli in 
hospitalised dogs (Gibson et al., 2011a) and was also reported to select for the carriage of 
blaCMY-2  (Damborg et al., 2011). In addition, therapy with cefovecin has been reported to 
select for beta-lactam antimicrobial resistance and carriage of blaCMY-2 gene when compared 
to untreated dogs (Lawrence et al., 2013). Similar findings have also been reported for 
humans with increased detection of ampicillin, clavulanate-amoxicillin and second-generation 
cephalosporin resistant faecal E. coli following beta-lactam antimicrobial therapy (Raum et 
al., 2008). One of the common MDR phenotypes in our study included resistance to 
clavulanate-amoxicillin, likely accounting for the selection of MDR isolates by clavulanate-
amoxicillin or cefovecin therapy. However unexpectedly, clavulanate-amoxicillin treatment 
was not significantly associated with the detection of AmpC-producing E. coli in our study, in 
agreement with the findings of (Gibson et al., 2011a), where the author proposed further 
investigation of this result. 
 
Multivariable analysis also found fluoroquinolone therapy to be statistically significant for the 
detection of ciprofloxacin resistant faecal E. coli following therapy. Fluoroquinolone therapy 
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has been previously reported to select for fluoroquinolone, ESBL-producing and MDR 
resistant E. coli isolates in dogs (Boothe and Debavalya, 2011; Gibson et al., 2011b; Moreno 
et al., 2008; Ogeer-Gyles et al., 2006), and fluoroquinolone resistant faecal E. coli in humans 
(Raum et al., 2008). E. coli strains with high level fluoroquinolone resistance have been 
reported to be frequently resistant to cephalosporins (Sato et al., 2013). In our study, 
cephalosporins also selected for fluoroquinolone resistance, suggesting co-selection of 
multidrug resistant isolates (Livermore and Hawkey, 2005). MDR with clavulanate-
amoxicillin and ciprofloxacin resistance were detected in 13% of samples. On the contrary, it 
was therefore surprising that fluoroquinolone therapy was not significant for MDR or 
cephalosporin resistance post treatment. It is likely that the full impact of fluoroquinolone 
therapy on canine faecal E. coli in our study may have been limited due to the small sample 
size of this treatment group.  
Multivariable analysis did not find any treatment groups at any time points to be associated 
with ESBL-producing E. coli whereas other studies have reported a link between 
cephalosporin or fluoroquinolone therapy with ESBL-producing E. coli (Cavaco et al., 2008; 
Moreno et al., 2008). The percentage of dogs that yielded faecal samples positive for ESBL-
producing E. coli was much lower than the other resistance outcomes examined in the models 
and therefore associations may have been missed, particularly as cephalosporin therapy was 
found to be a risk factor for third generation cephalosporin resistance; an outcome that 
included phenotypic ESBL-producing E. coli.  
There was an overall trend for the number of positive samples for the majority of resistance 
outcomes, for the majority of treatment groups to recover to baseline levels by M3; an 
average of 100 days post-therapy. For some outcomes and treatment groups, including MDR, 
ciprofloxacin resistant or CTX-M carrying ESBL-producing E. coli, recovery to baseline 
appeared to occur by M1; an average of 35 days. Statistically, there was no difference from 
baseline in any resistance outcome for any treatment group at one and three months post 
therapy apart from 3GCR at M1 following clavulanate-amoxicillin therapy.  A much shorter 
recovery period of two weeks was reported by a large prospective cohort study in humans 
treated with various antimicrobials and a small study of four dogs treated with amoxicillin 
(Gronvold et al., 2010; Raum et al., 2008). However, the treatment duration in these studies 
was less than ten days and may have allowed for faster recovery. In addition, the studies only 
examined one isolate per sample and therefore had lower sensitivity to detect resistance than 
our study methods. Conversely, our study only sampled four weeks post therapy and may 
have missed samples with faster recovery time. Other authors have also reported longer 
recovery times, in agreement with our findings, particularly with longer treatment durations 
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(Horcajada et al., 2002; Nyberg et al., 2007; Trott et al., 2004). In a canine model, recovery 
from MDR faecal E. coli following oral bacterial inoculation and three weeks of enrofloxacin 
therapy took one month compared to one week for control animals (Trott et al., 2004), and in 
humans receiving one month of ciprofloxacin, recovery to baseline took two months 
(Horcajada et al., 2002). Longer recovery times of up to nine months have been reported for 
E. coli isolates following short-term treatment with clindamycin in humans (Nyberg et al., 
2007). 
The selection of antimicrobial resistant isolates in the gastrointestinal tract may be a direct 
effect of treatment suppressing susceptible flora and allowing either pre-existing, possibly 
undetectable, resistant isolates (either from mutation and/or from acquired resistant 
determinants) and/or ingested exogenous antimicrobial resistant bacteria to survive and 
multiply. Also bacterial stress response induced by antimicrobial exposure, may prompt 
mobilisation and dissemination of resistance determinants amongst the gastrointestinal flora 
(Donskey, 2006; Edlund and Nord, 2000; Sullivan et al., 2001; Wellington et al., 2013). The 
exact mechanism of the changes detected in faecal E. coli in this study has not yet been 
elucidated. One prospective study in humans found that isolates detected following therapy 
were genetically distinct from those detected before or during antimicrobial therapy 
(Horcajada et al., 2002), suggesting an exogenous source. In the absence of antimicrobial 
exposure, susceptible isolates (endogenous or exogenous) may out-compete resistant isolates 
due to the fitness cost of resistance (Andersson and Hughes, 2010; Lenski, 1998). However, 
compensatory mechanisms have been reported (Cottell et al., 2012; Karami et al., 2008; 
Lofmark et al., 2008) and together with co-selection, may result in long term gut carriage of 
antimicrobial resistant isolates and/or genes in the absence of direct antimicrobial pressure 
(Jernberg et al., 2010). 
 
Faecal E. coli populations in humans and other animals are diverse and changeable (Anderson 
et al., 2006; Damborg et al., 2009). Many factors, including diet and environment (Wang and 
Schaffner, 2011), in addition to antimicrobial therapy, can be involved in the emergence and 
dissemination of antimicrobial resistance. A number of factors were found to be associated 
with certain resistance outcomes.  These included: 1) the association of dogs eating animal 
stools and ciprofloxacin resistance, 2) the owner working in health care and occurrence of 
MDR and 3) living in a multi-dog household and occurrence of 3GCR and ESBL-producing 
faecal E. coli detection. In addition, large dogs and referral consultations tended to be 
associated with AmpC-producing E. coli and a ‘diagnosis of pyoderma’ with ESBL-
producing E. coli. Stenske et al., (2009) reported a link between dogs drinking from toilets 
and ciprofloxacin resistant faecal E. coli and given that antimicrobial resistant faecal E. coli 
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are present in the faeces of wildlife and farmed animals (Guenther et al., 2011; Horton et al., 
2011) there is a potential reservoir of resistant bacteria and determinants for ingestion by 
dogs. Health care contact may be a risk factor for ESBL-producing (Livermore and Hawkey, 
2005) and MDR E. coli in humans (Stenske et al., 2009) and given the possibility that humans 
and pets living in the same household can share E. coli isolates (Johnson et al., 2008), humans 
may also be a source of MDR E. coli for dogs (Stenske et al., 2009). In addition, Johnson et 
al., (2008) reported that within-household sharing of E. coli was correlated with the number 
of household members. In particular, living in a multi-dog household was associated with 
phenotypic ESBL-production, which may be readily transmitted between bacteria by 
horizontal transmission on mobile genetic elements (Livermore and Hawkey, 2005). One 
other study has reported large mixed-breed dogs to be at increased risk for AMR (to at least 
one antimicrobial) and MDR faecal E. coli (Procter et al., 2013); perhaps smaller dogs are 
less likely to scavenge and more likely to undergo regular bathing than larger dogs. A number 
of other variables including age, duration of therapy and gender appeared significant for 
various outcomes on univariable analysis but were excluded during the multivariable analysis, 
in agreement with other studies (Gibson et al., 2011a, b). 
 
Even though the dogs on this study had not received systemic antimicrobials for three months 
before enrolment, baseline antimicrobial resistance prevalence was high compared to a large 
cross-sectional study that investigated the prevalence of AMR amongst faecal E. coli for vet-
visiting dogs in the UK (Wedley, 2012), but similar to AMR prevalence reported for 
hospitalised dogs, with or without antimicrobials (Guo et al., 2013; Moreno et al., 2008). The 
high baseline resistance outcomes in our study may be associated with the population 
demographics and previous health-care contact. Half the dogs had been in contact with 
veterinary premises, including referral practice, and received systemic antimicrobials during 
the 12 months prior to the three-month exclusion period for enrolment. Gibson et al., (2011b) 
reported cumulative veterinary admission of greater than or equal to four days and previous 
fluoroquinolone therapy as risk factors for rectal carriage of antimicrobial resistant E. coli in 
dogs. This may also account for the finding that dogs with ‘a diagnosis of pyoderma’, often a 
recurrent condition requiring ongoing veterinary care, or dogs recruited from referral rather 
than first opinion practice, were more likely to carry AmpC-producing faecal E. coli.  
 
There were a number of limitations to this study. The recruitment of a clinically-led sample of 
dogs rather than a fully randomised sample may have introduced sampling bias; however 
antimicrobial selection and treatment length is based on a number of important individual 
case factors (diagnosis, culture and susceptibility testing, compliance, cost, contraindications 
or previous adverse events, drug cascade and UK authorisation) and all antimicrobials under 
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investigation in this study were not appropriate for all cases. The small number of dogs 
enrolled in each treatment group, particularly the fluoroquinolone group, would have reduced 
the power of the study. Furthermore there was drop out of samples at M1 and M3 time points. 
This was mainly associated with owner compliance; however 19 samples from 12 dogs were 
missed due to further prescription of antimicrobials. As these dogs were diagnosed with 
pyoderma, it is likely that recurrent infection was associated with ongoing underlying disease. 
Whilst AMR to the initial prescription was possible, and may be a source of bias, this 
information was not available. In addition the non-randomisation to treatment groups led to 
significant differences of the baseline variables between treatment groups, which may have 
also introduced bias. However the significant variables were all retested in the final models to 
ensure they did not alter the results.  After accounting for the baseline variables there was no 
significant difference in baseline resistance outcomes across treatment groups; however, the 
high level of AMR at baseline made it more difficult to detect changes following therapy, 
increased the risk of antimicrobial resistance in the following sample and may have 
influenced the recovery time. Other limitations included potential regional bias in the 
sampling of animals and samples delivered by post, possibly with delayed processing in some 
cases; however Maule (2000) reported E. coli could survive in aerated manure for at least a 
month.  
 
5. Conclusions 
 
Our results suggest that the use of systemic antimicrobials in some dogs will impact the 
commensal gut flora with a transient shift towards a more resistant bacterial population of E. 
coli. There appears to be at least a month window following the end of therapy where the 
probability increases for treated dogs to have antimicrobial resistant faecal E. coli. This is a 
potential hazard to the dog, should an infection occur, and for potential transfer to in-contact 
individuals and the environment. Proactive strategies such as antimicrobial guidelines and 
stewardship programs to promote judicious and rationale antimicrobial use amongst 
veterinary health care professionals will help to limit the development and dissemination of 
antimicrobial resistance. Future research might include the genotyping of E. coli isolates to 
determine the change in populations during and following therapy. In addition, wider spread 
and longer lasting perturbations may be found with more in depth examination of the canine 
gut microbiome. 
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8. Concluding Discussion 
 
8.1 Discussion 
 
The main aim of this work was to examine the effects of routine antimicrobial treatment using 
five different antibacterial drugs, on canine commensal bacterial populations. Mucosal and 
intestinal commensal populations were investigated by examining staphylococci and faecal E. 
coli respectively in healthy dogs and those receiving treatment.  
 
Studies of this nature in dogs are rare, particularly longitudinal studies of carriage and AMR. 
Most studies have only followed a small number of dogs for a limited period after the end of 
treatment and have not compared different therapies. One longitudinal case-controlled canine 
study examined the shedding of MDR faecal E. coli for three weeks following the end of a 
three-week course of oral enrofloxacin in dogs (n = 4) (Trott et al., 2004). Additionally, a 
case-controlled study in laboratory beagles (n = 7) followed AMR faecal E. coli for four 
weeks, after one injection of cefovecin (Lawrence et al., 2013), and Gronvold et al., (2010) 
followed AMR faecal E. coli in healthy community dogs (n = 4), for two weeks, following 
one-week of amoxicillin. This work encompassed a longitudinal study, comparing the impact 
of different antimicrobial therapies, on the mucosal staphylococci or faecal E. coli of dogs. In 
addition, recovery was monitored for up to three months following the end of treatment. 
Studies were not case controlled rather comparison with baseline was used due to expected 
high inter-individual dog variation of intestinal E. coli based on previous studies (Dethlefsen 
et al., 2008; Engelbrektson et al., 2006; Gronvold et al., 2010; Jernberg et al., 2010; 
Turnbaugh et al., 2009). 
 
Before performing the main study, it was necessary to investigate the canine commensal 
bacterial populations in healthy dogs, without the confounding factors of antimicrobial 
therapy or veterinary premise contact that have been reported as risk factors for AMR bacteria 
in dogs (Gibson et al., 2011b; Nienhoff et al., 2011). Firstly, a small cross-sectional 
questionnaire-based study in healthy Labrador retrievers attending dog shows (n = 73) was 
performed to collect mucosal swab samples and faecal samples. Studies such as these, that 
report AMR prevalence at the canine level are lacking. Most studies report AMR prevalence 
at the isolate level, even though multiple colonies per sample are tested. Without genotyping 
this may lead to an overestimation of resistance prevalence if the results are not aggregated to 
the canine level. In addition, most studies have concentrated on clinical isolates rather than 
commensal populations. Commensal bacteria are often the source of infections (von Eiff et 
al., 2002) and commensal populations may be inadvertently affected by therapy targeting the 
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infecting pathogen. These populations may then go on to amplify and disseminate AMR. The 
close relationship between ‘man and dog’ means that commensal AMR bacteria may be 
shared between owners and pets in both directions. Furthermore, they may be transferred to 
the environment and in-contact animals within veterinary premises, representing a possible 
source for clinical outbreaks. It is therefore just as important, if not more so, to investigate 
AMR prevalence amongst commensal bacteria.  
 
In addition to reporting AMR prevalence in a cohort of non-antimicrobial treated and non-
vet-visiting dogs, the mucosal staphylococci were characterised to the species level using 
three different methodologies, highlighting the difficulties in performing this accurately. In 
particular, MALDI-TOF-MS was used for the first time to identify the majority of the canine 
commensal staphylococcal species in this study. In addition, two different methods to test 
antimicrobial susceptibility (Disc Diffusion and Minimum inhibitory concentration [MIC]) of 
oxacillin resistant staphylococci were compared and related to the carriage of antimicrobial 
resistance genes (mecA). Similarly, the healthy dog cohort study reported the prevalence of 
AMR E. coli and examined the population structure by determining phylogenetic groups and 
investigating the association of these outcomes with potential risk factors. In addition, MDR, 
ESBL- and AmpC-producing E. coli were examined for potential conjugative transfer of 
antimicrobial resistance determinants.  
 
The healthy cohort study revealed a high level of AMR amongst both mucosal staphylococci 
and faecal E. coli in dogs that had not received antimicrobials or had veterinary premises 
contact. Amongst mucosal staphylococci, 42% of dogs had MRS and 34% of dogs had MDR 
isolates. However no MR-CoPS and few MDR-CoPS were identified, in agreement with other 
studies (Wedley et al., 2014). There was good agreement for the majority of tested 
antimicrobials for antimicrobial susceptibility testing by Disc Diffusion and MIC methods. In 
addition, 20 different staphylococcal species were detected from this healthy dog cohort. 
S. epidermidis was the overall predominant species, similar to humans, which is perhaps not 
surprising given the close association between dogs and their owners, as already mentioned. 
S. pseudintermedius, the main commensal CoPS of dogs, was detected in 44% of dogs, within 
the reported prevalence range (Devriese and De Pelsmaecker, 1987; Fazakerley et al., 2010; 
Griffeth et al., 2008; Hanselman et al., 2009; Paul et al., 2012; Rubin et al., 2011). 
S. pseudintermedius were commonly detected along with CoNS species (n = 16) and 
S. aureus, however there was no significant association between S. pseudintermedius and any 
other species, as reported between S. epidermidis and S. aureus (Park et al., 2011). 
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While the healthy dog cohort study detected a high prevalence of AMR (63% of dogs), MDR 
(30% of dogs) and AmpC-producing E. coli (mainly blaCIT; 16% of dogs), compared to other 
cohort studies, few dogs carried ESBL-producing E. coli (blaCTX-M; 1%); resistance to 
ampicillin, tetracycline and/or trimethoprim was most common (Procter et al., 2013; Wedley 
et al., 2011). Ampicillin resistant E. coli was also commonly detected amongst dogs in the 
longitudinal healthy study. While the presence of this resistance phenotype may mirror 
common use of beta-lactam antimicrobials in dogs in the UK, it is also possible that it poses 
little fitness cost allowing it to persist in intestinal E. coli populations, as previously reported 
in humans (Karami et al., 2008). CTX-M and CIT (blacmy-2) are the most widespread types of 
ESBL- and AmpC- beta-lactamases respectively, and are prevalent amongst E. coli isolated 
from humans and animals, including dogs (Ewers et al., 2012; Jacoby, 2009; Wedley et al., 
2011), however further characterisation of the ESBL- or AmpC-producing E. coli isolates by 
sequencing was not performed in the current work. 
 
The healthy dog study also found a predominance of phylogenetic group B1, followed by 
group A E. coli isolates in healthy dogs. These phylo-groups are less likely to carry virulence 
genes and less likely to be associated with extra-intestinal infections compared with the other 
two phylo-groups (B2 or D) that predominate in humans. Phylo-group B2 isolates were less 
likely (P < 0.001) to be AMR and phylo-group D were more likely (P = 0.04) to be AMR 
compared to the other phylo-groups. This finding concurs with previous work in canine 
E. coli isolates (Platell et al., 2011; Sato et al., 2014). The cohort studies provided a baseline 
for the antimicrobial treatment study. As the sample population included only one breed type 
and dogs were recruited at shows, the results may not be fully representative of the general 
UK dog population. However the prevalence of ESBL-producing E. coli was similar to the 
prevalence reported in a larger UK cohort study in healthy community dogs (Wedley et al., 
2011). 
 
 
In addition, due to the high diversity reported amongst intestinal E. coli populations in 
humans, cattle, horses and dogs (Anderson et al., 2006; Damborg et al., 2009) and the 
possible influence of external factors such as diet, a longitudinal study was performed to 
investigate the carriage of faecal E. coli in healthy, mainly staff-owned dogs (n = 28), 
recruited from the University of Liverpool. Only one longitudinal faecal E. coli study has 
been reported in healthy dogs (n = 13) and this study did not report AMR phenotypes, other 
than the presence of ESBL-producing E. coli, and did not assess potential risk factors for 
carriage.  
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It was presumed that staphylococcal mucosal populations are more stable over time as has 
been reported for S. aureus in humans (VandenBergh et al., 1999) and S. pseudintermedius in 
dogs (Hartmann et al., 2005). Therefore a similar longitudinal investigation of mucosal 
staphylococci to the E. coli study was not performed in this body of work. However in 
hindsight, following new information from recent publications following S. pseudintermedius 
strains carried by dogs over time (Gomez-Sanz et al., 2013; Paul et al., 2012), a similar 
longitudinal investigation of mucosal staphylococci would have added further information to 
a growing body of evidence and, along with the cohort study, provided a baseline for the 
antimicrobial study.  
 
The healthy dog longitudinal study found marked inter- and intra-individual diversity of 
phenotypic antimicrobial resistance traits and genotypes under natural conditions, in 
agreement with previous work (Anderson et al., 2006; Damborg et al., 2009). This highlights 
the potential for exogenous E. coli isolates to influence the intestinal microbiome. 
Conjugation experiments revealed the transfer of phenotypic resistance and resistance 
determinants (blaCTX-M, blaCIT) from commensal faecal E. coli isolates, from the healthy dog 
cohort study, to a recipient strain. Although conjugation experiments and detection of 
conjugative plasmids was not performed on the isolates from the longitudinal study, transfer 
of resistance traits between identical genotypes over time is one explanation for the findings 
in that study.  Gene transfer of ampicillin resistance to initially susceptible E. coli strains has 
been reported to occur during intestinal colonisation in human infants (Karami et al., 2008). 
However intermittent shedding of isolates with identical genotypes and different resistance 
phenotypes may have also occurred, possibly due to the presence of low numbers.  
 
In the longitudinal healthy dog study, AMR to at least one tested antimicrobial was frequent 
and prolonged detection occurred in some dogs, whereas MDR, ESBL- or AmpC-producing 
E. coli were less common and detected for shorter periods. Intermittent shedding was 
common and agrees with previous studies (Anderson et al., 2006), highlighting the lack of 
sensitivity of cohort analysis to detect AMR prevalence. We cannot however fully exclude 
non-detection due to the presence of low isolate numbers, rather than intermittent shedding, 
however the methods used (non-selective and selective media with and without enrichment) 
were meant to increase the sensitivity to detect both major and minor clones and both 
susceptible and resistant isolates (Bartoloni et al., 2006). Schlager et al., (2002) calculated 
that from the random selection of five colonies per plate there was a 99% change of detecting 
at least one dominant clone. In the longitudinal healthy dog study three random colonies were 
selected from non-selective media and only one out of three dogs carried resident clone. 
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Therefore, ten E. coli colonies were randomly selected from non-selective media in addition 
to selective media for the antimicrobial treatment study. 
 
Survival analysis using Kaplan-Meier plots were performed in the longitudinal healthy dog 
study to calculate the duration of carriage of certain resistance phenotypes. As many dogs 
continued to carry E. coli with resistance to at least one tested antimicrobial when they left or 
completed the study, the median shedding of this particular outcome was not calculated; 
however the mean shedding of any AMR was approximately 60 days in agreement with one 
study following hospitalised/antimicrobial treated horses (Johns et al., 2012). Shedding of 
MDR, ESBL or AmpC-producing E. coli was significantly shorter (median of 14 days), 
similar to healthy and recently hospitalised/antimicrobial treated horses (Maddox, 2010). The 
majority of dog owners in the longitudinal healthy dog study worked in veterinary health-
care, many in veterinary clinical practice, which may be a source of bias. Therefore the results 
of this study may not be fully applicable to the general UK dog population. 
 
To determine the effects of anti-bacterials, dogs attending veterinary consultations (n = 127) 
were recruited that required systemic antimicrobial treatment for a bacterial infection. 
Following therapy, for the majority of antimicrobials, the prevalence of dogs with AMR 
bacteria increased and then gradually decreased to baseline by three months after the end of 
therapy. The use of clinically led samples may be a source of selection bias; however the 
prescription of antimicrobials could not be assigned randomly. In addition, the interest of this 
work was to investigate normal dogs in the community. Bias may have also been introduced 
with non-random allocation to treatment group. There were significant baseline differences 
for the different independent variables and they were forced back into all final models to 
ensure that they did not affect the results, particularly treatment and time. In addition, after 
allowing for independent variables other than treatment, preliminary multivariable regression 
models were performed for each resistance outcome at baseline to ensure there was no 
significant difference between treatment groups. Although baseline AMR did not differ across 
treatment groups, the high prevalence at baseline made it more difficult to detect changes 
following therapy increased the chance to detect AMR in the following sample and may have 
influenced the recovery time.  
 
All variables in all studies, other than age, were dichotomous or categorical and all outcomes 
were dichotomous. Analysis of the cohort studies was performed using Pearson’s Chi-square 
and multivariable regression. However, multilevel multivariable logistic regression was used 
to investigate the effects of antimicrobials and other independent variables in the 
antimicrobial treatment study, to allow for potential clustering within dogs due to repeat 
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sampling over time. This method was also used in the healthy longitudinal study to allow for 
potential clustering in dogs and in households as more than one dog could be recruited from 
the same owner in this study. For a number of the resistance outcomes there was still 
considerable clustering (high variance partition coefficients) that was not accounted for by the 
tested variables, including antimicrobial therapy. This may be associated with the presence of 
the resistance outcome in the previous sample for clustering within dogs or sharing of bacteria 
in multi-dog households, however other unknown variables may also be relevant. Owner-
based questionnaires were used as the source of independent test variables in all studies and 
may be a source of recall bias. In the antimicrobial treatment study this information was 
supplemented by a veterinarian-based questionnaire and patient clinical history. For all 
studies the number of observations may have reduced the statistical power, in particular for 
the fluoroquinolone treatment group in the antimicrobial studies.  
 
In the healthy dog E. coli cohort study, the main finding from multivariable logistic 
regression was that eating raw meats was associated with beta-lactam resistance, including 
3GCR, and with phylo-groups B1 and D, which were frequently also AMR. In addition, 
multi-dog households were associated with 3GCR and phylo-groups A and C (potentially 
commensal E. coli isolates).  
 
Multilevel, multivariable modelling in the longitudinal healthy dog study found that eating 
dog treats was associated with MDR E. coli, whereas the E. coli cohort study found them to 
be protective. The overall effect of eating dog treats may depend on the type of treat, not 
documented by the questionnaire, which may have differed between the different study 
populations. Procter et al., (2013) also found that eating cooked meat or proprietary dog food 
was protective against MDR E. coli. However, the low number of observations, particularly 
in the longitudinal study, may have resulted in this discrepancy between the two studies. In 
agreement with the cohort study, the healthy longitudinal study also found that eating raw 
meat was a risk factor for AMR (MDR and ESBL/AmpC-producing faecal E. coli) E. coli. 
Farm-animal meat, particularly chicken meat, has been reported as a possible source of AMR 
E. coli, including ExPEC, for people and dogs (Johnson et al., 2009; Johnson et al., 2007; 
Vincent et al., 2010). 
 
There was a high baseline prevalence of AMR in the dog population participating in the 
antimicrobial treatment study, most likely due to potential risk factors, including frequent 
veterinary premises visits, previous antimicrobial therapy and recurrent pyoderma. For 
instance, in the current work, a diagnosis of pyoderma was associated with increased 
detection of ESBL-producing E. coli, and dogs enrolled via referral clinic rather than first 
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opinion clinics were more likely to harbour AmpC-producing E. coli. There was also an 
association between beta-lactam therapy and MDR, 3GCR, fluoroquinolone resistance and 
carriage of AmpC-producing E. coli.  This highlights the potential for co-selection to drive 
the selection of AMR isolates. An association was also found between fluoroquinolone 
therapy and fluoroquinolone resistance in E. coli. The antimicrobial study also found an 
association between dogs eating animal faeces and living in multi-dog households with 
increased detection of AMR faecal E. coli. This last risk factor was also identified in the 
healthy dog cohort and longitudinal studies.  
 
For staphylococci in the antimicrobial treatment study, multilevel, multivariable modelling 
found an association between fluoroquinolone treatment with fluoroquinolone resistance, 
MDR and MRS directly after therapy. However, similar to the findings for faecal E. coli, one 
month after the end of treatment, there was no significant difference from baseline for the 
majority of treatment groups and outcomes. Surprisingly beta-lactams were not found to 
influence changes in AMR staphylococci. While this may be associated with insufficient 
power, the fluoroquinolone group had fewer observations than the other treatment groups and 
other factors, such as upregulation of adherence factors and/or mutation rate amongst MRS 
under fluoroquinolone selection pressure, may be involved. Further work is required to 
investigate these findings. In addition, although the prevalence of MRSP detection (10% of 
dogs) in this study was higher than reported in healthy dogs, it was still low, preventing 
assessment of potential risk factors associated with detection.  
 
8.3 Further work 
 
While this body of work was able to provide valuable information of the canine commensal 
bacterial populations in healthy dogs and during and after antimicrobial therapy the small 
number of dogs recruited in each study potentially reduced the statistical power. In addition, 
the study populations were either convenience based or clinically led samples, therefore 
increasing the likelihood of introducing selection bias. Therefore further similar, ideally 
randomised, studies with more observations are required to validate the findings of this work. 
In particular, few dogs carried MRSP (10%; 95% CI: 6 – 17%) in the antimicrobial treatment 
study. While this is a positive finding, due to the number of dogs enrolled, a larger study is 
needed to corroborate this prevalence (previous studies report carriage in up to 4.5% and 3.5 -
 66% of healthy and sick dogs, respectively) and may help to identify potential risk factors. 
There are few published studies that have examined the detection of MRSP, and in addition, 
antimicrobial therapy has not been consistently identified as a risk factor.  
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In addition, a longitudinal study investigating the carriage of mucosal staphylococci, 
particularly MRSP, in healthy dogs without antimicrobial pressure or veterinary admission 
would be beneficial. The fitness of MRSP isolates, compared to meticillin susceptible 
S. pseudintermedius, in the absence of antimicrobial pressure is currently unknown. 
Longitudinal studies are more likely to detect AMR isolates compared to cohort studies due to 
transient carriage in some individuals. In addition, speciation and/or genotyping would 
provide information on the carriage of both CoPS and CoNS species in dogs, the later of 
which has not been previously reported. Finally, assessment of risk factors for AMR in dogs 
under natural conditions would provide information that could be used to formulate 
preventative strategies and used as a baseline for other studies investigating the effects of 
antimicrobial or veterinary hospital selective pressures.  
 
Further characterisation of the isolates from this work would help to elucidate the findings. 
For instance, further genotyping, assessment of fitness, phylogenetic grouping and detection 
of virulence genes with risk factor assessment, particularly in the longitudinal studies, would 
provide further insight on the carriage of canine gut commensals in healthy dogs versus dogs 
under antimicrobial therapy. In particular, it would be interesting to investigate the 
epidemiology of AMR isolates carried by dogs in multi-dog households and in dogs on raw 
meat diets.  
 
Furthermore, for all E. coli studies, characterisation of resistance determinants and plasmids 
amongst phenotypic ESBL- and AmpC-producing E. coli and sequencing of resistance genes 
and multi-locus sequence typing of (MLST) would provide further information for dogs under 
different selection pressures e.g. 12% of dogs in the E. coli antimicrobial study carried blaTEM 
and/or blaOXA, but these isolates were not sequenced to examine variants and determine the 
significance of such genes for phenotypic resistance. In particular MLST may identify certain 
dominant ESBL clones and allow comparison with other studies. Moreover, blaDHA-1 and 
blaMOX were detected in dogs in the antimicrobial resistance study; blaDHA-1 is uncommon and 
blaMOX has not been previously reported in dogs, so further characterisation would allow 
comparison with similar isolates detected in humans and other animals. Similarly, for 
staphylococci, further characterisation of meticillin resistant isolates including determining 
relative fitness, SCCmec, spa and strain typing would provide epidemiological information 
for MRSP isolates carried by dogs in the community in the UK. 
 
Finally, assessment of the microbiomes by metagenomics in healthy dogs and dogs under 
antimicrobial therapy could investigate the full impact of potential risk factors such as diet, 
in-contacts and antimicrobial therapy. Examining the impact of different antimicrobials on 
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anaerobic gut bacteria and the duration of any change is of interest. This is being undertaken 
as an extension of this work and will be reported elsewhere. Metagenomic determination of 
the mucosal and skin microbiomes has been recently performed in healthy dogs. Similar 
longitudinal studies in healthy dogs and dogs under antimicrobial pressure, would give further 
information on the diversity and stability of such populations. 
 
8.3 Conclusions 
 
The prevalence of antimicrobial resistance was high amongst mucosal staphylococci and 
faecal E. coli in both healthy and sick dogs and the faecal E. coli population structure was 
diverse and dynamic in healthy dogs. In healthy dogs, these findings are likely to be 
associated with external influences such as diet, environment and in-contact humans and 
other animals. In particular, dogs that ate raw meat or animal faeces, lived in multi-dog 
households or had contact with individuals that had been exposed to health-care  
environments were at increased risk for AMR commensal bacteria. This highlights the 
potential of bacterial sharing within households and veterinary premises and may represent a 
human health risk.  
 
Antimicrobial therapy was also associated with the increased risk of antimicrobial resistance 
amongst these bacterial populations. In particular, beta-lactam treatment was a risk factor for 
carriage of MDR and AmpC-producing E. coli, with fluoroquinolone therapy a risk factor for 
MDR or MRS staphylococci. The percentage of dogs with each resistance outcome generally 
returned to baseline within three months of finishing treatment and in the multilevel 
multivariable models, there was no significant difference for the majority of resistance 
outcomes and treatment groups between baseline and one month after the end of therapy. 
 
Antimicrobial therapy is a risk factor for the detection of antimicrobial resistant commensal 
bacteria in dogs and recovery to baseline may take between one to three months after the 
treatment has finished. This highlights the importance of prudent antimicrobial use, which 
may be aided by antimicrobial prescribing guidelines. However other factors, such as diet, in-
contacts, co-selection and bacterial fitness may be involved in the carriage of resistant 
bacteria and should be considered
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Detection of antibiotic resistant bacteria in canine faecal samples and mucosal swabs in healthy 
dogs 
 
Why are we doing this study? Antibiotic resistant normal (commensal) bacteria that live on the 
mucous membranes of the nose and bottom and in the faeces may cause opportunistic bacterial 
infections in animals or people or they may pass the resistance onto pathogenic (more invasive) 
bacteria. Antibiotic resistance is a growing problem in human and canine medicine. 
The study will find out whether commensal bacteria of healthy dogs carry antibiotic resistant genes. A 
questionnaire will be used to try to determine if the findings are related to external influences. By 
determining the factors that promote antibiotic resistance in bacteria our aim is to develop guidelines 
that will minimise this occurrence. 
 
To be included in the study your dog must be:  
 
• Healthy without any gastrointestinal (vomiting or diarrhoea) or skin disease e.g. allergy. 
• Only one dog from each household can be included in the study. 
 
You dog cannot be included in the study if: : 
 
• It has received antibiotics or been hospitalised at a veterinary surgery in the last 12 months 
• Has had diarrhoea in the last 4 weeks. 
 
What does the study involve? Your participation is voluntary and you can decline involvement at any 
time. Firstly it involves answering a questionnaire. Secondly we will collect the samples (see below). 
This will take approximately 10 minutes. 
 
Mucosal samples: We will take one surface swab from each of your dog’s nostrils and one swab from 
the rear end. This procedure is non-painful and well tolerated, but if your dog objects at any stage we 
will not continue. 
 
Faecal sample: We will supply rubber gloves and a faecal pot. Please collect a small amount of faeces 
and return to us today. 
 
What next? If you are happy to participate in this study please read, initial and sign the consent form.  
 
Thank you for your time. 
 
Vanessa Schmidt BVSc CertVD DipECVD MRCVS 
University of Liverpool 
Leahurst Campus 
Chester Road 
Neston 
CH64 7TE 
vetderm@liv.ac.uk 
0151 7956100 
 
If there are any problems, please let us know by contacting Vanessa Schmidt on 0151 7956100, 
and we will try to help. If you are unhappy or have a complaint which you feel you cannot come 
to us with then you should contact the Research Governance Officer on 0151 794 8290 
(ethics@liv.ac.uk). When contacting the Research Governance Officer, please provide details of 
the name or description of the study (so that it can be identified), the researcher(s) involved, and 
the details of the complaint you wish to make. 
 
 
Version # 3; Created on 01/09/10 at 18.30 pm. 
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Detection of antibiotic resistant bacteria in canine faecal samples and mucosal swabs in healthy dogs: 
Questionnaire 
 
Case number:    
 
Please answer all questions to the best of your knowledge. 
 
Name        
 
Dogs Name      
 
           
About your dog. 
 
1) Age  Years   Months   Weeks  Don’t Know   
a) Is this age Exact     Estimate                                                                                                
 
2) Breed  Pedigree (please specify)      
Cross (please specify)        
 
3) Sex        Male  Female  Neutered  
 
4) How long have you owned him/her?   
 
 
About your dog’s diet. 
 
5) What is s/he fed?  Tinned meat   Dry mixer   
(Tick all that apply)  Dry Complete   Raw chicken  
     Cooked chicken   Raw red meat 
  
Cook red meat   Don’t Know   
Other        
 
6) Is s/he fed commercial dog treats? Never  Rarely  Sometimes 
 Often  Don’t know  
 
7) Is s/he fed human titbits/ scraps?  Never  Rarely  Sometimes 
 Often  Don’t know  
 
8) Does your dog ever eat stools (faeces)?  Never  Rarely  Sometimes 
 Often  Don’t know       
  If so what types of stools? (Please tick all that apply)    
 Rabbit  Cat  Dog  Horse   Cow 
 Sheep  Badger  Other    
 
 
About your household. 
 
9) Are there any other dogs in the household?  
Yes   No  Don’t Know     
  If yes, how many?  1  2  3 or more  
 
10) Do you own any other animals (other than dogs)? 
Yes   No  Don’t Know     
  If yes, what animals? (Please tick all that apply) 
Cat    Bird  Rabbit   
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Rodent (e.g. hamster)  Reptile (e.g. snake)   
Don’t know   Other     
  
11) Does anyone in your household work with farm animals? 
Yes   No  Don’t know     
  If yes, please state which species are worked with    
           
   
 
12) Has anyone in your family (including other pets) to your knowledge in the last month taken 
antibiotics? 
Yes   No  Don’t know  
 
a) If yes, was this a Family Member   Pet  
 
b) Which antibiotic was prescribed (if known)      
           
  
 
13) Does anyone in your household work in medical or veterinary healthcare?  
Yes   No  Don’t Know  
 
a) If yes, in what setting? Hospital  Community Nursing  
GP surgery  Nursing Home   
Dentist   Veterinary practice  
    Don’t Know  Other    
 
14) Has anyone in your household attended hospital in the last month?  
Yes   No  Don’t Know  
 
a) If yes, why? Admission to hospital   Visit   
Outpatient appointment   Don’t Know   
Other      
 
Thank you for your time. 
Version # 3; Created on 01/09/10 at 19.00 pm. 
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Table 3-1. Details of PCR assays for nuc, tuf and mecA gene identification.  
1multiplex assay 
  
Primer 
  
         Sequence (5’-3’) Amplicon 
size (bp) 
Annealing 
Temperature 
(°C) 
Control Strain Reference 
au-F3 
au-nucR1 
TCGCTTGCTATGATTGTGG 
GCCAATGTTCTACCATAGC 
 
 
359 57 S. aureus ATCC®25923 
(LGC Standards, 
Teddington, UK) 
 Sasaki et al., 
2010 
pse-F2 
pse-R51 
TRGGCAGTAGGATTCGTTAA 
CTTTTGTGCTYCMTTTTGG 
 
 
926 57 S. pseudintermedius 412 
(clinical isolate) 
 Sasaki et al., 
2010 
SSnucF 
SSnucR1 
AATGGCTACAATGATAATCAC
TAA 
CATATCTGTCTTTCGGCGCG 
 
526 57 S. schleiferi subspecies 
coagulans 
ATCC®49545 
 Sasaki et al., 
2010 
tuf-F 
tuf-R 
GCCAGTTGAGGACGTATTCT 
CCATTTCAGTACCTTCTGGTAA 
412 55 S. epidermidis 
ATCC®12228 
Carpaij et al., 
2011 
mecAF 
mecAR 
mA1 
mA2 
TGGCTATCGTGTCACAATCG 
CTGGAACTTGTTGAGCAGAG 
TGCTATCCACCCTCAAACAGG 
AACGTTGTAACCACCCCAAGA 
310 
 
286 
55 
 
57 
MRSA (clinical isolate) Francois et al., 
2003; Kondo et 
al., 2007 
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Table 3-2 The number and percentage of dogs enrolled from different areas of the UK 
Location in the UK Number of dogs Percentage of dogs 
Berkshire1 1 1 
Cambridgeshire1 1 1 
Cheshire1 8 11 
Cleveland1 1 1 
Cornwall1 2 3 
Derbyshire1 4 5 
Essex1 3 4 
Hampshire1 1 1 
Isle of Man2 1 1 
Lancashire1 13 18 
Leicestershire1 3 4 
Lincolnshire1 2 3 
London1 1 1 
Merseyside1 6 8 
Middlesex1 1 1 
Nottinghamshire1 3 4 
Northamptonshire1 2 3 
Northern Ireland* 1 1 
Northumbria1 1 1 
Scotland* 5 7 
Staffordshire1 3 4 
Somerset1 2 3 
West Bromwich1 1 1 
West Midlands1 1 1 
West Sussex1 1 1 
Yorkshire1 6 8 
1English counties; *Countries of the UK, 2Country associated with the UK 
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Figure 3-1 Map of the UK (England, Northern Ireland, Scotland and Wales) with markers indicating the 
location of each dog recruited for this study  
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APPENDIX II 
(Pertaining to chapter 4) 
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Table 4-1: Details of the primer sequences used in PCR assays in this study 
1-5 denotes multiplex assays; [Primer] = primer concentration; bp = base pairs
Primer 
 
Sequence (5’-3’) Amplicon  
Size (bp) 
Annealing 
(°C) 
[Primer] 
/reaction 
Reference 
uidAF 
uidAR 
CCAAAAGCCAGACAGAGT 
GCACAGCACATCAAAGAG 
623 58 0.25 µM McDaniels et 
al., 1996 
CTXMU1 
CTXMU2 
ATGTGCAGYACCAGTAARGTKATGGC 
TGGGTRAARTARGTSACCAGAAYCAGCGG 
593 58 0.25 µM Bachelor et al., 
2005 
CTXM1F  
CTXM1R  
ATGGTTAAAAAATCACTGCG 
TTACAAACCGTCGGTGAC 
876 58 0.25 µM Bachelor et al., 
2005 
CTXM2F  
CTXM2R  
ATGATGACTCAGAGCATTCGC 
TCAGAAACCGTGGGTTACGAT 
892 58 0.25 µM Hopkins et al., 
2006 
CTXM9F  
CTXM9R  
ATGGTGACAAAGAGAGTGCAAC 
TTACAGCCCTTCGGCGATG   
876 58 0.25 µM Hopkins et al., 
2006 
SHVF1 
SHVR 
AGCCGCTTGAGCAAATTAAAC 
ATCCCGCAGATAAATCACCAC 
713 60 0.25 µM Dallenne et al., 
2010 
TEMF1 
TEMR 
CATTTCCGTGTCGCCCTTATTC 
CGTTCATCCATAGTTGCCTGAC 
800 60 0.25 µM Dallenne et al 
2010 
OXA-1F1 
OXA-1R 
GGCACCAGATTCAACTTTCAAG  
GACCCCAAGTTTCCTGTAAGTG 
564 60 0.25 µM Dallenne et al., 
2010 
CITMF2 
CITMF 
TGGCCAGAACTGACAGGCAAA 
TTTCTCCTGAACGTGGCTGGC 
462 64 0.25 µM Perez-Perez & 
Hanson 2002 
MOXMF2 
MOXMR 
GCTGCTCAAGGAGCACAGGAT 
CACATTGACATAGGTGTGGTGC 
520 64 0.25 µM Perez-Perez & 
Hanson 2002 
DHAMF2 
DHAMR 
AACTTTCACAGGTGTGCTGGGT 
CCGTACGCATACTGGCTTTGC 
405 64 0.25 µM Perez-Perez & 
Hanson 2002 
ACCMF2 
ACCMR 
AACAGCCTCAGCAGCCGGTTA 
TTCGCCGCAATCATCCCTAGC 
346 64 0.25 µM Perez-Perez & 
Hanson 2002 
EBCMF2 
EBCMR 
TCGGTAAAGCCGATGTTGCGG 
CTTCCACTGCGGCTGCCAGTT 
302 64 0.25 µM Perez-Perez & 
Hanson 2002 
FOXMF2 
FOXMR 
AACATGGGGTATCAGGGAGATG 
CAAAGCGCGTAACCGGATTGG 
190 64 0.25 µM Perez-Perez & 
Hanson 2002 
gadAF3 
gadAR 
GATGAAATGGCGTTGGCGCAAG 
GGCGGAAGTCCCAGACGATATCC 
373 65 1 µM Doumith et al., 
2012 
chuAF3 
chuAR 
ATGATCATCGCGGCGTGCTG 
AAACGCGCTCGCGCCTAAT 
281 65 1 µM Doumith et al., 
2012 
yjaAF3 
yjaAR 
TGTTCGCGATCTTGAAAGCAAACGT 
ACCTGTGACAAACCGCCCTCA 
216 65 1 µM Doumith et al 
2012 
TSPE4.C2F3 
TSPE4.C2R 
GCGGGTGAGACAGAAACGCG 
TTGTCGTGAGTTGCGAACCCG 
152 65 1 µM Doumith et al., 
2012 
chuA.1b4 
chuA.2  
ATGGTACCGGACGAACCAAC 
TGCCGCCAGTACCAAAGACA 
288 59 1 µM Clermont et al 
2013 
yjaA.1b4 
yjaA.2b  
CAAACGTGAAGTGTCAGGAG 
AATGCGTTCCTCAACCTGTG 
211 59 1 µM Clermont et al., 
2013 
TspE4C2.1b4  
TspE4C2.2b  
CACTATTCGTAAGGTCATCC 
AGTTTATCGCTGCGGGTCGC- 
152 59 1 µM Clermont et al 
2013 
AceK.f4 
ArpA1.r 
AACGCTATTCGCCAGCTTGC 
TCTCCCCATACCGTACGCTA 
400 59 2 µM Clermont et al., 
2013 
ArpAgpE.f 
ArpAgpE.r 
GATTCCATCTTGTCAAAATATGCC 
GAAAAGAAAAAGAATTCCCAAGAG 
301 57 1 µM Clermont et al., 
2013 
trpAgpC.1 
trpAgpC.2 
AGTTTTATGCCCAGTGCGAG-
TCTGCGCCGGTCACGCCC 
219 59 1 µM Clermont et al., 
2013 
trpBA.f 
trpBA.r 
CGGCGATAAAGACATCTTCAC 
GCAACGCGGCCTGGCGGAAG 
489 57 or 59 0.6 µM Clermont et al., 
2013 
qnrAf5 
qnrAr 
ATTTCTCACGCCAGGATTTG 
GATCGGCAAAGGTTAGGTCA 
516 53 0.25 µM Robiseck et al., 
2006 
qnrBf5 
qnrBr 
GATCGTGAAAGCCAGAAAGG 
ACGATGCCTGGTAGTTGTCC 
468 53 0.25 µM Robiseck et al., 
2006 
qnrSf5 
qnrSr 
ACGACATTCGTCAACTGCAA 
TAAATTGGCACCCTGTAGGC 
417 53 0.25 µM Robiseck et al., 
2006 
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Table 4-2: Association of phylogenetic groups and the presence or absence of one of six antimicrobial resistance outcomes for of 188 faecal E. coli isolates  
Phylo-group Number (%) of ACR isolates Number (%) of PAS isolates P value Number (%) of CipR isolates Number (%) of CipS isolates P value 
A 6 (25) 52 (32) 0.5 8 (42) 50 (30) 0.27 
B1 11 (46) 67 (41) 0.65 8 (42) 70 (41) 0.95 
B2 0 33 (20) *0.002 2 (11) 31 (18) 0.37 
D 7 (29) 12 (7) *0.004 1 (5) 18 (11) 0.43 
C 5 (21) 34 (21) 0.99 6 (32) 33 (20) 0.24 
E, F, Clades 2 (8) 14 (9) 0.97 0 16 (10) 0.06 
Total  24 (100) 164 (100)  19 (100) 169 (100)  
Phylo-group Number (%) of BLR isolates Number (%) of BLS isolates P value Number (%) of 3GR isolates Number (%) of 3GS isolates P value 
A 36 (33) 22 (28) 0.45 5 (26) 53 (31) 0.65 
B1 48 (44) 30 (38) 0.4 8 (42) 70 (41) 0.95 
B2 11 (10) 22 (29) *0.002 0 33 (20) *0.005 
D 14 (13) 5 (6) 0.13 6 (32) 13 (8) *0.005 
C 26 (24) 13 (17) 0.21 4 (21) 35 (21) 0.97 
E, F, Clades 9 (8) 7 (9) 0.88 1 (5) 15 (9) 0.59 
Total  109 (100) 79 (100)  19 (100) 169 (100)  
Phylo-group Number (%) of AMR isolates Number (%) susceptible isolates P value Number (%) of MDR isolates Number (%) not MDR isolates P value 
A 50 (34) 8 (20) 0.08 24 (39) 34 (27) 0.08 
B1 65 (44) 13 (33) 0.19 31 (51) 47 (37) 0.07 
B2 15 (10) 18 (45) *0.00 0 33 (26) *0.00 
D 18 (12) 1 (3) *0.04 6 (10) 13 (10) 0.93 
C 35 (24) 4 (10) *0.044 19 (31) 20 (16) *0.02 
E, F, Clades 11 (7) 5 (13) 0.33 4 (7) 12 (9) 0.5 
Total  148 (100) 40 (100)  61 (100) 127 (100)   
P value is from the Likelihood ratio test and univariable logistic regression (reference category is absence of phylo-group); ACR = potentiated amoxicillin resistance; PAS = potentiated amoxicillin susceptible; CipR = 
ciprofloxacin resistant; CipS = ciprofloxacin susceptible; BLR = beta-lactam resistant; BLR = beta-lactam susceptible; 3GR = third generation cephalosporin resistant; 3GS = third generation cephalosporin susceptible; 
AMR = any antimicrobial resistance; MDR = multidrug resistant; phylo-groups A, B1, B2 and D based on Doumith et al (2012); C, E, F and Clades based on (Clermont et al (2013) *significant P < 0.05 
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Table 4-3. Univariable analysis results for the association of the antimicrobial resistance outcomes with covariates amongst faecal E. coli from 73 dogs. 
 Potentiated amoxycillin resistance  Ciprofloxacin resistance Beta-lactam resistance 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Dog eats raw meat1 6.67 1.67-26.57 0.007* 2.97 0.72-12.34 0.146* 1.93 0.58-6.38 0.273 
Dog eats animal carcass or faeces1 2.46 0.6-9.98 0.209* 0.68 0.18-2.58 0.567 0.84 0.33-2.16 0.719 
Dog eats tinned or cooked meat1 0.29 0.03-2.43 0.189* 0.8 0.15-4.23 0.793 0.55 0.18-1.71 0.300 
Dog fed treats1 2.14 0.43-10.78 0.326 0.11 0.03-0.5 0.002* 0.39 0.13-1.2 0.09* 
Dog fed table scraps1 1.4 0.4-4.91 0.597 1.5 0.39-5.84 0.556 0.79 0.31-2.00 0.622 
Multi-dog household1 3.25 0.38-27.58 0.219* 2.3 0.27-19.95 0.410 3.48 0.95-12.69 0.050* 
Multi-animal household1 1.65 0.45-6.04 0.448 2.13 0.54-8.35 0.275 1.18 0.45-3.08 0.74 
Owner works with farm animals1 0.31 0.04-2.62 0.220* 1.64 0.37-7.32 0.525 0.33 0.1-1.1 0.063* 
Owner works in healthcare1 0.86 0.23-3.2 0.817 0.39 0.08-2.01 0.230* 0.7 0.26-1.88 0.480 
In-contact been hospitalised1,2 1.22 0.33-4.54 0.764 1.45 0.34-6.18 0.609 1.03 0.39-2.72 0.955 
In-contact had antimicrobials1,2 0.35 0.1-1.24 0.101* 2.67 0.52-13.66 0.207* 1.32 0.5-3.48 0.580 
Age  1.01 0.99-1.02 0.766 0.99 0.98-1.02 0.748 1.01 0.99-1.02 0.324 
Gender (Reference is males) 1.35 0.39-4.75 0.635 1.45 0.37-5.66 0.590 1.85 0.72-4.76 0.200* 
 Antimicrobial resistance (AMR) Multidrug resistance (MDR) 3rd generation cephalosporinR 
 OR 95% CI P-value OR 95% CI   P-value OR 95% CI P-value 
Dog eats raw meat1 1.7 0.48-6.03 0.400 2.33 0.72-7.56 0.161* 6.67 1.67-26.57 0.007* 
Eat animal carcass or faeces1 0.63 0.23-1.7 0.360 0.8 0.29-2.2 0.666 1.3 0.34-4.91 0.697 
Dog eats tinned or cooked meat1 0.86 0.27-2.74 0.795 0.65 0.18-2.3 0.493 0.29 0.03-2.43 0.189* 
Dog fed treats1 0.69 0.23-2.08 0.499 6.3 2.04-19.49 0.001* 1.03 0.24-4.35 0.968 
Dog fed table scraps1 0.53 0.2-1.4 0.194* 0.71 0.26-1.9 0.504 1.16 0.32-4.21 0.820 
Multi-dog household1 1.52 0.55-4.21 0.415 3.06 0.62-15.18 0.136* 2.61 0.3-22.43 0.333 
Multi-animal household1 1.81 0.53-6.17 0.347 1.08 0.39-3.01 0.88 2.59 0.68-9.86 0.155* 
Owner works with farm animals1 0.9 0.27-3.01 0.857 0.25 0.05-1.24 0.058* 0.31 0.04-2.62 0.220* 
Owner works in healthcare1 1.02 0.37-2.82 0.980 0.44 0.14-1.39 0.147* 1.01 0.26-3.85 0.992 
In-contact been hospitalised1,2 0.93 0.34-2.56 0.883 0.79 0.28-2.23 0.660 1.7 0.41-7.1 0.452 
In-contact had antimicrobials1,2 2.04 0.75-5.6 0.163* 1.4 0.48-4.08 0.530 0.427 0.12-1.57 0.200* 
Age  1.01 0.99-1.02 0.355 1.01 0.99-1.02 0.732 1.00 0.99-1.02 0.716 
Gender (Reference is males) 2.13 0.79-5.75 0.131* 1.98 0.7-5.56 0.190* 1.12 0.31-4.08 0.860 
2In contact person or pet within 12 months of enrolment; OR = odds ratio; 95% CI = 95% confidence interval; P values are from the likelihood ratio test; AMR = antimicrobial resistance to at least one of the seven 
antimicrobials tested; MDR = antimicrobial resistance to three or more of the seven antimicrobials tested; *included for analysis in final model P < 0.25. 
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Table 4-4. Univariable analysis results for the association of phylogenetic groups with covariates amongst faecal E. coli from 73 dogs. 
 
 Phylo-group A Phylo-group B1 Phylo-group B2 
 OR 95% CI P-value OR 95% CI   P-value OR 95% CI   P-value 
Dog eats raw meat1 2.13 0.66-6.87 0.207* 2.84 0.88-9.18 0.077* 0.32 0.04-2.74 0.240* 
Eat animal carcass or faeces1 1.53 0.55-4.26 0.414 0.39 0.15-1.04 0.056* 1.00 0.29-3.52 1.000 
Dog eats tinned or cooked meat1 0.38 0.1-1.5 0.143* 0.85 0.29-2.67 0.774 0.7 0.14-3.62 0.661 
Dog fed treats1 1.64 0.56-4.83 0.369 2.31 0.81-6.6 0.116* 5.1 0.61-42.39 0.070* 
Dog fed table scraps1 0.96 0.35-2.57 0.927 1.56 0.6-4.01 0.360 0.26 0.06-1.04 0.042* 
Multi-dog household1 7.2 0.87-59.42 0.022* 1.2 0.35-4.13 0.772 0.56 0.13-2.47 0.453 
Multi-animal household1 0.54 0.19-1.5 0.232* 1.09 0.41-2.89 0.861 1.32 0.34-5.06 0.686 
Owner works with farm animals1 0.65 0.2-2.13 0.479 0.75 0.24-2.38 0.626 0.35 0.04-3.0 0.284 
Owner works in healthcare1 1.12 0.39-3.24 0.832 0.52 0.18-1.44 0.200* 2.46 0.67-9.11 0.176* 
In-contact been hospitalised1,2 0.6 0.21-1.68 0.333 0.94 0.35-2.52 0.909 1.04 0.27-4.0 0.953 
In-contact had antimicrobials1,2 0.6 0.21-1.68 0.333 1.57 0.58-4.29 0.371 0.66 0.18-2.44 0.538 
Age  0.99 0.98-1.01 0.472 0.99 1.01-1.02 0.306 0.99 0.98-1.02 0.910 
Gender (Reference is males) 1.69 0.62-4.65 0.305 1.56 0.6-4.05 0.361 0.9 0.26-3.13 0.872 
 Phylo-group D Phylo-group C Phylo-groups E,F,Clade 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Dog eats raw meat1 2.94 0.79-10.88 0.116* 3.94 1.16-13.39 0.030* 5.44 1.4-20.72 0.014* 
Eat animal carcass or faeces1 1.18 0.34-4.03 0.795 2.00 0.62-6.45 0.234* 0.44 0.13-1.57 0.203* 
Dog eats tinned or cooked meat1 0.55 0.11-2.77 0.443 0.15 0.02-1.27 0.031* 1.13 0.26-4.79 0.871 
Dog fed treats1 0.84 0.23-3.1 0.792 0.22 0.07-0.71 0.011* 0.73 0.19-2.75 0.643 
Dog fed table scraps1 0.17 0.77-0.23 0.677 0.58 0.9-1.76 0.334 1.4 0.4-4.9 0.597 
Multi-dog household1 3.27 0.39-27.75 0.215* 4.8 0.58-40.02 0.084* 2.9 0.34-25.03 0.269 
Multi-animal household1 1.62 0.48-5.47 0.434 1.17 0.39-3.53 0.778 0.89 0.25-3.13 0.850 
Owner works with farm animals1 0.59 0.12-3.0 0.505 0.7 0.17-2.84 0.606 1.22 0.29-5.23 0.789 
Owner works in healthcare1 2.46 0.72-8.39 0.149* 0.95 0.3-2.97 0.926 1.32 0.37-4.71 0.669 
In-contact been hospitalised1,2 1.41 0.39-5.15 0.594 0.58 0.19-1.75 0.335 0.53 0.15-1.85 0.318 
In-contact had antimicrobials1,2 0.93 0.27-3.23 0.913 0.8 0.26-2.44 0.694 0.795 0.22-2.82 0.723 
Age  0.99 0.97-1.02 0.470 0.99 0.97-1.01 0.243* 0.99 0.97-1.02 0.475 
Gender (Reference is males) 1.6 0.47-5.48 0.450 1.43 0.47-4.3 0.524 2.07 0.56-7.62 0.264 
1 Reference category is absence of risk factor; 2In contact person or pet within 12 months of enrolment; OR = odds ratio; 95% CI = 95% confidence interval; P values are from the likelihood ratio test; AMR = 
antimicrobial resistance to at least one of the seven antimicrobials tested; MDR = antimicrobial resistance to three or more of the seven antimicrobials tested; * included for analysis in final model P < 0.25
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APPENDIX III 
(Pertaining to chapter 5)
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Owner information sheet: A longitudinal study to determine if the faecal bacteria of healthy dogs is 
stable over time 
 
Why are we doing this study? This study forms part of a larger study into the way bacteria develop 
resistance to antibiotics. In this study we are looking at the bacteria in the gut of healthy dogs and seeing if 
the types of bacteria change over time.  
 
To be included in the study we need the following (Inclusion Criteria): 
• Healthy dogs without a history of chronic gastrointestinal (vomiting or diarrhoea) or skin disease e.g. 
allergy. 
• Only one dog from each household. 
• Stable health, environment and diet during the study period. 
 
Your dog cannot be entered into the study if any of the following apply (Exclusion Criteria): 
• Received antibiotics or been hospitalised at a veterinary surgery in the last 12 months 
• Had diarrhoea in the last 4 weeks. 
• Dogs that experience illness, visit and/or are hospitalised at a veterinary surgery/hospital and/or 
receive medication during the study period will not be eligible to continue in the study. 
 
What does the study involve? Collecting a stool sample once daily for 7 days, then once weekly for 4 weeks 
and then once two months later. We will supply gloves and faecal (stool) pots. If you would like, we can 
arrange reminders by phone, text or email to collect the faeces (stools) (please see consent form). Your 
participation is voluntary and you can decline involvement at any time.  
 
Personal information. All information collected during the course of the study will be anonymous and stored 
on a secure database. You have the right to see any information that you provide during the course of the 
study. See also the consent form that we ask you to sign.  
 
Withdrawing from the study. You can withdraw from the study at any time and if you wish all information 
will be destroyed. See also the consent form, which we ask you to sign.  
 
Complaints. We are happy to discuss any complaints that you may have or if you feel that you cannot contact 
us then you should contact the Research Governance Officer.  Contact details are provided at the end of this 
information sheet.  
 
Risks. The sample collection we ask you to perform is no more than you would carry out normally during the 
course of cleaning up after your dog and carries no more additional risk.  
 
What next? If you are happy to participate in this study please read, initial and sign the consent form.  
 
Thank you for your time. 
 
Vanessa Schmidt BVSc CertVD DipECVD MRCVS 
University of Liverpool, Leahurst Campus, Chester Road, Neston CH64 7TE 
vetderm@liv.ac.uk 
0151 7956100 
 
If there are any problems, please let us know by contacting Vanessa Schmidt on 0151 7956100, and we 
will try to help. If you are unhappy or have a complaint which you feel you cannot come to us with then 
you should contact the Research Governance Officer on 0151 794 8290 (ethics@liv.ac.uk). When 
contacting the Research Governance Officer, please provide details of the name or description of the 
study (so that it can be identified), the researcher(s) involved, and the details of the complaint you wish 
to make. 
 
 
Version # 3; Created on 24/11/10 at 08.14 
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Detection of antibiotic resistant bacteria in dogs longitudinal: Questionnaire 
 
Case number:    
 
Please answer all questions to the best of your knowledge. 
 
Name        
 
Dogs Name      
 
           
About your dog. 
 
15) Age  Years   Months   Weeks  Don’t Know   
a) Is this age Exact     Estimate                                                                                                
 
16) Breed  Pedigree (please specify)      
Cross (please specify)        
 
17) Sex        Male  Female  Neutered  
 
18) How long have you owned him/her?   
 
 
About your dog’s diet. 
 
19) What is s/he fed?  Tinned meat   Dry mixer   
(Tick all that apply)  Dry Complete   Raw chicken   
    Cooked chicken   Raw red meat   
Cook red meat   Don’t Know   
Other        
 
20) Is s/he fed commercial dog treats? Never  Rarely  Sometimes 
 Often  Don’t know  
 
21) Is s/he fed human titbits/ scraps?  Never  Rarely  Sometimes 
 Often  Don’t know  
 
22) Does your dog ever eat stools (faeces)?  Never  Rarely  Sometimes 
 Often  Don’t know        
 If so what types of stools? (Please tick all that apply)     Rabbit
  Cat  Dog  Horse   Cow  Sheep 
 Badger  Other    
 
 
About your household. 
 
23) Are there any other dogs in the household?  
Yes   No  Don’t Know      
 If yes, how many?  1  2  3 or more  
 
24) Do you own any other animals (other than dogs)? 
Yes   No  Don’t Know      
 If yes, what animals? (Please tick all that apply) 
Cat    Bird  Rabbit   
Rodent (e.g. hamster)  Reptile (e.g. snake)   
Don’t know   Other     
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25) Does anyone in your household work with farm animals? 
Yes   No  Don’t know      
 If yes, please state which species are worked with      
            
 
26) Has anyone in your family (including other pets) to your knowledge in the last month taken antibiotics? 
Yes   No  Don’t know  
 
a) If yes, was this a Family Member   Pet  
 
b) Which antibiotic was prescribed (if known)       
            
 
27) Does anyone in your household work in medical or veterinary healthcare?  
Yes   No  Don’t Know  
 
a) If yes, in what setting? Hospital  Community Nursing  
GP surgery  Nursing Home   
Dentist   Veterinary practice  
    Don’t Know  Other    
 
28) Has anyone in your household attended hospital in the last month?  
Yes   No  Don’t Know  
 
a) If yes, why? Admission to hospital   Visit   
Outpatient appointment   Don’t Know   
Other      
 
Thank you for your time. 
Version # 3; Created on 24/11/10 at 09.00 
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Case number: 
 
Detection of antibiotic resistant bacteria in dogs longitudinal follow-up: Questionnaire   
Please answer all questions to the best of your knowledge. If you are uncertain of any of the answers please 
indicate. You may decline to answer any question. 
 
Dog’s Name:        
 
Owner’s name:        
 
 
1) Has your dog visited your own veterinary surgeon since the first faecal sample?  
Yes   No  don’t know  
a. What was the date of the visit (s)        
          
          
     
b. What was the problem/diagnosis?       
          
          
     
c. Was an antibiotic prescribed?  Yes  No  Don’t 
know  
 
i. If yes, what was prescribed? (if known, please provide details of drug name and 
dose)         
         
       
ii. For how long was the medication prescribed? 
One off injection   Up to 5 days  Up to 10 days 
  
Up to 2 weeks   Up to 3 weeks  Over 3 weeks 
  
Don’t know    Other       
 
d. Was your dog left at the vet premises? Yes  No   Don’t 
know  
i. If yes, for how long was s/he hospitalised?    Don’t 
know  
 
2) Has your dog’s diet changed or has she / he eaten anything out of the ordinary since the first sample 
was taken?  
Yes   No  don’t know  
 
Please give details with dates:          
            
             
             
             
 
3) Have any member of your family or other pets visited hospital since the last questionnaire?  
Yes   No  don’t know  
 
Please give details with dates:          
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4) Have any member of your family or other pets received antibiotics since the last questionnaire?  
Yes   No  don’t know  
 
Please give details with dates:          
            
             
             
             
 
Thank you for your time. 
Version # 3; Created on 24/11/10 at 9.30 
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Table 5-1. Multilevel, univariable models for outcomes AMR, MDR and ESBL/AmpC-producing E. coli 
 
 AMR MDR ESBL/AmpC 
Variable OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Time 1.01 1-1.02 *0.113 0.99 0.98-1.01 0.309 0.99 0.91.01 0.383 
Gender (male REF) 1.02 0.5-2.2 0.965 0.95 0.37-2.5 0.920 0.64 0.14-2.96 0.564 
Breed (purebreed REF) 1.57 0.6-4.13 0.362 1.54 0.52-4.6 0.437 1.57 0.51-4.79 0.431 
Weight small  REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Weight medium 0.41 0.1-1.7 0.213 0.70 0.16-2.99 0.632 0.57 0.07-4.69 0.605 
Weight large 2.34 0.45-11.97 0.308 1.87 0.38-9.3 0.444 6.49 0.44-95.6 0.173 
Weight overall  ⎯ ⎯ *0.172 ⎯ ⎯ 0.580 ⎯ ⎯ 0.263 
Age 0.99 0.98-1.01 0.384 1.00 0.98-1.01 0.963 0.98 0.97-1 0.119 
Dog eats tinned food 3.45 0.5-22.5 *0.195 1.88 0.35-10.13 0.464 1.91 0.09-40.95 0.680 
Dog eats treats 2.57 0.43-15.2 0.298 5.46 0.85-34.98 *0.073 5.98 0.21-166.27 0.292 
Dog fed table scraps 6.66 0.95-46.6 *0.056 2.66 0.34-20.8 0.351 2.73 0.47-15.8 0.264 
Dog eats raw meat 11.23 0.8-149.4 *0.067 91.92 8.52-991.9 *0.000 70.10 2.31-2126.9 *0.015 
Dog eats carcass 0.75 0.26-2.2 0.603 1.30 0.42-4.05 0.653 2.76 0.77-9.9 *0.120 
Dog eats faeces 1.42 0.5-3.8 0.481 2.29 0.68-7.7 *0.180 2.30 0.49-10.8 0.290 
Multi-dog household 1.60 0.3-8.3 0.577 1.22 0.24-6.2 0.809 11.58 0.53-251.3 *0.119 
Multi-animal household (not dog) 1.60 0.3-8.3 0.577 1.22 0.2-7.4 0.827 0.68 0.02-20 0.824 
Owner works in health care 0.30 0.05-1.96 *0.207 2.84 0.4-19.86 0.294 1.00 0.04-27.2 1.000 
In contact hospital admission1 0.30 0.05-1.96 *0.207 4.04 1-16.28 *0.050 4.79 0.31-74.54 0.263 
In contact had antimicrobials1 1.24 0.22-6.8 0.809 2.28 0.49-10.49 0.291 5.50 0.31-97.1 *0.244 
Owner works with farm animals 7.79 1.15-52.7 *0.035 2.26 0.41-12.4 0.347 3.19 0.11-94.2 0.502 
1Within 12 months or during enrolment; OR = odds ratio; 95% CI = 95% confidence interval; P values are from the Wald chi-squared test; REF = reference category; *P < 0.25 included in multivariable model
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Figure 5-1. Residuals plot for AMR (antimicrobial resistance to at least one isolate) multilevel, multivariable model 
(n = 21 households) 
 
 
 
 
Figure 5-2. Residuals plot for AMR multilevel, multivariable model (n = 28 dogs) 
 
 
 
Figure 5-3. Residuals plot for MDR (multidrug resistance to ≥  3 antimicrobial classes) multilevel, multivariable 
model (n = 21 households) 
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Figure 5-4. Residuals plot for MDR multilevel, multivariable model (n = 28 dogs) 
 
 
 
Figure 5-5. Residuals plot for ESBL/AmpC-producing E. coli multilevel, multivariable model (n = 21 households) 
 
 
 
Figure 5-6. Residuals plot for ESBL/AmpC-producing E. coli multilevel, multivariable model (n = 28 dogs) 
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APPENDIX IV 
(Pertaining to chapter 6) 
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Detection of antibiotic resistant bacteria in canine faecal samples and mucosal swabs before and 
after treatment with antibiotics 
 
Dear Client: Your dog has been chosen as an eligible candidate for our study as she/he has been 
diagnosed with an infection     that requires treatment with systemic 
(oral or injectable) antibiotics. We would be very grateful if you could fill in a short questionnaire 
detailing your dogs’ environment, diet and previous veterinary treatments along with any antibiotic 
treatment of in-contact animals and people in the household that could influence the findings in your 
dog. We ask for your contact details so that we can keep in contact with you during the study and these 
will remain confidential. The information that you give in the questionnaire will be anonymous. 
Please read below for further information on this study and please feel free to ask us for further 
information or you can contact me at the contact details below. 
 
Why are we doing this study? Dogs have bacterial flora on their mucous membranes (mouth, nose, 
rear end) and in their gut (faeces/stool). We know that the bacterial flora carried by one member of a 
household may be shared with the other members i.e. between dogs and people and vice-versa. We also 
know that the use of antibiotics may increase the spread of antibiotic resistance. We are monitoring the 
bacteria carried by dogs for the presence of antibiotic resistance and for the changes that occur in these 
bacterial populations in response to routine antibiotic therapy. We are also very interested to see what 
happens 60 days after the antibiotics have finished i.e. does the bacterial flora go back to normal? In 
summary we are interested in the safe and appropriate use of antibiotics to limit the spread of antibiotic 
resistance in the community. 
 
What does the study involve? Your participation is voluntary and you can decline involvement at any 
time. Firstly it involves answering the questionnaire which will take ~ 10 minutes.  We would like to 
take samples (see below for details) from your dog to collect bacteria before and after the antibiotic 
course that she/he is due to receive. That means we would like to sample your dog today and again 
when you bring she/he back for re-examination in     weeks. We would also like to repeat 
the sampling one more time in two months (60 days) after the antibiotic course has finished. This is 
important to see if the bacteria are recovering. There will be three options for the final sampling (see 
below). 
 
Antibiotic treatment: If you agree to participate in the study we will randomly assign your dog to 
receive one of five different UK licensed antibiotics, which are appropriate treatment for your dog’s 
infection. The antibiotic course will be free of charge. We would ask you to strictly follow the 
directions given for the antibiotics. Some dogs may develop gastro-intestinal upset (vomiting, 
diarrhoea, inappetance) when receiving any antibiotic. Please contact us if this occurs so that we can 
offer advice. One of the antibiotics is an injection that is given every two weeks. If your dog is assigned 
to this particular antibiotic and the required length of the antibiotic course is longer than two weeks we 
would ask that you visit your normal veterinary surgery for repeat injections every two weeks. We will 
contact your veterinary surgeon with this information. 
 
What next? If you are happy to participate in this study please read and sign the consent form. We will 
then ask you to fill in the questionnaire while we are taking the mucosal swab samples from your dog 
(this should only take 5 minutes). We will then dispense and explain the antibiotic course. 
 
Mucosal samples: We will take a swab from each of your dog’s nostrils (5 seconds each) and from the 
rear end (5 seconds). This will be repeated at the next re-examination (at the end of the antibiotic 
course) and again in 60 days after finishing the antibiotics. 
 
Faecal sample: After leaving us, we would ask that you collect the very next stool sample i.e. before 
the antibiotic tablets are started. Please collect the sample into the faecal collection pot and place in the 
postage paid/addressed envelope to be posted back to us as soon as possible. We will also supply non-
powdered, non-sterile rubber gloves. We will supply extra collection pots, gloves and packaging so that 
you may collect a sample on the final day of antibiotic therapy i.e. the day of your next re-
examination appointment and 60 days after the antibiotics have finished. Please bring the stool 
sample with you to the next appointment. For the third sample please bring the stool sample with you 
on your appointment date or alternatively please post it to us as soon as possible (see below). 
 
Options for the final sampling (60 days after the antibiotic course is finished): 
  Appendix IV 
 215 
 
1. If your dog has a re-examination appointment with us then we can take the mucosal samples 
while you wait. Again we would ask if you could bring a fresh faecal (stool) sample in for this 
appointment. 
2. If your dog does not need to be re-examined on the date of the 3rd collection then you can 
either: 
• Make an appointment with Vanessa or the dermatology nurse to come into the 
hospital free of charge for mucosal sample collection. Please bring the stool sample 
will you. 
• Visit your own veterinary surgery to have the mucosal samples taken. We would ask 
if you could post both the mucosal swabs and stool sample into us in the packing that 
we provide. If you choose this option we will contact your veterinary surgery to 
arrange this for you. 
• Take the mucosal samples yourself (as demonstrated in the first and second 
consultations) and collect the faecal sample and post all the samples to us in the 
packing that we provide. If you choose this option we will also supply you with a 
demonstration card on how to take the mucosal samples. Please contact us at any 
stage if you have any questions. 
 
As a gesture of our appreciation for participating in our study we offer discounted flea prevention for 
your dog. We will dispense or post this product to you once we have received our final samples. 
  
Thank you for your time and co-operation. 
 
Vanessa Schmidt BVSc CertVD DipECVD MRCVS 
University of Liverpool 
Leahurst Campus 
Chester Road 
Neston 
CH64 7TE 
vetderm@liv.ac.uk 
0151 7956100 
 
If there are any problems, please let us know by contacting Vanessa Schmidt on 0151 7956100, 
and we will try to help. If you remain unhappy or have a complaint which you feel cannot come 
to us with then you should contact the Research Governance Officer on 0151 794 8290 
(ethics@liv.ac.uk). When contacting the Research Governance Officer, please provide details of 
the name or description of the study (so that it can be identified), the researcher(s) involved, and 
the details of the complaint you wish to make. 
 
 
Version # 1; Created on 30/03/2014 11:28 
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Detection of antibiotic resistant bacteria in dogs with bacterial infections before and after  treatment 
with antibiotics: Questionnaire 
 
Case number:    
 
Please answer all questions to the best of your knowledge. 
 
About you (owner or carer) 
 
Could you please provide us with your contact details?  
(This information will be held in the strictest of confidence) 
 
Name       
 
Address      
      
Post Code      
 
Contact Telephone Number         
 
Contact Email           
      
Dogs Name      
 
Date of visit      
        
About your dog. 
 
1) Age  Years   Months  Weeks  Don’t Know   
a. Is this age Exact     Estimate                                                                                                
 
2) Breed  Pedigree (please specify)   
Cross (please specify)        
 
3) Sex        Male  Female  Neutered  
 
4) How long have you owned him/her?     
 
 
 
 
About your dog’s diet. 
 
5) What is s/he fed?  Tinned meat   Dry mixer   
(Tick all that apply)  Dry Complete   Raw chicken  
     Cooked chicken   Raw red meat 
  
Cook red meat   Don’t Know   
Other        
 
6) Is s/he fed commercial dog treats? Never  Rarely  Sometimes 
 Often  Don’t know  
 
7) Is s/he fed human titbits/ scraps?  Never  Rarely  Sometimes 
 Often  Don’t know  
 
8) Does your dog ever eat stools (faeces)?  Never  Rarely  Sometimes
  Often  Don’t know     
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    If so what types of stools? (Please tick all that apply) 
    Rabbit  Cat  Dog 
 Horse   Cow  Sheep  Badger  Other 
   
 
About your dog’s health. 
 
9) Has your dog received any veterinary treatment (other than today) in the last 12 months 
Yes   No  don’t know  
 
a. Please provide further details      
         
         
         
b. Was any medication prescribed? Yes  No  Don’t know
  
c. Was it an antibiotic?  Yes  No  Don’t know
  
 
i. If yes, what was prescribed? (if known, please provide details of drug name 
and dose)       
        
        
  
ii. For how long was the medication prescribed? 
One off injection   Up to 5 days  Up to 10 days 
  
Up to 2 weeks   Up to 3 weeks  Over 3 weeks 
  
Don’t know    Other     
 
d. Was your dog left at the vet premises? Yes  No  
 Don’t know  
 
i. If yes, for how long was s/he hospitalised?  Don’t know  
 
About your household. 
 
10) Are there any other dogs in the household?  
Yes   No  Don’t Know     
  If yes, how many?  1  2  3 or more  
 
11) Do you own any other animals (other than dogs)? 
Yes   No  Don’t Know     
  If yes, what animals? (Please tick all that apply) 
Cat    Bird  Rabbit   
Rodent (e.g. hamster)  Reptile (e.g. snake)   
Don’t know   Other     
  
12) Does anyone in your household work with farm animals? 
Yes   No  Don’t know     
  If yes, please state which species are worked with    
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13) Has anyone in your family (including other pets) to your knowledge in the last month taken 
antibiotics? 
Yes   No  Don’t know  
 
a. If yes, was this a Family Member   Pet  
 
b. Which antibiotic was prescribed (if known)     
         
     
 
13) Does anyone in your household work in medical or veterinary healthcare?  
Yes   No  Don’t Know  
 
a. If yes, in what setting? Hospital  Community Nursing  
GP surgery  Nursing Home   
Dentist   Veterinary practice  
    Don’t Know  Other    
 
14) Has anyone in your household attended hospital in the last month?  
Yes   No  Don’t Know  
 
a. If yes, why? Admission to hospital   Visit   
Outpatient appointment   Don’t Know   
Other      
 
 
 
Thank you for your time. 
 
 
Version # 1: Created on 13th March 2011 at 19.30  
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Detection of antibiotic resistant bacteria in dogs with bacterial infections before and after  treatment 
with antibiotics: Follow-up sample questionnaire 
 
Case number:   
 
Please answer all questions to the best of your knowledge. If you are uncertain of any of the answers 
please indicate. You may decline to answer any question. 
 
Date swab sample was obtained:        
 
Date faecal sample was obtained:        
        
Dog’s Name:        
 
Owner’s name:        
 
 
5) Has your dog visited your own veterinary surgeon since the last samples (swabs and/or faeces) 
were taken?  
Yes   No  don’t know  
 
a. What was the problem / diagnosis?      
         
         
        
b. Was an antibiotic prescribed?  Yes  No 
 Don’t know  
 
i. If yes, what was prescribed? (if known, please provide details of drug name 
and dose)       
        
         
ii. For how long was the medication prescribed? 
One off injection   Up to 5 days  Up to 10 days 
  
Up to 2 weeks   Up to 3 weeks  Over 3 weeks 
  
Don’t know    Other       
c. Was your dog left at the vet premises? Yes  No  
 Don’t know  
i. If yes, for how long was s/he hospitalised?   
 Don’t know  
 
6) Has your dog’s diet changed or has she / he eaten anything out of the ordinary since the last 
samples (swabs and/or faeces) were taken?  
Yes   No  don’t know  
 
Please give details:          
           
            
 
 
7) Have any member of your family or other pets visited hospital since the last samples (swabs 
and/or faeces) were taken?  
Yes   No  don’t know  
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Please give details:          
           
            
 
 
8) Have any member of your family or other pets received antibiotics since the last samples 
(swabs and/or faeces) were taken?  
Yes   No  don’t know  
 
Please give details:          
           
            
 
 
 
 
Thank you for your time. 
 
 
Version # 1: Created on 13th March 2011 at 20.00  
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Table 6-1. Number and percentage (%) of samples with oxacillin resistant staphylococci or oxacillin 
resistant CoPS at each time point for each treatment group and for treatment overall (95% CI). 
  Oxacillin resistant staphylococci Oxacillin resistant CoPS 
Antimicrobial treatment group 
Time Point 
(Total samples) 
Number (%) 
positive 
samples 95% CI 
Number (%) 
positive 
samples 95% CI 
CFX D0 (n = 31) 7 (23) 7.9-37.3 0 ⎯ 
 E (n = 31) 11 (35) 18.64-52.33 3 (10) 0-20 
 M1 (n = 26) 7 (27) 9.87-43.97 1 (4) 0-11.24 
 M3 (n = 24) 9 (38) 18.13-56.87 1 (4) 0-12.16 
AC D0 (n = 29) 6 (21) 5.95-35.43 2 (7) 0-16.12 
 E (n = 29) 5 (17) 7.60-34.5 2 (7) 0-16.12 
 M1 (n = 27) 5 (19) 3.87-22.17 0 ⎯ 
 M3 (n = 25) 5  (20) 4.32-35.68 0 ⎯ 
CVN D0 (n = 26) 6 (23) 6.88-39.27 1 (4) 0-11.24 
 E (n = 26) 11 (42) 23.32-61.3 4 (15) 1.5-29.25 
 M1 (n = 20) 6 (30) 9.92-50.08 1 (5) 0-14.55 
 M3 (n = 21) 6 (29) 9.25-47.9 2 (10) 0. -22.1 
CD D0 (n = 28) 7 (25) 8.96-41.04 0 ⎯ 
 E (n = 28) 6 (21) 6.23-36.63 1 (4) 0-10.45 
 M1 (n = 24) 9 (28) 18.13-56.87 2 (8) 0 -19.39 
 M3 (n = 24) 7 (29) 10.98-47.35 1 (4) 0-12.16 
FL D0 (n = 13) 4 (31) 5.68-55.86 2 (15) 0-35 
 E (n = 13) 8 (62) 35.09-87.99 1 (8) 0-22.18 
 M1 (n = 9) 4 (44) 11.98-76.91 1 (11) 0-31.64 
 M3 (n = 9) 5 (56) 23.09-88.02 1 (11) 0-31.64 
Total D0 (n = 127) 30 (23) 16.23-31 5 (4) 0.55-7.3 
 E (n = 127) 42 (33) 24.89-41.25 11 (9) 3.77-13.55 
 M1 (n = 106) 31 (29) 20.59-37.91 5 (5) 0.68-8.75 
 M3 (n = 103) 32 (31) 22.13-40 5 (5) 0.70-9 
95% CI = 95% confidence intervals; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; 
FL = fluoroquinolone; Total = treatment overall; D0 = baseline day zero; E = end of therapy; M1 = one month after therapy; M3 
= three months after therapy; CoPS = coagulase positive staphylococcci 
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Table 6-2. Number and percentage (%) of samples with mecA positive staphylococci or mecA positive CoPS 
at each time point for each treatment group and for treatment overall (95% CI). 
  mecA positive staphylococci mecA positive CoPS 
Antimicrobial treatment group 
Time Point 
(Total samples) 
Number (%) 
positive 
samples 95% CI 
Number (%) 
positive 
samples 95% CI 
CFX D0 (n = 31) 6 (19) 5.45-33.26 0 ⎯ 
 E (n = 31) 10 (32) 15.80-48.7 0 ⎯ 
 M1 (n = 26) 8 (31) 13.03-48.5 2 (8) 0-17.94 
 M3 (n = 24) 8 (33) 14.47-52.19 2 (8) 0-19.39 
AC D0 (n = 29) 3 (10) 0.00-21.43 1 (3) 0-10.09 
 E (n = 29) 5 (17) 3.49-30.99 1 (3) 0-10.09 
 M1 (n = 27) 4 (15) 1.41-29.2 0 ⎯ 
 M3 (n = 25) 6 (24) 7.26-40.74 0 ⎯ 
CVN D0 (n = 26) 6 (23) 6.88-39.27 1 (4) 0-11.24 
 E (n = 26) 10 (38) 19.76-57.16 3 (12) 0-23.8 
 M1 (n = 20) 4 (20) 2.47-37.53 1 (5) 0-14.55 
 M3 (n = 21) 5 (24) 5.59-42.03 2 (10) 0-22.08 
CD D0 (n = 28) 7 (25) 8.96-41.04 0 ⎯ 
 E (n = 28) 5 (18) 3.67-32.04 0 ⎯ 
 M1 (n = 24) 7 (29) 10.98-47.35 1 (4) 0-12.16 
 M3 (n = 24) 6 (25) 7.68-42.32 1 (4) 12.16 
FL D0 (n = 13) 4 (31) 5.68-55.86 1 (8) 0-22.18 
 E (n = 13) 9 (69) 44.14-94.32 1 (8) 0-22.18 
 M1 (n = 9) 4 (44) 11.98-76.9 1 (11) 0-31.64 
 M3 (n = 9) 1 (11) 0.00-31.64 0 ⎯ 
Total D0 (n = 127) 26 (20) 13.45-27.49 3 (2) 0 
 E (n = 127) 39 (31) 22.69-38.73 5 (4) 0.55-7.32 
 M1 (n = 106) 27 (25) 17.18-33.77 5 (5) 0.68-8.75 
 M3 (n = 103) 26 (25) 16.85-33.63 5 (5) 0.70-9 
95% CI = 95% confidence intervals; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; 
FL = fluoroquinolone; Total = treatment overall; D0 = baseline day zero; E = end of therapy; M1 = one month after therapy; M3 
= three months after therapy; CoPS = coagulase positive staphylococci; mecA = oxacillin resistant staphylococci carrying the 
mecA gene 
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Table 6-3. Number and percentage (%) of samples with MDR staphylococci or MDR CoPS at each time point for each treatment group and for treatment overall (95% CI). 
  MDR staphylococci mecA positive MDR staphylococci CipR & MDR staphylococci 
Antimicrobial treatment group Time Point 
(Total samples) Positive number of samples Lower 95% CI 
Positive number of samples 
Lower 95% CI 
Positive number of samples 
Lower 95% CI 
CFX D0 (n = 31) 2 (6) 0.00-15 2 (6) 0.00-15 2 (6) 0-15 
 E (n = 31) 9 (29) 13-45 7 (23) 7.86-37.3 8 (26) 10.4-41.2 
 M1 (n = 26) 7 (27) 9.87-43.97 7 (27) 9.87-43.97 7 (27) 9.87-43.97 
 M3 (n = 24) 9 (38) 18.13-56.87 6 (25) 7.68-42.32 5 (21) 4.59-37.08 
AC D0 (n = 29) 4 (14) 1.24-26.34 2 (7) 0.00-16.2 2 (7) 0-16.12 
 E (n = 29) 4 (14) 1.24-26.34 3 (10) 0.00-21.43 2 (7) 0-16.12 
 M1 (n = 27) 3 (11) 0-22.97 1 (4) 0.00-10.83 2 (7) 0-17.3 
 M3 (n = 25) 4 (16) 1.63-30.37 4 (16) 1.63-/37 4 (16) 0.00-30.4 
CVN D0 (n = 26) 12 (46) 27-65.3 4 (15) 1.5-29.25 4 (15) 1.52-29.25 
 E (n = 26) 10 (38) 19.76-57.16 6 (23) 6.88-39.27 5 (19) 4.08-34.38 
 M1 (n = 20) 6 (30) 9.92-50 3 (15) 0.00-30.65 3 (15) 0-30.65 
 M3 (n = 21) 7 (33) 13.17-53.5 3 (14) 0.00-29.25 2 (10) 0-22.08 
CD D0 (n = 28) 7 (25) 8.96-41 4 (14) 1.32-27.25 5 (18) 3.67-32 
 E (n = 28) 5 (28) 3.67-32 2 (7) 0.00-16.68 2 (7) 0-16.68 
 M1 (n = 24) 9 (38) 18.13-56.87 6 (25) 7.68-42.3 6 (25) 7.68-42.32 
 M3 (n = 24) 6 (25) 7.68-42.3 4 (17) 1.76-31.58 4 (17) 1.76-31.58 
FL D0 (n = 13) 5 (38) 12.01-64.9 3 (23) 0.17-45.98 3 (23) 0-45.98 
 E (n = 13) 9 (69) 44.14-94.3 8 (62) 35.09-88 8 (62) 35.09-87.99 
 M1 (n = 9) 5 (56) 23.09-88 4 (44) 11.98-76.9 4 (44) 11.98-76.9 
 M3 (n = 9) 4 (44) 11.98-76.9 0 ⎯ 0 ⎯ 
Total D0 (n = 127) 30 (24) 16.23-31 15 (12) 6.20-17.42 16 (13) 6.83-18.4 
 E (n = 127) 37 (29) 21.23-37 26 (20) 13.45-27.49 25 (20) 12.77-26.6 
 M1 (n = 106) 30 (28) 19.73-36.9 21 (20) 12.22-27.4 22 (21) 13.03-28.48 
 M3 (n = 103) 30 (29) 20.35-37.9 17 (17) 9.34-23.67 15 (15) 7.75-21.38 
95% CI = 95% confidence intervals; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; FL = fluoroquinolone; Total = treatment overall; D0 = baseline day zero; E = end of therapy; 
M1 = one month after therapy; M3 = three months after therapy; CoPS = coagulase positive staphylococci; MDR = multi-drug resistant (≥ 3 drug classes); CipR = ciprofloxacin resistant; mecA = oxacillin resistant 
staphylococci carrying the mecA gene 
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Table 6-4. Number and percentage (%) of samples with ciprofloxacin resistant staphylococci or mecA 
positive ciprofloxacin resistant staphylococci at each time point for each treatment group and for treatment 
overall (95% CI). 
  CipR CipR & mecA 
Antimicrobial treatment group Time Point 
(Total samples) 
Positive number 
of samples Lower 95% CI 
Positive number 
of samples Lower 95% CI 
CFX D0 (n = 31) 4 (13) 1-24.7 2 (6) 0-15 
 E (n = 31) 6 (19) 5.45-33.26 5 (16) 3.18 
 M1 (n = 26) 7 (27) 9.87-43.97 4 (15) 1.5 
 M3 (n = 24) 4 (17) 1.76-31.58 3 (13) 0-25.7 
AC D0 (n = 29) 4 (14) 1.24-26.34 1 (3) 0-10 
 E (n = 29) 3 (10) 0-21.34 2 (7) 0-16.12 
 M1 (n = 27) 1 (4) 0-10.83 1 (4) 0-10.8 
 M3 (n = 25) 3 (12) 0-24.74 3 (12) 0-24.7 
CVN D0 (n = 26) 5 (19) 4-34.38 2 (8) 0-17.9 
 E (n = 26) 7 (17) 9.87-43.97 4 (15) 1.5-29.25 
 M1 (n = 20) 3 (15) 0-30.65 0 ⎯ 
 M3 (n = 21) 2 (10) 0-22 0 ⎯ 
CD D0 (n = 28) 5 (18) 3.67-32 4 (14) 1.3-27.25 
 E (n = 28) 2 (7) 0-16.68 0 ⎯ 
 M1 (n = 24) 5 (21) 4.59-37 4 (17) 1.76-31.6 
 M3 (n = 24) 6 (25) 7.68-42.3 4 (17) 1.76-31.6 
FL D0 (n = 13) 2 (15) 0-35 2 (15) 0-35 
 E (n = 13) 6 (46) 19-73.25 5 (38) 12-65 
 M1 (n = 9) 4 (44) 11.98-76.9 3 (33) 2.5-64 
 M3 (n = 9) 2 (22) 0-49.4 0 ⎯ 
Total D0 (n = 127) 20 (16) 9.4-22 11 (9) 3.8-13.55 
 E (n = 127) 24 (19) 12-25.7 15 (12) 6.2-17.4 
 M1 (n = 106) 20 (19) 11.42-26.3 12 (11) 5.3-17.35 
 M3 (n = 103) 17 (17) 9.34-23.7 10 (10) 4-15.4 
95% CI = 95% confidence intervals; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; 
FL = fluoroquinolone; Total = treatment overall; D0 = baseline day zero; E = end of therapy; M1 = one month after therapy; M3 
= three months after therapy; CoPS = coagulase positive staphylococci; CipR = ciprofloxacin resistant; mecA = oxacillin 
resistant staphylococci carrying the mecA gene 
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Table 6-5. Number and percentage (%) of CoPS or CoNS at each time point for each treatment group and 
for treatment overall (95% CI). 
  CoPS CoNS 
Antimicrobial treatment group 
Time Point 
(Total samples) 
Number (%) 
positive 
samples 95% CI 
Number (%) 
positive 
samples 95% CI 
CFX D0 (n = 31) 21 (68) 51.29-84.20 19 (62) 44.14-78.44 
 E (n = 31) 14 (45) 27.60-62.68 17 (55) 37.32-72.36 
 M1 (n = 26) 18 (69) 51.49-86.97 18 (69) 51.49-86.97 
 M3 (n = 24) 19 (79) 62.90-95.41 14 (58) 38.61-78.06 
AC D0 (n = 29) 17 (59) 40.70-76.55 14 (48) 30.09-66.46 
 E (n = 29) 17 (59) 40.70-76.55 21 (72) 56.15-88.68 
 M1 (n = 27) 15 (56) 36.81-74.30 14 (52) 33.00-70.70 
 M3 (n = 25) 16 (64) 45.18-82.82 14 (56) 36.54-75.46 
CVN D0 (n = 26) 23 (88) 76.18-100.0 13 (50) 30.78-69.22 
 E (n = 26) 15 (58) 38.70-76.68 16 (62) 42.84-80.24 
 M1 (n = 20) 15 (75) 56.00-93.98 12 (60) 38.53-81.47 
 M3 (n = 21) 16 (76) 57.97-94.41 10 (48) 26.26-68.98 
CD D0 (n = 28) 22 (79) 63.37-93.77 17 (61) 42.62-78.80 
 E (n = 28) 6 (21) 6.23-36.63 17 (61) 42.62-78.80 
 M1 (n = 24) 11 (46) 25.90-65.77 12 (50) 30.00-70.00 
 M3 (n = 24) 15 (63) 43.13-81.87 14 (58) 38.61-78.06 
FL D0 (n = 13) 9 (69) 44.14-94.32 7 (54) 26.75-80.95 
 E (n = 13) 7 (54) 26.75-80.95 10 (77) 54.02-99.83 
 M1 (n = 9) 8 (89) 68.36-100.0 6 (67) 35.87-97.47 
 M3 (n = 9) 5 (56) 23.00-88.02 7 (78) 50.62-104.9 
Total D0 (n = 127) 92 (72) 64.67-80.21 70 (55) 46.47-63.77 
 E (n = 127) 59 (46) 37.78-55.13 81 (65) 55.42-72.14 
 M1 (n = 106) 67 (63) 54.00-72.39 62 (58) 49.11-67.87 
 M3 (n = 103) 71 (69) 59.99-77.87 59 (57) 47.73-66.83 
95% CI = 95% confidence intervals; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; 
FL = fluoroquinolone; Total = treatment overall; D0 = baseline day zero; E = end of therapy; M1 = one month after therapy; M3 
= three months after therapy; CoPS = coagulase positive staphylococci; CoNS = coagulase negative staphylococci 
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Table 6-6. Number and percentage (%) of CipR CoPS or MDR CoPS at each time point for each treatment 
group and for treatment overall (95% CI). 
  CipR CoPS MDR CoPS 
Antimicrobial treatment group 
Time Point 
(Total samples) 
Number (%) 
positive 
samples 95% CI 
Number (%) 
positive 
samples 95% CI 
CFX D0 (n = 31) 1 (3) 0.00-9.45 0 ⎯ 
 E (n = 31) 0 ⎯ 0 ⎯ 
 M1 (n = 26) 3 (12) 0.00-23.82 4 (15) 1.52-29.25 
 M3 (n = 24) 1 (4) 0.00-12.16 2 (8) 0.00-19.39 
AC D0 (n = 29) 2 (7) 0.00-16.12 3 (10) 0.00-21.43 
 E (n = 29) 2 (7) 0.00-16.12 3 (10) 0.00-21.43 
 M1 (n = 27) 0 ⎯ 1 (4) 0.00-10.83 
 M3 (n = 25) 0 ⎯ 0 ⎯ 
CVN D0 (n = 26) 3 (12) 0.00-23.82 8 (31) 13.03-48.51 
 E (n = 26) 4 (15) 1.52-29.25 7 (27) 9.87-43.97 
 M1 (n = 20) 2 (10) 0.00-23.15 3 (15) 0.00-30.65 
 M3 (n = 21) 2 (10) 0.00-22.08 3 (14) 0.00-29.25 
CD D0 (n = 28) 1 (4) 0.00-10.45 2 (7) 0.00-16.68 
 E (n = 28) 0 ⎯ 1 (4) 0.00-10.45 
 M1 (n = 24) 1 (4) 0.00-12.16 2 (8) 0.00-19.35 
 M3 (n = 24) 1 (4) 0.00-12.16 1 (4) 0.00-12.16 
FL D0 (n = 13) 1 (8) 0.00-22.18 2 (15) 0.00-35.00 
 E (n = 13) 1 (8) 0.00-22.18 3 (23) 0.17-45.98 
 M1 (n = 9) 0 ⎯ 2 (22) 0.00-49.38 
 M3 (n = 9) 0 ⎯ 2 (22) 0.00-49.38 
Total D0 (n = 127) 8 (6) 2.07-10.52 15 (12) 6.20-17.42 
 E (n = 127) 7 (6) 1.54-9.48 14 (11) 5.58-16.47 
 M1 (n = 106) 6 (6) 1.26-10.06 12 (11) 5.29-17.35 
 M3 (n = 103) 4 (4) 0.15-7.61 8 (8) 2.60-12.94 
95% CI = 95% confidence intervals; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; 
FL = fluoroquinolone; Total = treatment overall; D0 = baseline day zero; E = end of therapy; M1 = one month after therapy; M3 
= three months after therapy; CoPS = coagulase positive staphylococci; CipR = ciprofloxacin resistance: MDR = multi-drug 
resistance (≥ 3 drug classes)
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Table 6-7. Multivariable logistic regression results for all baseline outcomes with baseline variables. 
Variables Oxacillin resistance mecA CipR 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Age 1.00 0.99-1.02 0.78 1.00 0.99-1.02 0.9 1.00 0.98-1.02 0.9 
Weight  (large) REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Weight   (small) 4.3 0.53-35.11 ⎯ 1.5 0.18-13.19 ⎯ 1.77 0.16-19.26 ⎯ 
Weight  (medium) 1.26 0.22-7.4 ⎯ ⎯ ⎯ ⎯ 0.1 0.03-1.4 ⎯ 
Weight overall ⎯ ⎯ 0.27 ⎯ ⎯ 0.044 ⎯ ⎯ 0.06 
Pyoderma diagnosis 1.3 0.26-6.36 0.76 2.5 0.36-17.24 0.35 0.9 0.08-9.00 0.9 
Gender (male REF) 2.3 0.69-7.8 0.17 3.9 0.95-16.8 0.049 7.3 1.4-37.63 0.01 
First opinion REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Referral consultation 0.98 0.21-4.6 0.98 1.14 0.2-6.57 0.89 3.18 0.3-33.65 0.32 
Previous antimicrobial1 1.11 0.16-7.72 0.9 3.36 0.4-27.62 0.26 1.2 0.12-12.77 0.87 
Previous beta-lactam1 1.45 0.2-10.54 0.7 0.86 0.11-6.8 0.88 0.54 0.05-6.09 0.62 
Dog eats animal faeces 2.56 0.64-10.24 0.18 3.07 0.59-16.07 0.18 5.14 0.74-35.77 0.085 
Owner works in healthcare  0.39 0.09-1.66 0.18 0.63 0.13-3.11 0.57 0.22 0.03-1.67 0.12 
In-contact been hospitalised2 0.63 0.14-2.9 0.54 0.9 0.16-5.00 0.9 2.00 0.28-14.23 0.49 
In-contact had antimicrobials2 0.37 0.09-1.6 0.17 0.39 0.06-2.5 0.3 0.4 0.05-3.14 0.37 
Previous vet admission1 0.24 0.04-1.4 0.096 0.37 0.05-2.77 0.32 1.5 0.11-11.9 0.9 
Multi-dog household 0.49 0.13-1.93 0.3 0.43 0.08-2.22 0.3 0.4 0.06-2.9 0.37 
 MDR CoPS CoNS 
Age 1.00 0.98-1.02 0.9 1.01 0.99-1.02 0.5 1.00 0.99-1.01 0.96 
Weight  (large) REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Weight   (small) 0.66 0.06-1.04 ⎯ 0.12 0.01-2.05 ⎯ 4.9 0.69-35.57 ⎯ 
Weight  (medium) 0.1 0.01-0.8 ⎯ 0.35 0.03-4.58 ⎯ 2.2 0.46-10.43 ⎯ 
Weight overall ⎯ ⎯ 0.027 ⎯ ⎯ 0.29 ⎯ ⎯ 0.26 
Pyoderma diagnosis 1.45 0.17-12.45 0.74 1.19 0.18-7.78 0.86 1.2 0.29-4.96 0.79 
Gender (male REF) 6.34 1.4-28.27 0.009 1.33 0.32-5.5 0.69 2.8 0.95-8.49 0.05 
First opinion REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Referral consultation 5.9 0.8-42.86 0.06 2.5 0.33-18.98 0.38 0.97 0.24-3.92 0.97 
Previous antimicrobial1 3.8 0.4-32.97 0.23 3.38 0.27-42.36 0.3 0.27 0.05-1.55 0.13 
Previous beta-lactam1 0.3 0.04-2.65 0.28 0.65 0.05-8.83 0.74 5.8 0.89-37.62 0.056 
Dog eats animal faeces 1.8 0.34-9.78 0.49 0.78 0.14-4.5 0.78 1.7 0.5-6.1 0.37 
Owner works in healthcare  0.63 0.12-3.4 0.58 ⎯ ⎯ 0.003 0.64 0.2-2.2 0.47 
In-contact been hospitalised2 1.69 0.29-10.00 0.57 0.6 0.09-3.9 0.59 0.44 0.11-1.8 0.25 
In-contact had antimicrobials2 0.5 0.08-3.27 0.47 0.54 0.11-2.7 0.46 1.4 0.39-5.2 0.6 
Previous vet admission1 0.4 0.05-3.6 0.42 0.43 0.06-3.12 0.4 1.3 0.29-5.67 0.75 
Multi-dog household 1.08 0.2-5.5 0.93p 1.17 0.2-6.3 0.86 0.67 0.19-2.39 0.53 
1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of enrolment; OR = odds ratio; 95% CI = 95% confidence interval; P values Likelihood ratio test; mecA = oxacillin resistant 
staphylococci with mecA gene; CipR = ciprofloxacin resistant; MDR = multi-drug resistant (≥ 3 drug classes); CoPS = coagulase positive staphylococci; CoNS = coagulase negative 
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Table 6-8. Multivariable logistic regression results for baseline outcomes with baseline variables and treatment. 
Variables Oxacillin resistance mecA CipR 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Treatment CD REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Treatment CFX 0.7 0.11-4.5 ⎯ 1.4 0.17-11.9 ⎯   ⎯ 
Treatment AC 1.18 0.15-9.2 ⎯ 0. 0.01-2.6 ⎯   ⎯ 
Treatment CVN 1.1 0.13-9.2 ⎯ 3.7 0.3-44.15 ⎯   ⎯ 
Treatment Fl 0.57 0.05-5.5 ⎯ 2.03 0.13-30.6 ⎯   ⎯ 
Treatment overall ⎯ ⎯ 0.95 ⎯ ⎯ 0.35 ⎯ ⎯  
Age 1.0 0.99-1.02 0.8 1.00 0.98-1.01 0.73 1.00 0.98-1.03 0.8 
Weight (large) REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Weight  (small) 5.3 0.58-48.27 ⎯ 2.00 0.2-19.68 ⎯ 2.36 0.07-82.19 ⎯ 
Weight (medium) 1.34 0.19-9.6 ⎯ 0.24 0.03-2.08 ⎯ 0.09 0.01-1.46 ⎯ 
Weight overall ⎯ ⎯ 0.22 ⎯ ⎯ 0.087 ⎯ ⎯ 0.024 
Pyoderma diagnosis 1.67 0.22-12.49 0.62 0.9 0.09-9.07 0.9 1.8 0.09-34.5 0.7 
Gender (male REF) 2.3 0.67-7.9 0.18 5.00 1.07-23.27 0.03 9.1 66.99 0.015 
First opinion REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Referral consultation 0.9 0.16-5.6 0.95 0.7 0.1-5.37 0.75 4.23 0.26-69.97 0.3 
Previous antimicrobial1 0.93 0.11-7.7 0.95 3.4 0.33-35.27 0.3 0.38 0.01-13.12 0.6 
Previous beta-lactam1 1.8 0.2-16.87 0.6 1.44 0.12-17.00 0.77 0.84 0.02-29.74 0.9 
Dog eats animal faeces 2.9 0.62-13.3 0.17 3.4 0.46-25.00 0.22 20.9 1.2-367.9 0.02 
Owner works in healthcare  0.38 0.08-1.75 0.2 0.44 0.08-2.48 0.34 0.24 0.02-3.65 0.27 
In-contact been hospitalised2 0.62 0.13-2.85 0.53 0.94 0.14-6.3 0.95 2.5 0.27-23.6 0.4 
In-contact had antimicrobials2 0.39 0.09-1.7 0.2 0.22 0.02-1.94 0.14 0.58 0.05-5.33 0.57 
Previous vet admission1 0.23 0.04-1.3 0.08 0.36 0.04-3.1 0.34 1.15 0.08-16.42 0.9 
Multi-dog household 0.5 0.11-2.22 0.4 0.2 0.03-1.45 0.097 0.13 0.01-1.38 0.06 
1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of enrolment; OR = odds ratio; 95% CI = 95% confidence interval; P values are from the Likelihood ratio test; mecA = 
oxacillin resistant staphylococci carrying the mecA gene; CipR = ciprofloxacin resistant 
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Table 6-9. Multivariable logistic regression results for baseline outcomes third generation cephalosporin resistance (3GR) and phenotypic ESBL- and AmpC-producing E. coli with 
baseline covariates and treatment. 
Variables MDR CoPS CoNS 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Treatment CD REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Treatment CFX 1.6 0.12-22.37 ⎯ 38.53 0.55-2693.29 ⎯ 0.49 0.09-2.84 ⎯ 
Treatment AC 9.4 0.467-187.78 ⎯ 35.75 0.76-1679.84 ⎯ 0.39 0.06-2.66 ⎯ 
Treatment CVN 22.34 0.88-566.74 ⎯ 11.76 0.29-479.11 ⎯ 0.52 0.07-3.88 ⎯ 
Treatment Fl 10.08 0.58-174.83 ⎯ 0.71 0.03-17.17 ⎯ 0.8 0.07-9.15 ⎯ 
Treatment overall ⎯ ⎯ 0.107 ⎯ ⎯ 0.115 ⎯ ⎯ 0.88 
Age 1.00 0.98-1.02 0.97 1.00 0.99-1.03 0.44 1.00 0.99-1.01 0.89 
Weight (large) REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Weight  (small) 0.8 0.04-17.19 ⎯ 0.03 0-1.59 ⎯ 5.9 0.7-49.54 ⎯ 
Weight (medium) 0.03 0.01-0.69 ⎯ 0.02 0-1.65 ⎯ 3.5 0.56-21.86 ⎯ 
Weight overall ⎯ ⎯ 0.007 ⎯ ⎯ 0.078 ⎯ ⎯ 0.22 
Pyoderma diagnosis 1.5 0.09-24.5 0.79 0.77 0.02-36.09 0.89 1.1 0.18-6.6 0.93 
Gender (male REF) 7.96 1.26-50.27 0.013 1.09 0.2-5.6 0.92 3.2 1.02-9.9 0.038 
First opinion REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Referral consultation 3.87 0.3-49.3 0.29 15.78 0.25-985.23 0.12 0.9 0.19-4.4 0.9 
Previous antimicrobial1 1.9 0.09-38.2 0.69 1.57 0.1-25.84 0.75 0.3 0.05-1.96 0.21 
Previous beta-lactam1 0.66 0.03-15.06 0.79 1.45 0.08-27.42 0.8 5.2 0.7-38.83 0.098 
Dog eats animal faeces 3.58 0.35-36.84 0.27 1.98 0.2-20.00 0.55 1.5 0.4-5.67 0.53 
Owner works in healthcare  0.8 0.1-6.27 0.84 ⎯ ⎯ 0.000 0.55 0.15-1.98 0.36 
In-contact been hospitalised2 1.88 0.24-14.77 0.55 0.68 0.07-6.5 0.74 0.34 0.09-1.7 0.2 
In-contact had antimicrobials2 0.33 0.04-3.1 0.3 0.55 0.1-2.97 0.49 1.5 0.39-5.89 0.55 
Previous vet admission1 0.39 0.04-4.13 0.4 0.52 0.07-3.9 0.52 1.4 0.29-6.6 0.68 
Multi-dog household 0.64 0.1-4.28 0.64 0.87 0.13-5.8 0.89 0.63 0.16-2.5 0.5 
1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of enrolment; OR = odds ratio; 95% CI = 95% confidence interval; P values are from the Likelihood ratio test; MDR = 
multi-drug resistant (≥ 3 drug classes); CoPS = coagulase positive staphylococci; CoNS = coagulase negative staphylococci 
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Table 6-10. Multilevel univariable results for outcomes third generation cephalosporin resistance (3GR), phenotypic ESBL- and AmpC-producing E. coli in 457 faecal samples from 
127 dogs. 
Variables Oxacillin resistance mecA CipR 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Time D0 and  REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Time End and CFX  1.78 0.76-4.19 0.185 1.98 0.79-4.97 0.148 1.35 0.45-4.07 0.598 
Time End and AC  0.85 0.31-2.3 0.749 0.85 0.27-2.62 0.771 0.61 0.15-2.56 0.500 
Time End and CVN  2.37 0.97-5.81 0.058 2.63 1.01-6.83 0.047 2.07 0.70-6.14 0.189 
Time End and CD  0.88 0.32-2.4 0.801 0.81 0.26-2.54 0.723 0.38 0.07-2.08 0.267 
Time End and FL  5.08 1.51-17.13 0.009 10.85 2.81-41.89 0.001 5.67 1.54-20.83 0.009 
Time M1 and CFX  1.20 0.45-3.17 0.711 1.86 0.69-5.06 0.223 2.19 0.74-6.43 0.155 
Time M1 and AC  0.75 0.26-2.16 0.589 0.70 0.20-2.4 0.571 0.20 0.02-2.06 0.178 
Time M1 and CVN  1.41 0.49-4.04 0.527 0.98 0.28-3.45 0.970 0.90 0.21-3.90 0.885 
Time M1 and CD  1.93 0.75-4.93 0.172 1.63 0.57-4.63 0.360 1.46 0.44-4.84 0.539 
Time M1 and FL  2.49 0.61-10.25 0.205 3.31 0.74-14.74 0.116 4.96 1.07-23.01 0.041 
Time M3 and CFX  1.95 0.76-4.98 0.164 2.07 0.75-5.7 0.160 1.13 0.31-4.11 0.854 
Time M3 and AC  0.81 0.28-2.38 0.705 1.31 0.44-3.86 0.627 0.75 0.18-3.16 0.694 
Time M3 and CVN  1.27 0.44-3.64 0.657 1.21 0.38-3.9 0.748 0.49 0.09-2.72 0.415 
Time M3 and CD  1.33 0.50-3.57 0.569 1.31 0.44-3.9 0.624 1.90 0.61-5.93 0.267 
Time M3 and FL  4.01 0.98-16.44 0.053 0.46 0.05-4.62 0.506 1.78 0.29-10.81 0.532 
Time treatment overall  ⎯ ⎯ 0.264 ⎯ ⎯ 0.110 ⎯ ⎯ 0.166 
Duration ≤ 1 week REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Duration > 1 or ≤ 3 weeks 1.52 0.83-2.8 0.177 1.45 0.75-2.83 0.273 1.27 0.57-2.81 0.561 
Duration > 3 weeks 1.63 0.88-3.01 0.119 1.79 0.92-3.48 0.085 1.37 0.61-3.03 0.444 
Duration overall ⎯ ⎯ 0.264 ⎯ ⎯ 0.226 ⎯ ⎯ 0.739 
Age 1.00 1.00-1.01 0.356 1.00 1.00 0.282 1.01 1.00-1.01 0.013 
Weight (large) REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Weight (small) 1.37 0.74-2.54 0.323 1.57 0.81-3.05 0.179 2.71 1.35-5.45 0.005 
Weight  (medium) 1.29 0.65-2.56 0.465 1.54 0.74-3.2 0.243 2.4 1.10-5.20 0.027 
Weight overall ⎯ ⎯ 0.526 ⎯ ⎯ 0.267 ⎯ ⎯ 0.006 
Pyoderma diagnosis 1.8 1.09-2.95 0.021 1.7 0.99-2.93 0.054 1.78 0.92-3.44 0.086 
Gender (male REF) 1.47 0.92-2.35 0.103 1.55 0.94-2.56 0.089 1.58 0.87-2.88 0.137 
First opinion REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Referral consultation 1.61 1.01-2.56 0.044 1.55 0.93-2.57 0.09 1.58 0.86-2.88 0.139 
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Previous antimicrobial1 1.47 0.89-2.43 0.132 1.51 0.88-2.62 0.137 0.83 0.44-1.56 0.563 
Previous beta-lactam1 1.7 0.99-2.91 0.056 1.54 0.85-2.81 0.156 1.03 0.54-1.98 0.926 
Dog eats animal faeces 1.41 0.83-2.41 0.203 1.28 0.7-2.31 0.421 0.87 0.45-1.67 0.679 
Owner works in healthcare  0.76 0.4-1.44 0.392 0.56 0.26-1.18 0.127 1.05 0.48-2.28 0.905 
In-contact been hospitalised2 2 1.11-3.61 0.021 1.59 0.83-3.07 0.163 1.42 0.67-3.00 0.355 
In-contact had antimicrobials2 1.43 0.79-2.59 0.234 1.54 0.8-2.94 0.193 1.78 0.89-3.59 0.106 
Previous vet admission1 0.8 0.46-1.37 0.413 1.01 0.56-1.81 0.972 0.73 0.38-1.40 0.341 
Multi-dog household 0.55 0.33-1.91 0.019 0.57 0.33-0.99 0.047 0.72 0.39-1.33 0.290 
1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of enrolment; OR = odds ratio; 95% CI = 95% confidence interval; P values are from the Wald chi-squared test; *P < 0.25 
included in multivariable model with treatment and time; mecA = oxacillin resistant staphylococci carrying the mecA gene; CipR = ciprofloxacin resistant 
  Appendix IV 
 232 
Table 6-11. Multilevel univariable results for outcomes third generation cephalosporin resistance (3GR), phenotypic ESBL- and AmpC-producing E. coli in 457 faecal samples from 
127 dogs. 
Variables MDR CoPS CoNS 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Time D0 and  REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Time End and CFX  1.56 0.60-4.08 0.362 0.20 0.07-0.57 0.003 0.95 0.41-2.16 0.895 
Time End and AC  0.52 0.15-1.84 0.313 0.53 0.18-1.58 0.257 2.33 0.92-5.93 0.076 
Time End and CVN  1.91 0.72-5.1 0.194 0.28 0.09-0.84 0.023 1.34 0.54-3.33 0.522 
Time End and CD  0.68 0.21-2.15 0.510 0.04 0.01-0.13 0.000 1.36 0.55-3.35 0.501 
Time End and FL  9.13 2.31-36.12 0.002 0.33 0.07-1.46 0.143 2.95 0.71-12.23 0.136 
Time M1 and CFX  1.35 0.47-3.87 0.577 0.87 0.26-2.88 0.817 1.92 0.74-4.97 0.182 
Time M1 and AC  0.42 0.10-1.7 0.223 0.40 0.13-1.22 0.108 0.87 0.37-2.09 0.761 
Time M1 and CVN  1.21 0.38-3.84 0.741 0.88 0.22-3.50 0.861 1.16 0.42-3.18 0.773 
Time M1 and CD  2.12 0.78-5.77 0.140 0.15 0.05-0.49 0.002 0.83 0.33-2.11 0.695 
Time M1 and FL  4.49 1.00-20.24 0.050 2.94 0.20-43.01 0.430 1.85 0.41-8.41 0.424 
Time M3 and CFX  2.36 0.86-6.48 0.096 1.59 0.41-6.24 0.506 1.12 0.44-2.85 0.809 
Time M3 and AC  0.87 0.27-2.79 0.811 0.67 0.20-2.23 0.517 1.03 0.42-2.55 0.948 
Time M3 and CVN  1.35 0.45-4.06 0.592 0.86 0.22-3.37 0.826 0.71 0.27-1.87 0.486 
Time M3 and CD  1.08 0.36-3.25 0.893 0.46 0.14-1.49 0.197 1.21 0.47-3.15 0.692 
Time M3 and FL  2.79 0.62-12.6 0.182 0.27 0.04-1.66 0.158 3.30 0.59-18.32 0.173 
Time treatment overall  ⎯ ⎯ 0.095 ⎯ ⎯ 0.000 ⎯ ⎯ 0.756 
Duration ≤ 1 week REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Duration > 1 or ≤ 3 weeks 1.67 0.79-3.52 0.179 1.55 0.71-3.39 0.274 0.83 0.48-1.44 0.502 
Duration > 3 weeks 2.27 1.08-4.76 0.031 3.17 1.41-7.11 0.005 1.14 0.65-2.00 0.648 
Duration overall ⎯ ⎯ 0.097 ⎯ ⎯ 0.017 ⎯ ⎯ 0.466 
Age 1.00 1.00-1.01 0.149 1.00 0.99-1.01 0.814 1.00 1.00-1.01 0.430 
Weight (large) REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Weight (small) 1.64 0.78-3.43 0.192 0.77 0.24-2.46 0.659 1.62 0.71-3.70 0.254 
Weight  (medium) 1.87 0.83-4.2 0.131 1.43 0.61-3.32 0.412 0.82 0.45-1.48 0.507 
Weight overall ⎯ ⎯ 0.189 ⎯ ⎯ 0.379 ⎯ ⎯ 0.139 
Pyoderma diagnosis 2.77 1.52-5.05 0.001 2.78 1.46-5.29 0.002 0.96 0.61-1.52 0.877 
Gender (male REF) 1.77 1.01-3.11 0.045 0.77 0.40-1.46 0.418 1.63 1.04-2.54 0.031 
First opinion REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Referral consultation 2.63 1.53-4.53 0.000 2.48 1.31-4.71 0.005 1.11 0.71-1.74 0.641 
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Previous antimicrobial1 1.71 0.96-3.05 0.068 1.54 0.79-2.98 0.201 0.89 0.57-1.40 0.622 
Previous beta-lactam1 1.97 1.03-3.77 0.041 1.35 0.66-2.75 0.411 1.13 0.70-1.84 0.610 
Dog eats animal faeces 2.08 1.16-3.73 0.014 1.47 0.74-2.93 0.271 1.16 0.72-1.88 0.542 
Owner works in healthcare  0.95 0.46-1.97 0.898 2.24 1.00-5.02 0.051 0.55 0.32-0.93 0.026 
In-contact been hospitalised2 2.61 1.36-5.00 0.004 1.94 0.90-4.20 0.091 1.06 0.63-1.79 0.828 
In-contact had antimicrobials2 1.47 0.75-2.88 0.261 1.00 0.48-2.08 0.991 1.64 0.97-2.75 0.062 
Previous vet admission1 0.64 0.34-1.20 0.165 0.43 0.23-0.83 0.011 1.23 0.76-1.98 0.403 
Multi-dog household 0.55 0.31-0.98 0.043 0.53 0.28-1.01 0.055 0.64 0.41-0.99 0.046 
1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of enrolment; OR = odds ratio; 95% CI = 95% confidence interval; P values are from the Wald chi-squared test; *P < 0.25 
included in multivariable model with treatment and time; MDR = multi-drug resistant (≥ 3 drug classes); CoPS = coagulase positive staphylococci; CoNS = coagulase negative staphylococci 
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Figure 6-1. Residuals plot for oxacillin resistance multilevel, multivariable model (n = 127 dogs) 
 
 
 
 
 
Figure 6-2. Residuals plot for oxacillin resistance and mecA carriage multilevel, multivariable model  
(n = 127 dogs) 
 
 
 
 
 
Figure 6-3. Residuals plot for ciprofloxacin resistance multilevel, multivariable model (n = 127 dogs) 
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Figure 6-4. Residuals plot for multidrug resistance multilevel, multivariable model (n = 127 dogs) 
 
 
 
 
 
Figure 6-5. Residuals plot for CoPS multilevel, multivariable model (n = 127 dogs) 
 
 
 
 
 
Figure 6-6. Residuals plot for CoNS multilevel, multivariable model (n = 127 dogs) 
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APPENDIX V 
(Pertaining to chapter 7)
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Table 7-1: Total number and percentage (%) of samples with each outcome at each time point for each 
treatment group. 
Outcome Time CFX AC CVN CD FL Total 
AMR D0 14 (44) 13 (46) 17 (71) 15 (54) 8 (57) 69 (54) 
End 24 (75) 21 (75) 23 (96) 20 (71) 5 (43) 94 (74) 
M1 20 (74) 15 (58) 11 (58) 20 (80) 4 (67) 70 (67) 
M3 11 (46) 12 (48) 13 (76) 15 (65) 5 (63) 54 (55) 
MDR D0 6 (19) 7 (25) 8 (33) 10 (34) 7 (50) 38 (30) 
End 10 (31) 15 (54) 15 (63) 11 (38) 4 (29) 55 (43) 
M1 9 (33) 6 (23) 6 (32) 10 (44) 3 (50) 34 (32) 
M3 4 (17) 6 (24) 5 (29) 6 (26) 1 (13) 22 (22) 
CipR D0 2 (6) 2 (7) 6 (25) 3 (7) 3 (21) 15 (12) 
End 9 (28) 3 (11) 9 (38) 3 (11) 6 (43) 30 (24) 
M1 4 (15) 4 (15) 2 (11) 3 (12) 2 (33) 15 (14) 
M3 1 (4) 2 (8) 4 (24) 1 (4) 2 (25) 10 (10) 
ESBL D0 2 (6) 1 (4) 5 (20) 2 (7) 4 (29) 14 (11) 
End 7 (22) 4 (14) 8 (32) 2 (7) 4 (29) 15 (12) 
M1 2 (7) 4 (15) 5 (26) 1 (4) 1 (17) 13 (12) 
M3 3 (13) 1 (4) 2 (12) 0 1 (4) 7 (7) 
blaCTX-M D0 1 (3) 0 5 (21) 0 2 (14) 8 (6) 
End 5 (16) 1 (4) 7 (29) 1 (4) 3 (21) 17 (13) 
M1 1 (4) 1 (4) 5 (26) 1 (4) 1 (17) 9 (9) 
M3 0 1 (4) 2 (12) 0 1 (13) 4 (4) 
3GCR D0 5 (16) 6 (21) 12 (50) 6 (21) 6 (43) 35 (28) 
End 20 (63) 12 (43) 18 (75) 7 (24) 4 (29) 61 (48) 
M1 11 (41) 12 (46) 9 (47) 5 (20) 2 (38) 39 (37) 
M3 5 (21) 5 (20) 8 (47) 3 (13) 2 (25) 23 (23) 
AmpC D0 8 (27) 10 (36) 10 (42) 7 (25) 4 (29) 39 (31) 
End 21 (65) 14 (50) 18 (75) 5 (18) 3 (21) 61 (48) 
M1 12 (44) 10 (38) 8 (42) 6 (24) 1 (17) 37 (35) 
M3 5 (21) 5 (20) 8 (47) 2 (9) 2 (25) 22 (22) 
blaAmpC D0 8 (25) 8 (29) 10 (42) 5 (17) 4 (29) 35 (28) 
End 19 (59) 10 (36) 16 (67) 3 (10) 3 (21) 51 (40) 
M1 11 (41) 7 (27) 6 (32) 3 (12) 1 (17) 28 (27) 
M3 4 (17) 5 (20) 7 (41) 1 (4) 2 (25) 19 (19) 
CFX = cefalexin, AC = clavulanate-amoxycillin; CVN = cefovecin; CD = clindamycin; FL = fluoroquinonlone; Day 0 = 
baseline; End = end of therapy; M1 = one month after therapy; M3 = three months after therapy 
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Table 7-2. Number and percentage (%) of samples with E. coli carrying either blaCTX or blaAmpC genes at 
each time point for each treatment group and for treatment overall (95% CI). 
  blaCTX blaAmpC 
Antimicrobial 
treatment group Time Point  
(Total samples) 
Number (%) 
 of positive  
samples 95% CI  
Number (%)  
of positive samples 95% CI 
CFX  D0 (n = 32) 1 (3) 0.00 – 9.15 8 (25) 10.00 – 40.00 
 E (n = 32) 4 (13) 1.04 – 23.96 19 (60) 42.36 – 76. 39 
 M1 (n = 27)  2 (7) 0.00 – 17.29 11 (41) 22.21 – 59.27 
 M3 (n = 24) 0 ⎯  4 (17) 1.76 – 31.58 
AC D0 (n = 28)  0 ⎯  8 (29) 11.84 – 45.30 
 E (n = 28) 1 (4) 0.00 – 10.45 10 (36) 17.97 – 53.46 
 M1 (n = 26) 1 (4) 0.00 – 11.24 7 (27) 9.87 – 43.97 
 M3 (n = 25) 1 (4) 0.00 – 11.68 5 (20) 4.32 – 35.68 
CVN D0 (n = 24)  5 (21) 4.59 – 37.08 10 (42) 21.94 – 61.39 
 E (n = 24)  6 (25) 7.68 – 42.32 16 (67) 47.81 – 85.53 
 M1 (n = 19)  5 (26) 6.52 – 46.12 6 (32) 10.68 – 52.48 
 M3 (n = 18) 1 (6) 0.10 – 25.80  7 (39) 20.30 – 61.40 
CD D0 (n = 29) 0 ⎯  5 (17) 3.49 – 30.99 
 E (n = 29) 1 (3) 0.00 – 10.09 3 (10) 0.00 – 21.43 
 M1 (n = 25) 1 (4) 0.00 – 11.68 3 (12) 0.00 – 24.74 
 M3 (n = 23) 0 ⎯  1 (4) 0.00 – 12.68 
FL D0 (n = 14) 2 (14) 0.00 – 32.62 4 (29) 4.91 – 52.24 
 E (n = 14) 3 (21) 0.00 – 42.92 3 (21) 0.00 – 42.92 
 M1 (n = 7) 1 (14) 2.60 – 51.30 1 (14) 2.60 – 51.30 
 M3 (n = 8) 1 (13) 0.00 – 35.42 2 (25) 0.00 – 55.01 
Total D0 (n = 127) 8 (6) 2.07 – 10.52 35 (28) 19.79 – 35.33 
 E (n = 127) 14 (11) 5.58 – 16.47 51 (40) 31.63 – 48.68 
 M1 (n = 105) 9 (9) 3.22 – 13.93 28 (27) 18.21 – 35.13 
 M3 (n = 98) 3 (3) 0.00 -6.47 19 (19) 11.56 – 27.21 
95% CI = 95% confidence intervals; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; 
FL = fluoroquinolone; Total = treatment overall; D0 = baseline day zero; E = end of therapy; M1 = one month after therapy; M3 
= three months after therapy 
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Table 7-3. Number and percentage (%) of samples with multidrug resistant and ciprofloxacin resistant ESBL-and AmpC-producing E.coli at each time point for each antimicrobial 
treatment group and treatment overall (95% CI).  
  MDR ESBL-producing E. coli MDR AmpC-producing E. coli CipR ESBL-producing E. coli CipR AmpC-producing E. coli 
Antimicrobial 
treatment group 
Time Point  
(Total samples) Number (%) of positive samples 95% CI 
Number (%) of 
positive samples 95% CI  
Number of 
positive samples 95% CI 
Number of 
positive samples 95% CI  
CFX D0 (n = 32) 0 ⎯  4 (13) 1.04 – 23.96 0 ⎯  2 (6) 0.00 – 14.64 
 E (n = 32) 4 (13) 1.04 – 23.96 6 (19) 5.23 – 32.27 3 (9) 0.00 – 19.47 4 (13) 1.04 – 23.96 
 M1 (n = 27)  0 ⎯  2 (7) 0.00 – 17.29 1 (4) 0.00 – 10.83 2 (7) 0.00 – 17.29 
 M3 (n = 24) 0 ⎯  0 ⎯  0 ⎯  0 0.00 
AC D0 (n = 28)  1 (4) ⎯  2 (7) ⎯  0 ⎯  1 (4) 0.00 – 10.45 
 E (n = 28) 3 (11) ⎯  4 (14) 1.32 – 27.25 0 ⎯ 1 (4) 0.00 – 10.45 
 M1 (n = 26) 2 (8) ⎯  3 (12) ⎯  1 (4) 0.00 – 11.24 1 (4) 0.00 – 11.24 
 M3 (n = 25) 0 ⎯  1 (4) ⎯  0 0.00 0 0.00 
CVN D0 (n = 24)  4 (17) 1.76 – 31.58 4 (17) 1.76 – 31.58 2 (8) 0.00 – 19.39 3 (13) 0.00 – 25.73 
 E (n = 24)  7 (29) 10.98 – 47.35 8 (33) 14.47 – 52.19 3 (13) 0.00 – 25.73 4 (17) 1.76 – 31.58 
 M1 (n = 19)  2 (11) 0.00 – 24.33 2 (11) 0.00 – 24.33 1 (5) 0.00 – 15.39 0 0.00 
 M3 (n = 18) 2 (11) 3.10 – 32.80 2 (11) 3.10 – 32.80 1 (6) 0.10 – 25.80  2 (11) 3.10 – 32.80 
CD D0 (n = 29) 1 (3) 0.00 – 10.09 3 (10) 0.00 – 21.43 1 (3) 0.00 – 10.09 1 (3) 0.00 – 10.09 
 E (n = 29) 1 (3) 0.00 – 10.09 1 (3) 0.00 – 10.09 0 ⎯  0 0.00 
 M1 (n = 25) 1 (4) 0.00 – 11.68 3 (12) 0.00 – 23.82 0 ⎯  1 (4) 0.00 – 11.24 
 M3 (n = 23) 0 ⎯  0 ⎯  0 ⎯  0 0.00 
FL D0 (n = 14) 1 (7) 0.00 – 20.63 2 (14) 0.00 – 32.62 2 (14) 0.00 – 32.62 1 (7) 0.00 – 20.63 
 E (n = 14) 3 (21) 0.00 – 42.92 2 (14) 0.00 – 32.62 4 (29) 4.91 – 52.24 3 (21) 0.00 – 42.92 
 M1 (n = 7) 1 (14) 2.60 – 51.30 0 ⎯  1 (14) 2.60 – 51.30 0 0.00 
 M3 (n = 8) 1 (13) 0.00 – 35.42 19 (13) 0.00 – 35.42 1 (13) 0.00 – 35.42 1 (13) 0.00 – 35.42 
Total D0 (n = 127) 7 (6) 1.54 – 9.48 15 (12) 6.20 – 17.42 5 (4) 0.55 – 7.32 8 (6) 2.07 – 10.52 
 E (n = 127) 17 (13) 7.46 – 19.31 21 (17) 10.07 – 23.00 10 (8) 3.19 – 12.56 12 (9) 4.36 – 14.54 
 M1 (n = 105) 6 (6) 1.27 – 10.15 10 (10) 3.91 – 15.14 4 (4) 0.15 – 7.47 4 (4) 0.15 – 7.47 
 M3 (n = 98) 3 (3) 0.00 – 6.47 4 (4) 0.16 – 8.00 2 (2) 0.00 – 4.84 3 (3) 0.00 – 6.47 
95% CI = 95% confidence intervals; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; FL = fluoroquinolone; Total = treatment overall; MDR = multidrug resistance; 
CipR = ciprofloxacin resistance; D0 = baseline; E = end of therapy; M1 = one month after the end of therapy; M3 = three months after the end of therapy
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Table 7-4. Number and percentage (%) of samples with ciprofloxacin resistant (CipR), third generation cephalosporin resistant (3GCR) and multidrug resistant (MDR) E.coli at each 
time point for each antimicrobial treatment group and treatment overall (95% CI). 
  CipR 3GCR MDR 
Antimicrobial 
treatment group Time Point  
(Total samples) 
Number (%) of 
positive samples 
95% CI 
 
Number (%) of 
positive samples 
95% CI 
 
Number (%) of 
positive samples 
95% CI 
 
 
CFX D0 (n = 32) 2 (6) 0.00-14.64 5 (16) 3.04-28.21 6 (19) 5.23 -32.37 
 E (n = 32) 9 (28)  12.55-43.7 20 (63) 45.73-79.27 10 (31) 15.19-47.31 
 M1 (n = 27)  4 (15) 1.41-28.21 11 (41) 22.21-59.27 9 (33) 15.55-51.11 
 M3 (n = 24) 1 (4) 0.00-12.16 5 (21) 4.59-37.08 4 (17) 1.76-31.58 
AC D0 (n = 28)  2 (7) 0.00-16.68 6 (21) 6.2-36.63 7 (25) 8.96-41.04 
 E (n = 28) 3 (11) 0.00-22.17 12 (43) 24.53-61.9 15 (54) 35.10-72.04 
 M1 (n = 26) 4 (15) 1.52-29.25 12 (46) 26.99-65.32 6 (23) 6.88-39.27 
 M3 (n = 25) 2 (8) 0.00-18.63 5 (20) 4.32-35.68 6 (24) 7.26-40.74 
CVN D0 (n = 24)  6 (25) 7.68-42.32 12 (50) 30.00-70.00 8 (33) 14.47-52.19 
 E (n = 24)  9 (38) 18.13-56.87 18 (75) 57.68-92.32 15 (63) 43.13-81.87 
 M1 (n = 19)  2 (11) 0.00-24.33 9 (47) 24.92-69.82 6 (32) 10.68-52.48 
 M3 (n = 18) 4 (22) 9.00-45.20 8 (44) 24.60-66.30 5 (28) 12.50-50.90 
CD D0 (n = 29) 2 (7) 0.00-16.68 6 (21) 5.95-35.43 10 (34) 17.18-51.78 
 E (n = 29) 3 (11) 0.00-22.17 7 (24) 8.56-39.71 11 (38) 20.27-55.59 
 M1 (n = 25) 3 (12) 0.00-24.74 5 (20) 4.32-35.68 11 (44) 24.54-63.46 
 M3 (n = 23) 1 (4) 0.00-12.68 3 (13) 0.00-26.81 6 (26) 8.14-44.03 
FL D0 (n = 14) 3 (21) 0.00-42.92 6 (43) 16.93-68.78 7 (50) 23.81-76.19 
 E (n = 14) 6 (43) 16.93-68.78 4 (29) 4.91-52.24 4 (29) 4.91-52.24 
 M1 (n = 7) 2 (29) 8.20-64.10 2 (29) 8.20-64.10 3 (43) 15.80-75.00 
 M3 (n = 8) 2 (25) 0.00-55.01 2 (25) 0.00-55.01 1 (13) 0.00-35.42 
Total D0 (n = 127) 15 (12) 6.20-17.42 35 (28) 19.79-35.33 38 (30) 21.96-37.89 
 E (n = 127) 30 (24) 16.23-31.01 61 (48) 39.34-56.72 55 (43) 34.69-51.92 
 M1 (n = 105) 15 (14) 7.59-20.98 39 (37) 27.90-46.39 34 (32) 23.43-41.33 
 M3 (n = 98) 10 (10) 4.21-16.2 23 (23) 15.08-31.86 22 (22) 14.19-30.71 
95% CI = 95% confidence intervals; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; FL = fluoroquinolone; Total = treatment overall; D0 = baseline; E = end of therapy; M1 = 
one month after the end of therapy; M3 = three months after the end of therapy 
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Table 7-5. Number and percentage (%) of samples with phenotypic ESBL- and AmpC-producing E. coli at 
each time point for each treatment group (95% CI). 
 ESBL-producing E. coli AmpC-producing E. coli 
Antimicrobial 
treatment 
group 
Time 
Point 
(Total 
samples) Number (%) of positive samples 95% CI Number (%) of positive samples 
95% CI 
CFX D0 (n = 
32) 2 (6) 0.00-14.64 8 (25) 
10.00-
40.00 
 
E (n = 32) 7 (22) 7.55-36.20 21 (66) 
49.17-
82.08 
 M1 (n = 
27)  2 (7) 0.00-17.29 12 (44) 
25.70-
63.19 
 M3 (n = 
24) 3 (13) 0.00-25.73 5 (21) 
4.59-
37.08 
AC D0 (n = 
28)  1 (4) 0.00-10.45 10 (36) 
17.97-
53.46 
 
E (n = 28) 4 (14) 1.32-27.25 14 (50) 
31.48-
68.52 
 M1 (n = 
26) 4 (15) 1.52-29.25 10 (38) 
19.76-
57.16 
 M3 (n = 
25) 1 (4) 0.00-11.68 5 (20) 
4.32-
35.68 
CVN D0 (n = 
24)  5 (21) 4.59-37.08 10 (42) 
21.94-
61.39 
 
E (n = 24)  8 (33) 14.47-52.19 18 (75) 
57.68-
92.32 
 M1 (n = 
19)  5 (26) 6.52-46.12 8 (42) 
19.90-
64.31 
 M3 (n = 
18) 2 (11) 3.10 – 32.80 8 (44) 
24.60-
66.30 
CD D0 (n = 
29) 2 (7) 0.00-16.12 7 (25) 
8.96-
41.04 
 
E (n = 29) 2 (7) 0.00-16.12 5 (18) 
3.67-
32.04 
 M1 (n = 
25) 1 (4) 0.00-11.68 6 (24) 
7.26-
40.74 
 M3 (n = 
23) 0 ⎯ 2 (9) 
0.00-
20.21 
FL D0 (n = 
14) 4 (29) 4.91-52.24 4 (29) 
4.91-
52.24 
 
E (n = 14) 4 (29) 4.91-52.24 3 (21) 
0.00-
42.92 
 
M1 (n = 7) 1 (14) 2.60 – 51.30 1 (14) 
2.60 – 
51.30 
 
M3 (n = 8) 1 (13) 0.00-35.42 2 (25) 
0.00-
55.01 
Total  D0 (n = 
127) 14 (11) 5.58-16.47 39 (31) 
22.69-
38.73 
 E (n = 
127) 25 (20) 12.77-26.6 61 (48) 
39.34-
56.72 
 M1 (n = 
105) 13 (12) 6.08-18.68 37 (35) 
26.10-
44.38 
 M3 (n = 
98) 7 (7) 2.04-12.24 22 (22) 
14.19-
30.71 
95% CI = 95% confidence intervals; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; 
FL = fluoroquinolone; Total = treatment overall; D0 = baseline day zero; E = end of therapy; M1 = one month after therapy; M3 
= three months after therapy
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Table 7-6. Multilevel univariable analysis for the outcomes ciprofloxacin resistance (CipR) and multidrug 
resistance (MDR) in 457 faecal samples from 127 dogs. 
Variables CipR MDR 
 OR 95% CI P-value OR 95% CI P-value 
Time D0  REF ⎯ ⎯ REF ⎯ ⎯ 
Time End and CFX  4.35 1.36-13.85 0.013 1.45 0.52-4.09 0.479 
Time End and AC  1.03 0.19-5.5 0.975 4.70 1.63-13.59 0.004 
Time End and CVN  5.67 1.57-20.45 0.008 7.50 2.24-25.15 0.001 
Time End and CD  0.95 0.18-5.12 0.950 1.72 0.56-5.25 0.343 
Time End and FL  8.32 1.81-38.31 0.007 0.65 0.14-3.02 0.581 
Time M1 and CFX  1.72 0.39-7.59 0.477 1.86 0.62-5.59 0.267 
Time M1 and AC  1.64 0.36-7.49 0.523 0.53 0.14-1.95 0.336 
Time M1 and CVN  0.68 0.09-4.89 0.699 1.08 0.27-4.39 0.910 
Time M1 and CD  1.15 0.21-6.25 0.869 2.26 0.71-7.14 0.166 
Time M1 and FL  3.39 0.38-29.88 0.272 1.68 0.24-11.93 0.602 
Time M3 and CFX  0.38 0.03-5.18 0.472 0.58 0.14-2.37 0.449 
Time M3 and AC  0.78 0.11-5.62 0.806 1.09 0.33-3.58 0.884 
Time M3 and CVN  2.10 0.43-10.13 0.357 0.85 0.19-3.78 0.835 
Time M3 and CD  0.38 0.03-5.47 0.476 0.51 0.13-2.04 0.344 
Time M3 and FL  4.28 0.50-36.98 0.186 0.26 0.02-3.88 0.327 
Time treatment overall  ⎯ ⎯ *0.111 ⎯ ⎯ *0.009 
Duration ≤ 1 week REF ⎯ ⎯ REF ⎯ ⎯ 
Duration > 1or ≤ 3 weeks 1.69 0.52-5.47 0.381 1.48 0.62-3.53 0.379 
Duration > 3 weeks 3.89 1.28-11.84 0.017 1.66 0.69-3.96 0.256 
Duration overall ⎯ ⎯ *0.034 ⎯ ⎯ 0.509 
Age 1.00 0.99-1.01 0.631 1.00 0.99-1.01 0.714 
Weight (large) REF ⎯ ⎯ REF ⎯ ⎯ 
Weight (small) 0.40 0.10-1.57 0.188 1.09 0.43-2.73 0.857 
Weight (medium) 0.28 0.06-1.38 0.117 0.40 0.13-1.23 0.109 
Weight overall ⎯ ⎯ *0.150 0.72 0.34-1.54 0.397 
Pyoderma diagnosis 3.47 1.32-9.15 *0.012 1.39 0.68-2.82 0.363 
Gender (male REF) 0.95 0.39-2.32 0.910 0.76 0.38-1.51 0.429 
First opinion REF ⎯ ⎯ REF ⎯ ⎯ 
Referral consultation 1.95 0.82-4.67 *0.133 1.12 0.56-2.23 0.745 
Previous antimicrobials1 1.68 0.69-4.07 *0.252 1.05 0.54-2.04 0.889 
Previous beta-lactam1 1.50 0.61-3.66 0.378 0.91 0.44-1.89 0.796 
Dog eats animal stools 2.85 1.22-6.70 *0.016 1.38 0.64-2.97 0.415 
Owner works in health care 1.33 0.43-4.11 0.620 2.84 1.17-6.90 *0.021 
In-contact hospital admission2 0.89 0.28-2.82 0.845 0.84 0.32-2.18 0.724 
In-contact had antimicrobials2 1.34 0.42-4.31 0.625 0.77 0.30-1.95 0.579 
Previous veterinary admission1 1.54 0.65-3.66 0.331 1.28 0.60-2.74 0.530 
Multi-dog household 2.21 0.88-5.55 *0.092 1.57 0.76-3.24 *0.227 
1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of enrolment; OR = odds ratio; 95% 
CI = 95% confidence interval; P values are from the Wald chi-squared test; *P < 0.25 included in multivariable model with 
treatment and time; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; FL = fluoroquinolone
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Table 7-7. Multilevel univariable results for outcomes third generation cephalosporin resistance (3GCR), phenotypic ESBL- and AmpC-producing E. coli in 457 faecal samples from 
127 dogs. 
Variables 3GCR ESBL AmpC 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Time D0 and  REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Time End and CFX  10.14 3.58-28.7 0.000 3.68 0.91-14.84 0.068 8.65 3.09-24.17 0.000 
Time End and AC  3.04 1.00-9.22 0.049 1.97 0.36-10.82 0.434 2.43 0.84-6.98 0.100 
Time End and CVN  12.98 3.49-48.25 0.000 5.75 1.38-23.97 0.016 12.37 3.51=43.57 0.000 
Time End and CD  0.92 0.28-3.07 0.895 0.61 0.06-6.01 0.669 0.62 0.18-2.09 0.440 
Time End and FL  0.80 0.17-3.83 0.781 3.34 0.51-21.8 0.208 0.57 0.11-3.06 0.509 
Time M1 and CFX  2.90 0.98-8.63 0.055 0.69 0.08-5.7 0.729 2.75 0.96-7.88 0.060 
Time M1 and AC  3.62 1.15-11.38 0.028 2.35 0.42-13.01 0.329 1.43 0.47-4.38 0.529 
Time M1 and CVN  2.43 0.70-8.51 0.164 3.33 0.66-16.67 0.144 2.32 0.68-7.84 0.177 
Time M1 and CD  0.65 0.17-2.49 0.530 0.33 0.01-7.09 0.475 0.78 0.23-2.66 0.690 
Time M1 and FL  0.90 0.11-7.22 0.920 0.76 0.04-14.46 0.856 0.47 0.03-6.53 0.572 
Time M3 and CFX  0.82 0.22-3.10 0.769 1.40 0.22-8.87 0.720 0.65 0.18-2.35 0.507 
Time M3 and AC  0.80 0.22-2.86 0.731 0.34 0.02-5.99 0.463 0.36 0.09-1.44 0.148 
Time M3 and CVN  2.23 0.62-8.01 0.220 0.79 0.10-6.2 0.824 2.29 0.65-8.00 0.196 
Time M3 and CD  0.33 0.07-1.68 0.183 0.39 0.02-8.33 0.547 0.21 0.03-1.34 0.099 
Time M3 and FL  0.97 0.13-7.44 0.973 1.33 0.07-24.72 0.846 1.06 0.14-8.00 0.952 
Time treatment overall  ⎯ ⎯ *0.000 ⎯ ⎯ *0.440 ⎯ ⎯ *0.000 
Duration ≤ 1 week REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Duration > 1 or ≤ 3 weeks 1.81 0.74-5.49 0.190 1.34 0.53-3.36 0.538 1.23 0.53-2.89 0.630 
Duration > 3 weeks 2.33 0.96-5.64 0.060 2.19 0.90-5.31 0.084 1.65 0.70-3.85 0.250 
Duration overall ⎯ ⎯ *0.168 ⎯ ⎯ *0.180 ⎯ ⎯ 0.500 
Age 0.99 0.99-1.00 *0.030 1.00 0.99-1.01 0.849 0.99 0.99-1.00 *0.130 
Weight (large) REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Weight (small) 0.32 0.12-0.85 0.023 0.61 0.22-1.66 0.330 0.37 0.15-0.90 0.030 
Weight  (medium) 0.16 0.05-0.52 0.002 0.28 0.07-1.09 0.066 0.10 0.03-0.35 0.000 
Weight overall ⎯ ⎯ *0.002 ⎯ ⎯ *0.140 ⎯ ⎯ *0.000 
Pyoderma diagnosis 2.63 1.28-5.39 *0.008 2.91 1.31-6.48 *0.009 1.70 0.85-3.41 *0.130 
Gender (male REF) 1.37 0.69-2.73 0.367 0.88 0.25-3.04 0.835 1.01 0.51-1.99 0.980 
First opinion REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
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Referral consultation 1.65 0.82-3.29 *0.158 1.71 0.51-5.70 0.382 1.74 0.89-3.42 *0.110 
Previous antimicrobial1 1.39 0.69-2.81 0.359 1.26 0.29-5.38 0.758 1.24 0.63-2.46 0.530 
Previous beta-lactam1 1.30 0.63-2.66 0.477 1.12 0.30-4.16 0.864 1.12 0.57-2.21 0.740 
Dog eats animal faeces 1.23 0.58-2.62 0.595 1.67 0.78-3.59 *0.185 1.05 0.51-2.20 0.890 
Owner works in healthcare  1.61 0.64-4.01 0.309 2.00 0.85-4.71 *0.113 1.11 0.47-2.66 0.810 
In-contact hospital admission1 0.96 0.38-2.43 0.925 0.41 0.15-1.16 *0.093 0.41 0.15-1.16 *0.093 
In-contact had antimicrobials1 1.10 0.44-2.73 0.838 0.61 0.23-1.62 0.324 0.61 0.23-1.62 0.324 
Previous vet admission1 1.29 0.60-2.79 0.511 1.08 0.51-2.30 0.838 1.08 0.51-2.30 0.838 
Multi-dog household 3.39 1.67-6.89 *0.001 3.12 1.44-6.75 *0.004 3.12 1.44-6.75 *0.004 
1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of enrolment; OR = odds ratio; 95% CI = 95% confidence interval; P values are from the Wald chi-squared test; *P < 0.25 
included in multivariable model with treatment and time; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; FL = fluoroquinolone
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Table 7-8. Multivariable logistic regression results for baseline outcomes ciprofloxacin resistance (CipR) 
and multidrug resistance (MDR) with baseline covariates. 
Variables CipR MDR 
 OR 95% CI P-value OR 95% CI P-value 
Age 1 0.95-0.99 0.946 1 0.99-1.00 0.701 
Weight (large) REF ⎯ ⎯ REF ⎯ ⎯ 
Weight  (small) 0.6 0.02-16.6 ⎯ 1.2 0.24-5.7 ⎯ 
Weight (medium) 1.7 0.12-24.49 ⎯ 0.64 0.12-3.5 ⎯ 
Weight overall ⎯ ⎯ 0.873 ⎯ ⎯ 0.822 
Pyoderma diagnosis 0.8 0.08-8.5 0.862 2.4 0.61-9.8 0.202 
Gender (male REF) 1.3 0.24-7 0.731 0.64 0.22-1.9 0.416 
First opinion REF ⎯ ⎯ REF ⎯ ⎯ 
Referral consultation 10.5 0.93-117.5 0.031 1.4 0.38-5.07 0.628 
Previous antimicrobials1 1.02 0.6-16.49 0.991 0.42 0.06-2.83 0.354 
Previous beta-lactam1 0.74 0.05-10.51 0.825 1.9 0.25-14.06 0.527 
Dog eats animal stools 0.74 0.11-4.85 0.753 0.72 0.19-2.62 0.617 
Owner works in health care 0.9 0.11-7.5 0.918 2.29 0.7-7.3 0.163 
In-contact hospital admission2 0.63 0.05-7.77 0.717 1.1 0.3-4.04 0.888 
In-contact had antimicrobials2 1.7 0.22-13.19 0.605 1.04 0.3-3.6 0.954 
Previous veterinary admission1 1.6 0.2-12.86 0.660 0.43 0.09-2.02 0.274 
Multi-dog household 0.64 0.02-17.77 0.796 1.2 0.14-11.14 0.844 
1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of enrolment; OR = odds ratio; 95% 
CI = 95% confidence interval; P values are from the Likelihood ratio test
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Table 7-9. Multivariable logistic regression results for baseline outcomes third generation cephalosporin resistance (3GCR), phenotypic ESBL- and AmpC-producing E. coli with 
baseline covariates. 
Variables 3GCR ESBL AmpC 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Age 1 0.99-1.02 0.622 1 0.98-1.02 0.779 1 0.99-1.02 0.397 
Weight  (large) REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Weight   (small) 0.67 0.13-3.5 ⎯ 0.49 0.03-7.16 ⎯ 1.1 0.11-10.53 ⎯ 
Weight  (medium) 0.56 0.09-3.4 ⎯ ⎯ ⎯ ⎯ 0.6 0.08-4.3 ⎯ 
Weight overall ⎯ ⎯ 0.768 ⎯ ⎯ 0.365 ⎯ ⎯ 0.824 
Pyoderma diagnosis 1.6 0.43-5.87 0.477 1.2 0.14-10.32 0.866 1.6 0.26-9.3 0.623 
Gender (male REF) 1.19 0.43-3.31 0.740 0.76 0.15-3.8 0. 739 0.4 0.13-1.26 0.110 
First opinion REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Referral consultation 1.36 0.37-4.95 0.639 6.46 0.88-47.46 0.048 1.04 0.21-5.2 0.960 
Previous antimicrobial1 0.6 0.11-3.3 0.551 0.48 0.04-6.22 0.560 0.74 0.12-4.53 0.742 
Previous beta-lactam1 0.8 0.14-4.5 0.802 1.06 0.08-14.95 0.964 1.48 0.22-9.99 0.683 
Dog eats animal faeces 1.5 0.48-4.95 0.475 0.74 0.13-4.12 0.729 1.16 0.29-4.63 0.831 
Owner works in healthcare  1.48 0.46-4.72 0.511 5.9 1.11-31.28 0.029 1.5 0.38-6.03 0.560 
In-contact hospital admission2 1.61 0.43-6.03 0.481 0.43 0.04-4.24 0.447 1.15 0.31-4.28 0.837 
In-contact had antimicrobials2 0.99 0.29-3.41 0.987 0.81 0.12-5.7 0.835 2 0.57-7 0.278 
Previous vet admission1 0.52 0.13-2.1 0.358 1.28 0.18-8.92 0.803 0.74 0.18-3.11 0.679 
Multi-dog household 1.07 0.13-8.85 0.947 0.62 0.04-10.69 0.741 10.5 0.8-137.24 0.073 
1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of enrolment; OR = odds ratio; 95% CI = 95% confidence interval; P values are from the Likelihood ratio test
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Table 7-10. Multivariable logistic regression results for baseline outcomes ciprofloxacin resistance (CipR) 
and multidrug resistance (MDR) with baseline covariates and treatment. 
Variables CipR MDR 
 OR 95% CI P-value OR 95% CI P-value 
Treatment CD REF ⎯ ⎯ REF ⎯ ⎯ 
Treatment CFX ⎯ ⎯ ⎯ 0.35 0.05-2.3 ⎯ 
Treatment AC ⎯ ⎯ ⎯ 0.38 0.04-3.6 ⎯ 
Treatment CVN ⎯ ⎯ ⎯ 1.2 0.12-9.6 ⎯ 
Treatment FL ⎯ ⎯ ⎯ 1.6 0.17-15.8 ⎯ 
Treatment overall ⎯ ⎯ 0.322 ⎯ ⎯ 0.596 
Age 1 0.97-1.02 1.000 0.99 0.98-1.01 0.906 
Weight (large) REF ⎯ ⎯ REF ⎯ ⎯ 
Weight  (small) 0.7 0.01-43.5 ⎯ 0.7 0.1-4.9 ⎯ 
Weight (medium) 5.6 0.2-142.11 ⎯ 0.58 0.09-3.8 ⎯ 
Weight overall ⎯ ⎯ 0.603 ⎯ ⎯ 0.836 
Pyoderma diagnosis 1.4 0.07 0.826 2.4 0.42-14.1 0.312 
Gender (male REF) 1.13 0.18-7.11 0.900 0.6 0.19-1.9 0.372 
First opinion REF ⎯ ⎯ REF ⎯ ⎯ 
Referral consultation 7.6 0.26-213 0.206 0.74 0.15-3.75 0.722 
Previous antimicrobials1 0.48 0.02-11.32 0.642 0.37 0.05-3.08 0.339 
Previous beta-lactam1 1.33 0.07-27.46 0.851 0.48 0.25-19.18 0.464 
Dog eats animal stools 1.11 0.12-10.84 0.925 0.55 0.12-2.59 0.438 
Owner works in health care 1.48 0.13-17.33 0.757 1.79 0.5-6.42 0.376 
In-contact been hospitalised2 0.4 0.03-6.5 0.529 0.88 0.22-3.5 0.852 
In-contact had antimicrobials2 2.06 0.23-18.26 0.521 1.19 0.32-4.42 0.799 
Previous veterinary admission1 2.25 0.24-21.36 0.479 0.49 0.1-2.4 0.371 
Multi-dog household 0.5 0.01-28.16 0.733 0.05 0.1-9.2 0.778 
1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of enrolment; OR = odds ratio; 95% 
CI = 95% confidence interval; P values are from the Likelihood ratio test; CFX = cefalexin; AC = clavulanate-amoxicillin; CVN 
= cefovecin; CD = clindamycin; FL = fluoroquinolone
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Table 7-11. Multivariable logistic regression results for baseline outcomes third generation cephalosporin resistance (3GCR) and phenotypic ESBL- and AmpC-producing E. coli 
with baseline covariates and treatment. 
Variables 3GCR ESBL AmpC 
 OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
Treatment CD REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Treatment CFX 0.66 0.09-4.52 ⎯ 1.57 0.07-33.52 ⎯ 1.66 0.26-10.85 ⎯ 
Treatment AC 0.91 0.1-8.6 ⎯ 0.76 0.025-23.1 ⎯ 4.55 0.49-42.38 ⎯ 
Treatment CVN 4.4 0.51-36.94 ⎯ 10.9 0.48-246.73 ⎯ 2.42 0.3-19.69 ⎯ 
Treatment FL 0.54 0.05-5.4 ⎯ 3.02 0.09-98.11 ⎯ 0.75 0.06-8.84 ⎯ 
Treatment overall ⎯ ⎯ 0.265 ⎯ ⎯ 0.434 ⎯ ⎯ 0.612 
Age 1 0.99-1.01 0.870 1.0 0.98-1.02 0.959 1.01 0.99-1.02 0.310 
Weight (large) REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Weight  (small) 0.54 0.07-4.02 ⎯ 0.39 0.02-9.14 ⎯ 0.85 0.08-9.15 ⎯ 
Weight (medium) 0.86 0.11-6.66 ⎯ ⎯ ⎯ ⎯ 0.58 0.07-4.77 ⎯ 
Weight overall ⎯ ⎯ 0.827 ⎯ ⎯ 0.326 ⎯ ⎯ 0.874 
Pyoderma diagnosis 1.35 0.23-7.8 0.737 0.34 0.03-4.44 0.407 1.56 0.26-9.34 0.465 
Gender (male REF) 0.87 0.29-2.66 0.808 0.51 0.09-2.99 0.451 0.41 0.13-1.26 0.068 
First opinion REF ⎯ ⎯ REF ⎯ ⎯ REF ⎯ ⎯ 
Referral consultation 0.87 0.15-5.1 0.878 3.76 0.32-44.9 0.288 1.04 0.21-5.2 0.223 
Previous antimicrobial1 0.24 0.03-1.98 0.159 0.14 0.01-3.2 0.178 0.74 0.12-4.53 0.499 
Previous beta-lactam1 1.9 0.24-15.02 0.538 3.44 0.15-78.08 0.421 0.69 0.22-9.99 0.296 
Dog eats animal faeces 2.44 0.63-9.42 0.194 1.7 0.25-11.79 0.587 1.16 0.29-4.63 0.666 
Owner works in healthcare  1.57 0.43-5.69 0.496 4.97 0.84-29.39 0.066 1.51 0.38-6.03 0.274 
In-contact hospital admission2 1.4 0.35-5.54 0.638 0.4 0.04-4.27 0.429 1.15 0.31-4.28 0.998 
In-contact had antimicrobials2 1.13 0.31-4.11 0.859 0.63 0.09-4.55 0.637 2.0 0.57-7.0 0.258 
Previous vet admission1 0.65 0.16-2.72 0.551 1.53 0.2-11.79 0.684 0.74 0.18-3.11 0.548 
Multi-dog household 0.5 0.05-5.18 0.166 1.01 0.15-7.79 0.944 0.1 0.01-1.55 0.091 
1Within 12-months but more than three months as per enrolment criteria; 2Within 12-months of enrolment; OR = odds ratio; 95% CI = 95% confidence interval; P values are from the Likelihood ratio test; CFX = 
cefalexin; AC = clavulanate-amoxicillin; CVN = cefovecin; CD = clindamycin; FL = fluoroquinolone
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Figure 7-1. Residuals plot for multidrug resistance multilevel, multivariable model (n = 127 dogs) 
 
 
 
 
 
Figure 7-2. Residuals plot for ciprofloxacin resistance multilevel, multivariable model (n = 127 dogs) 
 
 
 
 
 
Figure 7-3. Residuals plot for third generation cephalosporin resistance multilevel, multivariable model (n = 127 
dogs) 
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Figure 7-4. Residuals plot for phenotypic AmpC-producing E. coli multilevel, multivariable model (n = 127 dogs) 
 
 
 
 
 
 
Figure 7-5. Residuals plot for phenotypic ESBL-producing E. coli multilevel, multivariable model (n = 127 dogs) 
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Results: Nasal and perineal samples were collected from 73 Labrador retrievers; staphylococci isolated and
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detected from 99% of dogs in this study. In 52% of dogs CoNS only were detected, with both CoNS and CoPS
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CoPS, but at least one MDR-CoNS isolate was detected in 34% of dogs. MR-CoNS were detected from 42% of dogs
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warneri (30%) and S. equorum (27%), with another 15 CoNS species isolated from ≤ 15% of dogs. S. pseudintermedius
and S. aureus were detected in 44% and 8% of dogs respectively.
Conclusions: MR- and MDR-CoPS were rare. However a high prevalence of MR- and MDR-CoNS were found in
these dogs, even though they had no prior antimicrobial treatment or admission to veterinary premises. These
findings are of concern due to the potential for opportunistic infections, zoonotic transmission and transmission of
antimicrobial resistant determinants from these bacteria to coagulase positive staphylococci.
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Staphylococci are normal commensal bacteria of the skin
and mucous membranes of humans and other animals.
They can be differentiated by their ability to produce
coagulase, with coagulase positive (CoPS) staphylococci
regarded as more pathogenic than coagulase negative
(CoNS) species [1-5].
Healthy humans and other animals may harbour mul-
tiple species and strains of staphylococci. Staphylococcus
aureus is the main human commensal CoPS species and
is carried in the nasal cavity of approximately 30% of
healthy people [6]. S. epidermidis is the most common
CoNS isolated from the nares, perineum, inguinal skin,
axillae and interdigital skin in man [2,7]. The main com-
mensal CoPS of dogs, S. pseudintermedius [8], has been
isolated from 37% to 92% of healthy dogs [9-14], while
S. aureus is carried by 4.3% to 12% of healthy dogs
[10,12,15-20]. Other species isolated from the mucosa
and skin of healthy dogs include the CoPS S. schleiferi
subspecies coagulans [10,21] and numerous CoNS (S.
schleiferi subspecies schleiferi, S. epidermidis, S. haemolyti-
cus, S. saprophyticus, S. devriesei, S. warneri, S. simulans,
S. xylosus, S.capitus, S. caprae, and S. sciuri) [12,15,22-26].
The carriage rate of CoNS isolated from the nasal mu-
cosae of healthy dogs was reported to be 38% in one large
cross-sectional study [15].
Staphylococci are frequent opportunistic pathogens
and commensal isolates are the most common source of
infection in humans [3] and dogs [12,16,27]. Antimicro-
bial resistance can increase the morbidity, mortality and
treatment cost of staphylococcal infections. Meticillin (oxa-
cillin) resistance associated with carriage of the mecA gene
confers resistance to all β-lactam antimicrobials [28]. The
mecA gene is located on a large mobile genetic element,
the staphylococcal cassette chromosome mec (SCCmec),
enabling horizontal transmission between staphylococcal
isolates [29]. Meticillin resistant staphylococci (MRS) are
important pathogens in human and veterinary healthcare
and are often multi-drug resistant (MDR; resistant to three
or more classes of antimicrobial) [30-35], extremely limit-
ing therapeutic options. MRSP clones with a broader
resistance spectrum than MRSA or MR-CoNS are increas-
ingly reported in domestic animals throughout Europe,
USA and Canada [32,34]. MR-CoNS are associated with
infections in humans and animals [31,36-38]. In humans
the most prevalent species is MR S. epidermidis (MRSE),
which may be a reservoir of MR for S. aureus [39,40]. In
addition, the SCCmec cassette of the major European
MRSP clone (ST71-J-t02-II–III) [34] consists of a combin-
ation of SCCmec II from MRSE and SCCmec III from
MRSA [41].
The prevalence of MRSA and MRSP carriage in
healthy humans and dogs in the community is low
[11,18,36,42-47]. However, human community-basedsurveys report a wider range of carriage rates for MR-
CoNS (11–50%) [39,48,49]. MR-CoNS have also been
isolated from the carriage sites of 13% of healthy dogs
[23,50]. The reported prevalence of MRS is higher in
animals exposed to veterinary healthcare environments
and antimicrobial therapy [47,51-53] suggesting that
these are risk factors for colonisation.
Previous studies looking at the commensal staphylo-
cocci in dogs have concentrated on CoPS species, particu-
larly MR-CoPS species, the CoNS group or MR-CoNS
species [9-11,13,14,17,23,50], but no study has charac-
terised the complete canine commensal staphylococcal
population. Moreover, reporting of the antimicrobial treat-
ment history of dogs in these studies have been inconsist-
ent. The aim of this study was to characterise the mucosal
staphylococcal population structure and antimicrobial
resistance profiles in healthy Labrador retrievers in the
UK in the absence of antimicrobial pressure. This will be
important in understanding changes in staphylococcal
populations and their antimicrobial susceptibility patterns
in dogs exposed to antimicrobials and other risk factors.
Methods
Study population
Labrador retriever dogs were recruited for the study from
dog shows in the UK between November 2010 and June
2011. One healthy dog was enrolled from each household
if the dog had not received topical or systemic antimicro-
bial therapy, or had not been admitted to a veterinary
clinic within the last 12 months. All dog owners gave
written informed consent before enrolment in this study
and completed a questionnaire regarding potential risk
factors for the carriage of antimicrobial resistant bacteria.
The University of Liverpool School of Veterinary Science
ethics committee approved the study protocol.
Staphylococci
Specimen collection and bacterial isolation
One nasal swab and one perineal swab were collected
from each dog (Copan Eswab LQ Amies Minitip Nylon
Flocked Applicator, Appleton Woods, Birmingham, UK).
A sterile swab was either inserted 5 mm into one nostril
or rubbed on the skin of the perineum for 3–5 seconds
before being placed in Amies transport media, stored at
4°C and processed within 36 hours. Swabs were incu-
bated aerobically overnight at 37°C in nutrient broth
with 6.5% sodium chloride. The broth was streaked onto
mannitol salt agar (MSA), oxacillin resistance screening
agar (ORSA) supplemented with 2 μg/ml of oxacillin and
Columbia 5% horse blood agar (CAB), and incubated
aerobically overnight at 37°C. Where present, isolates typ-
ical of staphylococci were selected from all plates, sub-
cultured onto CAB and incubated aerobically overnight at
37°C. Fresh staphylococcal cultures on CAB were subject
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UK), tested for catalase (Sigma-Aldrich Company Ltd.,
Gillingham, UK) and free coagulase production (Rabbit
plasma, Pro-Lab, Bromborough, UK) according the manu-
facturer’s instructions and stored at − 80°C in Microbank
vials (Pro-Lab, Bromborough, UK). All media were obtained
from LabM Ltd, Bury, UK.
Antimicrobial susceptibility testing
Disc diffusion testing was performed on all staphylococ-
cal isolates in accordance with the Clinical and Labora-
tory Standards Institute (CLSI) and the following panel
of ten antimicrobial discs were applied: 1 μg oxacillin
(OX), 1 μg ciprofloxacin (CIP), 10 μg gentamicin (GM),
10 μg fusidic acid (FA), 30 μg cefalexin (CFX), 30 μg
cefovecin (CVN), 25 μg trimethoprim-sulfamethoxazole
(TS), 10 μg tetracycline (Tet), 2 μg clindamycin (CD)
and 5 μg vancomycin (Va) [54]. All the discs were pur-
chased from MAST Group Ltd., Liverpool, UK, except
for CVN, which were obtained from Oxoid, Basingstoke,
UK. Micro-dilution susceptibility testing (Trek Diagnos-
tic Systems, Cleveland, Ohio, USA) was performed on a
subset of the CoNS isolates using the same antimicrobial
panel, except vancomycin [54]. Interpretation was based
on the CLSI guidelines for animal species-specific zone
diameter (mm) interpretive standards and minimal inhibi-
tory concentration (MIC; mg/l) breakpoints for veterinary
pathogens or human-derived interpretive standards when
available. The European Committee on Antimicrobial
Susceptibility Testing (EUCAST) zone diameter interpret-
ive standards and MIC breakpoints were used for CIP and
FA [55]. The breakpoints used for interpretation of OX re-
sistance were a zone of inhibition of ≤ 17 mm and MIC ≥
0.5 mg/l for S. pseudintermedius and CoNS, and ≤ 10 mm
and MIC ≥ 4 mg/l for S. aureus [56,57]. The breakpoints
used for interpretation of resistance to CVN as a zone of
inhibition of ≤ 19 mm and MIC ≥ 8 mg/l in accordance
with the manufacturer’s recommendations. The reference
strain S. aureus ATCC®25923 (LGC Standards, Teddington,
UK) was used for quality control for MIC and zone
diameter determinations.
DNA extraction
Three colonies of each staphylococcal isolate were
homogenised in 90 μl of sterile distilled water (SDW)
and 10 μl of lysostaphin (1 mg/ml; Sigma-Aldrich Com-
pany Ltd., Gillingham, UK) and vortexed for 5 seconds.
The suspensions were then incubated at 37°C for 10 mi-
nutes and heated at 100°C for 10 minutes before adding
400 μl of SDW. Samples were stored at 4°C.
Characterisation of antimicrobial resistance genes
PCR assays were performed to detect the presence of
mecA gene (Table 1) in staphylococcal isolates that werephenotypically resistant to oxacillin. All the PCR assays
were performed with 0.5 μl of each primer (10 pmol/μl),
1 μl of DNA and 1.1x PCR master mix (ReddyMix™,
Thermo Fisher Scientific Inc., Surrey, UK) made up to a
total reaction volume of 25 μl. Molecular grade water
(Sigma-Aldrich Company Ltd., Gillingham, UK) was
used as the negative control in all PCR assays. PCR
products were analysed by agarose gel (1.5%) electro-
phoresis and the DNA fragments were visualised under
UV light after ethidium bromide staining.
Species identification
Genotypic species identification
PCR assays to detect the presence of the nuc genes of S.
pseudintermedius, S. aureus and S. schleiferi were per-
formed on all CoPS isolates using Qiagen® Multiplex
PCR Mix (Qiagen, Crawley, UK), according to the man-
ufacturer’s instructions with minor modifications. In
short, the PCR assays were performed in a reaction vol-
ume of 25 μl, consisting of 5 μl of bacterial DNA extract,
12.5 μl of master mix, 2.5 μl of 10x primer mix (2 μM of
each primer) and 5 μl of RNase-free water. The cycling
conditions consisted of an initial activation step at 95°C
for 15 minutes, followed by 30 cycles of 95°C for 30
seconds, 57°C for 90 seconds and 72°C for 60 seconds, and
a final extension step at 72°C for 10 minutes (Table 1).
MALDI-TOF-MS
All isolates were subjected to matrix-assisted laser desorp-
tion ionisation time-of-flight mass spectrometry (MALDI-
TOF-MS) according to the manufacturer’s protocol. Raw
spectra were analysed by the MALDI Biotyper 2.0 soft-
ware programme with default settings (Bruker Daltonics,
Bremen, Germany). The extraction method was per-
formed as previously described [58] on overnight col-
onies grown on CAB at 37°C and all isolates were tested
in duplicate. The bacterial test standard (E. coli DH5
alpha, Bruker, Bremen, Germany) was used for calibra-
tion before each experiment and included in duplicate
on each target plate. The mass peak profiles were matched
to the reference database and a score generated based on
similarity [59].
Sequencing
Two subsets of isolates detected from our group of dogs
underwent sequencing following PCR amplification of the
tuf gene [59,60]; a control group of CoNS isolates (n = 27)
identified by MALDI-TOF-MS and a test group of isolates
(n = 52) that had not been identified by MALDI-TOF-MS.
Initial PCR assays were performed using HotStarTaq®
Master Mix Kit (Qiagen, Crawley, UK) in a 25 μl reaction
volume with an initial activation step at 95°C for 15 mi-
nutes followed by 35 cycles of 95°C for 30 seconds, 55°C
for 30 seconds and 72°C for 30 seconds, with a final
Table 1 Details of PCR assays used in this study for nuc, tuf and mecA gene identification
Primer Sequence (5′-3′) Amplicon
size (bp)
Annealing
Temperature (°C)
Control strain Reference
au-F3 TCGCTTGCTATGATTGTGG 359 57 S. aureus ATCC®25923 (LGC Standards,
Teddington, UK)
[77]
au-nucR* GCCAATGTTCTACCATAGC
pse-F2 TRGGCAGTAGGATTCGTTAA 926 57 S. pseudintermedius (clinical isolate)
pse-R5* CTTTTGTGCTYCMTTTTGG
SSnucF AATGGCTACAATGATAATCACTAA 526 57 S. schleiferi subspecies coagulans
ATCC®49545
SSnucR* CATATCTGTCTTTCGGCGCG
tuf-F GCCAGTTGAGGACGTATTCT 412 55 S. epidermidis ATCC®12228 [105]
tuf-R CCATTTCAGTACCTTCTGGTAA
mecAF TGGCTATCGTGTCACAATCG 310 55 MRSA (clinical isolate) [103,104]
mecAR CTGGAACTTGTTGAGCAGAG
mA1 TGCTATCCACCCTCAAACAGG 286 57
mA2 AACGTTGTAACCACCCCAAGA
(*multiplex assay).
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manufacturer’s protocol. The resulting amplicons were
sequenced using BigDye Terminator version 1.1 cycle
sequencing (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s protocol on the ABI3131
genetic analyser at the Department of Microbiology, Royal
Liverpool University Hospital. The sequences were aligned
using the ABI Sequencing analysis software, with contigu-
ous sequences matched to the GenBank database using
the Basic Local Alignment Search Tool (BLAST) [61] and
positively identified if there was ≥ 98% sequence similarity
with a reference sequence. S. epidermidis ATCC®12228
was used as the control strain.Statistical analysis
Data were analysed using SPSS software package (SPSS
20.0 for Mac, SPSS Inc, Chicago, Illinois).
To examine the association between isolation of S.
pseudintermedius with each of the 16 different CoNS
species Pearson’s chi-square was calculated (P < 0.003;
Bonferroni correction). To examine the association be-
tween MR and MDR with potential risk factors (previous
antimicrobial therapy or hospitalisation within 12 months
of enrolment, health-care or large animal-association by
in-contact people or pets) identified from the question-
naires Pearson’s chi-square was calculated (P < 0.0125;
Bonferroni correction). To examine the agreement be-
tween antimicrobial susceptibility tests by disc diffusion
and MIC a kappa statistic was calculated [62] and an
independent t-test was conducted to compare the MIC of
oxacillin resistant CoNS isolates that were either positive
or negative for the mecA gene.Results
Staphylococci
Specimen collection
Seventy-three Labrador retriever dogs were recruited.
Twenty-one dogs were aged between 3 to 12 months, 25
dogs were aged between 12 months to 2 years, and 27
dogs were > 2 years old, with 35 female dogs and 38
male dogs in total.
Bacterial isolation
Staphylococci were isolated from in 72 out of 73 dogs
(99%; 95% confidence interval (CI): 99.6-95.8) and from
both sample sites in the majority of dogs (78%; 95% CI:
67.3, 86.0). Isolation of staphylococci from the nasal mu-
cosae (16%, 95% CI 9.7, 26.6) or perineum (4%, 95% CI
1.4, 11.4) only occurred in a small number of dogs. If
only the nasal mucosae had been sampled, CoPS (all S.
pseudintermedius) would not have been detected in
seven dogs (10%, 95% CI 4.7, 18.5) and CoNS in six dogs
(8%, 95% CI 3.8, 16.8). CoNS were detected in the ma-
jority of dogs (95%, 95% CI 86.7, 97.8) either alone (52%,
95% CI 40.8, 63.1) or with CoPS (43%, 95% CI 31.8, 53.9).
Detection of CoPS alone was significantly less common
(4%, 95% CI 1.4, 11.4). In total, there were 436 staphylo-
coccal isolates; 102 of which were CoPS and 334 were
CoNS isolates.
Antimicrobial susceptibility testing by disc diffusion
The overall prevalence of antimicrobial resistance among
the isolates detected in this study appeared high, with at
least one MDR isolate detected in 34% of dogs. Anti-
microbial resistant CoNS isolates were detected in more
dogs than antimicrobial resistant CoPS isolates for OX,
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http://www.biomedcentral.com/1746-6148/10/17GM, FA, CFX, CVN and CD and MDR (Figure 1). At
least one OX resistant isolate was detected in 58% dogs
(n = 126 oxacillin resistant isolates), but resistance to the
other tested β-lactam antimicrobials, CVN (25%) and
CFX (29%), was less common. Few CoPS demonstrated
antimicrobial resistance; isolates from twelve dogs had
Tet resistance (all S. pseudintermedius), seven with FA
resistance (S. pseudintermedius = 5, S. aureus = 3); two
with TS resistance (both S. pseudintermedius); two with
CD resistance (S. pseudintermedius = 1, S. aureus = 1)
and two with CIP resistance (both S. pseudintermedius).
MDR CoPS was detected from only one dog (S. pseudin-
termedius with FA, Tet and CD resistance) (Figure 1).
MIC compared to disc diffusion testing for
antimicrobial resistance
Micro-dilution susceptibility testing (Trek Diagnostic
Systems, Cleveland, Ohio, USA) was performed on 172
CoNS isolates, of which 52 were OX susceptible and 120
were OX resistant by disc diffusion. The OX resistant
isolates were further divided into those found to be posi-
tive (n = 74) or negative (n = 46) for carriage of the mecA
gene by PCR. The strength of agreement between anti-
microbial resistance detected by MIC and disc diffusion0
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Figure 1 The proportion of dogs (n = 73) carrying at least one staphy
mecA gene positive oxacillin resistance by the disc diffusion method.was very good for OX, GM, CVN, Tet and CD resist-
ance, good for CFX and TS resistance and moderate for
CIP (Kappa = 0.593) and FC resistance (Kappa = 0.589).
MIC testing identified more isolates as resistant to OX,
GM, CFX, CVN and Tet compared to disc diffusion, and
disc diffusion identified more isolates as resistant to CIP,
FA, TS and CD compared to MIC testing (Table 2).
Characterisation of antimicrobial resistance genes
Of the 126 OX resistant CoNS isolates detected by disc
diffusion, 75 isolates (60%, 95% CI 51, 68) from 31 dogs
(42%, 95% CI 32, 54) were positive for the mecA gene
(Figure 1). Nine additional oxacillin resistant isolates
were detected by MIC and two of these were positive for
the mecA gene, resulting in two additional dogs with
MR-CoNS and one additional dog with phenotypic oxa-
cillin resistant CoNS. There was a significant difference
between the MIC of mecA positive (M= 3.84, SD = 0.18)
and mecA negative isolates (M= 0.97, SD = 0.12, P < 0.001).
In addition the epidemiological breakpoint for OX resistant
CoNS isolates with mecA gene carriage isolated in this
study was consistent with the clinical CLSI breakpoint
(≥ 0.5 mg/l) (Figure 2). Eleven different CoNS species
(S. epidermidis, S. warneri, S. sciuri, S. equorum, S. fleurettii,X CVN Tet TS CD MDR
timicrobial
Total
CoNS
CoPS
lococcal isolate with resistance to each antimicrobial, MDR and
Total = CoNS and CoPS.
Table 2 Cross tabulation of the results of 172
staphylococcal isolates classified as resistant or
susceptible to the antimicrobials tested in this study by
both MIC and disc diffusion testing
Antimicrobial
resistance
MIC
No Yes Total
Oxacillin (OX) Disc diffusion No 50 10 60
Yes 2 110 112
Total 52 120 172
Kappa = 0.842
No Yes Total
Oxacillin mecA
positive
No 115 0 115
Yes 1 56 57
Total 116 56 172
Kappa = 0.987
No Yes Total
Ciprofloxacin (CIP) No 146 0 157
Yes 14 12 15
Total 160 12 172
Kappa = 0.593
No Yes Total
Gentamicin (GM) No 156 1 157
Yes 0 15 15
Total 156 16 172
Kappa = 0.965
No Yes Total
Fusidic acid (FA) No 36 5 41
Yes 25 106 131
Total 61 111 172
Kappa = 0.589
No Yes Total
Cefalexin (CFX) No 117 15 132
Yes 0 40 40
Total 117 55 172
Kappa = 0.784
No Yes Total
Cefovecin (CVN) No 130 11 141
Yes 0 31 31
Total 130 42 172
Kappa = 0.810
No Yes Total
Tetracycline (T10) No 148 1 149
Yes 0 23 23
Total 148 24 172
Kappa = 0.975
Table 2 Cross tabulation of the results of 172
staphylococcal isolates classified as resistant or
susceptible to the antimicrobials tested in this study by
both MIC and disc diffusion testing (Continued)
Yes Total
Trimethoprim-
sulfamethoxazole (TS)
No 156 2 158
Yes 3 11 14
Total 159 13 172
Kappa = 0.799
No Yes Total
Clindamycin (CD) No 148 2 150
Yes 4 18 22
Total 152 20 172
Kappa = 0.837
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http://www.biomedcentral.com/1746-6148/10/17S. vitulinus, S. saprophyticus, S. haemolyticus, S. lentus, S. suc-
cinus and S. pettenkoferi) were found to carry the mecA
gene. Among oxacillin resistant CoNS species, S epidermi-
dis and S. sciuri were more likely to carry the mecA gene
than S. saprophyticus, S. equorum, S. vitulinus and S. succi-
nus (Figure 3). MRSE isolates were detected in 18 dogs
(25%, 95% CI 14.8, 34.5), meticillin-resistant S. warneri were
detected in 7 dogs (10%, 95% CI 2.8, 16.3) and meticillin-
resistant S. sciuri were detected in 5 dogs (7%, 95% CI 1.1,
12.6). The remaining species were only isolated from one
or two dogs. MDR mecA positive CoNS were detected in
19 dogs (26%, 95% CI 17.3, 37.1). There was no significant
association between detection of MR-CoNS or MDR
isolates and potential risk factors tested in this study
(Pearson’s chi-square; P < 0.0125).Species identification
Phenotypic and biochemical methods identified 436
isolates as Staphylococcus species. Using a combination of
nuc gene PCR, MALDI-TOF-MS and sequencing of the tuf
gene, 399 isolates (92%, 95% CI 88.5, 93.8) were identi-
fied to the species level. MALDI-TOF-MS identified
345 isolates to the species level including 264 of 334
CoNS isolates (79%, 95% CI 74.4, 83.1). Amplification
and sequencing of the tuf gene identified 33 out of 51
CoNS isolates (65%, 95% CI 51, 76.4) to the species level
(n = 11 species; ≥ 98% sequence similarity) and an add-
itional control group (n = 27) of CoNS isolates that had
also been identified by MALDI-TOF-MS. There was
100% agreement between the two methods for the iden-
tification of the control group. In particular, sequencing
of the tuf gene identified all of the S. fleurettii, S. arlettae
and S. pettenkoferi isolates, 12 isolates closely related to
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Figure 2 The MIC (μg/ml) data for staphylococcal isolates (n = 172). The isolates consisted of 52 oxacillin susceptible isolates, 46 oxacillin
resistant mecA negative isolates and 74 oxacillin resistant mecA positive isolates.
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isolates to the genus level (Staphylococcus spp. ≥ 98%
sequence similarity). PCR amplification of the nuc gene
detected all of the S. aureus n = 11 (100%, 95% CI 74.1,
100) and S. pseudintermedius isolates n = 91 (100%, 95%
CI 96.0, 100). There was 100% agreement of this assay
with MALDI-TOF-MS for the identification of S. aureus0
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Figure 3 The percentage of each oxacillin-resistant staphylococcal sp
or negative (mecA-) for the mecA gene.isolates, however MALDI-TOF-MS only identified 69
out of 91 S. pseudintermedius isolates.
Overall from the combined results using PCR amplifi-
cation of the nuc gene, MALDI-TOF-MS and sequen-
cing of the tuf gene we detected S. epidermidis in 52%
(95% CI 41, 63) and S. pseudintermedius in 44% (95% CI
33, 55) of the dogs. S. warneri and S. equorum were themecA+
mecA-
ecies by disc diffusion and MIC that was either positive (mecA+)
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http://www.biomedcentral.com/1746-6148/10/17next most common species, isolated from 30% and 27%
of dogs respectively, and the remaining staphylococcal
species were carried by no more than 15% of the dogs.
S. aureus was detected in 6 of the dogs, exclusively from
the nasal mucosae, and usually with S. pseudintermedius
(88%, 95% CI 52.9, 97.8). S. pseudintermedius was concur-
rently isolated with 16 different CoNS species, although
there was no significant association between the presence
of S. pseudintermedius and any CoNS species (Pearson’s
chi-square; P < 0.003) (Figure 4 and Table 3).
Discussion
This is the first study incorporating MALDI-TOF-MS to
successfully characterise commensal staphylococcal pop-
ulations in a group of healthy dogs in the absence of0
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Figure 4 The percentage of dogs (n = 73) carrying each staphylococca
nuc gene and sequencing of the tuf gene (CoNS grey and CoPS blackantimicrobial pressure. We isolated staphylococci from
99% of our dogs, with 95% carrying CoNS and 47% car-
rying CoPS. The relative prevalence of the staphylococci
concurs with other published studies in humans [2,3],
horses [63-67] and dogs [15,17,68], although the overall
staphylococcal prevalence was double that reported for
healthy vet visiting dogs [15]. This could be related to
the study population and techniques, as we sampled
both the nose and the perineum to increase detection of
CoPS [12,13,68,69].
We were able to assign 92% of the staphylococcal
isolates to 20 different species, including 18 CoNS. This is
the first study to demonstrate such diversity in dogs, and
carriage of this number of different species has only been
previously reported for humans [2,10,12,15,21-26,70]. Thel species identified in this study by MALDI-TOF-MS, PCR of the
).
Table 3 The number of staphylococcal isolates identified to species level by MALDI-TOF-MS, nuc gene PCR (CoPS), and
tuf gene sequencing
Staphylococcal species Number of isolates Number (%) of
positive dogs
Number (%) identified by
MALDI-TOF-MS
Number (%) of CoPS
identified by nuc PCR
Number (%) identified
by tuf gene sequencing
S. pseudintermedius 91 32 (44) 70 (77) 91 (100) 0
S. aureus 11 6 (8) 11 (100) 11 (100) 0
S. epidermidis 67 38 (52) 64 (96) N/A 3 (4)
S. warneri 35 22 (30) 35 (100) N/A 0
S. equorum 39 20 (27) 36 (92) N/A 3 (8)
S. saprophyticus 19 11 (15) 15 (79) N/A 4 (21)
S. sciuri 27 11 (15) 21 (78) N/A 6 (22)
S. succinus 19 10 (14) 16 (84) N/A 3 (16)
S. simulans 15 9 (12) 15 (100) N/A 0
S. capitus 7 8 (11) 7 (100) N/A 0
S. pasteuri 8 6 (8) 8 (100) N/A 0
S. xylosus 17 6 (8) 17 (100) N/A 0
S. lentus 9 5 (7) 4 (44) N/A 5 (56)
S. hominis 6 4 (5) 6 (100) N/A 0
S. cohnii 5 3 (4) 3 (60) N/A 2 (40)
S. vitulinus 14 3 (4) 13 (93) N/A 1 (7)
S. haemolyticus 4 3 (4) 4 (100) N/A 0
S. fleurettii 4 2 (3) 0 N/A 4 (100)
S. arlettae 1 1 (1) 0 N/A 1 (100)
S. pettenkoferi 1 1 (1) 0 N/A 1 (100)
Total ID 399d 72e 345f 101f 33f
Staphylococcus spp. 3 N/A N/A N/A 3
Species related to S. felis 12 N/A N/A N/A 12
No ID 22 N/A N/A 2 3
Total 436a 73b 436c 102c 51c
Values in the table are expressed as total numbers and percentage in parenthesis where applicable. aTotal number of isolates in study, btotal number of dogs in
study, ctotal number of isolates tested by each method, dtotal number of isolates with positive identification (ID), enumber of dogs with staphylococcal detection,
fnumber of isolates with positive ID from each method.
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detected in 52% of the dogs, mainly from the nasal cavity.
This is similar to human reports [71], but apart from one
canine study [23], S. epidermidis has not been commonly
reported in different animal species [67,72,73]. S. pseudin-
termedius was the second most common species and the
most common CoPS detected, also in agreement with
previous reports [9-11,13]. Unlike S. epidermidis, S.
pseudintermedius was carried equally in the nose and
on the perineum, suggesting that this species may have
a wider range of mucosal niches. Very few dogs carried
S. aureus (8%), which is comparable to other studies
that reported carriage rates of approximately 7% from
healthy vet visiting dogs [12,15]. The majority of the CoNS
in our study were human-associated and included S. epi-
dermidis, S. hominis, S. haemolyticus, S. capitus, S. sapro-
phyticus, S. warneri, S. cohnii, S. simulans, S. pettenkoferi
and S. pasteuri. Human associated CoNS species havepreviously been isolated from dogs, horses, cows and pigs
[23,67,72,74-76]. The other CoNS species isolated from
our dogs are reported as indigenous to animals (S.
equorum, S. vitulinus, S. arlettae S. sciuri, S. lentus and
S. fleurettii) [2].
We used several methods to identify staphylococcal
isolates to species level. Multiplex PCR for the nuc gene
is an accurate, rapid and cost efficient method to speciate
CoPS [77], which identified 100% of our S. pseudinterme-
dius (n = 91) and 100% of our S. aureus isolates (n = 11).
Recently MALDI-TOF-MS has been reported as a rapid
and reliable method to characterise CoNS, S. aureus and
S. intermedius group (SIG) strains [59,72,78-80]. MALDI-
TOF-MS identified all of our S. aureus isolates, 77% of
our S. pseudintermedius isolates and 79% of our CoNS
isolates, identified by phenotypic and biochemical charac-
teristics, to the species level. Similar results for the identi-
fication of S. aureus, S. pseudintermedius and CoNS by
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have been reported [79-81]. The overall performance of
MALDI-TOF-MS to speciate the staphylococcal isolates
in this study, similar to other reports [80], is likely to be
directly related to the database, which at the time of ana-
lysis consisted mainly of common human-derived species
and only one S. pseudintermedius strain. However species
level identification will improve as more highly charac-
terised reference isolates are added to the database. Amp-
lification and sequencing of the tuf gene is regarded as the
gold standard to speciate CoNS isolates [59,60]. This
method identified 77% of the tested staphylococcal isolates
(n = 79) to the species level. The performance of this
method in our study may have been affected by the lack of
certain-animal derived isolates representing different spe-
cies in the database. Additionally, we may have improved
identification by sequencing a larger region of the tuf
gene. We sequenced a previously described 412 base
pair region of the tuf gene that was reported to have
successfully identified 88% of human-derived staphylo-
coccal strains [60]. However, a more recent publication
that sequenced a 660 bp region of the tuf gene, reported
98.9% identification of 186 human and animal-derived
staphylococcal strains.
We did not detect any MR-CoPS isolates. Other studies
of healthy dogs have similarly reported a low prevalence
[15,82,83]. In contrast, 58% of the dogs in our study carried
at least one CoNS isolate with phenotypic meticillin resist-
ance and 42% carried a meticillin resistant mecA positive
isolate. Other studies have also reported high levels of
meticillin resistance among CoNS isolates from humans
[31,35,84], horses [23,64-66] and livestock [72,85]. How-
ever, the prevalence of MR-CoNS carriage in our study is
markedly higher than the levels reported in other commu-
nity canine studies [15,23,50,74,83]. High community
carriage rates of MR-CoNS are of concern for animals and
humans, as these organisms may not only be reservoirs
of resistance genes for CoPS [39,40,86], but also act as
pathogens [31,36-38,87-89]. Cross-transmission is re-
ported to be an important mechanism for dissemination
of MRS [49,90], and transmission between dogs and
in-contact humans may occur in the community and in
veterinary premises [36,83].
Nine different CoNS species carried the mecA gene in
our study with MRSE detected in 25% of our dogs.
MRSE is the predominant MR-CoNS species in humans
both in hospital and community settings [39,48,49], and
has been reported in one study investigating nasal
carriage of MRS in dogs [23]. Other canine studies have
isolated meticillin resistant S. sciuri and meticillin
resistant S. warneri [23,74]. Our research found that the
majority of the S. sciuri and S. fleurettii isolates were
mecA positive, which is consistent with other studies in
humans, livestock and horses [35,64,66,67,72].MDR CoNS (n = 38) were isolated from 34% of dogs
in this study. MDR was generally associated with resist-
ance to β-lactams, FA and additional antimicrobials. In
particular MDR-MRSE were resistant to at least four anti-
microbial classes tested in our study. A similar finding
was reported in a study of hospitalised animals, medical
equipment and veterinary staff [68]. MDR among CoNS
isolates is widely reported [15,49,72,73,91] and may be
associated with the carriage of multiple antimicrobial re-
sistance genes on SCCmec cassettes [40]. In contrast, the
majority of our commensal CoPS isolates were susceptible
to a broad range of antimicrobials (apart from Tet), in line
with previous reports for clinical isolates [92-94] and iso-
lates from healthy vet-visiting dogs [15]. There was good
to very good agreement between disc and MIC antimicro-
bial susceptibility testing apart for FC and CIP. These two
antimicrobials were the only ones where human break-
points were applied and emphasises potential species
differences in pharmacokinetic and pharmacodynamic
data for individual antimicrobials.
The mecA gene was not identified in 40% of the
phenotypic oxacillin resistant isolates in this study and
may include some isolate duplication due to our sam-
pling methods. Other studies have reported phenotypic
meticillin resistance with absence of the mecA gene in
staphylococci [95-98]. Our OX-resistant mecA negative
isolates may be truly negative for the mecA gene as they
were less likely to be resistant to the other antimicrobials
tested in this study, including CVN and CFX, and had sig-
nificantly lower MICs compared to the OX resistant mecA
positive isolates. It is possible that they had low-level
resistance associated with other mechanisms such as
hyperproduction of β-lactamases [99], or production of an
oxacillin-specific β-lactamases [100]. There are bovine
mastitis CoNS isolates with oxacillin MICs of 0.5 – 1 mg/l
that lack the mecA gene [97], and the CLSI guidelines
state that ‘oxacillin interpretive criteria may overcall resist-
ance for these CoNS strains’ [57]. In addition, many of the
published PCR assays to identify and characterise the
mecA gene have been developed for MRSA [101-104] and
may therefore lack sensitivity for some CoNS isolates.
However, other authors have successfully employed the
same methods for mecA detection among CoNS isolates
as used in our study [68,98,105]. Nevertheless it is possible
that additional PCR assay [106], or latex agglutination for
PBP2a [107] may have improved the sensitivity of mecA
detection or detected phenotypic mecA-associated resist-
ance in our oxacillin resistant mecA negative isolates.
Our study had some limitations, including the small
sample size. Still, these dogs yielded 436 staphylococcal
isolates and a high prevalence of resistance was identi-
fied among the CoNS isolates even in the absence of
antimicrobial exposure. Another weakness was that the
study population was limited to one breed (Labrador
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Kennelled dogs have been shown to have higher levels of
antimicrobial resistance in faecal E. coli than individually
owned and non-kennelled dogs [108]. Kennelling was
transient in our dogs, but this may have affected the
results. Many of the dogs came from multi-dog house-
holds but only one dog from each household was sam-
pled to avoid cluster effects.Conclusions
This is the first comprehensive study of commensal
staphylococcal populations in a group of healthy dogs.
Staphylococci, particularly CoNS, form a normal part of
the canine commensal population and were detected from
almost all the dogs. The most commonly isolated staphylo-
coccal species in this group of dogs was S. epidermidis,
although a wide variety of other human- and animal-
associated CoNS were found. CoPS were less common,
and the major species was S. pseudintermedius. Antimicro-
bial resistance among the CoPS was uncommon, and no
MRSP or MRSA were isolated, however the sample size
was small. Antimicrobial resistance (including MDR and
meticillin resistance) was common among the CoNS
isolates, even though this was a community population of
healthy dogs in the absence of direct-antimicrobial pres-
sure or veterinary contact. The clinical significance of com-
mensal CoNS and MR-CoNS is unclear, but S. epidermidis
carries a number of virulence factors and is an increasing
cause of nosocomial and community-acquired infections in
humans. The possibility of similar infections escalating in
companion animals cannot be excluded. In addition, there
is potential for cross-species transmission of antimicrobial
resistant bacteria and exchange of resistance determinants
between bacterial species. In particular, MR- and MDR-
CoNS may provide a reservoir of antimicrobial resistance
genes that could rapidly spread within bacterial popula-
tions under the selection pressure exerted by antimicrobial
therapy. Further longitudinal studies in healthy dogs and in
dogs receiving antimicrobials are required to assess the
population diversity, antimicrobial resistance profiles and
persistence of antimicrobial resistant staphylococci in dogs.
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